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Abstract 
Pulmonary arterial hypertension (PAH) is a progressive and fatal vascular disease that is 
more prevalent in women than men. The underlying pathology of the disease involves 
various factors, including genetic risk (i.e. bone morphogenetic protein receptor type II 
(BMPR-II) mutations) as well as the influence of hormones such as estrogen. Among the 
frontline treatments for PAH is prostacyclin therapy; however, the short half-life and 
associated problems with the need for continuous intravenous administration of synthetic 
prostacyclin have led to the development of newer analogues such as treprostinil. These 
have the advantages of a longer half-life and the possibility of subcutaneous and inhaled 
administration. Mortality rates for PAH are still high despite advancements in treatment, 
with male survival rates remaining lower than females.  The BMPR-II signalling pathway 
may underlie some of the sex disparity that exists in incidence of PAH. However, patient 
responses to treatments for PAH have also demonstrated sex-specific effects. A key aim 
of this study was to identify the influence that sex may have on the actions of treprostinil 
with in-vivo and in-vitro models of PH. The ability to target treatment to specific sub-cohorts 
of PH is important to maximise the therapeutic effect of treprostinil. A greater 
understanding of how the effects of treprostinil are mediated could assist this objective. 
To examine any potential influence of sex on the effects of treprostinil, we examined the 
chronic hypoxic model of pulmonary hypertension (PH). Female and male rats were dosed 
with sub-cutaneously implanted pellets releasing treprostinil at 100ng/kg/min or 
400ng/kg/min. Under hypoxic conditions both male and female rats had increases in right 
ventricular systolic pressure (RVSP), right ventricular hypertrophy (RVH) and pulmonary 
artery remodelling. 100ng/kg/min of treprostinil partially reversed RVSP, RVH and 
pulmonary artery remodelling in female hypoxic rats but not in male rats. Quantitative real-
time polymerase chain reaction (qRT-PCR) analysis revealed that a possible mechanism 
of treprostinil was increasing BMPR-II signalling, specifically Id1 and Id3 (inhibitor of DNA 
binding protein 1/3). This was only observed in female hypoxic rats. Despite no difference 
in terminal plasma levels of treprostinil, hypoxic males remained unaffected by treprostinil 
at 100ng/kg/min. However, 400ng/kg/min of treprostinil led to slightly greater decreases in 
RVSP, RVH and remodelling indices in female rats, also it partially reversed RVSP, RVH 
and remodelling in male rats. Taqman qRT-PCR of the prostaglandin receptors 
demonstrated an increase in prostaglandin E2 receptor 2 (EP2) under hypoxic conditions 
with 100ng/kg/min and 400ng/kg/min treprostinil treatment, specific to female rats.  Also 
under hypoxic conditions female and male rats had significant increases in mRNA 
expression of potassium two pore domain channel subfamily K (KCNK3). 
To translate clinical relevance from the in-vivo findings, the influence of sex on treprostinil 
was investigated in human pulmonary artery smooth muscle cells (hPASMCs) taken from 
non-PAH (control) and PAH patients. In female control hPASMCs FBS (fetal bovine serum) 
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induced proliferation was partially ablated by treprostinil; this effect was only observed in 
male control hPASMCs at the highest treprostinil concentration (10µM). In patient 
hPASMCs, treprostinil had a similar effect in reducing FBS-induced proliferation in both 
female and males. The addition of a low dose (30nM) of endothelin-1 (ET-1) increased the 
anti-proliferative effect of treprostinil, specifically, in female control hPASMCs. The addition 
of a dual endothelin receptor antagonist (SB-217242) partially reduced the anti-
proliferative effect of treprostinil in combination with ET-1. Taqman qRT-PCR and western 
blot analysis demonstrated no difference between sexes or hPASMC groups in the 
expression of the prostaglandin receptors. Using receptor specific antagonists, it was 
determined that the anti-proliferative actions of treprostinil in PAH patient hPASMCs were 
partially mediated via the EP2 receptor. However, in female control hPASMCs, the IP 
receptor was primarily responsible for this effect. BMPR-II signalling was investigated to 
ascertain its role in the anti-proliferative effects of treprostinil. Taqman qRT-PCR indicated 
treprostinil (100nM and 1µM) induced increases in Id1 and Id3 mRNA in female control 
hPASMCs, this did not occur in male control hPASMCs. Treprostinil (100nM and 1µM) led 
to Id3 mRNA increases in female PAH patient hPASMCs, whereas in male PAH patient 
hPASMCs treprostinil (1µM) led to a significant Id3 mRNA increase. Western blots 
indicated that Id3 was upregulated by treprostinil (1µM) stimulation in female control and 
female PAH hPASMCs vs non-stimulated hPASMCs; this effect was not observed in 
males. The combination of ET-1 and treprostinil did not influence BMPR-II signalling. After 
24 hours of treprostinil stimulation increased Id3 mRNA expression was observed in all 
hPASMCs groups. Treprostinil only increased Id1 mRNA in PAH patient hPASMCs. 
Although western blots confirmed treprostinil (100nM and 1µM) mediated increases in Id1 
protein expression in female control hPASMCs. Treprostinil (100nM and 1µM) increased 
Id3 protein expression in female control and female PAH patient hPASMCs. Treprostinil 
(1µM) in combination with ET-1 led to a significant increase in Id3 protein expression in 
male control hPASMCs. As with 72-hour treprostinil stimulation, BMPR-II signalling was 
not influenced by the combination of ET-1 and treprostinil in the other hPASMC groups. 
The increased BMPR-II signalling in female control and female PAH patient hPASMCs at 
24 hours led to the investigation of prostaglandin receptors role in activating BMPR-II 
signalling. After 24-hours of stimulation with treprostinil (100nM), Id protein induction was 
partially blocked by dual antagonism of the IP and EP2 receptor in both female control and 
female PAH patient hPASMCs.  
To summarise these findings, we have identified sex differences in the action of treprostinil 
in both in-vivo and in-vitro models of PH. Treatment with a low dose (100ng/kg/min) of 
treprostinil led to a significant reduction in chronic hypoxic induced PH in female rats but 
not in males. These differences are driven partially by increases in BMPR-II signalling. 
Treatment with a higher dose (400ng/kg/min) of treprostinil led to significant reductions in 
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chronic hypoxic PH in both female and male rats. In hPASMCs the results demonstrate 
that treprostinil can induce the Id proteins of the BMPR-II signalling pathway and that this 
may account for the greater anti-proliferative effect observed in female control hPASMCs. 
The induction of the Id proteins was found to be partially mediated by activation of the IP 
and EP2 prostaglandin receptors. The results suggest that sex may influence the beneficial 
effects of treprostinil in an in-vivo model of PH and in hPASMCs. 
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1.1. The pulmonary circulation 
1.1.1. Structural and functional organisation 
The primary function of the pulmonary circulation is to enable for the exchange of gases 
between inspired air and red blood cells, especially oxygen and carbon dioxide. The right 
ventricle receives venous blood from the systemic circulation via the right atria. The 
pulmonary artery extends from the right ventricle and splits to become the left and right 
pulmonary artery. Each part of the artery extends into the hilum of the corresponding lungs. 
The right lung can be sub-divided into three distinct lobes; superior, middle and inferior, 
which are separated by intra-lobar fissures, each lobe receiving a branch from the right 
pulmonary artery. The left lung is sub-divided into two lobes; superior and inferior, each of 
these lobes receives a branch from the left pulmonary artery. The lobes of the lungs are 
further sub-divided into distinct bronchopulmonary segments (Sealy et al., 1993). The 
pulmonary artery continues to branch into smaller arteries parallel to the bronchial tree 
until the capillary bed of the terminal alveoli. Each branch of the pulmonary artery was 
assigned an order diameter corresponding to the diameter of the vessel, as defined by the 
Strahler ordering system (Singhal et al., 1973). The Strahler ordering system was updated 
to the Diameter-Defined Strahler system due to the overlap in the diameter of successive-
order vessels (Jiang et al., 1994). Based on the update, fifteen orders of pulmonary arteries 
were identified between the main pulmonary artery to capillary level (Huang et al., 1996). 
The lung function is related to the changes in the intima and media of the pulmonary 
arteries. The most distal arteries before capillaries are known as order 1, the numbering 
increases with each branch back to the main pulmonary artery, which is order 15 (Huang 
et al., 1996).  The most proximal arteries (order 13-15) have diameters ranging from 4mm 
to 14mm. These arteries are highly compliant demonstrating a developed elastic laminae, 
which facilitates compliance. Decreasing order number leads to a decreasing diameter of 
pulmonary arteries ranging from 1.75mm to 0.1mm. The branching of the pulmonary artery 
leads to an increase in smooth muscle cell population relative to other cells in the 
vasculature (Heath and Edwards, 1958). The final 4 orders of the pulmonary arteries 
(0.08mm to 0.02mm) have low numbers of smooth muscle cells  (Meyrick and Reid, 1983, 
deMello et al., 1997). These vessels are primarily comprised of endothelial cells and 
undifferentiated smooth muscle cells (pericytes), which mediate blood gas exchange 
(Figure 1-1). 
The pulmonary arteries eventually become the pulmonary capillary network. Capillaries 
have very small diameters of less than 10µm and are associated with alveoli. The 
combined capillaries have a large surface area, which helps facilitate the blood 
oxygenation. After oxygenation, the blood progresses to the left atria of the heart through 
the pulmonary venous circulation, which branches from venules to pulmonary veins until 
the formation of the right and left pulmonary veins that supply the left atria. 
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1.1.2. Development of pulmonary circulation 
Development of the pulmonary artery is linked to the development of the airways. Smooth 
muscle cells are thought to have developed in pulmonary arteries from three different 
sources. Proximal smooth muscle cells are related to bronchial smooth muscle cells, other 
smooth muscle cells are thought to develop from the lung mesenchyme. The last source 
of smooth muscle is from endothelial cells. These endothelial cells can differentiate into 
smooth muscle cells (DeRuiter et al., 1997, Hall et al., 2000). 
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Figure 1-1 Pulmonary artery musculature 
Decreasing levels of muscularisation occurs progressively as the size of pulmonary artery decreases. Last pre-capillary level arteries consist primarily of endothelial cells 
and pericytes. Taken from (MacLean et al., 2000). 
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1.1.3. Pulmonary vascular wall structure 
The pulmonary vascular wall can be separated into three separate layers or tunics; the 
tunica intima, tunica media and tunica adventitia (Figure 1-2). The tunica adventitia, which 
is the outermost layer of the pulmonary vascular wall, consists of various contractile and 
extracellular matrix proteins, which combined with fibroblasts and progenitor cells form 
stromal cells (Stenmark et al., 2006a). These cells act to support the structural integrity of 
the vascular wall.  They can also direct response to specific stimuli by interaction with other 
cells in the adventitia or in other tunics. The largest layer of the vascular wall is known as 
the tunica media. It contains an arrangement of a mixed population of immature/mature 
pulmonary artery smooth muscle cells (PASMCs). The importance of this layer (tunic) is 
determined by the ability of the PASMCs to produce a contractile response to stimulation, 
therefore they regulate the tone and blood pressure in the artery (Frid et al., 1997, 
Stenmark and Frid, 1998). The innermost tunic is the tunica intima, which consists of a 
connective tissue matrix with an attached monolayer of endothelial cells. Endothelial cells 
are the only cells that are in contact with the blood in the vessels and are believed to be 
important in the regulation of the lumen environment. Overall vascular tone can be 
modulated by the release of vasodilators and vasoconstrictors from endothelial cells 
(Aaronson et al., 2002). 
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Figure 1-2 Cell types and morphology of pulmonary vascular wall 
Pulmonary vascular wall comprised of intimal, medial and adventitial layers. Endothelial cells predominately located in the intimal layer, smooth muscle cells in medial, 
which decrease in number as the artery reduces in size, fibroblasts are in the outermost adventitial layer of vascular wall. 
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1.1.4. Function of the pulmonary circulation 
The primary function of the pulmonary circulation is to facilitate the exchange of oxygen 
and carbon dioxide between air and blood. Under normal conditions the pulmonary 
circulation is a high flow, low resistance, low pressure system that carries deoxygenated 
blood from the systemic circulation and facilitates its re-oxygenation (Comroe, 1966). 
Additionally, the pulmonary circulation can act as a filtration system, preventing foreign 
objects passing between respiratory and cardiovascular systems (Comroe, 1966). The 
capillaries within the pulmonary circulation can also act as a blood reservoir, which can be 
used to receive the cardiac output and supply the left ventricle of the heart (Comroe, 1966). 
1.1.5. Regulation of pulmonary circulation and pulmonary vascular resistance  
The pulmonary arteries contain less smooth muscle cells and elastin than arteries from 
the systemic circulation allowing greater distensibility (Kilner, 2004). Consequently, 
pulmonary arterial pressure is only one-fifth to one-tenth of total systemic resistance. The 
low vascular tone of the pulmonary arteries is dependent on the resting membrane 
potential of the PASMCs. This involves the activity of both potassium and calcium 
channels. Depolarisation of the cell membrane leads to the opening of voltage gated 
potassium (Kv) channels, these allow the outflow of potassium ions (K+) thereby restoring 
the membrane potential (Yuan, 1995). A blockade of the Kv channels leads to an increase 
in intracellular calcium (Ca2+) resulting in vasoconstriction of PASMCs. In PASMCs derived 
from pulmonary arterial hypertensive (PAH) patients, the Kv channel were found to be 
dysfunctional leading to greater depolarisation of the cell membranes. This enhanced the 
vasoconstriction in PAH PASMCs compared to control PASMCs (Yuan et al., 1998). Some 
forms of heritable PAH have been found to have a loss of function of the alternative 
potassium channel KCNK3 (Ma et al., 2013, Girerd et al., 2014). Interestingly, the 
monolayer of pulmonary artery endothelial cells (PAEC) of the tunic intima are important 
regulators of the pulmonary vascular tone. PAEC are known to release both nitric oxide 
(NO) (Nong et al., 1997) and prostacyclin (PGI2) (Gryglewski et al., 1988). These 
vasodilators can lead to relaxation in the PASMCs of the tunica medial. PAEC can also 
release vasoconstrictors like endothelin-1 (Giaid et al., 1993) and thromboxane (Christman 
et al., 1992). Pulmonary vascular resistance (PVR) is the total peripheral resistance which 
is overcome to maintain constant blood flow through the pulmonary arteries. Small 
alterations in the lumen size can have a significant impact on PVR therefore can affect 
pulmonary arterial pressure (PAP) (Krenz et al., 1994). In pulmonary hypertension, 
increased proliferation of the smooth muscle cells of the tunic intima can lead to a narrower 
lumen leading to increased PVR and PAP. The autonomic nervous system can influence 
the pulmonary circulation via both the sympathetic and parasympathetic branches. In all 
species, sympathetic noradrenergic innervation density is higher in blood vessels outside 
the lung, this decreases as the vessel size decreases (Fisher, 1965). In humans, 
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sympathetic noradrenergic axons extend to 50µM sized small arteries, in rats and mice 
innervation stops after the lung hilus (Fisher, 1965, Čech, 1969). Increased sympathetic 
nerve signalling leads to increases in both PVR and PAP (Kadowitz et al., 1974). This is 
mediated by noradrenaline acting at the α-adrenoreceptors, which leads to 
vasoconstriction of smooth muscle cells (Hyman et al., 1986, Crystal, 1997). 
Noradrenergic sympathetic axons can release many transmitters (co-transmission), an 
example would ATP releasing with noradrenaline from sympathetic axons (Burnstock, 
2009). However, different populations of axons have different combinations of transmitter. 
Additionally, sympathetic neurones can also synthesise and release neuropeptides like 
neuropeptide-Y (NPY) (Abe et al., 2010). NPY was found to cause contraction of isolated 
pig pulmonary arteries, however isolated rabbit pulmonary arteries were not dependent on 
NPY for contraction (Martling et al., 1990, Jackson et al., 2002). Interestingly, in isolated 
rabbit pulmonary arteries, electrically stimulated contraction was not altered by α-
adrenoceptor blockade or mediated by endothelin-1, angiotensins or acetylcholine 
(Jackson et al., 2002). NPY was also found to be a mediator of ischemic angiogenesis via 
activation of Y2 and Y5 receptors as well as a inducer of smooth muscle proliferation (Abe 
et al., 2007, Movafagh et al., 2006)  Alternatively, β1 and β2 adrenoreceptors mediate 
vasodilation of the smooth muscle cells of the pulmonary arteries (Hyman et al., 1981, 
Hyman et al., 1990). β-adrenoreceptor obstruction led to increases in resting PAP in dogs, 
sheep and humans (Crystal, 1997). Interestingly, the parasympathetic branch of the 
autonomic nervous system is found to be less influential in altering pulmonary vascular 
tone (Downing and Lee, 1980, Murray et al., 1986). However, cholinergic fibres are 
distributed in a similar fashion to noradrenergic fibres, with less density (El-Bermani et al., 
1982). The role of NO on the vasodilatory effects of acetylcholine on isolated rat pulmonary 
arteries was demonstrated by the blockade of nitric oxide synthase by either L-NG-
nitroarginine methyl ester (L-NAME) or L-NG-monomethyl arginine (L-NMMA) (Yaghi et al., 
1997). A NO-dependent relaxation was observed after vagal nerve stimulation in 
precontracted feline pulmonary arteries (McMahon et al., 1992). Vasoactive intestinal 
peptide (VIP) relaxes precontracted arteries partially dependent on NO action (Iwabuchi et 
al., 1997). VIP importance in relaxation is underlined by the observable decrease in VIP 
serum and lung expression in PAH patients. Also, VIP knock out mice suffer from moderate 
PH, decreased lumen of small arteries and upregulation of pro-proliferative genes like 
angiopoietin 1 and pro-collagen type V alpha1 (Petkov et al., 2003, Hamidi et al., 2008). 
1.2. Pulmonary hypertension 
Pulmonary hypertension is a general name for a group of progressive vasculopathies of 
the pulmonary vasculature. It is characterised by lower blood flow through the pulmonary 
circulations, this results in an increase PVR therefore increased PAP. Restrictive blood 
flow occurs due to significantly increased levels of remodelling, due to excessive 
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proliferation of both endothelial and smooth muscle cells. The increase pressure leads to 
a greater strain placed on the right ventricle of the heart. Hypertrophy of the right ventricle 
occurs as a compensatory mechanism; however, this eventually leads to right ventricle 
failure and the death of the patient. There are many different aetiologies of PH therefore 
the disease is grouped into subcategories to target the most appropriate medical 
intervention. 
1.2.1. Diagnosis and classification  
Clinically, PH is defined as a resting mean PAP (mPAP) greater than 25mmHg or a mPAP 
above 30mmHg during exercise (Badesch et al., 2009). This is approximately double the 
mPAP (14-20mmHg) that is observed in normal women and men. Patients with PH usually 
present with several symptoms, which may include shortness of breath, dizziness, fatigue 
and oedema (Rich et al., 1987) . However, these symptoms may not be a direct sign of 
PH. It is therefore important to conduct further examinations to properly diagnose the 
disease. The application of an electrocardiogram (ECG) may suggest the presence of right 
ventricle hypertrophy, as 87% of PAH patients have RV hypertrophy confirmed by a ECG 
(Rich et al., 1987). Magnetic resonance imaging (MRI) can be used as a companion 
diagnostic test to ECG to discern RV size allowing for non-invasive measurements of 
cardiac and stroke volume (Marrone et al., 2010). Blood tests can also be used to identify 
the level of anti-nuclear antibodies, which are known to be elevated in a subset of PH 
patients (Rich et al., 1986). Right heart catheterization (RHC) is carried out to confirm the 
diagnosis of PH. Although it is an invasive procedure RHC is associated with low morbidity 
and mortality rates (Hoeper et al., 2006). During RHC, vasoreactivity of the pulmonary 
vasculature is tested to identify if patients would respond to calcium channel blocker (CCB) 
therapy. NO and PGI2 are predominately used to test vasodilatory response, a good 
response in patients is characterised by a drop in mPAP of more than 10mmHg (Sitbon et 
al., 1998, Rubin et al., 1982, Sitbon et al., 2005). However, this response does not always 
occur despite successful long term clinical outcomes (Sitbon et al., 2005). Despite different 
forms of PH having common features, patients are categorised into groups to aid 
understanding of disease aetiology and to assist in the therapeutic management of the 
disease (Table 1-1). Due to the severe effects that PH can have on the heart, patients are 
also classified according the New York Heart Association (NYHA) scale on heart failure 
(Table 1-2). The NYHA classifies PH patients as per the manifestations of the symptoms 
of the disease. Its range covers class I, at which no symptoms are present, to class IV, 
were symptoms are present even at rest. 
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Table 1-1 World Health organisation (WHO) classification of pulmonary hypertension 
Classification of Pulmonary hypertension 
1. Pulmonary Arterial Hypertension (PAH) 
1.1. Idiopathic PAH (IPAH) 
1.2. Heritable PAH (HPAH) 
1.4.1. BMPR-II 
1.4.2. ALK-1, ENG, SMAD9, CAV1, KCNK3 
1.4.3. Unknown 
1.3. Drug and toxin induced 
1.4. Associated with 
1.4.1. Connective tissue disease 
1.4.2. HIV infection 
1.4.3. Portal hypertension (PPHTN) 
1.4.4. Congenital heart disease 
1.4.5. Schistosomiasis 
1.4.6. Chronic haemolytic anaemia 
1.5. Persistent pulmonary hypertension of the newborn (PPHN) 
2. Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital 
cardiomyopathies 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease (COPD) 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive patterns 
3.4 Sleep-related breathing behaviour 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitudes 
3.7 Developmental lung diseases 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1 Hematologic disorders: chronic haemolytic anaemia, , splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis,  
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thryroid 
disorders 
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure 
BMPR-II: Bone morphogenetic receptor type 2; ALK-1: Activin receptor like kinase-1 CAV1 = caveolin-1; 
ENG = endoglin; HIV = human immunodeficiency virus; PAH = pulmonary arterial hypertension. 
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Table 1-2 New York Heart Association (NYHA)/WHO classification of functional assessment 
of patients with pulmonary hypertension (PH). 
Class 1/Class I No symptoms with ordinary physical activity/ 
Patients with PH but without resulting 
limitation on physical activity. 
Class 2/Class II Symptoms with ordinary activity/Patients with 
PH resulting in slight limitation of physical 
activity. 
Class 3/Class III Symptoms with less than ordinary 
activity/Patients with PH resulting in marked 
limitation of physical activity. 
Class 4/Class IV Symptoms with any activity or even at 
rest/Patients with PH with inability to carry 
out any physical activity without symptoms. 
 
1.2.2. Epidemiology and prognosis 
There has been much revision and re-assessment of the epidemiology of PAH. There are 
several different registries of PAH constructed from clinical trials across different countries 
(McGoon et al., 2013). Recent analysis of the French and United Kingdom and Ireland 
registries concluded that the incidence of PAH was 2.4 and 1.1 cases per million 
respectively (Montani et al., 2010, Ling et al., 2012).  The mean age of PAH diagnosis can 
vary between separate registries. A NIH cohort study from the 1980s found a lower mean 
age of 36 years with 62.5% of patients being female (Rich et al., 1987). More recent data 
suggests that the mean age has increased. The UK and Ireland registry found that the 
mean age was 50 years with 70% of patients being female (Ling et al., 2012). The French 
registry found similar results; 50 year mean age with 65% female (Montani et al., 2010). 
The registry to evaluate early and long-term PAH disease management (REVEAL) from 
the United States found that the mean age of the predominately (80%) female patients 
was 53 years (Badesch et al., 2010). At 1, 2 and 3 years’ post diagnosis PAH survival 
rates were found to be 83%, 67% and 58% respectively (Humbert et al., 2010a). Younger 
PAH patients have been found to have better survival rates compared to those over 50 
years (Ling et al., 2012). Despite improvements in therapeutic intervention and diagnosis, 
survival rates for PAH remains stubbornly low, it remains a progressive and fatal disease. 
A major outcome from the registry studies is the confirmation of female predominance 
diagnosed with PAH; the underlying reasons for this sex difference are the subject of 
current experimental research. Despite the female predisposition for PAH, male sex is 
identified as a risk factor associated with poorer survival (Humbert et al., 2010a). 
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1.2.3. Pathobiology of PAH 
PAH is a complex disease with many factors contributing to its development. Severe PAH 
is defined by excess proliferation and apoptosis of smooth muscle, endothelial and 
fibroblast cells. Localised hypoxia can occur in pulmonary arteries with decreasing lumens, 
these hypoxic conditions can lead to greater vasoconstriction and alterations in the Ca2+ 
and K+ balance in the local cells (Yuan et al., 1998)  
1.2.3.1 Vasoconstriction in PAH 
Much of the early research into the PAH pathobiology focused on vasoconstriction and its 
contribution to increased PVR and PAP. Increasing vasoconstriction has been 
demonstrated to increase PASMC hypertrophy and hyperplasia (Barst et al., 2004). 
Hypoxic vasoconstriction (HPV) of pulmonary arteries occurs in PH associated with 
cardiopulmonary diseases like Eisenmenger’s syndrome or chronic obstructive pulmonary 
disease (COPD). Pulmonary arteries denuded of their endothelium have increased 
vasoconstriction when exposed to hypoxia (Marshall and Marshall, 1992). 
Vasoconstriction also occurred in isolated bovine PASMCs exposed to hypoxia (Murray et 
al., 1990). To ensure maximum oxygenation of the blood, HPV redirects blood flow to 
areas of the lung that have the best ventilation. As mentioned previously both Ca2+ and K+ 
signalling is important in maintaining vessel homeostasis. Increased levels of cytosolic free 
Ca2+ can trigger smooth muscle contraction. This occurs by the activation of myosin light 
chain (MLC) by a Ca2+/calmodulin complex. Myosin cross-bridges then forms with actin 
filament leading to vasoconstriction of the smooth muscle cell (Somlyo and Somlyo, 1994). 
Several signalling pathways have been proposed to influence Ca2+ increases in smooth 
muscle cells including the Rho-kinase and p38-mitogen activated (MAP) kinase. Studies 
have suggested that the endothelial cells can release an endothelium derived constricting 
factor (EDCF) (Giaid and Saleh, 1995, Robertson et al., 2001). In IPAH patient PASMCs, 
the activity and expression of Kv channels are reduced, which can lead to increased 
intracellular Ca2+ levels and vasoconstriction (Murray et al., 1986, Cumming et al., 1970). 
In PAH, there is an imbalance in the productions of both vasodilator and vasoconstrictive 
agents. PGI2 and NO are two key vasodilatory agents produced by the endothelium in the 
pulmonary circulation. Levels of PGI2 are found to be significantly reduced in pulmonary 
hypertension patients (Christman et al., 1992). NO is locally produced in endothelial cells 
however, in PAH the bioavailability of NO is reduced (Klinger et al., 2013). This is possibly 
due to several factors, these include increased oxidative stress and reduced levels of NO 
synthase (Michelakis et al., 2002). Increased levels of asymmetric dimethylarginine 
(ADMA) exist in IPAH, ADMA is a competitive inhibitor of NO synthase (Kielstein et al., 
2005). IPAH lung samples were also found to have reduced expression of dimethylarginine 
dimethylaminohydrolase (DDAH2), which is an important enzyme involved in the 
breakdown of ADMA (Zakrzewicz and Eickelberg, 2009). In PAH, cyclic guanosine 
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monophosphate (cGMP) expression levels are reduced due to the bioavailability of NO. 
The cGMP enzyme phosphodiesterase type 5 (PDE5) has been found at elevated levels 
in both lung and right ventricle of PAH patients (McLaughlin et al., 2009). The 
vasoconstrictor endothelin-1 (ET-1) is known to regulate vascular tone through both the 
ETA and ETB receptors. Across a range of PH patients; including IPAH, COPD and CTEPH, 
ET-1 circulating and local lung levels of ET-1 were increased (Behr and Ryu, 2008, Bauer 
et al., 2002, Giaid et al., 1993). ET-1 has also been implicated in fibrogenesis through 
association with matrix metalloproteinases (MMP) (Chelladurai et al., 2012, Jain et al., 
2007). ET-1 and the reduced expression of the ETB receptor have been linked to increased 
expression of MMP9 in a MCT rat model of PAH (Ivy et al., 2005). 
1.2.3.2 Hypoxic pulmonary vasoconstriction 
Hypoxic pulmonary vasoconstriction (HPV) is a process by which in response to low levels 
of oxygen pulmonary blood flow to distributes to areas with high oxygen levels. This allows 
for the efficient gas exchange between blood and inspired air (Marshall et al., 1981). This 
was initially discovered by von Euler and Liljestrand (Euler and Liljestrand, 1946). In 
humans, HPV was eventually determine to be a 50% increase in pulmonary arterial 
resistance to an alveolar oxygen partial pressure of less than 50mmHg (Motley et al., 
1947). In the pulmonary arteries PASMCs not endothelial cells are thought to monitor for 
changes in oxygen levels, this is supported by HPV continuing to occur in feline 
endothelium free arteries (Marshall and Marshall, 1992). However, in other animal models 
a pre-treatment of cells with ET-1 led to greater levels of hypoxic-induced vasoconstriction 
(Sham et al., 2000). Endothelin receptor antagonists were also found to block HPV, 
suggesting that an intact endothelium releasing ET-1 is required for PASMCs to respond 
to hypoxia (Oparil et al., 1995, Liu et al., 2001). Key components of the response to hypoxia 
in lung tissue is the action of both Ca2+ and K+ channels. Importantly, intracellular Ca2+ is 
elevated in PASMCs exposed to hypoxic conditions (Wang et al., 2005a). Both L-type 
Ca2+channels and nonspecific cation channels (NSCC) are believed to be involved, this 
was highlighted when blocking L-type Ca2+ channels where only a partial elimination of 
HPV (Savineau et al., 1995, Ohe et al., 1989). Interestingly, a blockade of NSCCs led to a 
complete block on HPV (Weigand et al., 2005). The method by which hypoxic regulates L-
type calcium channels has been shown to be at least partially dependent on membrane 
depolarisation through K+ channels (Hasunuma et al., 1991, Yuan et al., 1993, Post et al., 
1992). 
Hypoxic mediated membrane depolarisation has been linked to several Kv including Kv 
2.1, 1.5 and 9.3 (Patel et al., 1997, Archer et al., 1998). However, research suggests that 
Kv are not the only mechanism of mediating HPV, the removal of the Kv 1.5 from mice led 
to an incomplete inhibition of HPV (Archer et al., 2001). Both Redox changes and NSCCs 
have been shown to regulate Kv channels (Post et al., 1992, Ward et al., 2005). NSCCs 
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are identified as transient receptor channels (TRP) that can be subdivided into store 
operated channels (SOCs) and receptor operated channels (ROCs) (Birnbaumer et al., 
1996, Ward et al., 2005). Weissmann and colleagues have demonstrated that ROCs can 
be activated by protein kinases and diacylglycerol and that they are essential in the 
response to acute HPV (Weissmann et al., 2006). They demonstrated that removal of 
TPRC6 from mice led to the removal of a vasoconstrictive response to hypoxia, however 
non-hypoxic mediated vasoconstriction was maintained (Weissmann et al., 2006). Also, 
PASMCs isolated from TRPC6 knock out mice did not have a hypoxic mediated Ca2+ 
increase compared to normal PASMCs (Weissmann et al., 2006).  
Reactive oxygen species (ROS) have also been implicated in HPV, ROS levels were found 
to increase in PASMCs exposed to hypoxia (Marshall et al., 1996, Killilea et al., 2000). 
ROS activates both L-type Ca2+ and intracellular Ca2+ channels and is thought by 
influenced by mitochondria (Wolin, 2000, Waypa et al., 2001). More recently HPV was 
confirmed to increase PASMCs Ca2+ by increasing ROS signalling from mitochondria 
(Waypa et al., 2006). ROS was generated from the electron transport chain (ETC) thereby 
increasing oxidative stress which led to an increase in cytosolic Ca2+ in PASMCs (Waypa 
et al., 2006). Latterly a further possible mechanism has linked hypoxic-induced Ca2+ 
increase with mitochondria. Liao and colleagues discovered that hypoxia led to ROS-
mediated dissociation of FK506 binding protein 12.6 from ryanodine receptor 2 thereby 
inducing Ca2+ release (Liao et al., 2011). 
1.2.3.3 Pulmonary vascular remodelling 
A key component of PAH pathobiology is the imbalance in the proliferation and apoptosis 
of PASMCs, PAEC and fibroblasts. This imbalance is manifested in tunica intimal 
thickening and muscularisation of the distal pulmonary arteries, which previously had little 
or no smooth muscle presence (Figure 1-3). This results in a narrowing of the artery lumen 
and a reduction in blood flow therefore leading to less blood oxygenation (Figure 1-4). 
Increased muscularisation occurs in distal and in more proximal pulmonary arteries, the 
primary difference between the two is in a healthy lung the distal arteries have little or no 
smooth muscle cell presence (Meyrick and Reid, 1983, deMello et al., 1997). Cells from 
the internal elastic laminae grow and differentiate into smooth muscle cells (Meyrick and 
Reid, 1978). However, in distal arteries lacking an elastic laminae, pericytes differentiate 
into cells with a similar phenotype to smooth muscle cells. Muscularisation of these distal 
arteries also involves the increased recruitment of fibroblasts from the surrounding lung 
tissue (Jones et al., 1999). The proximal pulmonary arteries also undergo increased 
muscularisation. There is an increase in collagen 1, which hardens the artery wall (Meyrick 
and Reid, 1980). Excessive muscularisation involves the activation of elastases, which 
disturbs the elastic laminae and contributes to increased proliferation and hypertrophy of 
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smooth muscle cells (Ilkiw et al., 1989). Severe pulmonary hypertension can be identified 
by the presence of neointima formations. Neointimas are formed from layers of 
extracellular matrix and various cells positioned between the endothelium and the internal 
elastic laminae (Yi et al., 2000, Botney et al., 1992). Neointima formation is also dependant 
on an increased blood flow. Okada and colleagues demonstrated that monocrotaline 
(MCT) rats that had undergone a left lung pneumonectomy developed neointimas in the 
intact right lung whereas rats without a pneumonectomy did not (Okada et al., 1997). 
Neointima are comprised of myofibroblasts, these cells express α-smooth muscle actin 
and vimentin (Maruyama et al., 1991). However, cells from the neointima do not express 
any endothelial cell markers (Maruyama et al., 1991). Increased dysfunctional proliferation 
of endothelial cells leads to the formation of plexiform lesions in severe PH. Within these 
lesions, the endothelial cells express vascular endothelial growth factor (VEGF), which is 
a marker of angiogenesis (Tuder et al., 2001, Hirose et al., 2000). A consequence of the 
formation plexiform lesions is the complete blockage of the pulmonary artery leading to 
drastic reduction in blood flow (Tuder et al., 1994). Peroxisome proliferator-activated 
receptor gamma (PPAR-γ) is an important anti-proliferative transcription factor, which has 
been shown to mediate beneficial effects in both experimental models of PH (Hansmann 
et al., 2008) and in PAH hPASMCs (Falcetti et al., 2007). Plexiform lesions were found to 
have decreased expression of PPAR-γ (Ameshima et al., 2003). 
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Figure 1-3 Pathogenesis of PAH in distal pulmonary arteries, control vs PAH 
Pulmonary arterial hypertension is a progressive vascular disease that primarily affects the 
pulmonary arteries. During PAH, distal pulmonary arteries have increased smooth muscle 
infiltration and proliferation narrowing the lumen, this can lead to complete blockage of the distal 
artery. Muscularisation of distal arteries contributes to increased pulmonary vascular resistance and 
pulmonary arterial pressure. 
 
 
Figure 1-4 Pulmonary arteriogram of both healthy and IPAH PAH patient 
Pulmonary arteriogram from a healthy adult lung (left) and from an idiopathic PAH patient lung 
(right).  Loss of distal pulmonary arteries/vascular pruning is extensive in PAH lung. Taken from 
(Reid, 1986).
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1.3. Genetic influence on PAH 
A genetic influence on PAH has been suspected for several decades. Initially the role of 
genetics was suggested by the occurrence of PAH within a single family (Dresdale et al., 
1954). An underlying genetic predisposition to PAH was originally termed familial PAH 
(FPAH) but is now identified as heritable PAH (HPAH). FPAH/HPAH was identified as 
having an autosome dominant inheritance, leading to 50% chance of a child of a PAH 
sufferer developing the disease (Thompson and McRae, 1970).  More recently, six families 
were identified as having an increase incidence of PAH with no obvious contributing 
secondary factors (Nichols et al., 1997). The gene associated with increased PAH 
incidence was identified on the long arm of chromosome 2. Latterly the gene was identified 
as the bone-morphogenetic protein receptor-2 (BMPR-II) (Deng et al., 2000, International 
et al., 2000). Other genetic risk factors have been identified in the activin receptor like 
kinase 1 (ALK-1), the potassium channel (KCNK3) (Harrison et al., 2003, Girerd et al., 
2010a, Girerd et al., 2014) and the eukaryotic translation initiation factor 2α kinase 4 
(EIF2AK4) (Eichstaedt et al., 2016). 
1.3.1. BMPR-II gene mutations 
BMPR-II gene mutations have been identified in 80% of cases of HPAH (Machado et al., 
2006, Morrell, 2010). Interestingly, the penetrance of the mutation is only 20% in HPAH 
patients suggesting a secondary risk factor, this could be an additional genetic factor or 
environmental influences (Newman et al., 2004). The severity of HPAH has been shown 
to vary depending on the type of BMPR-II mutation that the carrier has. BMPR-II carriers 
with missense mutations were found to have greater PAH severity than those with a 
truncating mutation (Austin et al., 2009). In establishing inheritance in the children of HPAH 
patients, a higher number of females were identified as both carriers of mutation and more 
females had HPAH (Loyd et al., 1995). 
1.3.1.1 Normal and dysfunctional BMPR-II signalling 
BMPR-II is a serine-threonine receptor kinase member of the TGF-β superfamily of type II 
receptors, which have TGF-β, BMPs, activins and inhibins as some of its many ligands. 
The BMPR-II pathway is known to play important roles in early development of the 
pulmonary circulation, specifically in maintaining PAEC survival (Teichert-Kuliszewska et 
al., 2006), BMPR-II signalling also assists in the repair of lung tissue injury in adults. 
(Sountoulidis et al., 2012). As stated previously BMPs (bone morphogenetic proteins) can 
activate BMPR-II signalling. BMPs can be divided into sub-groups including BMP-2/4, 
BMP-5/6/7/8, GDF-5/6/7 and BMP-9/10 (Kawabata et al., 1998). Subsequently, it was 
found that BMPs have many functions in regulating cell proliferation, apoptosis and 
differentiation (Massague and Chen, 2000, Miyazono et al., 2010). When a ligand binds to 
the BMPR-II receptor, it forms a heterodimer complex with a TGF-β type 1 receptor 
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(BMPR-I) and phosphorylates and activates the transmembrane region of the TGF-β type 
1 receptor (Cai et al., 2012) (Figure 1-5). The activated type 1 receptor then activates 
Smad (small mothers against decapentaplegic) proteins (Massague et al., 2005). Smad 
proteins can be divided into three distinct groups; receptor-regulated Smads (R-Smads) 
including Smad 1/5/9, inhibitory Smads (I-Smads) such as Smad 6/7 and common 
mediator Smad (Co-Smad) like Smad4 (Heldin et al., 1997). Activation of the TGF--β type 
1 receptor phosphorylates R-Smads, which then form heteromeric complexes with Co-
Smads. These complexes then translocate to the nucleus of the cell, where they can 
influence and regulate gene expression by binding to Smad-binding elements (SBE). The 
inhibitors of DNA binding (Id) are among the key genes that the Smad complex influence. 
The Id proteins (1-4) inhibit DNA binding ability by blocking the action of the basic helix 
loop helix (BHLH) transcription factors. BHLH bind to promotor E boxes to form a 
heterodimer allowing the cell to progress to a proliferative state. Id proteins bind to E 
proteins to prevent their interaction with BHLHs thereby preventing proliferation of the cell 
(Russell et al., 2008). Id2, 3 and Id4 have a cyclin-dependent kinase 2 (CDK2) 
phosphorylation site that Id1 does not (Deed et al., 1997). Id4 is expressed at a much 
lower level in the vascular wall than Id1, Id2 and Id3 (Yang et al., 2014). BMP-4 and BMP-
6 have been implicated in increasing expression of both Id1 and Id3 in PASMCs and 
different animal models of PH. (Yang et al., 2013b, Yang et al., 2013a, Yang et al., 2011). 
Smad signalling can be regulated via SMAD ubiquitination and regulatory factors 
(SMURF1/2) which can supress SMAD activity (Zhang et al., 2001a). 
Despite known association between BMPR-II mutations and PAH, the overarching 
mechanisms that lead to the development of the disease are not completely understood. 
Although the BMPR-II mutations are ubiquitous, the pulmonary vasculature appears to be 
the most affected system in the body. The different cells in the pulmonary vasculature have 
divergent responses to BMPR-II mutations. PAECs with BMPR-II mutations have been 
shown to lose mitochondrial function and undergo apoptosis (Diebold et al., 2015). BMPR-
II also supresses leukocyte transmigration by maintaining the PAEC barrier function in the 
vasculature (Burton et al., 2011). Interestingly, BMPR-II loss of function mutations lead to 
increased release of growth factors, which increase proliferation of PASMCs (Jen et al., 
1996). HPAH patients with reduced BMPR-II expression in PAEC and PASMCs also 
demonstrate reduced Smad signalling (Atkinson et al., 2002, Yang et al., 2005). BMPR-II 
mutant PASMCs with reduced Smad dependant signalling have been shown to have an 
increase in Smad-independent signalling through the pro-proliferative extracellular signal 
regulated kinases (ERK1/2) (Yang et al., 2008). The reductions in BMPR-II signalling have 
also been demonstrated in the hypoxic, MCT and sugen hypoxic (SU-Hx) models of PH 
(Takahashi et al., 2006, Takahashi et al., 2007, Long et al., 2009, Mair et al., 2014). The 
expression levels of BMPR-II, SMAD1, Id1 and Id3 were found to be lower in female control 
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hPASMCs compared to male control hPASMCs, suggesting the influence of sex on BMPR-
II signalling (Mair et al., 2015). In a heterozygous BMPR-II+/- mouse model of PH, the 
addition of a second insult, serotonin, led to a more severe PH phenotype compared to 
their wildtype littermates (Long et al., 2006). The ability to reverse or mitigate reductions 
in BMPR-II signalling in PAH is now a focus of novel therapeutic strategies. Therapeutic 
agents, like iloprost and treprostinil can target specific aspects of the BMPR-II signalling 
pathway have been identified (Yang et al., 2010, Yang et al., 2013b). These therapies 
focus on increasing Smad dependent signalling leading to increases in the Id proteins 
expression.
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Figure 1-5 BMPR-II activation and downstream signalling  
BMPR-II is co-expressed with a TGF-β type 1 receptor (BMPR-I). Upon BMP binding BMPR-II forms heterodimer complex with BMPR-I, which then stimulates 
phosphorylation of Smad 1/5/9. Smad 1/5/9 forms a complex with Smad4 that then translocates to the nucleus where it can regulate gene transcription (primarily the Id 
genes). Activation of Id gene leads to an inhibition of cellular proliferation. Dysfunctional BMPR-II signalling can lead to greater activation of the MAPK pathway and therefore 
lead to cellular proliferation. SMAD= Sma and MAD (mothers against decapentaplegic), Id= inhibitor of DNA binding, MAPK= mitogen activated protein kinase, ERK= 
extracellular signal-regulated kinases. Adapted from (Clapp and Gurung, 2015).
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1.3.2. ALK-1 mutations 
ALK-1 is a similar serine-threonine receptor to BMPR-II and is a member of the TGF-β 
superfamily. ALK-1 mutations were found to be associated with HPAH patients and with 
hemorrhagic telangiectasia type 2 (HHT) (Harrison et al., 2003). These mutations were 
identified as missense, which led to a loss of receptor function. The detrimental impact of 
dysfunctional ALK-1 and BMPR-II signalling demonstrate the importance of a functional 
TGF-β signalling pathway in the pulmonary vasculature. PAH patients with ALK-1 
mutations have been identified as having less severe haemodynamics but an overall worse 
prognosis than other PAH patients (Girerd et al., 2010a, Girerd et al., 2010b).  
1.3.3. KCNK3 mutations 
The gene KCNK3 encodes for the potassium channel subfamily K member 3, through 
whole exome sequencing this has been identified as an important gene in the development 
of PAH (Girerd et al., 2014). KCNK3, also known as TASK-1 (TWK-related acid sensitive 
potassium channel) is identified by its two pore domains per subunit and its ability to control 
K+ efflux (Reyes et al., 1998).  The main roles of the KCNK3 is to control cellular resting 
membrane potential and to contribute to the relaxation of vessels (Patel et al., 1999). The 
mutation variant identified involved a loss of channel gate function, this would negatively 
impact ability of the KCNK3 to control K+ flow (Ma et al., 2013). KCNK3 expression was 
recently identified as downregulated in both IPAH and HPAH patients as well as in the 
MCT rat model of PH (Antigny et al., 2016). ET-1 has also been implicated in inhibiting 
KCNK3 through ETA and ETB receptors via Rho kinase in hPASMCs (Tang et al., 2009, 
Seyler et al., 2012). Also, hypoxia can downregulate KCNK3 in hPASMC (Olschewski et 
al., 2006b). The phospholipase A2 inhibitor ONO-RS-082 reversed MCT supressed 
expression of KCNK3 (Antigny et al., 2016). The prostacyclin analogue treprostinil 
activates KCNK3 via protein kinase A (PKA) dependent phosphorylation in hPASMCs 
(Olschewski et al., 2006a). An increasing understanding of the impact of KCNK3 mutations 
may lead to greater targeting by therapeutic intervention. 
1.3.4. Serotonin transporter 
Serotonin (5-hydroxytryptamine, 5-HT) was initially described and isolated from serum 
(Rapport et al., 1948). Serotonin can exert its effects through 14 distinct G protein coupled 
5-HT receptors, subdivided into seven classes according the structure and downstream 
signalling mechanisms (5HT1-7) (Alexander et al., 2007). The 5-HT1B receptor has been 
implicated in both cerebral and pulmonary vasoconstriction, it has also been shown to be 
upregulated in experimental PAH (van den Broek et al., 2002, Morecroft et al., 1999, 
Rondelet et al., 2003). The 5-HT1B was found to regulate calcium binding protein 
S100A4/Mts1 (MTS1) induced proliferation in cooperation with the serotonin transporter 
(SERT) (Lawrie et al., 2005). Increased 5-HT1B expression in female PAH hPASMCs 
contributes to 5-HT-induced proliferation and the pathobiology of PAH, this has been linked 
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to reduced expression of microRNA-96 (Wallace et al., 2015). The SERT is encoded by a 
single gene on chromosome 17q11.2 and is expressed in blood platelets, neurones, 
PAECs and PASMCs (Lesch et al., 1993, Ramamoorthy et al., 1993). SERT is sodium 
dependent transporter, which is like other Sodium/chloride (Na+/Cl-) transporters. Na+ 
binds to SERT followed by 5-HT and Cl-, this creates a conformational change which 
allows the release of 5-HT into the cell. To restore the original confirmation of SERT a K+ 
ion is released. Interestingly, SERT expression is higher in human lung tissue than in the 
brain (Ramamoorthy et al., 1993). In a small cohort of PAH patient, 65% presented 
homozygous for the LL allele SERT polymorphism compared to 8% and 27% for the SS 
and LS polymorphisms respectively. The LL allele corresponded with an increase in 
hPASMC proliferative response to 5-HT and serum suggesting a role for SERT in the 
pathological process of PAH (Eddahibi et al., 2001). However, latterly the LL allele 
polymorphism was found not to influence PAH survival. However, the LL polymorphism 
did occur at earlier age in HPAH patients possibly suggesting a link between SERT+ and 
BMPR-II mutations (Willers et al., 2006). Female mice overexpressing the human SERT 
(SERT+) leads to the development of severe PAH without additional insult (MacLean et 
al., 2004). Specific overexpression of SERT in the PASMCs of mice causes the 
development of PAH whereas mice with the SERT gene knocked out do not develop 
hypoxic induced PAH (Guignabert et al., 2006, Eddahibi et al., 2000).  
1.4. Animal models of pulmonary hypertension 
To gain a greater understanding of PAH, different models of the disease have been 
examined in animals. However, there are disputes as to whether animal models of PH 
accurately represent the human disease. 
1.4.1. Hypoxic induced pulmonary hypertension 
The chronic hypoxic model of PH can be used in a variety of animals, hypoxic conditions 
can be stimulated either via normobaric hypoxia or hypobaric hypoxia. Under hypoxic 
conditions muscularisation of small arteries occur, this is evidenced by the increase in α-
smooth muscle actin (Stenmark et al., 2009). Indeed, early research into hypoxic induced 
PH in specific sets of animals linked the level of intrinsic vascular smooth muscle to 
severity of disease (Tucker et al., 1975). The ease of inducing hypoxic PH and the 
reproducibility of results led to popularity of this model of PH (Stenmark et al., 2009). Many 
types of cells involved in the vascular wall structure; endothelial cell, smooth muscle cells 
and fibroblasts all undergo changes that range from proliferation to changing expression 
of cytokines and receptors (Stenmark et al., 2006b). Additionally, hypoxia induces an 
inflammatory response within the artery which influences structural remodelling and 
vasoconstriction (Stenmark et al., 2006b). A stronger PH phenotype was found in hypoxic 
rats rather than hypoxic mice, with less vascular remodelling in mice (Hoshikawa et al., 
2003). This believe to be due to changes in gene expression, in rats hypoxia induces 
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genes that promote; repression of endothelial cell apoptosis and endothelial cell 
proliferation (Hoshikawa et al., 2003). However, despite the simplicity of the chronic 
hypoxic model of PH, it does not fully represent the damage to the pulmonary vasculature 
observed in human PAH (Voelkel and Tuder, 2000, Campian et al., 2006).  
1.4.2. Monocrotaline induced pulmonary hypertension 
Monocrotaline (MCT) is a toxic pyrrolizidine alkaloid which exist within the plant Crotalaria 
spectabilis. Initial experimentation involving MCT required the oral administration of 
crotalaria spectabilis seeds to rats after-which they developed PH (Kay et al., 1967). More 
recently MCT is given as a single injection to rats to stimulate PH symptoms (Ghodsi and 
Will, 1981). MCT is metabolised in the liver to monocrotaline pyrrole (MCTP) via the action 
of cytochrome enzyme (CYP) 3A4  (Kasahara et al., 1997, Reid et al., 1998). The severity 
of MCT-induced PH is thought to originate from extensive endothelial cell damage, 
however other studies has demonstrated that a build-up  of inflammatory cells in the 
adventitia of the small pulmonary arteries leads to increase in pulmonary pressure and 
vascular remodelling (Wilson et al., 1989). Interestingly, MCT can be combined with a 
pneumonectomy, this led to the formation of neointimal lesions and severe right ventricular 
hypertrophy (Okada et al., 1997). Unlike human PAH, the MCT PH model does not form 
obstructive intimal lesions in the pulmonary arteries. MCT induced PH has been shown to 
be improved by many different therapeutic agents,  which is also different to how human 
PAH responds to therapy (Stenmark et al., 2009). 
1.4.3. Sugen-5419-Hypoxic model 
To create an animal model of PH that closely resembled human PAH, a study which 
compared rats under normoxic and hypoxic conditions dosed with the vascular endothelial 
growth factor (VEGF) inhibitor Sugen 5416 (SU-5416) (Taraseviciene-Stewart et al., 
2001). Under normoxic conditions SU-5416 dosing led to mild PH symptoms, however in 
rats with SU-5416 combined with hypoxia developed a severe and irreversible PH, which 
was not reversible after removal from hypoxic conditions (Taraseviciene-Stewart et al., 
2001). SU-5416 triggered endothelial apoptosis however under hypoxic conditions this led 
to increased endothelial cell proliferation, this was also accompanied by higher smooth 
muscle cell proliferation (Taraseviciene-Stewart et al., 2001). A comparison of changes in 
gene expression was made between lungs of human PAH patients and those from a SU-
5416 under hypoxic conditions (SU-Hx). Interestingly, only four genes were found to be 
common between both (Moreno-Vinasco et al., 2008). 
1.5. Established therapeutic strategies 
Since the original identification of PAH, therapies have been developed to combat the 
progressive disease. Unfortunately, the multifactorial nature of PAH has hampered this 
development. Since many of the underlying molecular mechanisms in PAH are still being 
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clarified, specific therapeutic strategies are difficult to plan. This is further complicated by 
a lack of symptomatic manifestation of PAH until the disease is well progressed. Current 
therapies target pathways and molecular mechanisms identified 10-20 years ago. Despite 
this, patients currently treated have demonstrated better response to drug therapy. This is 
observed in the reduction in the 5-year mortality rate observed in the NIH registry in 1980s 
from 66% to 40% in the UK and Ireland registry from 2012 (Rich et al., 1987, Ling et al., 
2012). Current therapeutic strategies for PAH revolve around targeting the increase PVR 
and PAP associated with increased proliferation and vasoconstriction in the pulmonary 
vasculature. PGI2 analogues and endothelin receptor antagonists have been developed to 
target the divergent levels of PGI2 and ET-1 found in PAH patients. As PAH remains an 
incurable disease, much greater strides should be made for therapeutic strategies to have 
serious impact on patient clinical outcomes. 
1.5.1. G-protein coupled receptors 
1.5.1.1 G-protein coupled receptors classification and signalling 
G protein coupled receptors (GPCRs) are a useful target for therapeutic intervention, 
GPCRs are the largest superfamily of receptors and are expressed in many tissues 
(Lagerstrom and Schioth, 2008). It is thought about 30% of marketed therapeutics target 
GPCRs, however this only accounts for 10% of the available GPCRs suggesting many 
more targets to be identified (Vassilatis et al., 2003). GPCRs help regulate downstream 
cellular machinery like metabolic enzymes, ion channels, transcriptions, motility, 
contractility and secretion (Neves et al., 2002). GPCRs are subdivided into 6 classes 
based upon sequence homology and functional similarity, these are: Class A (Rhodpsin-
like receptors) (Attwood and Findlay, 1994), Class B (Secretin receptor family) (Harmar, 
2001), Class C (Metabotrophic glutamate receptor) (Hans et al., 2007), Class D (Fungal 
mating pheromone receptors) (Marsh and Herskowitz, 1988), Class E (Cyclic AMP 
receptors) (Klein et al., 1988) and Class F (Frizzled/Smoothened) (Malbon, 2004). 
Transmembrane nature of GPCRs made it difficult to understand structure, until the 
structure of rhodopsin was elucidated (Palczewski et al., 2000). Latterly β1 and β2 
adrenergic structures identified via new crystallization techniques (Cherezov et al., 2007, 
Warne et al., 2008). Classical GPCR are thought to exist in either an active or inactive 
state. In the active state the receptor has a high affinity of G-proteins, which form a 
heterotrimer of GDP bound Gαβγ when inactive. GPCR activation leads to the G-protein 
binding to the C-terminus of the receptor facilitating GDP to GTP exchange followed by 
detachment of the Gα and Gβγ subunits, which activated their respective downstream 
mediators like adenylyl cyclase or phospholipase C (PLC) (Figure 1-6) (Bridges and 
Lindsley, 2008). 
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Figure 1-6 Schematic of G-protein coupled receptor signalling 
After agonist binding to extracellular or transmembrane region of receptor, the receptor facilitates the exchange of GDP for GTP on the Gα subunit. The Gβγ subunit 
dissociates, which then can regulate ion channels. The activated Gα subunit has many subtypes including; Gαs, Gα12/13, Gαq and Gαi. These can activate different effectors like 
adenylyl cyclase, RhoGEF and phospholipase C. Activation of the Gαi subunit leads to the inhibition of adenylyl cyclase activity. GTP= Guanosine-5'-triphosphate, PKA/PKC= 
protein kinase A/C, PLC= phospholipase C, DAG= diacylglycerol, Ins(1,4,5)P= inositol 1,4,5 triphosphate, EPAC=, exchange factor directly activated by cAMP 1, Adapted 
from  (Ritter and Hall, 2009).
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1.5.1.2 Regulation of GPCRs 
A key aspect of GPCR signalling is the regulation of the receptors, this includes modulators 
that can increase GPCR signalling or those that reduce GPCR signalling. Homer proteins 
have been found to increase the signalling of β-adrenergic receptors through association 
with A-kinase anchoring protein (AKAP) thereby increasing receptor mediated ERK 
signalling (Fraser et al., 2000). Arrestins are well known modulators that can reduce the 
activity of GPCRs. Spinophilin interacts with the third intracellular loop of GPRCs like 
dopamine and adrenergic receptor families (Smith et al., 1999, Richman et al., 2001). 
Spinophilin is also know to interact with several regulators of G-protein signalling (RGS). 
Spinophilin can tether RGS proteins closely to GPCRs thereby inhibiting signalling (Wang 
et al., 2005b, Wang et al., 2007a). RGS can stimulate GTPase activity in Gα subunits 
(Neitzel and Hepler, 2006). RGS have also been postulated as targets for therapeutic 
intervention in cardiovascular disease (Cho et al., 2004). Another modulator of GPCR 
signalling is calmodulin, which is a calcium binding protein that is known to interact with 
several different GPCRs like serotonin receptors (Turner et al., 2004). Calmodulin can act 
as feedback inhibition to prevent specific GPCRs increasing intracellular Ca2+ levels 
(Turner et al., 2004, Turner and Raymond, 2005). Another important regulatory function in 
GPCRs is desensitisation, internalisation and either degradation or recycling of the 
receptor (Hanyaloglu and von Zastrow, 2008) (Figure 1-7). G-protein coupled receptor 
kinases (GRKs) and arrestins are key to receptor internalisation (Reiter and Lefkowitz, 
2006). Both groups can be subdivided with GRKs consisting of GRK1 and GRK7 which 
expressed to retinal rods and cones, this also applies to arrestin 1 and arrestin 4. These 
are contrasted by the other GRKs, which are expressed more widely along with arrestin 2 
and arrestin 3, these are also known as β-arrestin 1 and β-arrestin 2 (Pitcher et al., 1998, 
Shenoy and Lefkowitz, 2003). GRKs and β-arrestins act at three different stages to 
eventually internalise GPCRs, these stages include: homologous desensitisation in which 
the receptor is decoupled from its associated G-protein. The next stage is receptor 
internalisation, resensitisation and possibly degradation. The final stage is the inhibition of 
intracellular signalling pathways (Reiter and Lefkowitz, 2006). A more recent investigation 
in GPCRs signalling has identified the presence of biased agonists. These are agonists to 
GPCRs that selectively favour the activity of either G-protein or β-arrestin. A ‘balanced’ 
agonist can activate both G-protein downstream signalling pathways and can promote the 
recruitment of β-arrestins to the GPCR for desensitisation (Rankovic et al., 2016). Over 
the last few years biased ligands have been identified for many receptors including the 
ligand Sar1 favouring β-arrestin activation of angiotensin type 1 receptor (Aplin et al., 
2007). The prostaglandin receptor EP4 has also been identified has having multiple biased 
agonists that activate either G-protein or β-arrestin (Leduc et al., 2009). 
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Figure 1-7 G-protein coupled receptor internalised by the action of G-protein coupled receptor kinases and β-arrestin 
G-protein signalling can be desensitised via receptor phosphorylation by G-protein coupled receptor kinases and recruitment of β-arrestin. These interact with clathrin and 
the clathrin adaptor AP2, which assists in internalisation of the receptor into endosomes. Internalisation can lead to production of arrestin mediated signalling pathways, the 
receptor could also be degraded in a lysosome or recycled back to the cell surface in an endosome thereby undergoing resensitisation. GRK= G-protein coupled receptor 
kinases, GTP= Guanosine-5'-triphosphate, AP2= Clathrin adaptor AP2. Adapted from  (Ritter and Hall, 2009).
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1.5.2. Calcium channel blockers 
Vasoconstriction of PASMCs is primarily influenced by the accessibility of intracellular 
calcium. An increased influx of calcium (Ca2+) into PASMCs will eventually increase the 
PVR. The ability to block calcium flow into PASMCs presents an opportunity to promote 
vasodilation, thereby reduce PVR. The impact of Ca2+ blocker therapy on PAH is quite 
limited. Ca2+ blocker therapy is only recommended in patients who respond to a 
vasodilatory test, with approximately 5-10% of patients responding positively.  
1.5.3. Endothelin receptors and antagonists 
Endothelin-1 (ET-1) is a potent vasoconstrictor that can regulate vascular tone through 
both the ETA and ETB receptors. The endothelin receptors are G-protein coupled receptors 
that belong to the rhodopsin-type receptor superfamily. The ETA receptor is found on 
vascular smooth muscle cells whereas the ETB receptor is located on both endothelial and 
smooth muscle cells (Seo et al., 1994). Upon ET-1 binding both receptors activate 
phospholipase C (PLC), this leads to an increase in inositol triphosphate, diacylglycerol 
and intracellular Ca2+ (Pollock et al., 1995). These increases lead to increased protein 
kinase C (PKC) activity therefore leading to greater vasoconstriction of the cell (Ohlstein 
et al., 1992). The activation of endothelial ETB receptors leads to increased release of both 
NO and PGI2 (Hirata et al., 1993). ETB receptor activation was also implicated in increased 
prevention in apoptosis as well as a reduction in endothelin converting enzyme-1 (ECE-1) 
(Shichiri et al., 1997, Clozel et al., 1993). In healthy adults, the plasma levels of ET-1 are 
low (1-2pg/ml), this suggests that ET-1 is not a circulating hormone. However, ET-1 does 
play role in maintaining basal blood pressure and vasomotor tone (Haynes et al., 1996). 
Across a range of PH patients; including IPAH, COPD and CTEPH, ET-1 circulating and 
local lung levels are increased (Behr and Ryu, 2008, Bauer et al., 2002, Giaid et al., 1993). 
The increase in ET-1 levels in PAH is associated with right atrial pressure, pulmonary 
artery oxygen saturation and PVR (Cacoub et al., 1993, Cacoub et al., 1997, Nootens et 
al., 1995). In isolated PASMC and PAEC, ET-1 can cause vasoconstriction and 
proliferation via both ET receptors, this can lead to structural changes in the pulmonary 
vasculature leading to vessel remodelling (MacLean et al., 1994, Davie et al., 2002).  
The endothelin system can be modulated by either reducing the level of ECE-1 or by 
antagonism of the ET receptors. By targeting ECE-1 the levels of ET-1 can be reduced, 
however several other pathways can influence the creation of ET-1 therefore targeting this 
enzyme would not be the ideal therapeutic strategy (Takahashi et al., 1998). Antagonism 
of both ET receptors may be the most effective method of treating the overactive 
endothelin system in PAH patients. In clinical studies, treatment of PAH patient with the 
dual ET receptor antagonist (ERA) bosentan leads to patients showing improvements in 
right atrial pressure, mean PAP, cardiac index, PVR, NYHA functional class and clinical 
worsening also improved with ET antagonist treatment (Sitbon et al., 2003). Dual 
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endothelin receptor antagonism reduces PAP and right ventricular hypertrophy (RVH) in a 
chronic hypoxic rat model of PAH, it also reverses ET-1 induced proliferation in hPASMCs 
(Davie et al., 2002). Bosentan and Macitentan are both dual ET receptor antagonists 
approved for use to treat human PAH and are both identified as improving clinical 
outcomes (Rubin et al., 2002, Pulido et al., 2013). As the ETB receptor is involved in ET-1 
clearance and can stimulate the release of nitric oxide and PGI2, selective antagonism of 
the ETA receptor may be preferable than dual antagonism. Ambrisentan and sitaxsentan 
are potent ETA receptor antagonists, however sitaxsentan was withdrawn from clinical use 
due to hepatic toxicity. Ambrisentan was developed to counter the associated side effects 
of bosentan therapy, which include elevations of serum aminotransferase that could lead 
to liver toxicity (Molina Fernández-Posse et al., 2014). Clinical trials with Ambrisentan 
demonstrated lower incidences of liver toxicity and lower levels of aminotransferases 
(McGoon et al., 2009). The influence of sex on ERAs has been explored by Gabler and 
colleagues, it was demonstrated that women have greater improvements in 6-minute walk 
distances (6MWD) than men (Gabler et al., 2012). This suggests that targeting PAH 
therapies to sex could improve therapeutic outcomes. 
1.5.4. Phosphodiesterase inhibitors 
NO is an important regulator of vascular tone in the pulmonary circulation. As stated 
previously, NO is produced locally in endothelial cells from the conversion of L-arginine by 
endothelial nitric oxide synthase (eNOS) (Palmer et al., 1988, Stamler et al., 1994). NO 
stimulates soluble guanylyl cyclase (sGC), which increases the conversion of guanosine 
5’ triphosphate to cyclic guanosine monophosphate (cGMP). The increased levels of 
cGMP lead to the activation of cGMP-dependent protein kinase (PKG) in PASMCs, which 
can contribute to vasodilation (Michelakis, 2003). The excessive vasoconstriction in PAH 
patient pulmonary arteries was linked to reduced expression levels of eNOS (Giaid and 
Saleh, 1995). Phosphodiesterases (PDEs) are a group of enzymes (PDE1-11) that 
inactivate both cyclic adenosine monophosphate (cAMP) and/or cGMP, PDE5 is known to 
degrade cGMP in the lung but also in the pulmonary arteries (Rybalkin et al., 2003, Rabe 
et al., 1994, Pauvert et al., 2002). PDE5 expression is increased in PAH patient lungs and 
in the right ventricle of the heart (Corbin et al., 2005, Nagendran et al., 2007). Both chronic 
hypoxic and MCT rodent models of PH also have elevated PDE5 expression (Murray et 
al., 2002, Schermuly et al., 2004). High expression of PDE5 in PAH led to the development 
of inhibitors of PDE5s actions, these inhibitors prevent the hydrolysis of cGMP. PDE5 
inhibitor therapies currently used to treat PAH include; sildenafil, vardenafil and tadalafil, 
all inhibitors demonstrated improved clinical outcomes in placebo-controlled 
experiments.(Galiè  et al., 2005, Jing et al., 2011, Galie et al., 2009a). Interestingly, clinical 
worsening did not improve with sildenafil or vardenafil, however tadalafil improved the 
incidence of clinical worsening (Galie et al., 2009a). Sex may influence the effectiveness 
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of PDE5 inhibitors. Male patients demonstrated greater achievement of a minimal 
important difference (MID) in the 6MWD compared to females (Mathai et al., 2009). 
1.5.5. Soluble guanylyl cyclase stimulators 
An alternative to targeting the increase levels of PDE5 in PAH patients is to increase the 
activation of soluble guanylyl cyclase (sGC) independently of NO, this can be achieved by 
direct drug stimulation of sGC. Both BAY 41-2272 and BAY 41-8543 were early sGC 
stimulators that reduced pulmonary vascular remodelling, right ventricular systolic 
pressure and right ventricle hypertrophy in both chronic hypoxic mouse and MCT rat 
models of PH (Dumitrascu et al., 2006, Schermuly et al., 2008). BAY 41-2272 and 41-8543 
have poor drug metabolism and high clearance rate therefore riociguat (BAY 63-2521) was 
developed to counteract these problems (Mittendorf et al., 2009). Riociguat is the first sGC 
drug available for clinical use to treat PAH, clinical trials have demonstrated its 
effectiveness at reducing PVR, improving disease functional class, time to clinical 
worsening and increased 6MWD (Ghofrani et al., 2013, Rubin et al., 2015). 
1.5.6. Prostaglandin receptors 
Prostanoids are a subclass of eicosanoids derived from arachidonic acid that consist of 
both thromboxanes and prostaglandins (Bos et al., 2004). Classification of prostanoids is 
determined by the presence of a cyclopentane (prostaglandin) or cyclohexane 
(thromboxane) ring. Arachidonic acid is metabolised by cyclooxygenase 1 or 2 (COX1/2) 
to prostaglandin H2 (PGH2), which is the forerunner to the prostaglandins. The action of 
individual prostaglandin synthase enzymes determines the creation of each specific 
prostaglandin (Figure 1-8). Thromboxane synthase (TxAS), prostaglandin D synthase 
(PGDS), prostaglandin E synthase (PGES), prostaglandin I synthase (PGIS), and 
prostaglandin F synthase (PGFS) synthesise the creation of thromboxane (TXA2), 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin I2/prostacyclin (PGI2) 
and prostaglandin F2α (PGF2α) respectively (Hata and Breyer, 2004). There are nine 
identified prostanoid receptors that exist on different cell types; thromboxane receptor 
(TP), prostaglandin D2 receptors 1 and 2 (DP1-2), prostaglandin E2 receptors 1-4 (EP1-4), 
prostacyclin receptor (IP) and the prostaglandin F receptor (FP) (Hata and Breyer, 2004). 
Prostanoid receptors are seven-transmembrane G-protein coupled receptors (GPCR), 
they can be sub-divided into different groups depending on the type of G-protein activated 
therefore the cell response generated. The IP, EP2, EP4 and DP receptors all associated 
with the G-protein Gs, this stimulates cAMP production by adenylyl cyclase leading to 
vasorelaxation in cells via PKA activation. The TP, EP1 and FP receptors activate the G-
protein Gq, which increases intracellular Ca2+ levels by altering phosphatidylinositol 
production thereby leading to vasoconstriction of cells (Figure 1-9). TXA2 has many actions 
on the cardiovascular systems ranging from altering platelet aggregation, contributing to 
heart failure and vasoconstriction and proliferation of smooth muscle cells (Oates et al., 
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1988, Castellani et al., 1997, Devillier and Bessard, 1997). The TP receptor can dimerise 
with the IP receptor to increase the production of cAMP (Wilson et al., 2004). As discussed 
previously, TXA2 levels are elevated in urine samples from PAH patients whereas PGI2 
levels are reduced (Christman et al., 1992). PGI2 is produced by endothelial cells and can 
reduce smooth muscle proliferation and migration (Moncada et al., 1976, Moncada and 
Vane, 1978, Clapp et al., 2002). In IPAH patient hPASMCs, IP receptor expression was 
found to be lower in comparison to control hPASMCs (Lai et al., 2008, Falcetti et al., 2010). 
PGE2 can cause both vasodilation and vasoconstriction due to the different consequences 
of EP1-4 receptor activation (Hata and Breyer, 2004). PGD2 has been implicated in airway 
remodelling and bronchoconstriction, it also primarily associated with type 1 allergic 
response upon release from mast cells (Hata and Breyer, 2004, Lewis et al., 1982). PGF2α 
has
 
been linked to encouraging cardiac hypertrophy in cardiac ventricular myocytes (Lai 
et al., 1996). Interestingly, both PGF2α and PGE2 can activate FP receptors (Abramovitz 
et al., 2000). As previously discussed prostaglandin receptors can be subdivided into two 
groups; relaxant receptors and contractile receptors depending on what G-protein they 
associate with (Alfranca et al., 2006). In pulmonary arteries, it was initially thought that the 
IP receptor was the only relaxant receptor expressed (Walch et al., 1999, Norel, 2007). 
However, more recently both EP2 and EP4 receptors have been confirmed in both proximal 
and distal pulmonary arteries in control and MCT rats (Lai et al., 2008). Both EP2 and EP4 
have also been shown to play a role in blocking proliferation of hPASMCs (Jigisha et al., 
2015, Lai et al., 2008). IP receptor expression has been found to be reduced in IPAH 
patients compared to non-PAH patients, however EP4 receptor expression was shown to 
remain stable in IPAH patients (Falcetti et al., 2010, Lai et al., 2008). The importance of 
the IP receptor to pulmonary artery homeostasis was highlighted by IP receptor knock-out 
mice (IP-KO). Hoshikawa and colleagues subjected IP-KO and wild type mice to high 
altitude (17,000 feet) for 3 weeks after-which IP-KO mice presented with a much greater 
pulmonary hypertensive phenotype (Hoshikawa et al., 2001). Both the TP and EP3 
receptors have been implicated in vasoconstriction in pulmonary arteries (Walch et al., 
1999, Norel, 2007). Blockade of the TP receptor was found to attenuate protamine-heparin 
induced pulmonary hypertension in sheep (Montalescot et al., 1990). EP3 expression 
would found to be elevated compared to controls in hPASMCs and pulmonary arteries 
exposed to hypoxia (Lu et al., 2015). Also, the study discovered that removing the EP3 in 
smooth muscle cells prevented increased pulmonary artery medial thickness (Lu et al., 
2015). 
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Figure 1-8 Prostaglandin biosynthesis from arachidonic acid 
COX 1 and/or 2 metabolise arachidonic acid to the unstable prostaglandin H2. Individual prostaglandin synthase enzyme act on prostaglandin H2 to create the five primary 
distinct prostaglandins. TXAS, PGDS, PGES, PGIS and PGFS respectively generate thromboxane A2, prostaglandin D2, E2, I2 and F2α. COX1/2= cyclooxygenase 1/ 2 
TXAS= thromboxane A synthase, PGDS= prostaglandin D synthase, PGES= prostaglandin E synthase, PGIS= prostaglandin I synthase and PGFS= prostaglandin F 
synthase. Adapted from (Mubarak, 2010). 
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1.5.6.1 Cyclic AMP signalling 
Cyclic AMP (cAMP) is a key intracellular second mediator that is produced after specific 
GPCRs are activated. Adenylyl cyclase (AC) catalyses the conversion of adenosine 
triphosphate to cAMP, which can then act on several downstream effectors (Tasken and 
Aandahl, 2004). The three main targets of cAMP are protein kinase A (PKA), exchange 
factor directly activated by cAMP 1 (EPAC) and cyclic nucleotide gated ion channels (Fimia 
and Sassone-Corsi, 2001). PKA is constructed from a regulatory subunit dimer and two 
catalytic subunits, which together form an inactive complex known as a holoenzyme. A-
kinase anchoring proteins (AKAPs) act as scaffolding proteins, which anchor the PKA 
holoenzyme and can help target the PKA to specific cellular locations (Wong and Scott, 
2004). Four cAMP molecules bind to two distinct binding sites on the regulatory subunit, 
this releases the catalytic subunits. PKA directly phosphorylates cAMP responsive 
element binding protein (CREB), phosphorylating CREB at serine residue 133 (Gonzalez 
and Montminy, 1989). Phosphorylation at serine 133 leads to the recruitment of CREB 
binding protein (CBP) (Chrivia et al., 1993). CREB mediates the actions of cAMP 
responsive genes by interacting with conserved cAMP response elements (CRE) 
(Montminy et al., 1986). Gene transcription mediate by cAMP peaks approximately 30 
minutes, however CREB activity continues for several hours and is dependent upon the 
dephosphorylation at the serine residue 133 by the serine/phosphatase PP-1 (Hagiwara 
et al., 1992). PKA can also phosphorylate adenylyl cyclase suggesting PKA functions as 
a feedback mechanism to prevent prolonged levels of cAMP (Iwami et al., 1995, Chen et 
al., 1997). The relationship between cAMP and EPAC was discovered after inhibition of 
PKA did not prevent the activation of the small GTPase Rap1 (de Rooij et al., 1998). 
Interestingly, EPAC contains a cAMP binding domain like that found on the PKA regulatory 
subunits. EPAC and PKA have been demonstrated as having differential actions in PC12 
cells, specific cAMP mediated PKA activation led to cell proliferation via ERK1/2 activation. 
EPAC extended the period of PKA dependent ERK1/2 activation, however it promotes 
anti-proliferation of the PC12 cells (Kiermayer et al., 2005). Activation of EPAC is 
implicated in inducement of cell adhesion in ovarian tumour cell lines as well activation of 
protein kinase B (Rangarajan et al., 2003, Mei et al., 2002). 
In pulmonary arteries mechanisms that elevate cAMP levels are crucial to maintain a 
relaxed state. Indeed, both cAMP and cGMP analogues have been shown to elicit smooth 
muscle cell vasodilation (Sakai and Voelkel, 1988, Francis et al., 1988). Forskolin, which 
is stimulator of AC and a cAMP analogue were shown to open the large-conductance, 
calcium- and voltage-activated potassium channel (BKCa) in PASMCs isolated from rats to 
induce vasodilation (Barman et al., 2003). In two studies β-adrenergic receptor mediation 
of cAMP led to the greatest relaxation, however the relaxations mediated by cAMP via the 
adenosine A2 receptor and the EP2 receptor closely matched that of the β-adrenergic 
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receptor (Fullerton et al., 1994, Fullerton et al., 1996). The overall effectiveness of cAMP 
in the pulmonary artery is strongly influenced by the action of PDEs. In IPAH patients the 
expression of several PDE isoforms was found to be increase, however PDE1C 
demonstrated the greatest impact on lowering cAMP levels and by association the 
increased proliferation of hPASMCs (Murray et al., 2007). Chronic hypoxic rats have 
shown to have decrease cAMP levels compared to their normoxic controls. (MacLean et 
al., 1996) The vasodilatory effects of cAMP on the pulmonary artery is a major reason why 
PDEs and cAMP elevating agents like prostaglandin analogues are used to treat PAH. 
1.5.7. Prostaglandin analogues 
1.5.7.1 Epoprostenol 
Epoprostenol was the first PGI2 therapy approved for the treatment of PAH (Chin and 
Rubin, 2008). However, it must be administered via continuous intravenous infusion due 
to its instability at a pH less than 10.5 and its very short half-life of 3-5 minutes (Vane and 
Corin, 2003). Despite its instability, epoprostenol therapy has been effective at improving 
exercise capacity, decreases in mean PAP and PVR in PAH patient vs control patients 
(Barst et al., 1996). A side effect common to epoprostenol treatment is the development 
of sepsis usually related to the method of drug administration (Barst et al., 1996, Humbert 
et al., 1999).  
1.5.7.2 Iloprost 
Iloprost is an alternative prostacyclin analogue used for the treatment of PAH. A major 
benefit of iloprost over epoprostenol is its stability at room temperature, the ability to vary 
the administration of the drug and its longer duration of vasodilation (Fitscha et al., 1987). 
The ability to inhale the drug allows for more direct treatment of the small peripheral 
pulmonary arteries (Olschewski et al., 2003). Both intravenous (IV) and inhaled forms of 
iloprost lead to significantly increased positive clinical outcomes in PAH patients. For 
inhaled iloprost this positive outcome was reached at a much lower dose than IV dosing 
(Olschewski  et al., 2002). Interestingly, a more sustained haemodynamic improvement 
was observed in intravenous dosing with epoprostenol although there are less side effects 
and associated therapy complications with inhaled iloprost (McLaughlin et al., 1998). As a 
prostacyclin analogue, iloprost is known to mediate its vasodilatory and anti-proliferative 
effects via the IP receptor. However, recently iloprost has been identified as an agonist for 
the Gs coupled EP4 receptor as well as the Gq coupled EP1 receptor (Lai et al., 2008, 
Whittle et al., 2012). This suggests that iloprost can cause both vasoconstriction and 
vasodilation by increasing calcium influx levels and increasing cAMP levels. Iloprost has 
been shown to mediate its anti-proliferative effects by the activation of BMPR-II signalling 
in both non-mutant and mutant PAH hPASMCs (Yang et al., 2010).  
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1.5.7.3 Beraprost 
Beraprost sodium was the first stable orally active prostacyclin analogue used in the 
treatment of PAH (Nishio and Kurumatani, 2001). In clinical studies, beraprost improved 
symptoms for NYHA class II and III PAH patients and increased exercise capacity as 
measured by 6WMD (Galie et al., 2002). However, the longer term clinical effectiveness 
of beraprost was questioned by Barst and colleagues. The clinical outcome improvements 
demonstrated after 3 months were not sustained at 9 or 12 months (Barst et al., 2003). 
Beraprost successfully prevented the development of PH in a MCT rat model primarily 
through anti-platelet aggregation and vasodilatory effects (Miyata et al., 1996). In isolated 
hPASMCs, beraprost reduced proliferation under normoxic and hypoxic conditions in a 
dose dependent manner through activation of cAMP (Kadowaki et al., 2007). 
1.5.7.4 Selexipag/MRE-269 
Common features of all prostacyclin analogue therapy are side effects associated with the 
vasodilation of the vasculature, these include flushing, headaches, nausea and jaw pain. 
This may be related to the variety of prostanoid receptors that specific prostaglandin 
analogues can activate. Selexipag/MRE-269 (active metabolite) is an orally active and 
highly selective IP receptor agonist that is not a prostacyclin analogue (Kuwano et al., 
2007). Both beraprost and iloprost can activate the EP3 receptor leading to 
vasoconstriction that can detrimentally effect their IP receptor mediated vasodilation in rat 
pulmonary arteries. Also, the vasorelaxation induced by Selexipag/MRE-269 was no 
different between control and MCT rats whereas the vasodilation by beraprost and iloprost 
were attenuated (Kuwano et al., 2008). This sustained vasorelaxation of rat arteries was 
also demonstrated when compared to reduced treprostinil induced vasorelaxation in MCT 
rat arteries or rat arteries pre-constricted with ET-1 or phenylephrine (Morrison et al., 
2012). In hPASMCs, MRE-269 reduces cellular proliferation through a IP receptor 
mediated increase in cAMP (Gatfield et al., 2014, Jigisha et al., 2015). A possible 
drawback of specific IP receptor targeting in PAH is the perceived reduction in the 
expression of the IP receptor in PAH patients (Falcetti et al., 2010). 
1.5.7.5 Treprostinil 
Treprostinil is a tricyclic benzindene analogue of PGI2 therefore like other PGI2 analogues 
it has similar vasodilatory and anti-platelet aggregation properties (Vachiery and Naeije, 
2004). One of the largest clinical trials conducted examined the effectiveness of a constant 
subcutaneous infusion of treprostinil. Like alternative prostacyclin analogues, treprostinil 
improved exercise capacity via the 6MWD and improved symptoms, signs and 
haemodynamics of PH (Simonneau et al., 2002). Infusion site pain is the most common 
side effect of subcutaneous treprostinil. Previously, beraprost was shown not to cause 
longer-term improvements on exercise capacity and haemodynamics (Barst et al., 2003); 
similar follow-up studies were conducted with subcutaneous treprostinil. The early clinical 
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improvements were sustained and survival rates were 87% after 1 year and 68% over 4 
years (Barst et al., 2006). As with inhaled iloprost therapy, inhaled treprostinil would reduce 
some of the associated side effects with prostacyclin analogue therapy, specifically 
infusion site pain. In smaller scale pilot studies, inhaled treprostinil produced a more 
sustained reduction on PVR and fewer systemic side effects than inhaled iloprost 
(Voswinckel et al., 2006). In symptomatic PAH patients on bosentan therapy, inhaled 
treprostinil significantly decreased mean PAP and PVR (Channick et al., 2006). In a larger 
clinical trial, PAH patients that were symptomatic on bosentan or sildenafil additional 
inhaled treprostinil therapy increased exercise capacity and quality of life measurements, 
however no improvements were detected in functional class or PAH signs and symptoms 
(McLaughlin et al., 2010). The development of an oral formulation of treprostinil has offered 
a potential advancement in the treatment of PAH. However, initial investigations 
demonstrated a lack of significantly positive clinical outcomes on patients with background 
therapies of ERAs and/or PDE5 inhibitors (Tapson et al., 2012, Tapson et al., 2013). 
Interestingly, oral treprostinil as a monotherapy was found to increase exercise capacity 
in NYHA functional class II or III PAH patients (Jing et al., 2013). A possible reason behind 
differences observed in therapeutic effectiveness of oral treprostinil has been the inability 
to identify a clinically effective dose (Chin et al., 2015). Treprostinil has been shown to 
partially reverse PH in different animal models; in chronic hypoxic mice treprostinil 
decreases RVSP, vascular remodelling and circulating fibrocytes (Nikam et al., 2010). 
Treprostinil also improved in pulmonary haemodynamics in the MCT rat model of PH 
(Yang et al., 2010). In initial studies in isolated hPASMCs, treprostinil induced greater 
increases in cAMP generation compared to alternative prostacyclin analogues; cAMP 
contributes to anti-proliferation mediated by treprostinil (Clapp et al., 2002). As a 
prostacyclin analogue, treprostinil was known to activate the IP receptor to mediate 
vasodilation and reduce proliferation. However, when the IP receptor was found to be 
downregulated in IPAH patients, the anti-proliferative effects of treprostinil were mediated 
through PPAR-γ (Falcetti et al., 2010). More recently treprostinil was found to only 
significantly reduce proliferation in IPAH hPASMCs in combination with the PDE2 inhibitor 
BAY 60-7550, this was also observed when PH indices were examined in a chronic 
hypoxic mouse model of PH (Bubb et al., 2014). In a comparative study examining the 
vasodilatory properties of both iloprost and treprostinil, human pulmonary arteries were 
found to vasodilate more effectively to iloprost than treprostinil (Benyahia et al., 2013). 
Recently both the EP2 and DP1 and to a lesser extent the EP4 receptor have been 
confirmed as treprostinil targets (Table 1-3). As previously stated the EP2, DP1 and EP4 
receptors are all Gs protein coupled receptors that lead to cAMP generation therefore can 
contribute to vasodilation or anti-proliferation (Whittle et al., 2012). Unlike iloprost, 
treprostinil has a very low binding affinity for the vasoconstrictive EP1 receptor, this 
highlights a possible difference in the vasorelaxation potential of the two prostacyclin 
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analogues (Table 1-3). Activation of the EP2 receptors by treprostinil and subsequent 
increases in cAMP was also observed in alveolar macrophages isolated from rats (Aronoff 
et al., 2007). Treprostinil has been shown to activate KCNK3, which restores the K+ current 
and membrane potential in hPASMCs leading to vasodilation (Olschewski et al., 2006a). 
Research continues to be conducted into the mechanism of action of prostacyclin 
analogues and how they interact with other therapies. Interestingly, in hPASMCs, 
treprostinil mediated clearance of ET-1 was blocked by the addition of ERAs; this may 
have clinical relevance for those patients on similar combination therapies (Patel et al., 
2014). Treprostinil metabolism has been identified to occur in the liver through the 
cytochrome enzyme 28C (CYP2C8) and through CYP2C9. A CYP2C8 inducer (rifampin) 
decreased the blood levels of treprostinil by 30% whereas the addition of an inhibitor of 
CYP2C8 (gemifibrozil) led to a doubling of treprostinil blood concentration (Skoro-Sajer et 
al., 2008, Rollins et al., 2009, Kumar et al., 2016).  PAH patients that have hepatic 
dysfunction have reduced clearance of treprostinil by up 80% (Skoro-Sajer et al., 2008). 
In PAH patients with inoperable CTEPH, treprostinil treatment improved exercise capacity, 
haemodynamic and patient survival (Skoro-Sajer et al., 2007). These positive clinical 
outcomes were believed to due to the anti-proliferative, vasodilatory and anti-platelet 
aggregation effects (Skoro-Sajer et al., 2007).  For many years anti-coagulation has been 
a recommended therapy in IPAH patients, more recently the effectiveness of the therapy 
was examined in other PAH groups with no conclusive results (Olsson et al., 2013). The 
anti-platelet aggregation effects of treprostinil led to the investigation of combination 
therapy of treprostinil with warfarin. Wade and colleagues found that no serious side 
effects or clinically important interactions occurred (Wade et al., 2003). 
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Table 1-3 Treprostinil and Iloprost Ki values at prostaglandin receptors 
Prostaglandin Receptor Treprostinil Ki (nM) Iloprost Ki (nM) 
IP 32.1 ± 0.2 3.9 ± 0.6 
EP1 212 ± 56 1.1 ± 0.3 
EP2 3.6 ± 0.3 1172 ± 159 
EP3 2505 ± 263 208 ± 26 
EP4 826 ± 116 212 ± 27 
DP1 4.4 ± 0.4 1016 ± 63 
FP 4680 ± 927 131 ± 17 
TP Not calculable 3778 ± 375 
Treprostinil and Iloprost binding profile for prostanoid receptors. Data gather using displacement 
radioligand binding from cell membranes that expressed recombinant human prostanoid receptors. 
Table taken from (Whittle et al., 2012) 
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Figure 1-9 Overview of prostaglandin analogue activation of prostaglandin receptors 
Each prostaglandin analogue has a different binding profile to prostaglandin receptors. Treprostinil binds with high affinity to the IP, EP2 and DP1 receptors (EP4 receptor 
not shown), Selexipag binds only the IP receptor, whereas Iloprost can activate both EP1 and IP receptors. IP, EP2 and DP1 receptors are Gs associated receptors, activation 
leads to adenylyl cyclase activating cAMP and PKA therefore vasodilation or anti-proliferation. The EP1 receptor associates with the Gq protein, activation leads to PLC 
mediated creation of IP3 and DAG, which leads to elevated levels of intracellular Ca2+. AC= adenylyl cyclase, cAMP, cyclic adenosine monophosphate; DAG= diacylglycerol, 
G= G protein, IP3= inositol triphosphate; PKA= protein kinase A, PLC= phospholipase C. 
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1.5.8. Developing therapies for PAH 
As the understanding of PAH pathophysiology increases, novel pathways are being 
investigated as potential therapeutic targets. 
1.5.8.1 Imatinib 
Imatinib is an anti-proliferative drug originally developed to block the Bcr-abl tyrosine 
kinase in chronic myeloid leukaemia. Imatinib can also block the action of platelet-derived 
growth factor (PDGF) and c-KIT signalling, both of which are implicated in PH development 
and smooth muscle proliferation (Hoeper et al., 2013, Humbert et al., 1998). In two animal 
models of PH; chronic hypoxic mice and MCT rats, imatinib was found to almost restore 
both right ventricle pressure and hypertrophy to control levels (Schermuly et al., 2005). 
Imatinib also demonstrated anti-proliferative and pro-apoptotic actions on PASMCs 
isolated from IPAH patients (Nakamura et al., 2012). Long term safety and efficacy trial 
with imatinib resulted in a high discontinuation rate, with 31% due to adverse events like 
subdural haematomas (Frost et al., 2015)  
1.5.8.2 Vasoactive intestinal peptide 
Vasoactive intestinal peptide (VIP) can relax pulmonary arteries and diminish the actions 
of vasoconstrictors like ET-1 (Hamidi et al., 2011). The role of VIP in PAH has been 
suggested in studies using a VIP knock out mouse model, which had increased RV 
pressures and pulmonary vascular remodelling. The increased vascular remodelling was 
also reversed by treatment with VIP (Stenmark et al., 2009). In the MCT rat model of PH, 
VIP treatment partially reversed PAH indices more efficiently than the dual ERA bosentan 
(Hamidi et al., 2011).  
1.5.8.3 Rho kinases 
Both vasoconstriction of smooth muscle cells and endothelial dysfunction are key 
causative agents in the development of PAH. The rho-kinase pathway can increase 
calcium sensitisation leading to increased vasoconstriction and smooth muscle 
proliferation (Schwenke et al., 2011). Fasudil, a rho-kinase inhibitor, has mediated 
reductions in RV pressure, mean PAP, pulmonary arterial remodelling and RV hypertrophy 
in the MCT rats (Mouchaers et al., 2010). Combination with an ERA or a PDE5 inhibitor 
did not produce any enhanced therapeutic effect (Mouchaers et al., 2010). 
1.5.8.4 Apelin 
Another developing target for PAH therapy is the peptide Apelin. Apelin is known to 
regulate both proliferation and apoptosis of smooth muscle and endothelial cells. Goetze 
and colleagues have demonstrated that PAH patients have lower levels of apelin 
compared to control patients (Goetze et al., 2006). A link exists between BMPR-II 
signalling dysfunction and lower expression of apelin. This is mediated through disruption 
of the peroxisome proliferator-activated receptor (PPAR-γ)/β-catenin complex. This leads 
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to greater PASMC proliferation and a reduction in endothelial cell apoptosis (Alastalo et 
al., 2011). Currently, the short half-life, administration problems and the systemic effects 
of apelin prevents its use as a PAH therapy (Andersen et al., 2011) 
1.5.8.5 PPAR-γ agonists 
The importance of PPAR-γ in maintaining pulmonary vascular homeostasis was 
demonstrated in endothelial and/or smooth muscle PPAR-γ knock out mice, which develop 
PAH (Hansmann et al., 2008, Guignabert et al., 2009a). The PPAR-γ agonist rosiglitazone 
diminished PH in chronic hypoxic rats, rosiglitazone was also found to induce relaxation in 
human pulmonary arteries (Kim et al., 2010, Kozłowska et al., 2013). Prostacyclin 
analogues can mediate their anti-proliferative effects through activation of PPAR-γ, also 
rosiglitazone was demonstrated to increase the anti-proliferative effect of treprostinil in 
PASMCs from IPAH patients (Falcetti et al., 2007, Falcetti et al., 2010). 
1.5.8.6 Dichloroacetate  
The normal cycle of adenosine trisphosphate (ATP) creation by the Krebs cycle is 
disrupted in PAH patients when, ATP production is mediated through glycolysis activated 
by pyruvate dehydrogenase kinase (PDK) (Piao et al., 2010).  This suggests that 
mitochondrial dysfunction occurs in PAH. In MCT mice and IPAH patients, the PDK 
inhibitor dichloroacetate (DCA) decreased proliferation and increased apoptosis of 
PASMCs (Guignabert et al., 2009b). DCA also reversed potassium channel (Kv1.5) 
downregulation in the pulmonary arteries of MCT rats (McMurtry et al., 2004). 
1.5.8.7 MicroRNAs 
MicroRNAs (miRNAs) have been identified as potential therapy targets for PAH. miR-204 
expression was reduced in the MCT rat model of PH and in hPASMCs from PAH patients. 
Treatment with a synthetic miR-204 led to decrease RVSP, RV hypertrophy and vascular 
remodelling in rats, proliferation was also reduced in PAH hPASMCs (Courboulin et al., 
2011). Depressed miR-96 levels were associated with increased 5-HT1B expression levels, 
contributing to serotonin (5-HT) induced proliferation. Increasing levels of miR-96 reduced 
5-HT1B expression and 5-HT induced proliferation, it also reduced indices of hypoxic 
induced PH in mice (Wallace et al., 2015). Interestingly, reducing expression of both miR-
17 and miR-20a by targeting with antagomirs lead to reductions in PH indices in hypoxic 
mice, reduced hPASMC proliferation and increased expression of important BMPR-II 
signalling mediators like Id1 and Id2 (Pullamsetti et al., 2012, Brock et al., 2014). The ability 
to target miRNAs involved in diseases like PAH is a growing area of research  
1.5.8.8 Endothelial progenitor cells and mesenchymal stromal cells 
Endothelial progenitor cells, derived from bone marrow, are thought to assist in therapeutic 
angiogenesis (Asahara et al., 1997).  In PAH patients, the circulating levels of EPC were 
found to be reduced (Diller et al., 2008, Junhui et al., 2008). Engrafted EPCs prevented 
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monocrotaline-induced RVSP increases in rats, interestingly EPCs transduced with eNOS 
demonstrated greater reversal of PH (Zhao et al., 2005). Administration of EPCs to PAH 
patients was found to be tolerated and led to improvements in both exercise capacity and 
short term haemodynamics (Wang et al., 2007b, Granton et al., 2015). Mesenchymal 
stromal cells (MSCs) like EPCs are derived from bone marrow. Interestingly, MCT rats 
treated with MSCs and MSCs overexpressing eNOS led to reductions in RVSP and RVH. 
However, the reductions in RVSP were much greater in rats treated with MSCs 
overexpressing eNOS (Kanki-Horimoto et al., 2006). Exosomes derived from MSCs 
inhibited the development of hypoxic pulmonary hypertension in mice, both the miR-17 
superfamily and miR-204 were increased as well as inhibiting signal transducer and 
activator of transcription 3 (STAT 3) signalling in PAECs (Lee et al., 2012). 
1.5.8.9 Anastrazole 
Blocking the localised synthesis of estrogen in lung was demonstrated to attenuate PH in 
both female hypoxic mice and SU-HX (Mair et al., 2014). The application of the aromatase 
inhibitor anastrazole in human PAH has been initially examined in a small clinical trial. 
Anastrazole increased the 6MWD in treated patients compared to placebo, also levels of 
17-β estradiol were decreased (Kawut et al., 2016). A large clinical trial is required to 
confirm the effectiveness of anastrazole in the treatment of PAH. 
1.6. Sex in PAH 
Registry data for PAH and other PH classifications demonstrate an increased female 
susceptibility to disease development. The ratio of disease development is 4 female 
patients to 1 male patient (Rich et al., 1987, Humbert et al., 2006, Ling et al., 2012). The 
increase female predisposition to PAH suggests that sex can influence the development 
of PAH. The increase frequency of females suffering PAH was first detected in the 1950s, 
however no obvious therapeutic strategy has been developed since to specifically target 
to females in PAH (Dresdale et al., 1951). Despite increased female susceptibly to PAH, 
females have greater survival than males, with less PAH severity in female patients 
(Humbert et al., 2010b, Humbert et al., 2010a). A critical difference between female and 
male patients is the presence of specific sex hormones. A key focus of ongoing PAH 
research is investigation of the survival difference and its potential link to sex hormones. 
Animal PH models can replicate the sex differences observed in clinical PAH patients, 
however, contradictions exist in these models, where the female sex hormone estrogen 
can have protective effects (Lahm et al., 2012). Other studies indicate that estrogen is a 
causative effect in PH development, mice overexpressing the serotonin transporter 
(SERT+) demonstrate female susceptibility to PH (White et al., 2011a). The conflicted role 
of estrogen in the development and susceptibility of PAH is commonly known as the 
‘estrogen paradox’. 
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1.6.1. Biosynthesis of estrogen and metabolism 
Female sex hormones are steroid hormones which include both progesterones and 
estrogens. Estrogens are primarily synthesised in the ovaries and corpus luteum in the 
female reproductive tract. Local estrogen synthesis can also take place in liver, adipose 
tissue and recently the estrogen-synthesising enzyme has been identified in endothelial 
and vascular smooth muscle cells (VSMC) (Tofovic, 2010). Synthesis of estrogen is 
controlled by the hypothalamic-pituitary-gonadal axis (HPG), which involves the action of 
endocrine hormones secreted from the hypothalamus and pituitary gland in the brain. 
Follicle stimulating hormone (FSH) can increase the transcription of aromatase, which is 
an important estrogen synthesising enzyme. The balance of estrogen synthesising 
hormones is controlled by positive and negative feedback, this forms the basis of the 
female reproductive cycle. The three primary naturally occurring isoforms of estrogen are: 
estrone, estradiol and estriol. In pre-menopausal women, estradiol is the highest 
circulating hormone whereas estrone is increased during menopause and estriol is highest 
post menopause. However, estriol also has role during pregnancy maintaining a healthy 
uterine lining (Khosla et al., 1997). 
Estrogen biosynthesis begins with the conversion of cholesterol to pregnenolone by the 
cytochrome P450 (CYP) 11A1 enzyme (Figure 1-10). Cholesterol will only be converted 
under the presence of specific sex hormones control by the HPG axis. As stated 
previously, VSMC can produce estrogen locally, which may have role in maintaining 
vascular homeostasis (Tofovic, 2010, Harada et al., 1999). Locally produced estrogen acts 
in a paracrine manner at the site of synthesis whereas a majority of gonadal produced 
estrogen acts in an endocrine fashion (Labrie et al., 1998). Pregnenolone is rapidly 
converted to progesterone by the 3β hydroxysteroid dehydrogenase (HSD) which is 
subsequently hydroxylased to androstenedione by CYP17A1. Androstenedione can be 
converted into two distinct products; testosterone by 17-β HSD or estrone by CYP19A1 
(aromatase). Both products can be converted to 17-β estradiol by aromatase or 17-β HSD 
respectively. Estrogens are metabolised by oxidation, this occurs primarily in the liver co-
ordinated by CYP 450 enzymes. However, as with estrogen production, metabolism can 
take place in other areas of the body including brain, lung and breast tissue.  
Estradiol can be oxidised at several difference carbon positions in its chemical structure. 
Oxidation at the carbon-17 (C17) position leads to estrone formation, whereas oxidation 
at C16, C4 and C2 produces alternative metabolites. The nicotinamide adenine 
dinucleotide phosphate (NADPH) dependent oxidation of estradiol to these metabolites is 
dependent on the action of CYP 450 enzymes. The formation of 2-hydroxyestradiol (2-
OHE2) is mediated by CYP1A1, A2 and 3A4 whereas CYP1B1 is essential for the 
formation of 4-hydroxyestradiol (4-OHE2). The CYP enzymes have different expression 
levels in different tissues in the body. CYP1B1 is expressed at high levels in breast cancer 
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tissue, leading to a bias in estrogen metabolism in favour of 4-OHE2 (Wen et al., 2007). 
CYP1B1 lung levels were found increase when exposed to tobacco smoke, females were 
also identified as having greater expression of CYP1B1 than males (Peng et al., 2013). 
There is increasing interest in targeting CYP1B1 due its potential pathogenic properties. 
17-β estradiol can engineer its own breakdown by increasing transcription of CYP1B1 
through an estrogen response element in the promotor region (Tsuchiya et al., 2005). Also, 
polymorphisms identified in the CYP1B1 gene have contributed to the development of 
estrogen positive cancers (Hanna et al., 2000). Both hydroxyestradiol metabolites are 
broken down further to 2 and 4 methoxyestradiol metabolites by the catechol-O-
methyltransferase (COMT) enzyme. Interestingly, the hydroxy or methoxy metabolites can 
undergo sulphation by sulphotransferases (SULTS) into water soluble molecules that are 
removed from the body via the kidneys in urine. 
The aromatase gene is present in both gonadal and non-gonadal tissue; transcription is 
dependent on signalling pathways that act at different sites in its promotor region. 
Aromatase expression in adipose tissue is influenced by glucocorticoids, cytokines and 
the Janus kinase/signal transducers and activators of transcription (Jak/STAT) (Zhao et 
al., 1995). In adipose tissue, cortisol was found to increase aromatase activity specifically 
in females (McTernan et al., 2002). Aromatase has been implicated in estrogen positive 
diseases like breast cancer (Harada, 1997, Harada and Honda, 1998, Kazmi et al., 2012). 
The aromatase inhibitor anastrozole is used as a part of a combination therapy in breast 
cancer patients (Forbes et al., 2008, Masuda et al., 2012). However, current aromatase 
inhibitors will act on all aromatase in the body, this lack of specificity can lead to off target 
effects in bone formation maintenance or can disrupt estrogen levels in the human vena 
cava (Sasano et al., 1997, Sasano et al., 1999). Aromatase expression is increased within 
non-small cell lung cancer (NSCLC) cells and is also a predictor of survival in NSCLC 
(Márquez-Garbán et al., 2009, Mah et al., 2007). 
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Figure 1-10 Overview of estrogen synthesis and metabolism 
Cholesterol is converted to androstenedione by enzymes CYP11A1, 3β HSD and CYP17A1. Androstenedione can be converted into either estrone or testosterone by 
CYP19A1 or 17β-HSD respectively. Both estrone and testosterone are converted to 17-β estradiol through 17β-HSD or CYP19A1 respectively. 17-β estradiol is converted 
to either 2, 4 or 16 hydroxyestradiol by the action of various CYPs (CYP1A1, CYP1B1). COMT can convert 2 and 4- hydroxyestradiol to 2 and 4 methoxyestradiol 
respectively. CYP= cytochrome P450, HSD= hydroxysteroid dehydrogenase, COMT= catechol-O-methyltransferase. 
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1.6.2. Estrogen receptors and signalling 
Estrogen actions and influence was initially thought to be limited to reproduction. Greater 
research has highlighted the role that estrogens can play throughout the body. Local 
estrogen synthesis separate from the gonadal tissue highlights the role of paracrine 
estrogen signalling. Estrogen signalling can be mediated through either a genomic 
pathway or a non-genomic pathway (Mendelsohn, 2002). Genomic signalling involves 
estrogens acting on intracellular/membrane bound estrogen receptors leading to a 
conformational change and results in direct regulation of gene transcription. Non-genomic 
signalling involves estrogen activation of second messengers and signal transduction to 
mediate its effects. It was initially believed that estrogen mediated its effects through a 
single estrogen receptor. However, more recently, two types of estrogen receptor have 
been identified, estrogen receptor α (ERα) and estrogen receptor β (ERβ) (Green et al., 
1986, Mosselman et al., 1996). Both ERα and ERβ are thought to act as membrane bound 
receptors as well as nuclear receptors however, an additional estrogen receptor known a 
G protein coupled estrogen receptor 1 (GPER/GPR30) has also been identified (Filardo et 
al., 2000). The ERα and ERβ are encoded by the ESR1 and ESR2 genes respectively and 
are identified as ligand activated transcription factors. Upon activation, the receptors 
translocate to the nucleus where they can influence gene transcription through estrogen 
response elements (EREs) found on target genes. Nuclear receptors like the estrogen 
receptors have five main domains; N-terminal regulatory domain, which contains the 
activation function 1 (AF-1) site. The DNA binding domain (DBD) region is highly 
conserved and binds nuclear response elements like EREs. The hinge region has an 
important function in receptor dimerization, the ligand binding region contains another 
activation function site (AF-2), this is required for activation by the specific estrogen ligand. 
The ligand binding domain can also bind chaperone proteins like heat shock protein, which 
aid in translocating the receptor to the nucleus. The ERs have different selectively 
regarding the AF regions, ERα facilitates transcription activation via AF-1, whereas ERβ 
acts through AF-2. A comparison of AF-1 regions on both ERs have identified that the 
receptor can have opposing effects on the cell under the same conditions (Nilsson et al., 
2001). The actions of EREs on gene expression can vary dependent on the co-regulator 
they associated with. Recruitment of short heterodimer partner (SHP) leads to a block on 
ER mediated transcription, however when the regulator p300 is associated with the 
transcription complex of ERα gene transcription occurs (Johansson et al., 1999, Hanstein 
et al., 1996). The impact of different co-regulators on estrogen signalling can vary between 
cell types. As stated previously this leads to the two estrogens having different effects on 
the same cell type (Nilsson et al., 2001). As well as being expressed in the cytoplasm of 
the cell, the ERs are also expressed as membrane bound receptors. Upon activation, they 
can influence the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), cAMP and 
ERK/MAPK signalling pathways (Filardo et al., 2000). The GPER has been identified as 
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playing a role in rapid and transcriptional actions in response to estrogen stimulation 
(Filardo and Thomas, 2005, Prossnitz et al., 2008). GPER is a membrane bound receptor 
that can activate adenylyl cyclase, trans-activate epidermal growth factor receptors 
(EGFRs), mobilise intracellular calcium (Ca2+), activate MAPK and phosphoinositide 3-
kinase (PI3K) signalling pathways (Putti et al., 2005, Luo et al., 2012). There is conflicting 
evidence to what effect GPER can have on cells. Previously it has been shown that GPER 
activation led to moderate the growth of endometrial and breast cancer (Filigheddu et al., 
2011, Ariazi et al., 2010). GPERs have also been confirmed as mediators of anti-
proliferative effects in vascular endothelial and smooth muscle cells (Holm et al., 2011, 
Haas et al., 2009, Murata et al., 2013). Paradoxically, GPER has also been implicated in 
activating genes that are associated with proliferation observed in breast and endometrial 
cancer (Pandey et al., 2009, Du et al., 2012). Several studies suggest that activation of 
the GPER by the specific agonist G-1 leads to cell cycle arrest and inhibition of proliferation 
in endothelial cells, prostate cancer and ovarian cancer cells (Holm et al., 2011, Chan et 
al., 2010, Wang et al., 2013). Broselid and colleagues discovered that the GPER receptor 
was found to be localised both intracellularly and in the plasma membrane (Broselid et al., 
2014). When activated the GPER, independently of the Gi subunit, creates a plasma 
membrane complex including guanylate kinase and protein kinase A anchoring protein 
(AKAP) 5, blocking cAMP production (Broselid et al., 2014).  SiRNA knock down of GPER 
led to increased cAMP production, interestingly removal of the type 1 PDZ motif at the 
receptor C terminus led to increased receptor endocytosis and disrupted the blockage of 
cAMP production (Broselid et al., 2014).  
1.6.1.1. Estrogen signalling in cardiovascular system 
In cancer, estrogen and its associated receptors are implicated as pathogenic, however in 
the cardiovascular system they are thought to mediate protective effects. The level of 
cardiovascular disease is higher in men than that of pre-menopausal women. This 
difference is reduced post-menopause due to the loss of the protective estrogen effect 
(Meyer et al., 2006). Ovariectomised mice underwent transaortic constriction, after which 
mice were dosed with either estrogen or vehicle. The estrogen dosed group demonstrated 
much lower levels of ventricular hypertrophy compared to vehicle (van Eickels et al., 2001). 
A further study demonstrated that both ovariectomised mice and mice with low expression 
ERα showed a reduction in hypertrophy when treated with estrogen. However, removal or 
reduction of the ERβ receptor led to no reduction in hypertrophy suggest ERβ mediates 
the beneficial effects of estrogen (Babiker et al., 2006). Estrogen administration prior to 
ischemic injury has been demonstrated to reduce infarct size in isolated rat hearts, this 
has also been demonstrated in both male and female rabbits (Lagranha et al., 2010, 
Sbarouni et al., 2003, Hale et al., 1996). Estrogen also improved the contractile function 
in rat hearts after ischemia and reperfusion by reducing p38/MAPK signalling (Wang et al., 
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2006). The mechanism by which estrogen has its cardioprotective effects is thought to 
involved both ERα and ERβ receptors increasing expression of nitric oxide synthase 
(Nuedling et al., 1999). However, the GPER receptor also has been shown to have 
protective effects in ischemia and reperfusion via inhibition of mitochondrial permeability 
(Bopassa et al., 2010). The ERα, ERβ and GPER are all expressed in cardiac fibroblasts 
and cardiac myocytes (Deschamps and Murphy, 2009).  Apolipoprotein E (ApoE) deficient 
mice dosed with estrogen have reduced the development of atherosclerosis lesion 
formation, decreased levels of low density lipoprotein (LDL) and increased levels of high 
density lipoprotein (HDL) (Bourassa et al., 1996, White, 2002). It is possible that the 
protective effects of estrogen are dependent on the presence of endothelial progenitor 
cells (EPCs), these cells are involved in maintaining cardiovascular homeostasis (Doyle et 
al., 2006). In coronary artery disease, therapy with an angiotensin-converting enzyme 
inhibitor, ramipril increased the functional activity of EPCs (Min et al., 2004). 17-β estradiol 
was found to increase EPC proliferation and adhesion through ER activation. The 
expression and pro-angiogenic properties of EPCs were also found to be higher in females 
compared to males (Fadini et al., 2008). Interestingly, the prostacyclin analogue treprostinil 
can increase the angiogenic properties and expression of EPCs in child PAH patients, this 
may aid endothelial repair and function (Smadja et al., 2011). However, women 
undergoing hormone replacement therapy (HRT) display the potential pathogenic effects 
of estrogen. This can include elevations in prothrombotic factors/fragments and reduced 
plasma fibrinolytic inhibitory activity contributing to a greater risk of venous thrombosis 
(Teede et al., 2000, Wu, 2005). Despite observing positive outcomes for estrogen based 
therapy in certain cardiovascular disorders, the risks associated with estrogen in HRT and 
estrogen linked cancers depict a complex profile of estrogen that must be accounted for 
when examining estrogen signalling. 
1.6.3. Estrogen pathway and PAH 
The predisposition for PAH in females has led to the investigation of estrogen as a possible 
causative or risk factor in the development of the disease. The complexity of estrogen 
signalling is again highlighted in the pulmonary vasculature as it was in the systemic 
vasculature. HRT has been implicated in the development and prevention of PAH (Morse 
et al., 1999, Beretta et al., 2006). The importance of aromatase expression in estrogen 
metabolism has been highlighted previously. Patients with PPHTN have a single 
nucleotide polymorphism (SNP) in the aromatase gene that leads to greater plasma levels 
of estrogen (Roberts et al., 2009). The activity of aromatase has not been examined in 
PAH, however expression of aromatase was found not to change between female control 
hPASMCs and female PAH patient hPASMCs (Mair et al., 2014). Interestingly, aromatase 
expression was elevated in both hypoxic mice and SU-HX rats, both also exhibited 
increased estrogen levels. In SU-HX rats, the increased estrogen levels were associated 
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with increases in RVH and pulmonary vascular remodelling (Mair et al., 2014). When 
ovariectomies are undertaken in female susceptible models of PH (SERT+ and 
dexfenfluramine (DFEN) dosed mice) there is a prevention of PH phenotype development 
(White et al., 2011a, Dempsie et al., 2013). Due to the increased incidence of females 
developing PAH, the implications of the female specific PH models SERT+ and DFEN 
responding negatively to estrogen may have clinical significance.  Estrogen also 
upregulated known mediators of PAH pathogenesis; tryptophan hydroxylase 1 (TPH1), 
SERT and 5-HT1B in hPASMCs (White et al., 2011a). This led to the investigation of directly 
blocking estrogen synthesis by inhibiting the activity of aromatase, this was achieved by 
anastrazole therapy. Anastrazole was found to reverse established PH phenotype in 
hypoxic mice and SU-HX rats, however this positive effect was only observed in females 
(Mair et al., 2014). 
The conflicting role of estrogens in PAH development and pathogenesis was expressed in 
specific experimental models of PH, females repeatedly demonstrate a less severe PH 
phenotype than males. Rabinovitch and colleagues discovered that hypoxic male rats 
have greater pulmonary vascular remodelling and RVH compared to hypoxic female rats 
(Rabinovitch et al., 1981). Mice have also been shown to demonstrate similar 
characteristics (Stupfel et al., 1984). Female rats that had underwent an ovariectomy 
developed a more severe hypoxic induced PH phenotype (Resta et al., 2001). Treatment 
with 17-β estradiol reduced the PH phenotype in ovariectomised rats, demonstrating the 
protective effects of estrogen (Resta et al., 2001). Similar effects were observed in rats 
with MCT induced PH; an ovariectomy increased the severity of MCT induced PH in rats 
and estrogen improved haemodynamics in an established MCT phenotype (Ahn et al., 
2003, Umar et al., 2011).  In male rats, estrogen therapy was found to decrease RVSP, 
RVH and pulmonary arterial remodelling suggesting estrogen positive benefits also 
extends to males (Lahm et al., 2012). Estrogen also promotes both prostacyclin and nitric 
oxide mediated endothelium dependent vasodilation in pulmonary circulation (Sherman et 
al., 2002, Gonzales et al., 2001, Lahm et al., 2008). In PAEC, 17-β estradiol increased 
expression of endothelial nitric oxide synthase (eNOS) activity and mRNA expression 
(MacRitchie et al., 1997). Additionally, 17-β estradiol also blocks hypoxia induced 
endothelin-1 gene expression (Earley and Resta, 2002). 
Female PAH patients were found to have increased expression of ESR1/ERα compared 
to non-PAH control patients (Rajkumar et al., 2010). Hypoxic female mice were also found 
to have increased expression of ERα compared to normoxic females, however males did 
not express any difference between groups (Mair et al., 2014). Dysfunctional BMPR-II 
signalling is an important factor in the development and pathogenesis of PAH. Estrogen 
has been implicated in reducing BMPR-II gene expression via the interaction of ERα with 
a estrogen receptor binding site present in the BMPR-II promoter (Austin et al., 2012). 
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Interestingly, the same study found that canonical BMPR-II signalling was increased with 
estrogen stimulation despite downregulation of the receptor (Austin et al., 2012). The 
negative implications of ERα in PAH were enhanced by the demonstration that inhibition 
of the receptor can prevent the development of a hypoxic induced PH phenotype in female 
mice (Mair et al., 2014). The ERβ was found to be decreased within pulmonary arteries of 
hypoxic female mice compared to normoxic controls, also loss of ERβ function was found 
to increase the development of RV hypertrophy in mice (Mair et al., 2014, Morani et al., 
2006). Similar reductions in ERβ were found within the right ventricle and lung of MCT rat 
models of PH (Matori et al., 2012). Combining the published data presents a complicated 
picture for estrogen in the development of PAH. The ERα appears to be responsible for 
the negative effects of estrogen stimulation whereas the ERβ receptor mediates some 
beneficial or protective effects of estrogen. The distribution of the receptors will influence 
the effects of estrogen.  
It would be simplistic to focus solely on estrogen effects in PAH and not consider the 
actions of its many metabolites. As discussed previously, the types of metabolites 
produced relies heavily on the action and expression of CYP enzymes. White and 
colleagues investigated the CYP1B1 enzyme and identified its elevated expression in 
hPASMCs from IPAH patients and in the pulmonary arteries of SERT+ mice, hypoxic mice 
and SU-HX rats (White et al., 2011b, White et al., 2012). Inhibition of CYP1B1 reduced 
and reversed PH indices in hypoxic and SU-HX PH models respectively (White et al., 
2012). In addition, CYP1B1 knock out mice exposed to hypoxia expressed a reduced PH 
phenotype compared to wildtype controls (White et al., 2012). CYP1B1 is an important 
enzyme in metabolism of 17-β estradiol to 2-OHE2. MCT rats dosed with 2-OHE2 
demonstrated decreases in RVSP and RVH (Tofovic et al., 2005). 2-OHE2 has been 
shown to demonstrate cell cycle arrest and reduce tumour growth and induce apoptosis in 
solid tumours (Schumacher and Neuhaus, 2001). CYP1B1 can also mediate the 
breakdown of 17-β estradiol to 16-alpha hydroxyestradiol (16αOHE1). 16αOHE1 is a 
known pro-proliferative mitogen that can affect the growth of hPASMCs, also in-vivo dosing 
with 16αOHE1 increased both RVSP, RVH and pulmonary artery remodelling (White et 
al., 2012). Recently 16αOHE1 has been implicated in increasing dinucleotide phosphate 
oxidase (NOX1) mediated reactive oxygen species (ROS) generation (Hood et al., 2016). 
Hood and colleagues found that 16αOHE1 increased ROS via NOX1 in both control and 
PAH patient hPASMCs (Hood et al., 2016). A NOX1 knock-out mouse model was also 
found to be protected from chronic hypoxic induced PH (Hood et al., 2016). 16αOHE1 was 
also found to promote the development of HPAH through upregulation of miR-29 (Chen et 
al., 2016). The treatment of BMPR-II female and male mutant mice with an antagomir (anti-
miR-29) led to improved haemodynamics. Chen and colleagues believed that the increase 
in miR-29 can impair energy metabolism. This was demonstrated by an increase in 
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ceramide, which they believe suggested a dysfunctional fatty acid oxidation pathway 
(Chen et al., 2016).  Interestingly, antagomir treatment also increased the size of PASMC 
mitochondria (Chen et al., 2016). The variety and diversity of estrogen metabolites 
produced will influence and modulate the severity and manifestation of PAH. 
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1.7. Aims 
The incidence of PAH among women is much higher than found in males but males suffer 
worse clinical outcomes. For this study, the general hypothesis was that this disparity in 
clinical outcomes can be explained by a differential response to PAH treatment. The 
overall aim of this research was to investigate the influence of sex on the anti-proliferative 
and to ascertain how the therapeutic actions of treprostinil are mediated. This was 
investigated through the following experimental study hypotheses and aims for each 
chapter: 
Chapter 3 
Slow-release subcutaneously implanted pellets have been used previously to dose 
animals in the treatment of pulmonary hypertension (Wright et al., 2015). We hypothesise 
that the PGI2 analogue treprostinil can be successfully delivered to chronic hypoxic rats 
using slow-release subcutaneously implanted pellets as an alternative to repetitive dosing. 
To investigate this hypothesis, the following aim was carried out. 
1. To examine the haemodynamic effects of treprostinil, administered via a slow release 
subcutaneously implanted pellet in the chronic hypoxic model of pulmonary 
hypertension. 
Females and males are known to differ in response to drug therapy for  variety of reasons 
(Soldin and Mattison, 2009). To investigate this, our hypothesis is that sex can play a 
role in altering the effectiveness of treprostinil in an animal model of PH. The following 
aim was carried out: 
2. Study to characterise the influence of sex on the actions of treprostinil in a chronic 
hypoxic rat model of PH and how these effects are mediated 
 
Chapter 4 
Sex has been shown to influence the clinical outcomes of patients receiving ERAs and 
PDE-5 inhibitors (Gabler et al., 2012, Mathai et al., 2015). We hypothesise that the PGI2 
analogue treprostinil can have sex specific effects in isolated hPASMCs. To investigate 
this hypothesis, the following aim was carried out. 
1. Characterisation of the influence of sex on treprostinil in human pulmonary artery 
smooth muscle cells  
BMPR-II signalling has been previously demonstrated to mediate the effect of prostacyclin 
analogues and other PAH therapies (Yang et al., 2010, Yang et al., 2013a). Also, sex 
differences have been identified in BMPR-II signalling in hPASMCs (Mair et al., 2015). The 
hypothesis is that increased BMPR-II signalling mediated by treprostinil accounted for the 
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differences in anti-proliferative properties of treprostinil. To investigate this hypothesis, the 
following aim was carried out. 
2. Investigation into the role of canonical BMPR-II signalling in the effects of 
treprostinil in human pulmonary artery smooth muscle cells  
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2.1 Chemicals and reagents 
All regents and chemicals were supplied by Fisher Scientific (Loughborough, United 
Kingdom) and Sigma Aldrich (Dorset, United Kingdom) unless stated otherwise. 
Constituents of protein and RNA analysis were obtained from Life Technologies (Paisley, 
United Kingdom) and Qiagen (Manchester, United Kingdom). Experiments involving RNA 
were conducted using nuclease-free plastics and reagents from Ambion/Life Technologies 
(Paisley, United Kingdom). Plate plastics for cell culture experiments were supplied by 
Corning via Fisher Scientific (Loughborough, United Kingdom). Treprostinil (Tyvaso®) was 
supplied by United Therapeutics (Silver Springs, United States). 
2.2 Ethical approval 
All animal procedures conform to the UK Animal Procedures Act (1986) and the Guide for 
the Care and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH publication No. 85–23, revised 1996). All in vivo procedures were performed under 
project licence 60/4404 held by Professor Margaret R. Maclean, University of Glasgow and 
personal licence I629F9947 held by Gerard Murphy, University of Glasgow. Ethical approval 
was granted by the University of Glasgow Ethics Committee. Experimental procedures 
using human lung issue and hPASMCs conform to the principles outlined in the Declaration 
of Helsinki and were approved by Cambridgeshire 1 Research Ethics committee (REC 
reference: 08/H0304/56). 
2.3 Animal study design 
When appropriate, animals were randomised into respective groups and haemodynamic 
data from these groups were obtained blinded. The identities of the groups were disclosed 
after haemodynamic analysis (Figure 2-1). 
2.3.1 Animal welfare conditions 
All animals were maintained in a 12-hour light/dark cycle under the same environmental 
conditions with access to food and water ad libitum. Animals were housed at the licenced 
facility in the West Medical Building, University of Glasgow or at the Central Research 
Facility (CRF), University of Glasgow. 
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2.3.2 Sprague-Dawley rats 
Male and female sprague-dawley rats aged 5-7 weeks were obtained from Harlan 
Laboratories/Envigo (Blackthorn (Oxfo), United Kingdom). Rats were housed at the CRF 
for a 1-week acclimatisation period, prior to experimental start. 
2.3.2.1 Chronic hypobaric hypoxia 
The chronic hypoxia model of pulmonary hypertension (PH) was studied. Rats were placed 
in a hypobaric hypoxic chamber for 28 days. On day 0, rats were placed into the chamber 
and the pressure was slowly reduced from an atmospheric (normoxic) 1013mbar to 
750mbar, and left overnight for acclimatisation. On day 1, the pressure was further slowly 
reduced to 550mbar, at this pressure the equivalent level of oxygen has been reduced to 
10%. This low level of oxygen stimulates vasoconstriction of the pulmonary arteries of the 
rat lungs which develops into a pulmonary hypertensive phenotype. Every 5 days, the 
chambers were slowly restored to atmospheric pressure to restock food and water and to 
change cage bedding and environment. The temperature and relative humidity were 
monitored and maintained at optimal levels. 
2.3.2.2 Sub-cutaneous implanted pellet 
Rats were anaesthetised in an anaesthetic chamber containing 3-3.5% (v/v) isoflurane 
(Abbot Laboratories, Berkshire, United Kingdom) supplemented with oxygen. After 
anaesthetic induction rats were weighed and transferred to a suitable facemask constantly 
administering 2.5-3% (v/v) isoflurane supplemented with oxygen flow (1L/min). In order to 
maintain a steady body temperature, rats were placed on a heat mat for the procedure and 
their temperature was monitored via a temperature probe. Pellets containing either 
treprostinil, (releasing 100ng/kg/min and 400ng/kg/min) or a vehicle (Innovative Research 
of America, Florida, United States) were implanted. These were implanted subcutaneously 
into the dorsal neck using a sterile 10-gauge trochar. These pellets were implanted in rats 
after 14-days in hypoxia or in normoxic conditions. The Matrix Driven Delivery (MDD) pellets 
continuously release treprostinil over a 14-day timespan. Vehicle pellets are designed to 
act in the same way as drug containing pellets but will not release any active product. The 
rats were allowed to recover in clean bedding cages before being transferred back to their 
original cage. This was the first study to examine the effects of treprostinil released in pellet 
form, however previous studies have demonstrated the effectiveness of this dosing method. 
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Figure 2-1 In-vivo experimental timeline 
(A) At day 0 male and female sprague-dawley rats were subjected to 14-day hypoxic or normoxic 
period. At day 14, rats were dosed with either 100ng/kg/min treprostinil or vehicle (containing no 
treprostinil).  After dosing rats were returned to hypoxic conditions until day 28 at which time 
haemodynamics were assessed and blood was taken via the carotid artery and centrifuged at 
8000xg to isolate plasma. (B) At day 0 male and female sprague-dawley rats were subjected to 14-
day normoxic period after dosing with 100ng/kg/min treprostinil. Blood plasma was taken via the 
carotid artery and rats sacrificed at day 4, 7, 10 and 14. (C) At day 0, male and female sprague-
dawley rats were subjected to 14-day hypoxic or normoxic period. At day 14, rats were dosed with 
either 400ng/kg/min treprostinil or vehicle (containing no treprostinil). Rats were returned to hypoxic 
conditions until day 28 at which time haemodynamics were assessed and blood plasma taken via 
the carotid artery.
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2.4 Haemodynamic assessment of pulmonary hypertension 
2.4.1. Anaesthesia 
Rats were anaesthetised in an anaesthetic chamber containing 3-4% (v/v) isoflurane 
supplemented with oxygen flow (1L/min). Confirmation of acceptable anaesthesia was 
achieved by the lack of hind-limb or tail reflex. Over the course of the procedure the level 
of anaesthesia was constantly measured via testing of the previously described reflexes, 
heart rate and breathing rate. After anaesthetic induction, rats were weighed and 
transferred to a suitable facemask constantly administering 2.5-3% (v/v) isoflurane 
supplemented with oxygen flow (1L/min). To maintain a steady body temperature, rats 
were placed on a heat mat for the entirety of the procedure and their temperature was 
monitored via temperature probe. 
2.4.2. Measurement of right ventricular systolic pressure 
To achieve an indirect measurement of pulmonary arterial pressure (PAP), right ventricular 
pressure (RVP) was measured by the cannulation of the right external jugular vein by the 
Mikro-Tip® Pressure Volume System Ultra Foundation System (Millar, Texas, United 
States). This was coupled to a PowerLab 16/36 data acquisition system (AD Instruments, 
Oxfordshire, United Kingdom) (Lawrie et al., 2011). After successful induction of 
anaesthetic, an incision was made into the ventral neck area of the rat to reveal the layer 
of muscle underneath. This layer was blunt dissected through until exposition of the right 
external jugular vein. The vein was isolated from the surrounding tissue, surgical non-
sterile nylon black monofilament suture size 3-0 (Harvard Apparatus, Massachusetts, 
USA) was placed underneath the vein and knotted at the proximal end (towards head) of 
the vein. A second suture was place at the distal end (towards heart) of the vein and taped 
down to expose a greater area of the jugular vein. Using a 25mm gauge needle a small 
incision was made into the jugular vein. A Mikro-tip catheter SPR-869 (Millar, Texas, 
United States) was inserted into the vein and advanced slowly until the catheter reached 
the right ventricle of the heart. At this point a typical pressure trace of RVP was obtained 
(Figure 2-2). Measurements of right ventricular systolic pressure (RVSP) and heart rate 
(HR) were taken at this point and analysed using Labchart 7 (AD Instruments, Oxfordshire, 
United Kingdom). After pressure measurement had been taken, the catheter was 
withdrawn from the jugular vein and the vessel was tied off using surgical suture. 
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Figure 2-2 Right ventricular pressure measurement 
(A) Diagram to show placement of catheter to attain RVP measurement. (B) A five second 
representative trace of RVP from a normoxic rat. (C) A five second representative trace of a RVP 
in a rat under hypoxic conditions for four weeks. Y axis in mmHg, RVP=right ventricular pressure. 
  
2.4.3. Measurement of left ventricular systolic pressure 
Post measurement of RVP, the right internal carotid artery was cannulated in-order to 
measure left ventricular pressure (LVP). In a similar manner to the isolation of the jugular 
vein, the carotid artery was exposed by blunt dissection of the overlapping muscle tissue. 
Once identified the artery was cautiously separated from the vagus nerve and any other 
surrounding tissue. As with the jugular vein, surgical suture was used to tie off the proximal 
end of the exposed artery while the distal end was exposed further. To prevent the flow of 
blood a microsurgical clip (Fine Science Tools, Heidelberg, Germany, FST#18055-04), 
was clamped at the distal end of the artery. A small incision was made in the vessel just 
below where the proximal suture was tied. This allowed the insertion of a Mikro-tip catheter 
SPR-838 (Millar, Texas, United States) into the artery, this was then advanced as the 
microsurgical clip was released, at this point the distal suture was tied around the catheter 
and the incision point on the artery to prevent an outflow of blood. The catheter was slowly 
advanced until it entered the left ventricle and the typical pressure trace was achieved 
(Figure 2-3). After receiving a suitable measurement, the catheter was withdrawn from the 
carotid artery, at this point blood was collected from the artery to calculate cardiac output 
 Chapter Two Materials and Methods 
60 
 
and to analyse for treprostinil levels in the plasma. The rats were then killed by an 
anaesthetic overdose. 
 
 
Figure 2-3 Left ventricular pressure measurement 
(A) Diagram to show of placement of catheter to attain LVP measurement. (B) A five second 
representative trace of LVP from a normoxic rat. Y axis in mmHg, LVP=left ventricular pressure. 
 
2.4.4. Cardiac output measurement 
To measure cardiac output from the left ventricle a cuvette calibration was used. Blood 
collected from carotid artery was supplemented with heparin sodium to prevent clotting 
and kept at 37°C. Heparinised blood was then added to a volume calibration cuvette (AD 
Instruments, Oxfordshire, United Kingdom), each well in the cuvette corresponds to a 
known volume. The Mikro-tip catheter SPR-869/838 was then inserted into each well of 
the cuvette to obtain volume measurements that resemble a standard curve (Figure 2-4). 
Labchart 7 software extrapolated the cardiac volume in the left ventricle from this standard 
curve when establishing the LVP measurements, thus calculating the cardiac output. 
 Chapter Two Materials and Methods 
61 
 
 
Figure 2-4 Cardiac output measurement 
Diagrammatic representation of catheter placement in increasing blood volumes in cuvette to attain 
accurate standard curve for cardiac output measurement. 
2.4.5. Right ventricular hypertrophy 
Following the sacrifice of the rat, the heart and lungs were flushed with ice cold Dulbecco’s 
phosphate buffered saline (DPBS) solution (Life Technologies Paisley, United Kingdom). 
The heart was then detached from the lungs and cleared of any excess connective tissue, 
vessels and the atria were removed. Right ventricular hypertrophy is defined by the use of 
Fulton’s index, which is the ratio of the free right ventricle (RV) wall weight to the left 
ventricle (LV) wall plus septum (S) weight (RV/LV+S) (Fulton et al., 1952). The right 
ventricle was dissected free of the heart, blotted dry and weighed. This was then carried 
out for the left ventricle and septum and the Fulton’s index was calculated. 
2.4.6. Tissue harvest 
To analyse underlying molecular mechanisms, the lobes of the right lung were flash frozen 
in liquid nitrogen and stored at -80°C. For immunohistochemistry analysis, the left lung 
was slowly infused with 5-10ml 10% (v/v) neutral buffered formalin (NBF) (90% (v/v) 
distilled water, 10% (v/v) formalin, 33mmol/L monosodium phosphate (NaH2PO4), 
45mmol/L disodium phosphate (Na2HPO4)) and dissected free of the cadaver. The 
inflated left lung was then submerged in 10% NBF on a gentle shaker for minimum of 24 
hours prior to embedding. 
2.4.7. Blood plasma isolation 
Blood not required for cardiac output measurement was collected in tri-potassium 
ethylenediaminetetraacetic acid (K3-EDTA) tubes (Teklab, Durham, United Kingdom) and 
mixed gently. The blood was stored on ice for a maximum of 1 hour, then the tubes were 
centrifuged at 8000xg at 4°C for 15 minutes. The plasma supernatant was then pipetted 
into chilled eppendorf tubes, snap frozen in liquid nitrogen then stored at -20°C. Treprostinil 
plasma analysis was carried out by Liquid Chromotography/Mass Spectrometry (LC/MS) 
by Tandem Labs/Covance (Durham, North Carolina, United States). Briefly, treprostinil 
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levels in plasma samples were assessed by extrapolation to a standard curve of known 
treprostinil concentrations for all in-vivo studies. 
2.5 Histology 
2.5.1. Lung preparation, paraffin embedding 
After a minimum of 24 hours on a gentle shaker the fixed left lung lobe underwent paraffin 
embedding.  Using a Citadel 1000 tissue processor (Thermo Fisher Scientific, United 
Kingdom) the lung went through water-alcohol-histoclear dehydration steps before 
embedding in paraffin wax (Table 2-1). 
2.5.1.1. Sectioning 
The embedded lung blocks were kept at room temperature for long term storage. Prior to 
sectioning they were placed at -20°C to harden the wax which assisted with the cutting 
process. Frontal plane lung sections were cut at 5µm thickness using a microtome (Leica 
RM2125, Lecia Microsystems, Milton Keynes, United Kingdom). Cut sections were placed 
in water at 37°C and then mounted onto polylysine coated slides, these were stored at 
room temperature. 
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Table 2-1 Paraffin embedding process for rat lung samples 
Step condition Time for step condition 
Water Instant 
70% Ethanol in water 2.5 hours 
80% Ethanol in water 2.5 hours 
95% Ethanol in water 2.5 hours 
95% Ethanol in water 2.5 hours 
100% Ethanol in water 2 hours 
100% Ethanol in water 2 hours 
100% Ethanol in water 2 hours 
Histoclear 1.5 hours 
Histoclear 1.5 hours 
Paraffin wax 1 hour 
Paraffin wax 1 hour 
Lung tissue was washed in running water to remove excess NBF before placement in processor. 
2.5.2. Immunohistochemistry 
Paraffin wax was removed from lung sections by incubation in xylene for 30 minutes, the 
sections were rehydrated through an alcohol-water gradient that consisted of; 100% 
ethanol for 10 minutes, 100% ethanol for a further 5 minutes, 90% ethanol for 2 minutes 
and 70% ethanol for 2 minutes. The sections were washed in running water for 10 minutes. 
Fixing of tissues in formalin can lead to the masking of antigen sites by protein cross-
linking, this was overcome by incubating the sections in 10mM citric acid buffer (pH 6.0 
2.1g/L) (Sigma Aldrich, Dorset, United Kingdom). Antigen retrieval was achieved by boiling 
the buffer containing the sections in a microwave for 4x 5 minutes, the sections were then 
left to cool in the buffer at room temperature for 20 minutes. Sections were washed in 
running water for 10 minutes before being immersed for 30 minutes in 3% hydrogen 
peroxide (v/v) in methanol solution. This solution blocks the action of endogenous 
peroxidases present in the tissue to prevent excess non-specific staining. The sections 
were washed in running water for 10 minutes before a further 10-minute wash in tris-
buffered saline (TBS) pH 8.4 (50mmol/L Tris, 150mmol/L NaCl). The sections were 
blocked for 1 hour with 2.5% (v/v) horse serum (ImmPRESS kit, Vector Labs, 
Peterborough, United Kingdom) in a humidified chamber. The primary antibody (Table 2-
3) was diluted in 1% (w/v) bovine serum albumin (BSA) in 10mM phosphate buffered saline 
(PBS) (Sigma Aldrich, Dorset, United Kingdom). The sections were incubated with the 
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primary antibody overnight at 4°C in a humidified chamber. The primary antibody was 
removed by 3x 10 minute washes in TBS and sections were incubated with anti-rabbit Ig 
peroxidase polymer secondary antibody (ImmPRESS kit, Vector Labs, Peterborough, 
United Kingdom) for 1 hour at room temperature in a humidified chamber. The sections 
were washed twice for 10 minutes in TBS before visualisation of the bound primary 
antibody. This was achieved by a 3-5 minute incubation of the sections with 3,3’-
diaminobenzidine (DAB) substrate kit (Vector Labs, Peterborough, United Kingdom). A 
positive visualisation was indicated by dark brown staining. To prevent excessive staining, 
sections were placed in running water for 10 minutes to terminate the reaction. To stain 
nuclei and cytoplasm the sections was counterstained with haematoxylin and eosin for 5 
minutes before a final wash in running water for 5 minutes to remove excess stain. The 
lung sections were rapidly dehydrated by an alcohol-water gradient that consisted of 70% 
ethanol for 2 minutes, 90% ethanol of 2 minutes, 100% ethanol for 5 minutes and 100% 
ethanol for 10 minutes. Sections were immersed twice in histoclear for 10 minutes each. 
Tissue-tek (Sakura Finetek, Netherlands) was used to mount cover slides onto lung 
sections and the antibody staining was identified and photographed on a Zeiss Image M.1 
AX10 and axiovision Rel 4.8 (Carl Zeiss Microscopy Ltd, Cambridge, United Kingdom). 
2.5.2.1. Elastin pico-sirius red staining 
To measure pulmonary vascular remodelling an adapted Millar’s Elastin protocol was used 
(Miller, 1971). Wax was removed from lung sections by immersion in histoclear for 20 
minutes, the sections were rehydrated through an alcohol-water gradient. This consisted 
of 100% ethanol for 5 minutes, 90% ethanol for 5 minutes and 70% ethanol for 5 minutes, 
sections were place in running water for 5 minutes. To enhance staining sections were 
placed in potassium permanganate (KMNO4) for 5 minutes, followed by rinsing in running 
water. To remove excess KMNO4 staining sections were immersed in 1% oxalic acid 
followed by a further rinse in running water. Lung sections were submerged in Millers 
Elastin stain (Thermo Fisher Scientific, United Kingdom) for 2 hours. Excess elastin stain 
was removed firstly by a short rinse in 95% ethanol followed by a rinse in running water. 
The sections were counter-staining with picro-sirius red for 2-3 minutes and rinsed in 
running water. Sections were rapidly dehydrated through an alcohol-water gradient 
consisting of 70% ethanol for 1 minutes, 90% ethanol for 1 minute, 2 100% ethanol 
incubations for 5 minutes each and 2 final immersions in histoclear for 5 minutes. As with 
immunohistochemistry, the sections were mounted by cover slips and staining was 
identified and analysed on a light microscope. The resultant staining visualised elastic 
fibres having a dark/black appearance and collagen as red. 
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2.5.2.2. Pulmonary vascular remodelling 
Pulmonary vascular remodelling was assessed in 5µm lung sections stained with Miller’s 
elastin and picro-sirius red as per section 2.5.2.1. Pulmonary arteries <80µm external 
diameter were microscopically assessed for a change in the elastic lamina. Pulmonary 
arteries were classified as non-remodelled vessels due to the presence of a single elastic 
lamina. Remodelled pulmonary arteries were identified by the presence of a double elastic 
laminae. The level of remodelling was expressed as a percentage of remodelled and non-
remodelled pulmonary arteries to the total number of pulmonary arteries. This assessment 
was carried out in a blinded fashion. 
2.6 Western Blotting 
2.6.1. Protein extraction 
Protein was isolated from human pulmonary artery smooth muscle cells (hPASMCs) grown 
in 6-well cell culture plates. Briefly, upon experimental conclusion the plates were placed 
on ice, the media was immediately removed and the cells were wash twice with 2ml of ice-
cold PBS. Following the removal of PBS, 120µl of ice-cold radio immuno precipitation 
assay (RIPA, Thermo Fisher Scientific, United Kingdom) buffer was added to each well. 
The buffer was supplemented with protease inhibitors; 0.1mmol/l PMSF 
(phenylmethylsulfonyl fluoride), 1µg/ml soybean trypsin inhibitor and 1µg/ml benzamidine. 
RIPA buffer with protease inhibitors lyse whole cells allowing solubilisation of protein while 
preventing denaturing. While on ice the cells were scraped using a sterile plastic scraper 
(#3010, Corning, United Kingdom) and collected in a 1.5ml eppendorf also on ice. The 
samples were left on ice for 30 minutes to allow for the dissociation of protein complexes. 
To isolate proteins from whole lung tissue, a portion of the frozen right lung lobe was placed 
in a 2ml eppendorf tube supplemented with 600µl of RIPA buffer with added protease 
inhibitors at 4°C. To homogenise the lung, a 5mm stainless steel ball was added to each 
eppendorf and they were placed in a Tissue Lyser II (Qiagen, United Kingdom). At a 
frequency of 25Hz the samples were shaken at high speed for 4x 30 second intervals with 
30 seconds pauses in between, to prevent excess heat build-up. The samples were left 
for 30 minutes on ice after-which they were sonicated on ice for 2 minutes to aid 
dissociation of protein complexes. Samples were then centrifuged at 8,500xg for 10 
minutes at 4°C. The supernatant from the sample was transferred into a fresh ice-cold 
eppendorf and stored at -80°C, the remaining sample pellet was discarded. 
2.6.2. Bicinchoninic acid assay 
Protein concentrations were determined using a bicinchoninic acid (BCA) assay (Thermo 
Fisher Scientific, United Kingdom). The reaction involves the reduction of Cu2+ to Cu+ by 
protein, the bicinchoninic acid binds to the reduced Cu+ to form a complex that is purple in 
colour and absorbs light at a 562nm wavelength (Smith et al., 1985). With hPASMCs and 
lung, protein concentration was evaluated against a standard curve of BSA (0.2mg/ml 
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diluted in RIPA buffer). Briefly, concentrations were determined by an average of 
experimental samples and BSA standards pipetted in duplicate into a 96-well plate. BCA 
assay solution was formulated by supplementing 9.8ml of reagent A with 200µl of reagent 
B and thoroughly mixed. 200ul of the BCA solution was added to each well and the plate 
was placed on a micro-plate shaker for 15-20 minutes until a colour change was evident. 
A POLARstar OPTIMA microplate reader (BMG Labtech, Germany) read the plate at a 
562nm wavelength. A standard curve of BSA standards was obtained and the 
experimental protein sample concentrations were determined. 
2.6.3. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Protein from hPASMCs and lung tissue was separated according to their molecular weight 
using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
NuPAGE reducing agent and sample buffer (Life Technologies, United Kingdom) was 
added to protein samples for loading visualisation. Prior to loading, protein samples were 
heated for 10 minutes at 70°C to ensure denaturing and protein reduction, this enabled 
greater antibody recognition. Protein samples were loaded into Noves NuPAGE 4-12% 
Bis-Tris mini gels, the concentration of protein examined was 10µg for hPASMCs and 25µg 
for lung tissue. SeeBlue Plus2 (Life Technologies, United Kingdom) was used as pre-
stained molecular weight marker, this allowed the electrophoresis progression to be 
examined and to check the molecular weight of proteins. The loaded gel was immersed in 
5% NuPAGE MOPS running buffer in distilled water (dH2O) and a constant current of 150 
volts was applied thereby the proteins were slowly separated due to molecular weight. 
2.6.4. Protein transfer 
Once electrophoresis was completed the proteins were transferred to a polyvinylidene 
difluoride (PVDF) membrane (Millipore Corporation, Massachusetts, United States). The 
PVDF membrane was pre-soaked in 100% methanol to activate it. The protein transfer 
solution contained 5% NuPAGE transfer buffer, 20% (v/v) methanol in dH2O. The transfer 
was run at a constant 30 volts for 2-3 hours, this allow for the proteins to migrate from gel 
to PVDF membrane. To ensure successful transfer, Ponceau S in a 5% (v/v) acetic acid 
solution was added to visualise protein bands on the PVDF membrane. Ponceau was 
washed from the blots with TBS-tween (TBS-T) (0.1% (v/v) Tween 20 (Fisher Scientific, 
United Kingdom)). PVDF membranes were then placed in 5% (w/v) non-fat milk (Marvel) 
solution in TBS-T for 1 hour to block non-specific background binding of antibodies. Before 
incubation with primary antibody the membrane was washed in TBS-T for 3x 10 minutes. 
2.6.5. Immunoblotting 
Specific protein analysis was carried out by incubating the membrane with a primary 
antibody (Table 2-3) diluted in 5% (w/v) marvel or 5% (w/v) BSA in TBS-T. Membranes 
were stored overnight on a shaker at 4°C. After incubation, the membranes were washed 
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for 3x 10 minutes in TBS-T, this removed any unbound excess primary antibody. Suitable 
secondary antibody, conjugated with HRP was added to membranes for 1 hour at room 
temperature, the membranes were placed on a shaker for the duration of incubation. The 
HRP allows detection by an enhanced chemiluminescence (ECL) solution, due to the 
presence of luminol. Luminol when oxidised by HRP which emits light which can be 
visualised by exposure to x-ray film. The two ECL solutions used were Immoblion western 
chemiluminescence HRP substrate (Merck Millipore, Massachusetts, United States) and 
Pierce ECL (Thermo Scientific, United Kingdom). The human IP receptor has been 
previously identified as having two sites for N-linked glycosylation (Zhang et al., 2001b). 
The choice of primary antibody for the IP receptor highlighted that due to receptor 
glycosylation visualisation of the receptor may occur at 67kDa or 40kDa. However, no 
band at 67kDa was identified therefore the protein band at 40kDa was used for analysis. 
After protein visualisation, membranes were washed in TBS-T for 10-15 minutes before 
being immersed in Restore western blot stripping buffer (Thermo Scientific, United 
Kingdom) for 15 minutes on a shaker. Consistent protein loading across the membrane 
was ensured by membranes being re-probed with a loading control antibody as above. For 
hPASMCs α-tubulin was used, whereas β-actin was used for lung tissue. Protein 
expression was quantified by densitometry analysis using TotalLab 1D gel analysis 
(TotalLab, United Kingdom). Expression was defined as protein: loading control ratio. 
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Table 2-2 Antibodies used across experiments 
Antibody Host animal Source Primary 
Dilution 
Secondary 
Dilution 
Molecular 
Weight 
BMPR-II Mouse 
monoclonal 
BD 
Biosystems 
(612292) 
1:500  1:10000 130/115kDa 
pSmad 1/5/9 Rabbit 
polyclonal 
Cell 
Signalling 
(9511) 
1:1000  1:10000  55-60kDa 
 
Id1 Rabbit 
polyclonal 
Cal 
Bioreagents 
(M085) 
1:1000  1:10000  20kDa 
Id3 Rabbit 
polyclonal 
Cal 
Bioreagents 
(M100) 
1:1000  1:10000 17kDa 
IP Receptor Rabbit 
Polyclonal 
Cayman 
Chemical 
(10005518) 
1:1000  
 
1:5000  40kDa (can be 
glycosylated at 
67kDa) 
EP2 Receptor Rabbit 
monoclonal 
Abcam 
(ab167171) 
1:1000  1:5000  50kDa 
 
DP1 receptor Rabbit 
polyclonal 
Abcam 
(ab99446) 
1:1000  1:5000 40kDa 
ETA Receptor Rabbit 
polyclonal 
Abcam 
(ab117521) 
1:1000  
 
1:5000 49kDa 
ETB Receptor Rabbit 
polyclonal 
Santa Cruz 
(sc-33537) 
1:1000  1:5000 55kDa 
 
α-tubulin Mouse 
monoclonal 
Abcam 
(ab80779) 
1:5000  1:5000  50kDa 
 
β-Actin Mouse 
monoclonal 
Sigma Aldrich 
(A5441) 
1:5000  1:5000  42kDa 
α-smooth 
muscle actin 
Rabbit 
polyclonal 
Abcam 
(ab5694) 
1:200  Immuno-
histochemistry 
stain 
BMPR-II = bone morphogenetic protein receptor-II; pSmad = phosphorylated smad; Id = inhibitor 
of DNA binding; IP = prostaglandin I2 receptor (prostacyclin); EP2 = prostaglandin E2 receptor 2; 
DP1 = prostaglandin D2 receptor 1; ET = Endothelin. 
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2.7 RNA analysis 
Ribonucleic acid (RNA) was isolated from human pulmonary artery smooth muscle cells 
(hPASMCs) grown in 6-well cell culture plates. Briefly, upon experimental conclusion the 
plates were placed on ice, the media was immediately removed and the cells were washed 
twice with 2ml of ice-cold PBS. Following the removal of PBS, 700µl of Qiazol (Qiagen, 
United Kingdom) was added to each well. Qiazol is a lysis reagent that facilitates the lysis 
of cells and/or tissue, while inhibiting RNases. While on ice the cells were scraped using 
a sterile plastic scraper (#3010, Corning, United Kingdom) and collected in a 1.5ml 
eppendorf, which was also on ice. To isolate RNA from whole lung tissue, a portion of the 
frozen right lung lobe was placed in a 2ml eppendorf tube, at 4°C, supplemented with 
700µl of Qiazol. To homogenise the lung, a 5mm stainless steel ball was added to each 
eppendorf and they were placed in a Tissue Lyser II (Qiagen, United Kingdom). At a 
frequency of 25Hz the samples were shaken at high speed for 4x 30 second intervals with 
30 seconds pauses in between to prevent excess heat build-up. Purification and extraction 
of RNA was carried out using the miRNEASY extraction kit (Qiagen, United Kingdom). 
Briefly, after homogenisation samples were left at room temperature for 5 minutes, this 
helps promote dissociation of nucleoprotein complexes. 140µl of chloroform was added to 
the samples and shaken vigorously for 15 seconds. The samples were left for 3 minutes 
at room temperature before being centrifuged at 4°C at 12,000xg for 15 minutes.  The 
samples separate into 3 distinct layers; an upper aqueous layer, a white interphase and a 
low red organic phase. The aqueous phase was carefully transferred to a new RNAse free 
1.5ml eppendorf. To precipitate the RNA, 525µl of ethanol was added to the separated 
aqueous phase and mixed thoroughly. 700µl of the mixed sample was transferred to a 
RNeasy mini column in a 2ml collection tube and centrifuged at 8,000xg for 15 seconds at 
room temperature. The flow through in the collection tube was discarded before the 
remaining mixed sample was added to the mini column and centrifuged as before. To 
prevent deoxyribonucleic acid (DNA) contamination of the RNA, a DNase digest was 
carried out. Firstly, the mini column was washed with 350µl of RWT buffer and centrifuged 
at 8,000xg at room temperature for 15 seconds, then the flow through was discarded. 80µl 
of DNase digestion solution (1:7 ratio DNAse1/RDD buffer) was added to each mini column 
to ensure complete digestion of DNA. After a room temperature incubation of 15 minutes 
the columns were washed with 350µl of RWT buffer and centrifuged at 8,000xg for 15 
seconds. Subsequently the flow through was discarded and 500µl of RPE buffer was 
added to the column. The column was centrifuged at 8,000xg for 15 seconds with the flow 
through discarded, the previous step was repeated with RPE buffer and the column 
centrifuged for 2 minutes. The mini columns were placed in a new 2ml collection tube and 
were centrifuged at 12,000xg for one minute to remove any excess RPE buffer. The mini 
columns were placed in 1.5ml eppendorf tubes and 33ul of RNase free water was added 
directly to the column membranes. The columns were centrifuged for 1 minute at 8,000xg, 
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this isolated the RNA from the column membrane. The collected RNA was immediately 
placed on ice or transferred to -80°C freezer.  
2.7.1. RNA quantification and integrity 
The concentration and integrity of RNA was assessed by a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific, United Kingdom). The absorbance of RNA was 
quantified by measuring the absorbance of the sample at 260nm and 280nm. RNA purity 
was determined by a 2.0 or greater ratio of 260nm/280nm measurements. The 
concentration of RNA was determined by the Beer-Lambert equation, the extinction 
coefficient for RNA is 40 ng-cm/µl:  
RNA (ng/µl) = (Absorbance (260nm) x wavelength-dependant extinction coefficient) 
                                                                  Path length in cm 
2.7.2. Reverse transcription 
To measure messenger RNA (mRNA) expression in RNA isolated from hPASMCs or lung 
tissue, they were first reverse transcribed to single stranded complementary DNA (cDNA). 
This was achieved using Taqman® reverse transcription reagents (Life Technologies, 
United Kingdom). For each 20µl reaction 500ng of RNA from hPASMCs and 1µg of RNA 
from lung samples were reverse transcribed. Each reaction mix consisted of: 10x RT 
buffer, MgCl2 (25mM), deoxyribonucleotide triphosphates (dNTPs) (10mM), random 
hexamers (50µM), RNase inhibitor (20U/µl) and Multiscribe™ (50u/µl). Each cDNA 
preparation was carried out in 96-well plates, which were centrifuged after addition of 
reaction mix and RNA. Reverse transcription (RT) was carried out using the Veriti® 
Thermal Cycler (Life Technologies, United Kingdom) with the temperature cycling 
sequence: 25°C for 10 minutes, 48°C for 30 minutes and 95°C for 5 minutes. The 
sequence allows for RNA template annealing, reverse transcription and transcription 
inactivation. The 96-well cDNA plate was then stored at -20°C. 
2.7.3. Quantitative real time-polymerase chain reaction 
MRNA expression was validated by quantitative real time-polymerase chain reaction (qRT-
PCR). This was achieved using Taqman® universal master mix and fluorescently tagged 
Taqman® primers (Life Technologies, United Kingdom) (Figure 2-4). Each Taqman® 
primer had a FAM® dye label on the 5’ end and nonfluorescent quencher on the 3’ end. 
Samples were loaded in triplicate using a 384-well plate format. For every Taqman® primer 
used a no template control (NTC) was added to ensure no contamination occurred. The 
ViiA7™ Real-Time PCR system (Life Technologies) was used under the following 
conditions: 50°C for 2 minutes, 95°C for 10 minutes then 50 cycles of 95°C for 15 seconds 
and 60°C for 1 minute. Comparative cycle threshold (CT) was used to quantify the 
expression results. The CT value was inversely proportional to the level of mRNA 
expression in the sample. A δCT is obtained from difference between CT of the mRNA of 
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interest and the CT of the housekeeper RNA. A δδCT value is obtained from the difference 
in δCT from test sample to the δCT of a control sample. Data is represented as the relative 
quantification (RQ:2-δδCT) or fold change compared to chosen control group.  
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Table 2-3 Taqman gene expression assay IDs 
Gene Species Assay ID 
IP Receptor 
 
Human 
Rat 
Hs00168765_m1 
Rn01764022_m1 
EP1 Receptor 
 
Human Hs00909194_g1 
 
EP2 Receptor 
 
Human 
Rat 
Hs00168754_m1 
Rn00579419_m1 
DP1 Receptor 
 
Human 
Rat 
Hs00235003_m1 
Rn04223963_g1 
BMPR-II Human 
Rat 
Hs00176148_m1 
Rn01437214_m1 
Id1 Human 
Rat 
Hs03676575_s1 
Rn00562985_s1 
Id3 Human 
Rat 
Hs00954037_g1 
Rn00564927_m1 
EDNRA Human Hs03988672_m1 
EDNRB Human Hs00240747_m1 
EDN1 Human Hs01115919_m1 
SMURF1 Rat Rn01412795_m1 
SMURF2 Rat Rn01452783_m1 
KCNK3 Rat Rn04223042_m1 
β2-Microglobulin 
 
Human 
Rat 
Hs00187842_m1 
Rn00560865_m1 
IP = prostaglandin I2 receptor (prostacyclin); EP1 = prostaglandin E2 receptor 1; EP2 = 
prostaglandin E2 receptor 2; DP1 = prostaglandin D2 receptor 1; BMPR-II = bone morphogenetic 
protein receptor-II; Id = inhibitor of DNA binding; EDNRA/B = endothelin receptor A/B; EDN1 = 
prepro-endothelin-1; SMURF1/2 = SMAD Specific E3 Ubiquitin Protein Ligase 1/2; KCNK3 = 
Potassium Two Pore Domain Channel Subfamily K Member 3. 
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2.8 Cell culture 
All cell culture procedures were carried out under sterile conditions using a Biological 
Safety Class II vertical laminar flow cabinet. All cells were maintained and stored in a 
humidified incubator (Eppendorf, United Kingdom) at 37° with a continuous supply of 5% 
CO2 and 95% air. 
2.8.1. Human pulmonary artery smooth muscle cells 
Human pulmonary artery smooth muscle cells (hPASMCs) were provided by Professor 
Nicholas. W. Morrell (University of Cambridge, Cambridge, United Kingdom). Briefly, both 
male and female hPASMCs were explanted from the distal pulmonary arteries (~1mm 
external diameter) of macroscopically lung tissue as described previously (Wharton et al., 
2000). Human PAH PASMCs were explanted from patients with either idiopathic, heritable 
or associated PAH. These PASMCs were studied collectively as PAH patient cells (Table 
2-5). Non-PAH/control PASMCs were explanted from patients with no evidence of PAH, 
these PASMCs were studied as controls (Table 2-5). The smooth muscle phenotype was 
confirmed by the general cell morphology (Figure 2-5) and by alpha smooth muscle 
staining in Cambridge. HPASMCs were grown in 75cm3 (T75) culture cell flasks in 
Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, United Kingdom). This 
was supplemented with 10% (v/v) fetal bovine serum (FBS, Life Technologies, United 
Kingdom), 1% (v/v) antibiotic antimycotic solution (10,000 units penicillin, 10mg 
streptomycin and 25µg amphotericin B, Sigma Aldrich, Dorset, United Kingdom). 
HPASMCs were grown to 90-95% confluency in T75 flasks to avoid growth arrest by cell-
cell contact inhibition. For passaging, the reagents used were warmed to 37°C before 
DMEM was removed from the flask and hPASMCs were washed twice in 5ml sterile DPBS. 
The cells were removed from the flask using 2ml of trypsin/EDTA solution (0.1% (w/v) 
EDTA in PBS, Life Technologies, United Kingdom) and incubation at 37°C for two minutes, 
to aid trypsinisation. Trypsin is a proteolytic enzyme that can detach the hPASMCs from 
the flask however it must be deactivated quickly to ensure cell viability. This was achieved 
by adding 8ml of 10% (v/v) FBS DMEM to the flask. The hPASMCs were then further sub-
cultured into 96, 24, 6-well plates and T75 flasks depending on experimental protocol. 
HPASMCs were used for experiments in between passages 3-8. 
2.8.2. Proliferation assay protocols 
For proliferation assays, hPASMCs were seeded in 24-well plates at a density of 10,000 
cells per well and grown in 10% (v/v) FBS DMEM to 50-60% confluency. HPASMCs were 
subsequently quiesced in 0.5% (v/v) FBS phenyl-red free DMEM (Life Technologies, 
United Kingdom) for 24 hours, this allows the synchronisation of hPASMCs’ cell cycles 
before experimental start. For experiments involving treprostinil with/without endothelin 
and prostaglandin receptor agonists, hPASMCs proliferation was carried out over 72 hours 
in presence 7% (v/v) FBS phenyl-red free DMEM. The concentrations of treprostinil used 
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over the course of hPASMCs study allowed the examination of all the prostaglandin 
receptors that treprostinil activates (Table 2-5). Previously published research involving 
treprostinil also influenced the range of concentrations chosen (Falcetti et al., 2007, 
Falcetti et al., 2010). Drugs and media were replaced after 48-hours in all 72-hour 
experiments. For collection of protein and RNA, hPASMCs were seeded in 6-well plates 
and grown to 60-70% confluency in 10% (v/v) FBS DMEM. When appropriate, antagonists 
were added 30 minutes prior to the addition of agonists and drugs and media were 
replaced after 48-hours. Concentrations of antagonists used in experiments were 
influenced by previous published research carried out in hPASMCs (Falcetti et al., 2010, 
Bubb et al., 2014, Patel et al., 2014). 
2.8.3. Haemocytometer cell counting 
To evaluate proliferation, hPASMCs were manually counted using a haemocytometer 
(Camlab, United Kingdom). At the end of experiments, DMEM was aspirated off and 
hPASMCs were washed in 1ml of 37°C sterile DPBS. After removing DPBS, 150µl of 
trypsin/EDTA solution (Life Technologies, United Kingdom) was added to each well. The 
plate was placed at 37°C to aid the detachment of the hPASMCs from the wells. The 
detached hPASMCs were re-suspended in 500µl of 10% (v/v) FBS DMEM per well and 
mixed. The suspended cells and media were transferred to a 1.5ml eppendorf tube and 
the suspension was centrifuged at 3,500xg at 4°C for 10 minutes, this produced a cell 
pellet. The media was carefully removed to ensure the pellet remained intact. The pellet 
was then re-suspended in a known volume of 10% (v/v) FBS DMEM and vortexed to 
ensure complete re-suspension. Using the haemocytometer, 10µl of cell suspension was 
pipette onto the grid. Via a hand tally counter, the cells in each 16-squared corner were 
counted. The haemocytometer is designed so that every 16-squared corner is equal to the 
number of cells 104/ml (Figure 2-6). An average of the 4 corners was used to calculate the 
mean number of cells 104/ml. These experiments were carried out in a blinded manner. 
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Figure 2-5 Morphology of human pulmonary artery smooth muscle cells. 
Photograph of sub-confluent human pulmonary artery smooth muscle cells grown in a T75 culture 
flask. Scale bar 100µM. 
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Figure 2-6 Haemocytometer layout 
Layout representation of haemocytometer grid. Pulmonary artery smooth muscle cells counted in 
16-square corners to produce an average cell number x104 per ml. 
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Table 2-4 Patient information for human pulmonary arterial smooth muscle cells (hPASMCs) 
Patient ID number Sex Age Disease state 
34MP Male 62 Control (Emphysema) 
103MP Male 52 Control 
(Adenocarcinoma) 
79MP Male 60 Control (Squamous 
cell carcinoma) 
75MP Male 78 Control (Metastatic 
disease) 
9MP Male 72 Control (N/A) 
105MP Female 57 Control (Emphysema) 
77MP Female 64 Control (Mild 
emphysema) 
106MP Female 70 Control (Lung 
carcinoma) 
32MP Female 58 Control (Mild 
emphysema) 
84MP Female 59 Control (Squamous 
cell carcinoma) 
82MP Female 71 Control 
(Adenocarcinoma) 
56MP Male N/A HPAH (C347R) 
67MP Male 22 HPAH (W9X) 
23MP Male 43 APAH (Eisenmengers 
Syndrome) 
74MP Male N/A PAH 
37MP Female 24 IPAH 
115MP Female N/A APAH 
35MP Female N/A HPAH (N903S) 
38MP Female N/A PAH 
73MP Female 30 HPAH (R899X) 
IPAH = Idiopathic pulmonary arterial hypertension: APAH = associated pulmonary arterial 
hypertension: HPAH = Heritable pulmonary arterial hypertension.  
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Table 2-5 Treprostinil Ki values at prostaglandin receptors 
Prostaglandin Receptor Treprostinil Ki (nM) 
IP 32.1 ± 0.2 
EP1 212 ± 56 
EP2 3.6 ± 0.3 
EP3 2505 ± 263 
EP4 826 ± 116 
DP1 4.4 ± 0.4 
FP 4680 ± 927 
TP Not calculable 
Treprostinil binding profile for prostanoid receptors. Data gather using displacement radioligand 
binding from cell membranes that expressed recombinant human prostanoid receptors. Table taken 
from (Whittle et al., 2012) 
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2.9 Statistical Analysis 
All statistical analysis was carried out using GraphPad Prism 6.0© (GraphPad Software 
Inc, United States). All values are expressed as mean ± standard error of the mean (SEM). 
Unpaired student’s t-tests were used for comparing two treatment groups. One or two-way 
ANOVA followed by Bonferroni’s post-hoc test was performed to evaluate the statistical 
significance between three or more groups where appropriate. A probability level of <0.05 
was defined as being statistically significant. 
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Chapter 3 
3 The effect of treprostinil in the chronic hypoxic model 
of pulmonary hypertension   
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3.1. Introduction 
Registry and epidemiological studies have demonstrated the increased incidence of 
females over males in developing pulmonary arterial hypertension (PAH) (McGoon et al., 
2013, Badesch et al., 2010). However, the estimated 5-year survival rate for males is lower 
than females, at 52% and 62% respectively (Shapiro et al., 2012). Studies have found that 
females with PAH have better compensation of the right ventricle of the heart in response 
to increased pulmonary arterial pressure than males. This leads to greater right ventricle 
function in PAH and this may contribute to greater survival (Humbert et al., 2010a, Benza 
et al., 2012). 
Much of the research into sex differences in PAH has focused on the female predisposition 
to the disease. Indeed, estrogen has been identified to be a possible risk factor in PAH. In 
serotonin-dependent animal models of pulmonary hypertension (PH) there is a female 
susceptibility related to circulating estrogen (Dempsie et al., 2011, Dempsie et al., 2013, 
White et al., 2011a). Recent studies from the Maclean lab have shown that aromatase, the 
enzyme synthesising estrogen, was found to have greater expression in female human, 
rat and muscle pulmonary artery smooth muscle (Mair et al., 2014). Inhibiting aromatase 
by anastrozole reversed PH in hypoxic and sugen-hypoxia (SU-HX) models of PH but only 
in females (Mair et al., 2014). In contrast, there is also some evidence to suggest that 
estrogen can have beneficial effects in PH models. 17-β estradiol has been shown to 
attenuate PH development in male hypoxic (Xu et al., 2010, Lahm et al., 2012) and 
monocrotaline animal models of PH (Farhat et al., 1993). Similar beneficial effects of 
estrogen were latterly discovered in female rats (Resta et al., 2001, Nadadur et al., 2012, 
Yuan et al., 2013). 
Mutations of the BMPR-II encoding gene are found in up to 75% of heritable PAH (HPAH) 
and 20% of idiopathic patients (IPAH) (Hamid et al., 2009, Atkinson et al., 2002). 
Dysregulated BMPR-II receptor can lead to a reduction in the function of its downstream 
signalling pathway.(Yang et al., 2005). In pulmonary arteries, reduced BMPR-II receptor 
expression has been associated with increased proliferation of smooth muscle cells (Yang 
et al., 2005) and increased apoptosis of pulmonary endothelial cells (Teichert-Kuliszewska 
et al., 2006). BMPR-II has been previously identified as a target for prostacyclin analogues 
such as treprostinil (Yang et al., 2010). The Maclean lab has detected sex differences in 
BMPR-II signalling expression, as female control hPASMCs have lower expression than 
in males (Mair et al., 2015).  
This was the first study to examine the impact of sex on the therapeutic actions of 
treprostinil, however the impact of sex on other drug therapies has been previously 
explored. Greater positive clinical outcomes for tadalafil, a phosphodiesterase 5 inhibitor, 
were associated with males over females (Mathai et al., 2015). However, females with 
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PAH had greater therapeutic responses to endothelin receptor antagonists than males 
(Gabler et al., 2012). Both studies suggest that sex can influence the response to drug 
therapy, however the molecular mechanisms associated with these sex differences were 
not identified.  
It is unclear if sex differences exist in the prostaglandin receptors (IP, EP2 and DP1), which 
are known as major targets of treprostinil (Clapp and Gurung, 2015). Although not 
examined in this current study, treprostinil metabolism occurs primarily through the action 
of CYP2C8 and to a lesser extent through CYP2C9. The addition of a CYP2C8 inducer 
(rifampin) was found to decrease treprostinil blood concentration by 30% whereas a 
CYP2C8 inhibitor (gemifibrozil) doubled treprostinil concentration (Rollins et al., 2009, 
Kumar et al., 2016). 
Clinically, prescribed doses of treprostinil range from an initial dose of 1.25ng/kg/min, this 
can be increased incrementally to 40ng/kg/min, in some cases this can increase to 
125ng/kg/min (Lang et al., 2006, McSwain et al., 2008). In the current study, the initial 
dose of treprostinil was 100ng/kg/min, which is closest to highest dose for clinical use. The 
higher dose (400ng/kg/min) was examined to explore if the female specific response to 
treprostinil was dose dependant. 
This data demonstrates that a slow release of treprostinil in a pellet that was 
subcutaneously implanted was effective method of drug delivery. Novel sex specific effects 
were also observed with a 100ng/kg/min treprostinil, partially reversing an established 
hypoxic PH phenotype in female rats, not in male rats. It demonstrates that the therapeutic 
effects of treprostinil may be partially mediated through increased signalling of the BMPR-
II pathway mRNA. At a higher dose of 400ng/kg/min treprostinil led to a therapeutic 
response in hypoxic male as well as an increased therapeutic response in female rats.  
Hypotheses and aims of this chapter: 
Slow-release subcutaneously implanted pellets have been used previously to dose 
animals in the treatment of pulmonary hypertension (Wright et al., 2015). We hypothesise 
that the PGI2 analogue treprostinil can be successfully delivered to chronic hypoxic rats 
using slow-release subcutaneously implanted pellets as an alternative to repetitive dosing. 
To investigate this hypothesis, the following aim was carried out. 
1. To examine the haemodynamic effects of treprostinil, administered via a slow release 
subcutaneously implanted pellet in the chronic hypoxic model of pulmonary 
hypertension. 
Females and males are known to differ in response to drug therapy for  variety of reasons 
(Soldin and Mattison, 2009). To investigate this our hypothesis is that sex can play a role 
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in altering the effectiveness of treprostinil in an animal model of PH. The following aim 
was carried out: 
2. Study to characterise the influence of sex on the actions of treprostinil in a chronic 
hypoxic rat model of PH and how these effects are mediated. 
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3.2. Results 
3.2.1. Rat blood plasma levels of treprostinil administered via a slow release 
subcutaneous pellet  
Treprostinil is a prostacyclin analogue that is used clinically for the treatment of PAH. We 
wished to investigate if treprostinil administered via a slow release subcutaneously 
implanted pellet could be an effective method of dosing in rats. Briefly, female and male 
rats were implanted with pellets releasing treprostinil at 100ng/kg/min for 14 days. After 4 
days of dosing female and male rats had similar levels of treprostinil in isolated plasma 
(Figure 3-1). After 10 days, we found a significant decrease in treprostinil when compared 
to 4 days in female and male rats. However, this significant reduction persists in male rats 
at 14 days (Figure 3-1). 
  
 Chapter Three In-vivo 
85 
 
 
Figure 3-1 Blood plasma concentration of subcutaneously implanted prostacyclin analogue 
treprostinil  
Female and male sprague-dawley rats were implanted with sub-cutaneous pellet containing 
treprostinil (100ng/kg/min). Blood taken after carotid artery catheterisation, treprostinil levels 
assessed by LC/MS. N=3, *P<0.05 cf. (Female) Day 4, ŦŦ P<0.01 cf. (Male) Day 4, Two-way 
ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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3.2.2. Treprostinil (100ng/kg/min) attenuates development of hypoxia induced PH 
in female rats 
To examine the effectiveness of treprostinil administered via slow release pellet on the 
chronic hypoxic PH model we examined right ventricular systolic pressure (RVSP), right 
ventricular end systolic pressure (RVESP), right ventricular end diastolic pressure 
(RVEDP), right ventricular hypertrophy (RVH) and the level of pulmonary artery 
remodelling. Chronic hypoxia significantly increased RVSP, RVESP, RVH and pulmonary 
remodelling but not RVEDP (Figure 3-2-3-5). Under normoxic conditions, treprostinil had 
no effect on any haemodynamic measurement. However, RVSP was significantly reduced 
by treprostinil in female hypoxic rats but no significant reduction was observed in male rats 
(Figure 3-2). Treprostinil also reduced RVESP (Figure 3-3) and RVH (Figure 3-4). In 
addition, treprostinil reversed pulmonary artery remodelling in females under hypoxic 
conditions, whereas no significant reduction was identified in male rats (Figure 3-5-Figure 
3-6). Right ventricular ejection fraction (RVEF) was significantly decreased in female and 
male hypoxic rats. RVEF was unchanged in female rats treated with treprostinil whereas 
RVEF was decreased by treprostinil in males (Table 3-1). 
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Figure 3-2 Chronic hypoxia increases right ventricular systolic pressure and prostacyclin 
analogue treprostinil attenuates increase in female chronic hypoxic rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Right ventricular systolic pressures (RVSP) were obtained by right heart catheterisation through 
jugular vein. N=5-6, ***P<0.001 c.f (Female) Normoxic Vehicle, ɸɸɸ P<0.001 c.f (Female) Normoxic 
Treprostinil, ξ P<0.05 cf. (Female) Hypoxic Vehicle, ŦŦŦ P<0.001 cf. (Male) Normoxic Vehicle, ǂǂǂ 
P<0.001 c.f (Male) Normoxic Treprostinil,  Two-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as mean ± SEM. 
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Figure 3-3 Chronic hypoxia increases right ventricular systolic end pressure and 
prostacyclin analogue treprostinil attenuates increase in female chronic hypoxic rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. (A) 
Right ventricular systolic end pressure (RVSEP) and (B) right ventricular diastolic end pressure 
(RVDEP) were obtained by right heart catheterisation through jugular vein. N=4-6, ***P<0.001 c.f 
(Female) Normoxic Vehicle, ɸɸɸ P<0.001 c.f (Female) Normoxic Treprostinil, ξξ P<0.01 cf. (Female) 
Hypoxic Vehicle, ŦŦŦ P<0.001 cf. (Male) Normoxic Vehicle, ǂǂǂ P<0.001 c.f (Male) Normoxic 
Treprostinil, Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM.  
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Figure 3-4 Chronic hypoxia increases right ventricular hypertrophy and prostacyclin 
analogue treprostinil attenuates increase in female chronic hypoxic rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Right ventricular hypertrophy (RV Hypertrophy) was assessed by the ratio of the dry weight of the 
right ventricle over the left ventricle plus septum (RV/LV+S; Fulton’s index). N=5-6, ***P<0.001 c.f 
(Female) Normoxic Vehicle, ɸɸɸ P<0.001 c.f (Female) Normoxic Treprostinil, ξ P<0.05 cf. (Female) 
Hypoxic Vehicle, ŦŦŦ P<0.001 cf. (Male) Normoxic Vehicle, ǂǂǂ P<0.001 c.f (Male) Normoxic 
Treprostinil,  Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Figure 3-5 Chronic hypoxia increases pulmonary vessel remodelling and prostacyclin 
analogue treprostinil attenuates increase in female chronic hypoxic rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
The level of pulmonary vessel remodelling was assessed by the ratio of the remodelled and non-
remodelled arteries and expressed as % of the remodelled vessels over the total number of vessels. 
N=5-6, ***P<0.001 c.f (Female) Normoxic Vehicle, ɸɸɸ P<0.001 c.f (Female) Normoxic Treprostinil, 
ξ P<0.05 cf. (Female) Hypoxic Vehicle, ŦŦŦ P<0.001 cf. (Male) Normoxic Vehicle, ǂǂǂ P<0.001 c.f 
(Male) Normoxic Treprostinil,  Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as 
mean ± SEM. Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Figure 3-6 Representative Miller’s elastin and α-smooth muscle actin staining in chronic 
hypoxic rats treated with treprostinil or vehicle 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Vessel remodelling was determined in (A) female and (C) male rats by Miller’s elastin stain, 
remodelled vessels determined by presence of double elastic laminae. Smooth muscle proliferation 
was visualised in (B) female and (D) male rats by α smooth muscle actin (α-SMA) staining. α-SMA 
visualised by DAB staining (dark brown/orange stain). Scale bar = 20µm. 
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3.2.3. Treprostinil (100ng/kg/min) does not change systemic haemodynamics 
As treprostinil is a vasodilator we wanted to examine any changes in systemic 
haemodynamic measures. Neither hypoxia nor treprostinil affected LVSP (Figure 3-7), 
cardiac output (CO) (Figure 3-8) or heart rate (HR) (Figure 3-9) (Table 3-1). 
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Figure 3-7 Chronic hypoxia and prostacyclin analogue treprostinil do not alter left ventricular 
systemic pressure 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Left ventricular systolic pressures (LVSP) were obtained by left heart catheterisation through carotid 
artery. N=4-6, Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Figure 3-8 Chronic hypoxia and prostacyclin analogue treprostinil do not alter cardiac output  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Cardiac output taken from left heart catheterisation through carotid artery. N=4-6, Two-way ANOVA 
with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Figure 3-9 Chronic hypoxia and prostacyclin analogue treprostinil do not alter heart rate  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Heart rate was measured by heart beats per minute (BPM). N=5-6, Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Table 3-1 Effect of prostacyclin analogue treprostinil (100ng/kg/min) in normoxic or hypoxic 
rats on haemodynamics and phenotypes 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions (1000/550mbar) for two 
weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or vehicle was implanted and rats 
returned to normoxic/hypoxic conditions for a further two weeks.  Mean right ventricle pressure (mRVP) and 
right ventricle ejection fraction (RVEF) was measured by cannulation of right external jugular vein. Mean left 
ventricle pressure (mLVP) was measured by cannulation of right internal carotid artery. N numbers indicated 
in brackets. *P<0.05 c.f normoxic vehicle, ***P<0.001 c.f female normoxic (Veh), ɸɸ P<0.01, ɸɸɸ P<0.001 cf. 
female normoxic (Trep), Ŧ P<0.05, ŦŦŦ  P<0.001 c.f male normoxic (Veh), ǂ P<0.05, ǂǂǂ P<0.001 cf. male 
normoxic (Trep),   Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. Veh = 
vehicle, Trep = treprostinil 
 
  
Group mRVP (mmHg) RVEF (%) mLVP (mmHg) Body Weight 
(g) 
Female 
Normoxic 
(Veh) 
13.1 ± 1.89  
(5) 
20.74 ± 1.69  
(4) 
42.19 ± 1.35  
(4) 
216.4 ± 5.14 
(5) 
Female 
Normoxic  
(Trep) 
14.22 ± 1.19  
(6) 
30.3 ± 3.74  
(6) 
44.39 ± 2.36  
(5) 
212.6 ± 5.69 
(6) 
Female 
Hypoxic 
(Veh) 
24.02 ± 1.19  
     (6) *** 
10.83 ± 1.79 
     (5) ɸɸɸ 
44.42 ± 4.47 (5) 228.8 ± 3.07 
(6) 
Female 
Hypoxic 
(Trep) 
19.32 ± 1.93  
(5) 
12.83 ± 2.73  
(5) ɸɸ 
41 ± 3.42  
(5) 
229.9 ± 3.25 
(6) 
     
Male 
Normoxic 
(Veh) 
17.94 ± 1.18  
(6) 
22.14 ± 2.10  
(6) 
47.3 ± 5.69  
(6) 
276.8 ± 7.91 
(6) 
Male 
Normoxic 
(Trep) 
15.2 ± 0.95  
(6) 
28.62 ± 4.18  
(6) 
46.44 ± 2.21 
 (5) 
276.1 ± 11.1 
(6) 
Male Hypoxic 
(Veh) 
30.2 ± 1.05  
    (6) ŦŦŦ 
11.69 ± 2.28  
(6)  Ŧ/ǂ 
46.32 ± 6.15 
 (5) 
262.9 ± 5.33 
(6) 
Male Hypoxic 
(Trep) 
27.95 ± 2.29  
(6) ŦŦŦ 
9.69 ± 0.96  
(6) Ŧ/ǂǂǂ 
41.36 ± 2.70 
 (6) 
251.9 ± 3.49 
(6) 
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3.2.4. No sex difference in terminal plasma treprostinil levels  
Having demonstrated a sex difference in response to treprostinil, it was important to 
ascertain the level of treprostinil from the blood plasma of rats collected at the termination 
of the study. Despite the low levels of treprostinil found in the plasma there was no 
difference between rats dosed under normoxic or hypoxic conditions (Figure 3-10). 
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Figure 3-10 Terminal measurements of prostacyclin analogue treprostinil from rat blood 
plasma 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Blood taken after carotid artery catheterisation, treprostinil levels assessed by LC/MS. n=3-4, Two-
way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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3.2.5. Treprostinil (100ng/kg/min) influence on prostaglandin receptors: increased 
expression of EP2 mRNA in hypoxic treprostinil treated female rats. 
As treprostinil is known to act through the activation of specific prostaglandin receptors, 
these were examined in the lung tissue of the rats. For this we examined the mRNA levels 
of the prostacyclin (IP), prostaglandin E2 receptor 2 (EP2) and the prostaglandin D2 
receptor 1 (DP1) by Taqman® analysis. Results showed that treprostinil, hypoxia and sex 
had no influence on the expression of any of the IP or DP1 prostaglandin receptors (Figure 
3-11A&C). Treprostinil increased the mRNA expression of the EP2 receptor under hypoxic 
conditions (Figure 3-11B). Interestingly, mRNA expression of the IP receptor was 
significantly higher than both EP2 and DP1 receptors in both female and male rats (Figure 
3-12A-B). Also, in untreated male normoxic rats EP2 mRNA expression was found to be 
significantly higher than DP1 mRNA expression (Figure 3-12B).  
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Figure 3-11 Lung expression of the EP2 receptor was increased by the addition of 
prostacyclin analogue treprostinil  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of the (A) IP,
 
(B) EP2 and (D) DP1 receptors was assessed from whole lung 
homogenates by Taqman® quantitative Real Time-PCR. Results were normalised to β2-
microglobulin. N=2-6 per group in triplicate (N=2 for Female Normoxic (Veh) DP1), ξξ P<0.01 cf. 
(Female) Hypoxic (Veh), Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as RQ 
± RQmax/RQmin. RQ= relative quantification, Veh= vehicle, Trep= treprostinil.   
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Figure 3-12 IP receptor mRNA expression in significantly higher in both female and male 
rats than the EP2 and DP1 receptors 
(A) Female and (B) male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of the IP, EP2 and DP1 receptors was assessed from whole lung homogenates by 
Taqman® quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=2-6 per 
group in triplicate (N=2 for Female Normoxic (Veh) DP1). ***P<0.001 cf. respective IP group, ɸɸɸ 
P<0.01 cf. respective EP2 group, Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed 
as RQ ± RQmax/RQmin. RQ= relative quantification, Veh= vehicle, Trep= treprostinil.  
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3.2.6. Treprostinil (100ng/kg/min) increases expression of Id mRNA in lungs of 
chronic hypoxic female rats 
As BMPR-II dysregulation occurs in PAH we investigated the effects of treprostinil on 
BMPR-II signalling within lung tissue. The mRNA expression of BMPR-II, Id1 and Id3 was 
examined by Taqman® analysis (Figure 3-13). Hypoxia had no impact on the expression 
of BMPR-II, Id1 or Id3. Interestingly we found that, in female hypoxic rats treated with 
treprostinil, there was a significant increase in the mRNA expression of Id1 compared to 
female hypoxic vehicle treated rats. (Figure 3-13B). Id3 mRNA expression was also 
significantly increased in female hypoxic rats treated with treprostinil compared to both 
normoxic treated and untreated female rats (Figure 3-13C). Id3 mRNA expression in 
treprostinil treated hypoxic rats was found to be significantly higher than BMPR-II mRNA 
levels in the equivalently treated female rats (Figure 3-14A). Also, Id3 mRNA levels were 
significantly higher than Id1 in hypoxic vehicle female rats (Figure 3-14A). A comparison 
of BMPR-II, Id1 and Id3 found no significant difference in mRNA expression in male rats 
(Figure 3-14B). MRNA expression of SMAD specific E3 ubiquitin protein ligase 1 and 2 
(SMURF1/2) was not altered by either hypoxic conditions or treprostinil treatment (Figure 
3-15A&B). Expression of the potassium two pore domain channel subfamily K member 3 
(KCNK3) was elevated in female chronic hypoxic rats treated with treprostinil (Figure 3-
15C). The protein levels of BMPR-II, pSmad 1/5/9, Id1 and Id3 were examined in lung 
tissue (Figure 3-16–Figure 3-17). BMPR-II, pSmad 1/5/9, Id1 and Id3 protein expressions 
were not affected by hypoxia (Figure 3-16A-D). Treatment with treprostinil did not 
significantly alter the protein expression of BMPR-II, pSmad 1/5/9, Id1 or Id3 (Figure 3-
17A-D).  
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Figure 3-13 Lung expression of BMPR-2 signalling was unchanged by chronic hypoxia 
however Id1 and Id3 mRNA expression was up-regulated with the addition of prostacyclin 
analogue treprostinil 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) BMPR-II, (B) Id1 and (C) Id3 mRNA were assessed from whole lung homogenates 
by Taqman® quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=3-6 per 
group in triplicate, *P<0.05, cf. (Female) Normoxic (Veh), ɸ P,0.05, ɸɸ P<0.01 cf. (Female) 
Normoxic (Trep), ξξ P<0.01 cf. (Female) Hypoxic (Veh), Two-way ANOVA with Bonferroni’s post-
hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Veh= vehicle, Trep= 
treprostinil. 
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Figure 3-14 Id3 mRNA expression was higher than BMPR-II expression under hypoxic 
conditions upon treprostinil treatment in female rats 
(A) Female and (B) male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of BMPR-II, Id1 and Id3 mRNA were assessed from whole lung homogenates by 
Taqman® quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=3-6 per 
group in triplicate, *P<0.05, cf. respective BMPR-II group, ɸ P<0.05 cf. respective Id1 group, Two-
way ANOVA with Bonferroni’s post-hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= relative 
quantification. Veh= vehicle, Trep= treprostinil. 
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Figure 3-15 Lung expression of SMURF1, SMURF2 were unchanged by chronic hypoxia; 
KCNK3 was increased by treprostinil in combination with hypoxia 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) SMURF1, (B) SMURF2 and (C) KCNK3 mRNA were assessed from whole lung 
homogenates by Taqman® quantitative Real Time-PCR. Results were normalised to β2-
microglobulin. N=3-5 per group in triplicate, ɸ P<0.05, cf. (Female) Normoxic (Trep), Two-way 
ANOVA with Bonferroni’s post-hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= relative 
quantification. Veh= vehicle, Trep= treprostinil. 
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Figure 3-16 Lung protein expression of BMPR-II signalling was not altered by chronic 
hypoxia 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from whole lung 
homogenates by western blot.  (E) Representative immunoblot, β-actin was used as the internal 
loading control. N=3-6 per group in duplicate (n=3 for Female Normoxic (Veh)), Two-way ANOVA 
with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. Veh= vehicle, Trep= treprostinil. 
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Figure 3-17 BMPR-II, pSmad 1/5/9, Id1 and Id3 protein expression was unchanged by 
treprostinil in female and male rats. 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (100ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from whole lung 
homogenates by western blot. (E) Representative immunoblot, β-actin was used as the internal 
loading control. N=5-6 per group in duplicate, Two-way ANOVA with Bonferroni’s post-hoc test. 
Data expressed as mean ± SEM. Veh= vehicle, Trep= treprostinil. 
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3.2.7. Higher treprostinil dose (400ng/kg/min) attenuates PH in female and male 
hypoxic rats 
Having demonstrated that the slow release pellet was an effective dosing method for 
reversing a PH phenotype in females we studied the effects of a higher dose of treprostinil 
(400ng/kg/min) in both female and male rats. This was to determine if the sex differences 
in response to treprostinil would still exist with a higher dose of treprostinil. As before, 
hypoxia caused increases in RVSP, RVSEP, RVH and remodelling in female and male 
rats. Treprostinil decreased RVSP and RVSEP in female and male rats under hypoxic 
conditions (Figure 3-18-Figure 3-19A). Treprostinil reduced RVH and remodelling in both 
female and male hypoxic rats (Figure 3-20-Figure 3-21). Reductions in female RVSP, RVH 
and remodelling were more significant than those observed in the 100ng/kg/min study, 
although the level of reductions were only a small improvement on the early study. As 
before, RVEF was reduced under hypoxic conditions and treprostinil treatment did not 
significantly alter RVEF (Table 3-2). The higher dose of treprostinil did not completely 
reverse the increased pulmonary haemodynamics in either female or male rats. 
The higher dose of treprostinil had no effect on the systemic haemodynamics including 
LVSP, CO, HR or body weight of both rats (Figure 3-23-Figure 3-25), Table 3-2). As 
observed previously, there was no difference in plasma levels of treprostinil between 
normoxic or hypoxic conditions in female and male rats (Figure 3-26). 
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Figure 3-18 Chronic hypoxia increases right ventricular systolic pressure and prostacyclin 
analogue treprostinil attenuates increase in female and male chronic hypoxic rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Right ventricular systolic pressures (RVSP) were obtained by right heart catheterisation through 
jugular vein. N=4-6, ***P<0.001 c.f (Female) Normoxic Vehicle, ɸɸɸ P<0.001 c.f (Female) Normoxic 
Treprostinil, ξξξ P<0.001 cf. (Female) Hypoxic Vehicle, ŦŦŦ P<0.001 cf. (Male) Normoxic Vehicle, 
ǂǂǂ P<0.001 c.f (Male) Normoxic Treprostinil, ƚ P<0.05 c.f (Male) Hypoxic Vehicle, Two-way 
ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Figure 3-19 Chronic hypoxia increases right ventricular systolic end pressure and 
prostacyclin analogue treprostinil attenuates increase in female and male chronic hypoxic 
rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. (A) 
Right ventricular systolic end pressure (RVSEP) and (B) right ventricular diastolic end pressures 
(RVDEP) were obtained by right heart catheterisation through jugular vein. N=4-6, ***P<0.001 c.f 
(Female) Normoxic Vehicle, ɸɸɸ P<0.001 c.f (Female) Normoxic Treprostinil, ξξξ P<0.001 cf. 
(Female) Hypoxic Vehicle, ŦŦŦ P<0.001 cf. (Male) Normoxic Vehicle, ǂǂǂ P<0.001 c.f (Male) 
Normoxic Treprostinil, ƚ P<0.05 c.f (Male) Hypoxic Vehicle, Two-way ANOVA with Bonferroni’s post-
hoc test. Data expressed as mean ± SEM. 
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Figure 3-20 Chronic hypoxia increases right ventricular hypertrophy and prostacyclin 
analogue treprostinil attenuates increase in female and male chronic hypoxic rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Right ventricular hypertrophy (RV Hypertrophy) was assessed by the ratio of the dry weight of the 
right ventricle over the left ventricle plus septum (RV/LV+S; Fulton’s index). N=5, ***P<0.001 c.f 
(Female) Normoxic Vehicle, ɸ P<0.05 c.f (Female) Normoxic Treprostinil, ξξ P<0.01 cf. (Female) 
Hypoxic Vehicle, ŦŦŦ P<0.001 cf. (Male) Normoxic Vehicle, ǂǂ P<0.01 c.f (Male) Normoxic 
Treprostinil, ƚ P<0.05 c.f (Male) Hypoxic Vehicle, Two-way ANOVA with Bonferroni’s post-hoc test. 
Data expressed as mean ± SEM. 
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Figure 3-21 Chronic hypoxia increases pulmonary vessel remodelling and prostacyclin 
analogue treprostinil attenuates increase in female and male chronic hypoxic rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
The level of pulmonary vessel remodelling was assessed by the ratio of the remodelled and non-
remodelled arteries and expressed as % of the remodelled vessels over the total number of vessels. 
N=5-6, ***P<0.001 c.f (Female) Normoxic Vehicle, ɸɸɸ P<0.001 c.f (Female) Normoxic Treprostinil, 
ξξ P<0.01 cf. (Female) Hypoxic Vehicle, ŦŦŦ P<0.001 cf. (Male) Normoxic Vehicle, ǂǂǂ P<0.001 
c.f (Male) Normoxic Treprostinil, ƚƚ P<0.05 c.f (Male) Hypoxic Vehicle, Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Figure 3-22 Representative Miller’s elastin and α-smooth muscle actin staining in chronic 
hypoxic rats treated with treprostinil or vehicle. 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Vessel remodelling was determined in (A) female and (C) male rats by Miller’s elastin stain, 
remodelled vessels determined by presence of double elastic laminae. Smooth muscle proliferation 
was visualised in (B) female and (D) male rats by α smooth muscle actin (α-SMA) staining. α-SMA 
visualised by DAB staining (dark brown/orange stain). Scale bar = 20µm. 
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Figure 3-23 Chronic hypoxia and prostacyclin analogue treprostinil do not alter left 
ventricular systemic pressure. 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Left ventricular systolic pressures (LVSP) were obtained by left heart catheterisation through carotid 
artery. N=4-6, Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Figure 3-24 Chronic hypoxia and prostacyclin analogue treprostinil do not alter cardiac 
output  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Cardiac output taken from left heart catheterisation through carotid artery. N=4-6, Two-way ANOVA 
with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Figure 3-25 Chronic hypoxia and prostacyclin analogue treprostinil do not alter heart rate  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Heart rate was measured by heart beats per minute (BPM). N=5-6, Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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Table 3-2 Effect of prostacyclin analogue treprostinil (400ng/kg/min) in normoxic or hypoxic 
rats on haemodynamics and phenotypes 
Group mRVP (mmHg) RVEF (%) mLVP (mmHg) Body Weight 
(g) 
Female 
Normoxic 
(Veh) 
12.7 ± 0.59 
(4) 
13.87 ± 1.41  
(4) 
48.42 ± 2.35  
(4) 
260.6 ± 8.49  
(6) 
Female 
Normoxic 
(Trep) 
11.05 ± 0.77 
(6) 
19.86 ± 2.66  
(6) 
42.73 ± 4.17  
(5) 
252.2 ± 5.04  
(6) 
Female 
Hypoxic 
(Veh) 
26.76 ± 2.06 
      (5) ***/ɸɸɸ 
8.304 ± 1.43  
(5) ɸɸ 
38.25 ± 6.58  
(5) 
251 ± 5.45  
(6) 
Female 
Hypoxic 
(Trep) 
17.26 ± 1.61 
     (6) ɸ/ξξ 
7.729 ± 0.93 
 (6) ɸɸɸ 
45.27 ± 4.24  
(4) 
254.4 ± 3.24  
(6) 
     
Male Normoxic 
(Veh) 
10.9 ± 1.25  
(5) 
16.8 ± 1.44 
 (5) 
49.34 ± 1.84  
(5) 
321.9 ± 3.99  
(6) 
Male Normoxic 
(Trep) 
14.4 ± 1.64 
(5) 
19.77 ± 2.69  
(5) 
40.25 ± 3.32  
(5) 
321.9 ± 1.68  
(6) 
Male Hypoxic 
(Veh) 
28.05 ± 0.82  
      (4) ŦŦŦ 
8.872 ± 0.71 
(4) ǂ 
47.33 ± 3.11  
(5) 
301.1 ± 8.24  
(6) 
Male Hypoxic 
(Trep) 
18.13 ± 1.45  
   (4) */ŦŦŦ/ƚƚ 
9.28 ± 2.18  
(4) ǂ 
50.91 ± 1.79  
(4) 
312.1 ± 6.79  
(6) 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions (1000/550mbar) for two 
weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or vehicle was implanted and rats 
returned to normoxic/hypoxic conditions for a further two weeks. Mean right ventricle pressure (mRVP) and 
right ventricle ejection fraction (RVEF) was measured by cannulation of right external jugular vein. Mean left 
ventricle pressure (mLVP) was measured by cannulation of right internal carotid artery. N numbers indicated 
in brackets., ***P<0.001 c.f female normoxic (Veh), ɸɸ P<0.01, ɸɸɸ P<0.001 cf. female normoxic (Trep), ξξ 
P<0.01 c.f female hypoxic vehicle, ŦŦŦ P<0.001 c.f male normoxic (Veh), ǂ P<0.05, ǂǂǂ P<0.001 cf. male 
normoxic (Veh), *P<0.05 c.f male normoxic (Veh), ƚƚ P<0.01 cf. male hypoxic (Veh), Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as mean ± SEM. Veh = vehicle, Trep = treprostinil 
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Figure 3-26 Terminal measurements of prostacyclin analogue treprostinil in rat blood plasma 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Blood taken after carotid artery catheterisation, treprostinil levels assessed by LC/MS. n=2-3, Two-
way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
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3.2.8. Higher treprostinil dose (400ng/kg/min) increases mRNA expression of EP2 
receptor in female rats under hypoxic conditions 
MRNA levels of the prostaglandin receptors; IP, EP2 and DP1 were assessed in the whole 
lung of the rats. Consistent with the previous results, hypoxia caused no change in any 
receptors (Figure 3-27A, B&C). However, the higher dose of treprostinil, under hypoxic 
conditions, led to a significant increase in the mRNA levels of the EP2 receptor in female 
rats compared to normoxic treated and untreated female rats (Figure 3-27C). IP mRNA 
expression was found to be significantly higher than both EP2 and DP1 receptors in both 
female and male rats (Figure 3-28A&B). Interestingly, DP1 mRNA expression was found 
to be significantly lower than EP2 mRNA levels (Figure 3-28A&B).  
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Figure 3-27 The addition of prostacyclin analogue treprostinil in combination with chronic 
hypoxia increases EP2 receptor expression in female rats 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of the (A) IP, (B) EP2 and (C) DP1 receptors was assessed from whole lung 
homogenates by Taqman® quantitative Real Time-PCR. Results were normalised to β2-
microglobulin. N=5-6 per group in triplicate. **P<0.01 cf. (Female) Normoxic (Veh), ɸɸɸ P<0.001 cf. 
(Female) Hypoxic (Trep), Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as RQ 
± RQmax/RQmin. RQ= relative quantification, Veh= vehicle, Trep= treprostinil. 
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Figure 3-28 IP and EP2 mRNA expression is significantly higher than DP1 receptor mRNA 
expression in both female and male rats. 
(A) Female and (B) male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of the IP, EP2 and DP1 receptors was assessed from whole lung homogenates by 
Taqman® quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=5-6 per 
group in triplicate. ***P<0.001 cf. respective BMPR-II group, ɸɸɸ P<0.001 cf. respective EP2 group, 
Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= 
relative quantification, Veh= vehicle, Trep= treprostinil. 
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3.2.9. Treprostinil (400ng/kg/min) did not change whole lung expression of Id3 in 
chronic hypoxic female and male rats 
Although sex differences in the effect of treprostinil on BMPR-II signalling were identified 
in the first dosing study it was important to also investigate the effects of the higher dose 
of treprostinil on BMPR-II signalling. As before there was no significant effect of treprostinil 
or hypoxia on BMPR-II mRNA levels (Figure 3-29A). Interestingly, there was significant 
increases in Id1 and Id3 mRNA levels in male rats treated with treprostinil under hypoxic 
conditions when compared to normoxic treprostinil dosed male rats (Figure 3-29B&C). 
Despite the higher dose, treprostinil did not increase Id1 or Id3 mRNA in female hypoxic 
rats (Figure 3-29B&C) as seen in the first study. BMPR-II mRNA expression was found to 
be higher than both Id1 and Id3 mRNA expression in female rats (Figure 3-30A). Normoxic 
female rats treated with treprostinil were found to have higher Id3 mRNA levels compared 
to Id1 mRNA expression (Figure 3-30A). Both treated and untreated normoxic male rats 
had higher BMPR-II mRNA expression than Id1 mRNA expression (Figure 3-30B). 
Interestingly, there was no difference in BMPR-II and Id1 mRNA levels in treated and 
untreated hypoxic male rats (Figure 3-30B). However, BMPR-II mRNA expression was 
found to be significantly higher than Id3 mRNA in all male rat groups (Figure 3-30B). 
Treprostinil treatment combined with hypoxia increased SMURF1 mRNA expression solely 
in female rats (Figure 3-31A). There was no significant change in SMURF2 mRNA 
expression in either female or male rats (Figure 3-31B). KCNK3 mRNA expression was 
significantly elevated in females under hypoxic conditions compared to normoxic female 
rats (Figure 3-31C). Protein levels of BMPR-II, pSmad 1/5/9, Id1 and Id3 were examined. 
Treprostinil at the higher dose did not change the protein expression of the BMPR-II 
signalling pathway under normoxic conditions (Figure 3-32). Interestingly, the protein 
expression of pSmad 1/5/9 protein expression was found to increase in female hypoxic 
rats (Figure 3-33B). However, Id1 protein expression was increased in both female and 
male rats under hypoxic conditions (Figure 3-33C). Under hypoxic conditions the higher 
dose of treprostinil did not influence the expression of BMPR-II or pSmad 1/5/9 (Figure 3-
34A&B). The higher dose of treprostinil did not significantly change the expression of both 
Id1 and Id3 (Figure 3-34C&D).  
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Figure 3-29 Id1 and Id3 mRNA expression increased in chronic hypoxic male rats treated 
with prostacyclin analogue treprostinil   
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) BMPR-II, (B) Id1 and (C) Id3 mRNA were assessed from whole lung homogenates 
by Taqman® quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=5-6 per 
group in triplicate. Ŧ P<0.05 cf. (Male) Normoxic (Trep), Two-way ANOVA with Bonferroni’s post-
hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Veh= vehicle, Trep= 
treprostinil. 
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Figure 3-30 Id1 and Id3 mRNA expression increased in chronic hypoxic male rats treated 
with prostacyclin analogue treprostinil   
(A) Female and (B) male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of BMPR-II, Id1 and Id3 mRNA were assessed from whole lung homogenates by 
Taqman® quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=5-6 per 
group in triplicate. *P<0.05, **P<0.01, ***P<0.001 cf. respective BMPR-II group, ɸ P<0.05 cf. 
respective Id1 group, Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as RQ ± 
RQmax/RQmin. RQ= relative quantification. Veh= vehicle, Trep= treprostinil. 
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Figure 3-31 Lung expression of SMURF1 and KCNK3 mRNA were increased by chronic 
hypoxia and treprostinil 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) SMURF1, (B) SMURF2 and (C) KCNK3 mRNA were assessed from whole lung 
homogenates by Taqman® quantitative Real Time-PCR. Results were normalised to β2-
microglobulin. N=5-6 per group in triplicate, *P<0.05, ***P<0.001 cf. (Female) Normoxic (Veh), ɸ 
P<0.05, ɸɸ P<0.01, ɸɸɸ P<0.001 cf. (Female) Normoxic (Trep), Two-way ANOVA with Bonferroni’s 
post-hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Veh= vehicle, 
Trep= treprostinil. 
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Figure 3-32 Lung protein expression of BMPR-II signalling was not altered under normoxic 
conditions in female and male rats  
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from whole lung 
homogenates by western blot. (E) Representative immunoblot, β-actin was used as the internal 
loading control. N=5-6 per group in duplicate, Two-way ANOVA with Bonferroni’s post-hoc test. 
Data expressed as mean ± SEM. Veh= vehicle, Trep= treprostinil. 
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Figure 3-33 Lung protein expression of BMPR-II signalling was altered by chronic hypoxia: 
Id1 expression increased in chronic hypoxic female and male rats 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from whole lung 
homogenates by western blot. (E) Representative immunoblot, β-actin was used as the internal 
loading control. N=5-6 per group in duplicate. *P<0.05, **P<0.01 cf. (Female) Normoxic (Veh), Ŧ 
P<0.05 cf. (Male) Normoxic (Veh), Two-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as mean ± SEM. Veh= vehicle, Trep= treprostinil. 
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Figure 3-34 Lung protein expression of BMPR-II signalling was unchanged with treatment 
with prostacyclin analogue treprostinil 
Female and male sprague-dawley rats were subjected to normoxic/hypoxic conditions 
(1000/550mbar) for two weeks, a sub-cutaneous pellet containing treprostinil (400ng/kg/min) or 
vehicle was implanted and rats returned to normoxic/hypoxic conditions for a further two weeks. 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from whole lung 
homogenates by western blot. (E) Representative immunoblot, β-actin was used as the internal 
loading control. N=3-6 per group in duplicate, (BMPR-II blot n=3 per group), Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as mean ± SEM. Veh= vehicle, Trep= treprostinil. 
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3.3.  Discussion 
A primary focus of PAH research has been to understand the gender disparity that exists 
in the incidence of the disease. Female gender has been identified as a risk factor for PAH, 
studies demonstrate a female to male ratio of 4.3:1 with total PAH (Walker et al., 2006) 
and 4.1:1 in IPAH patients (Badesch et al., 2010). Despite an increased incidence of PAH 
in females, males have poorer survival despite treatment (Humbert et al., 2010b, Benza et 
al., 2010)  This was the first study to examine the role of sex on the therapeutic action of 
treprostinil in the chronic hypoxic rat model of PH.  
The findings suggest that sex may influence the actions of treprostinil. This study 
demonstrated that female chronic hypoxic rats are more responsive to 100ng/kg/min of 
treprostinil than chronic hypoxic male rats. The sex-specific therapeutic response 
appeared to be partially mediated through an increase in Id1 and Id3 mRNA expression. 
A higher treprostinil dose of 400ng/kg/min led to a therapeutic response in male hypoxic 
rats, but also an increased response in chronic hypoxic female rats. The higher dose of 
treprostinil did not alter BMPR-II signalling in female or male rats. However, in females 
exposed to hypoxia it triggered an increase in the expression of prostaglandin E2 receptor 
2 (EP2) mRNA.  
Initially, the viability of treprostinil administered through a subcutaneously implanted slow-
release pellet as a method for dosing a chronic hypoxic model of PH was investigated. 
Initially we investigated the level of treprostinil in the blood plasma of female and male rats 
under normoxic conditions. Both females and males had small but significant decreases 
in treprostinil plasma levels after 10 days compared 4 days. Male rats maintained a 
significant lower treprostinil plasma levels after 14 days whereas females did not. The very 
low levels of treprostinil may explain the significant changes observed between different 
days. Previous studies have found that treprostinil is not at detectable levels in rat plasma 
after 4 hours, suggesting a rapid clearance rate (Malinin et al., 2014). The effectiveness of 
subcutaneously implanted pellets has been previously demonstrated in two different PH 
models and cardiovascular knock-out models (Wright et al., 2015, Karas et al., 2001, 
Frump et al., 2015b). 
The chronic hypoxic rat model of PH demonstrates increased PH indices, for example; 
increased RVSP, remodelling including smooth muscle proliferation and RV hypertrophy 
(Meyrick and Reid, 1980, Meyrick and Perkett, 1989). These changes were evident in the 
present study. Treprostinil is a prostacyclin analogue that has similar vasodilatory 
properties to prostacyclin (Vachiery and Naeije, 2004) as well as anti-proliferative actions 
(Clapp et al., 2002). Previously, treprostinil was found to decrease both RVSP and RVH 
in the monocrotaline rat model of PH (van Albada et al., 2006, Yang et al., 2010). 
Therapeutic effects of treprostinil have also been examined in the chronic hypoxic mouse 
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model of PH (Nikam et al., 2010, Liu et al., 2015). The present study used a reversal 
protocol, rats were dosed with treprostinil after developing hypoxic induced PH, then were 
restored to hypoxic conditions. This approach was deemed more relevant to the clinical 
disease; however, remodelling is not as severe. However, previous studies used either a 
preventative protocol, in which animals were dosed before being placed in hypoxic 
conditions (Nikam et al., 2010) or did not restore mice to a hypoxic environment after 
dosing with treprostinil (Liu et al., 2015). All the treprostinil studies involve the use of male 
rodents exclusively, therefore offer little insight into PAH therapy in a disease that 
predominately effects women.  
This study is the first to demonstrate a female-specific reduction in PH indices by 
treprostinil. Several previous studies have demonstrated female-specific therapies in 
animal models of PH; including targeting estrogen (Wright et al., 2015, Mair et al., 2014) 
and serotonin pathways (White et al., 2012, Dempsie et al., 2013, Wallace et al., 2015). 
As treprostinil is a prostacyclin analogue, it can act through the G-protein (Gs) coupled 
prostaglandin receptors (GPCRs); prostacyclin (IP) receptor, prostaglandin E2 receptor 2 
(EP2) and prostaglandin D2 receptor 1 (DP1) (Falcetti et al., 2010, Li et al., 2012, Whittle 
et al., 2012). Other prostacyclin analogues have been shown to act through more than one 
receptor; iloprost can mediate its therapeutic effects through the prostaglandin E2 receptor 
4 (EP4) (Lai et al., 2008, Whittle et al., 2012).  IP receptor knock-out studies have 
demonstrated that mice with IP receptor knock-out have a much more severe PH 
phenotype after chronic hypoxic exposure than wildtype animals (Hoshikawa et al., 2001). 
Previously, has been shown that the IP receptor is down-regulated in the monocrotaline 
model of PH (Lai et al., 2008). Although a beraprost dosing study carried out in chronic 
hypoxic rats demonstrated no downregulation of IP mRNA expression in the lungs (Abe et 
al., 2001). In the present study, hypoxic conditions did not change the expression of the 
prostaglandin receptors suggesting that different models of PH can have differing effects 
on the expression of the prostaglandin receptors. Interestingly, the lower treprostinil dose 
led to an increase in female EP2 mRNA expression compared to the untreated female 
hypoxic rats. Also, the higher dose of treprostinil combined with hypoxia increased the 
mRNA expression of the EP2 receptor exclusively in female hypoxic rats. This may offer a 
possible explanation for the greater response to treprostinil in females. 
Despite highlighting increases in the expression of the EP2 receptor, this does not offer a 
complete picture as to why female rats responded better to treprostinil. The mRNA 
expression of the prostaglandin receptors was obtained from whole lung lysates from the 
rats, however the specific distribution of the receptors was not investigated. Endothelin 
receptors have been shown to have different distribution in different sections of the rat 
pulmonary artery; ETA receptors were primarily found in the media of the pulmonary artery. 
Whereas the ETB receptor was found in the intima and media of pulmonary arteries (Soma 
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et al., 1999). The distribution of the receptors influences the vasoconstrictive response to 
ET-1, where the ETA was responsible for vasoconstriction in the proximal artery, however 
both ETA and ETB mediate this response in distal arteries (Soma et al., 1999). This 
highlights that receptor expression and function can vary depending on location in the 
pulmonary artery. A possible explanation of the weaker response to treprostinil may 
involve receptor desensitization. Morrell and colleagues discovered that in rat hPASMCs, 
stimulation of the IP receptor by a PGI2 analogue, cicaprost, led to desensitization of the 
receptor (Sobolewski et al., 2004). The desensitization of the receptor was dependant on 
protein kinase A (PKA) inhibiting the enzyme adenylyl cyclase (AC) 5/6 (Sobolewski et al., 
2004). AC is the key enzyme in converting ATP to cAMP therefore any changes in 
functionality or expression could impact the effectiveness of a cAMP increasing drug like 
treprostinil. In isolated rat PASMCs, AC2, AC3, AC5 and AC6 were the predominate 
isoforms of AC detected by RT-PCR and western blots (Jourdan et al., 2001). Sex 
differences in AC expression have been investigated in isolated mice hearts, where a 
forskolin, an inducer of cAMP, had a greater contractile effect in male mice than in females 
(McIntosh et al., 2011). Exchange factor directly activated by cAMP 1/2 (EPAC) are 
downstream mediators of cAMP that have been shown to influence the effectiveness of 
treprostinil in fibroblasts (Nikam et al., 2011). EPAC-1 mRNA and protein expression were 
also found to be downregulated in MCT-rats (Murray et al., 2009). Although it was not 
examined in the current study It may be possible that any reduced EPAC expression in 
the current study may influence the effectiveness of treprostinil in male rats. Another 
potential mechanism that could account for the weaker response to treprostinil in the male 
rats could be changes in phosphodiesterases (PDEs), which break down cAMP. 
Previously, Wang and colleagues discovered that sex plays a role in the expression of 
PDEs in rat vascular endothelial cells. MRNA levels of PDE1A were found to be higher in 
males than females (Wang et al., 2010a). Interestingly, they also discovered that females 
had higher mRNA expression of PDE3B (Wang et al., 2010a).  
Dysfunctional BMPR-II signalling plays a key role in endothelial/smooth muscle cell 
proliferation and apoptosis (Machado et al., 2009a). BMPR-II dysfunction mediates 
proliferation by lowering the induction of Id proteins, which are regulators of cell 
cycle.(Yang et al., 2005). BMPR-II expression in the lungs of female and male rats have 
been found to be decreased in 3-week hypoxic, monocrotaline and SU-HX rat models of 
PH (Takahashi et al., 2006, Long et al., 2009, Mair et al., 2014). In this present study, there 
was no observable decrease in mRNA or protein expression of BMPR-II under 4-week 
hypoxic conditions. This may suggest an eventual recovery of BMPR-II expression under 
hypoxic conditions. Presently, pSmad 1/5/9 was found to increase in the second hypoxic 
study, this may also suggest a recovery of BMPR-II signalling. Sex has been proven to 
influence BMPR-II signalling both in animal models of PH and human patients. BMPR-II 
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signalling expression was recently found to be lower in females compared to males in 
rodent lungs and in human pulmonary artery smooth muscle cells (hPASMCs) (Mair et al., 
2014, Mair et al., 2015). Treprostinil can activate BMPR-II signalling, specifically Id1, in 
human and animals PH models (Yang et al., 2010). This is the first study to demonstrate 
that treprostinil can induce expression of Id3 mRNA. The female-specific therapeutic effect 
of 100ng/kg/min treprostinil was partially mediated through increases in both Id1 and Id3 
mRNA. Interestingly, the present study does not correlate with other research which 
suggests Id down-regulation under hypoxic conditions (Xiao-Hui et al., 2012). The effect 
of estrogen in animal models of PH has been disputed; studies suggest that the addition 
of exogenous estrogens can reverse established PH in animal models (Resta et al., 2001, 
Lahm et al., 2012, Farhat et al., 1993). However, others find that endogenous estrogen is 
a risk factor contributing to greater incidence of PH in female animal models (White et al., 
2011a, Dempsie et al., 2011, Wright et al., 2015, White et al., 2012). In human breast 
cancer studies, 17-β estradiol increased the levels of cAMP in a dose dependent manner 
via the estrogen alpha (ER-α) receptor, suggesting a negative feedback effect (Aronica et 
al., 1994, Zivadinovic et al., 2005). This was also observed in rat pulmonary vascular 
smooth muscle cells (Farhat et al., 1996). Estrogen was also found to attenuate the 
activation of MAPK signalling via stimulation of adenylyl cyclase and cAMP through ER-α 
and GPR30 receptors in MCF-7 breast cancer cells (Filardo et al., 2002). Treprostinil and 
other prostacyclin analogues are known to increase the expression of Id proteins via 
activation of cyclic AMP (cAMP) (Yang et al., 2010). The cumulative effect of estrogen and 
treprostinil activating adenylyl cyclase and cAMP may explain why, in the present study 
there was a greater induction of Id1 and Id3 mRNA in female rats. Interestingly, the 
increase in Id mRNA expression was not supported by increases in protein expression. 
However, in the second hypoxic study we observed increases in Id1 and Id3 mRNA in 
male rats under hypoxic conditions and an increase in Id1 protein expression in female 
and male hypoxic rats. This may be a compensatory response to hypoxic conditions. 
Lowery and colleagues have demonstrated that in hypoxic mice both Id1 and Id3 
expression was increased and may play a role in regulating responses to chronic hypoxia 
(Lowery et al., 2010). SMURF1 is a E3 ubiquitin protein ligase, which suppress BMP 
signalling by degrading SMAD proteins (Fukunaga et al., 2008). Interestingly, the mRNA 
expression of the E3 ubiquitin protein ligase SMURF1 was found to be increased in female 
hypoxic rats treated with treprostinil. Previously, SMURF1 was shown to be increased in 
the pulmonary arteries of hypoxic and monocrotaline rat models of PH (Murakami et al., 
2010). Also, the deletion of SMURF1 has been demonstrated to protect mice from PH 
development (Rothman et al., 2016). The main roles of the KCNK3 channel is to control 
cellular resting membrane potential and to contribute to the relaxation of vessels (Patel et 
al., 1999) The role of missense variants of the KCNK3 gene in PAH development have 
recently been identified, these variants lead to reduced potassium channel current thereby 
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contributing to PAH development (Ma et al., 2013). Presently, both studies demonstrate 
increases in KCNK3 mRNA under hypoxic conditions, although the first study only showed 
a significant increase in female hypoxic rats. Conversely, it was recently shown that both 
PAH patient and monocrotaline rat lungs have reduced expression of KCNK3 (Antigny et 
al., 2016). We did not observe treprostinil altering the expression of KCNK3, however 
treprostinil has been previously shown to activate KCNK3 via cAMP dependent 
phosphorylation to mediate vasodilatory effects in hPASMCs (Olschewski et al., 2006a).  
Over the two in-vivo studies, both prostaglandin receptors and the BMPR-II signalling 
pathway were examined by processing whole lung tissue isolated from female and male 
rats. Although this technique is often used due to experimental limitations or time 
constraints, it may portray changes in gene expression that are not reflecting in more 
physiologically relevant areas like pulmonary arteries. This has been reflected in lung 
airway studies, these demonstrated the differences in specific gene expression (CYP2F4) 
from whole lung, to proximal then to distal airways (Baker et al., 2004). This was also 
highlighted was the differing expression of ET receptors from proximal to distal pulmonary 
arteries (Soma et al., 1999). For future studies, pulmonary arteries could be isolated from 
untreated/treated animals, however the level of protein or RNA isolated would be 
significantly lower than from whole lung. Alternatively, immunohistochemistry (IHC) could 
confirm if changes to the BMPR-II pathway or prostaglandin receptors are localised to 
pulmonary arteries and more specifically to smooth muscle cells or endothelial cells.  
It is possible that the level of remodelling observed in the hypoxic rats played a role in 
leading to the sex difference observed in response to treprostinil. In the current in-vivo 
studies hypoxic male rats have higher pressures than female rats, this was in line with 
previously published research (Rabinovitch et al., 1981). It may be possible that the 
weaker response to treprostinil in males may be due to the greater PH severity. Clinical 
studies involving the use of treprostinil do not split the end-points into female and male 
data therefore it is difficult to conclude if what was seen in the hypoxic rats can be 
extrapolated into humans.  
Recently it has been hypothesised that better right ventricular compensation is a reason 
why female PAH patients have greater survival than males (Jacobs et al., 2014). Females 
were also found to have better improvements in right ventricular ejection fraction (RVEF) 
after PAH therapy (Jacobs et al., 2014). In the present study, RVEF was found significantly 
decreased in both studies under hypoxic conditions, although, females exhibited small but 
insignificant increases in RVEF with treprostinil (100ng/kg/min) treatment. In accordance 
with RVSP and remodelling analysis, there was a female-specific reversal of hypoxic-
induced RVH by treprostinil at 100ng/kg/min. This effect appeared to be dose-dependent 
as 400ng/kg/min treprostinil dosing reduced RVH in male rats. Previously treprostinil was 
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found to reduce RVH in a monocrotaline rat model of PH (Yang et al., 2010). However, it 
was not determined if the reduction in hypertrophy was an indirect result of the therapeutic 
effects of treprostinil in the lungs or direct action in the right ventricle. However, treprostinil 
was found to have no significant therapeutic effect on a pulmonary trunk banding rat model 
of PH, which induces pronounced right ventricular hypertrophy and near heart failure 
(Axelgaard et al., 2016). Both treprostinil and MRE-269 were found to improve RV function 
in isolated healthy rat heart, however both drugs had no effect on hearts that had been 
subjected to pulmonary trunk banding (Holmboe et al., 2016)  . 
In conclusion, the use of sub-cutaneous pellets to release treprostinil was a valid method 
of drug delivery in the chronic hypoxic rat model of PH. Firstly, the data indicates a novel 
observation that treprostinil can have sex-specific therapeutic effects in a chronic hypoxic 
model of PH. The results also suggest that the sex-specific effects were dose dependant, 
with a greater dose of treprostinil leading to greater therapeutic effects in both sexes of 
hypoxic rats.  
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Chapter 4 
4 The influence of prostaglandin receptors, BMPR-II 
signalling and sex on the in-vitro effects of treprostinil 
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4.1. Introduction 
Pulmonary arterial hypertension (PAH) is associated with reduced levels of vasodilators, 
such as prostacyclin and increased levels of vasoconstrictors such as endothelin and 
thromboxane (Tuder et al., 1999, Christman et al., 1992, Giaid et al., 1993) . The ability to 
manipulate these pathways has been a basis of therapy for PAH. Originally prostacyclin 
was investigated for its effects in peripheral vascular disease (Hossmann et al., 1984). 
This led to the investigation into the effectiveness of prostacyclin (epoprostenol) as a 
therapy for PAH (Barst et al., 1996). Despite clinical outcomes improving, the short half-
life of epoprostenol and associated side effects of a constant catheter infusion of 
epoprostenol led to the development of prostacyclin analogues. Prostacyclin analogues 
such as treprostinil and iloprost were developed as alternatives to epoprostenol therapy. 
Prostacyclin analogues offered a variety of dosing methods including inhalation and oral 
dosing, they also provided greater durations of vasodilation and better stability at room 
temperature (Fitscha et al., 1987). 
The major signalling mechanism of treprostinil and other prostacyclin analogues is via 
activation of G-protein coupled prostaglandin receptors. The prostacyclin (IP), the 
prostaglandin E2 receptor 2 (EP2) and prostaglandin D2 receptor 1 (DP1) are receptors that 
treprostinil binds to with the greatest affinity (Whittle et al., 2012). These receptors are 
associated with the Gs subunit and increase cAMP levels in smooth muscle cells (Breyer 
et al., 2001). Additionally, the anti-proliferative effects of treprostinil have been examined 
in the idiopathic patient subset of PAH (IPAH). It has also been shown that treprostinil 
mediates its effects via the IP receptor and peroxisome proliferator-activated receptor 
gamma (PPAR-γ) (Falcetti et al., 2010). It has been well established that reduced 
expression of the BMPR-II signalling pathway has a deleterious role in the development of 
PAH (Atkinson et al., 2002). Treprostinil has been found to play a role in activating BMPR-
II signalling in both BMPR-II mutants and non-mutant human pulmonary artery smooth 
muscle cells (hPASMCs), either dependant or independent of SMAD activation (Yang et 
al., 2010). 
This was the first study to examine if sex could influence the effects of treprostinil in an in-
vitro setting. As stated previously (chapter 3) the influence of sex on drug therapy has 
already been demonstrated (Mathai et al., 2015, Gabler et al., 2012). However, by 
examining the underlying mechanisms of treprostinil in hPASMCs we hoped to gain more 
clinically relevant observations than those found in animal models of PH. 
Treprostinil and prostaglandin receptor antagonist concentrations were chosen due to 
previously published research (Falcetti et al., 2007, Falcetti et al., 2010, Patel et al., 2014, 
Jigisha et al., 2015). The data demonstrates that in control hPASMCs, female cells have 
a greater response to treprostinil stimulation than male cells. Interestingly, the pro-
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proliferative vasoconstrictor endothelin-1 (ET-1) was found to significantly increase the 
anti-proliferative effect of treprostinil in female control hPASMCs. The addition a dual 
endothelin receptor antagonist (SB-217242) blunted the anti-proliferative effect of 
treprostinil in combination with ET-1. The IP receptor antagonist (RO1138452) partially 
inhibited the anti-proliferative effects of treprostinil in the presence of ET-1 in female control 
hPASMCs. In PAH patient hPASMCs, the addition of the EP2 receptor antagonist (PF-
04418948) partly blocked the anti-proliferative effects of treprostinil. Treprostinil was found 
to increase the Id mRNA and proteins of the BMPR-II signalling pathway in hPASMCs. 
Female control hPASMCs were consistently found to have higher induction of the Id mRNA 
and protein at two different time-points compared to male control hPASMCs. Female PAH 
patients hPASMCs, were found to have a slightly higher induction of the Id3 protein 
compared to male PAH patient hPASMCs after 24-hour stimulation with treprostinil. The 
induction of Id proteins in female control and PAH patient hPASMCs was found to be 
partially dependant on the activation of the IP and EP2 prostaglandin receptors suggesting 
a role for cAMP in the activation of the Id proteins under these experiment conditions. 
Hypotheses and aims of this chapter:  
Sex has been shown to influence the clinical outcomes of patients receiving ERAs and 
PDE-5 inhibitors (Gabler et al., 2012, Mathai et al., 2015). We hypothesise that the PGI2 
analogue treprostinil can have sex specific effects in isolated hPASMCs. To investigate 
this hypothesis, the following aim was carried out. 
1. Characterisation of the influence of sex on treprostinil in human pulmonary artery 
smooth muscle cells  
BMPR-II signalling has been previously demonstrated to mediate the effect of prostacyclin 
analogues and other PAH therapies (Yang et al., 2010, Yang et al., 2013a). Also, sex 
differences have been identified in BMPR-II signalling in hPASMCs (Mair et al., 2015). The 
hypothesis is that increased BMPR-II signalling mediated by treprostinil accounted for the 
differences in anti-proliferative properties of treprostinil. To investigate this hypothesis, the 
following aim was carried out. 
2. Investigation into BMPR-II signalling role in the effects of treprostinil in human 
pulmonary artery smooth muscle cells  
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4.2. Results 
4.2.1. The anti-proliferative effects of treprostinil in the presence of endothelin-1 in 
control and PAH patient hPASMCs 
Treprostinil is an established clinical treatment for PAH. As a prostacyclin analogue, its 
effects are mediated though vasodilation of pulmonary arteries and proliferation of 
hPASMCs. The effect of treprostinil on the proliferation of hPASMCs derived from women 
and men were examined as was the influence of endothelin-1 on the anti-proliferative 
effects of treprostinil. These results were determined by cell counts via a haemocytometer 
after 72-hour stimulation with treprostinil. Treprostinil (100nM, 1µM and 10µM) significantly 
decreased serum induced proliferation in female control hPASMCs (Figure 4-1A). The 
addition of 30nM endothelin-1, at the beginning of the experiment, increased the anti-
proliferative effect of treprostinil. This was exhibited by significant decreases in proliferation 
induced by treprostinil at 10nM, 100nM, 1µM and 10µM (Figure 4-1B). In male control 
hPASMCs, treprostinil (10µM) significantly reversed serum-induced proliferation (Figure 
4-1C). The addition of endothelin-1 did not significantly increase the anti-proliferative effect 
at any additional treprostinil concentrations (Figure 4-1D). The anti-proliferative effects of 
treprostinil were also explored in female and male PAH patient hPASMCs. Treatments 
with treprostinil (1µM and 10µM) significantly reduced proliferation in female patient 
hPASMCs (Figure 4-2A). The addition of endothelin-1 led to a significant reduction in 
proliferation after 10nM and 100nM stimulation with treprostinil (Figure 4-2B). Serum-
induced proliferation was significantly reduced in male patient hPASMCs by treprostinil 
(10µM) (Figure 4-2C). The addition of endothelin-1 led to a significant reduction in 
proliferation with treprostinil (1µM) (Figure 4-2D). The combination of treprostinil and 
endothelin-1 was investigated across a greater range of concentrations of treprostinil. 
Each hPASMCs group was stimulated with treprostinil ranging from 1pM-10µM. The 
greatest effect of endothelin-1 was observed in female control hPASMCs (Figure 4-3A). 
Endothelin-1 was found to significantly increase the anti-proliferative effect of treprostinil, 
specifically at 100pM (Figure 4-3A). As before, there was no significant effect of 
endothelin-1 in male control hPASMCs, however the overall anti-proliferative effect of 
treprostinil was lower in male control hPASMCs compared to female controls (Figure 4-
3B). Endothelin-1 did not significantly increase the anti-proliferative effect of treprostinil in 
female and male PAH patient hPASMCs (Figure 4-4A-B6). Area under the curve (AUC) 
analysis was used as an overall measure of the anti-proliferative response of treprostinil. 
The presence of endothelin-1 significantly reduced the AUC compared to treprostinil 
without endothelin-1 in female control hPASMCs (Figure 4-5A). Endothelin-1 did not 
significantly change the AUC in either male control or female and male PAH patient 
hPASMCs (Figure 4-5B-D) This data suggests that treprostinil has anti-proliferative effects 
in all hPASMCs groups, however differences in anti-proliferation can be observed between 
female and male control hPASMCs. 
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Figure 4-1 The anti-proliferative effect of treprostinil is increased by the addition of 30nM 
endothelin-1 in female but not male control hPASMCs 
HPASMCs from (A, B) female and (C, D) male control patients were quiesced for 24 hours in 0.5% 
FBS phenol free DMEM media. (A, C) PASMCs were then stimulated by treprostinil (10nM, 100nM, 
1µM and 10µM) in the presence of 7% FBS. (B, D) Identical experiments carried out in the presence 
of endothelin-1 (30nM). Cell counts were assessed 72 hours later by haemocytometer. N=3 human 
samples per group, in duplicate/triplicate, **P<0.01, ***P<0.001 cf. 0.5% FBS; ɸ P<0.05, ɸɸ P<0.01, 
ɸɸɸ P<0.001 cf. 7% FBS; ξξ P<0.01, ξξξ P<0.001 cf. 7% FBS + Endothelin-1 (30nM). One-way 
ANOVA with Bonferroni’s post-hoc test. Data expressed as % of 7% FBS.  
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Figure 4-2 The anti-proliferative effect of treprostinil is increased by the addition of 30nM 
endothelin-1 in female and male patient hPASMCs 
HPASMCs from (A, B) female and (C, D) male PAH patients were quiesced for 24 hours in 0.5% 
FBS phenol free DMEM media. (A, C) PASMCs were then stimulated by treprostinil (10nM, 100nM, 
1µM and 10µM) in the presence of 7% FBS. (B, D) Identical experiments carried out in the presence 
of endothelin-1 (30nM). Cell counts were assessed 72 hours later by haemocytometer. N=2-3 
human samples per group, in duplicate/triplicate (N=2 male patient hPASMCs), **P<0.01, 
***P<0.001 cf. 0.5% FBS; ɸ P<0.05, ɸɸ P<0.01, ɸɸɸ P<0.001 cf. 7% FBS; ξ P<0.05, ξξ P<0.01, ξξξ 
P<0.001 cf. 7% FBS + Endothelin-1 (30nM). One-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as % of 7% FBS. 
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Figure 4-3 The anti-proliferative effect of treprostinil is significantly increased by the addition 
of 30nM endothelin-1 in female control hPASMCs not in male control hPASMCs 
HPASMCs from (A) female controls and (B) male controls were quiesced for 24 hours in 0.5% FBS 
phenol free DMEM media. PASMCs were then stimulated by treprostinil (1pM, 10pM, 100pM, 1nM, 
10nM, 100nM, 1µM and 10µM) in the presence or absence of endothelin-1 (30nM). Experiments 
were carried out in the presence of 7% FBS phenol free DMEM media. Cell counts were assessed 
72 hours later by haemocytometer. N=4-5 human samples per group, in duplicate/triplicate, 
**P<0.01 cf. Trep, Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as % of 7% 
control. Trep= treprostinil, ET-1= endothelin-1. 
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Figure 4-4 The anti-proliferative effect of treprostinil is not significantly increased by the 
addition of 30nM endothelin-1 in female and male patient hPASMCs 
HPASMCs from (A) female and (B) male PAH patients were quiesced for 24 hours in 0.5% FBS 
phenol free DMEM media. PASMCs were then stimulated by treprostinil (1pM, 10pM, 100pM, 1nM, 
10nM, 100nM, 1µM and 10µM) in the presence or absence of endothelin-1 (30nM). Experiments 
were carried out in the presence of 7% FBS phenol free DMEM media. Cell counts were assessed 
72 hours later by haemocytometer. N=3-4 human samples per group, in duplicate/triplicate, Two-
way ANOVA with Bonferroni’s post-hoc test. Data expressed as % of 7% control. Trep= treprostinil, 
ET-1 = endothelin-1. 
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Figure 4-5 The area under the curve of treprostinil is significantly decreased by the addition 
of 30nM endothelin-1 in female control hPASMCs 
HPASMCs from (A) female control, (B) male control, (C) female PAH patient and (D) male PAH 
patients were quiesced for 24 hours in 0.5% FBS phenol free DMEM media. PASMCs were then 
stimulated by treprostinil (1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM) in the presence 
or absence of endothelin-1 (30nM). Experiments were carried out in the presence of 7% FBS phenol 
free DMEM media. N=3-5 human samples per group, *P<0.05 cf. Trep, un-paired t-test. Data 
expressed as mean ± SEM. Trep = treprostinil, ET-1 = endothelin-1. 
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4.2.2. The enhanced treprostinil response in combination with endothelin-1 may be 
partially dependent on the ETA+B receptors 
To investigate the greater treprostinil response in combination with ET-1 occurs, the role 
of the endothelin receptors was examined. Expression of endothelin receptors (ET) in 
hPASMCs were examined by both Taqman® analysis (mRNA) and Western blot (protein) 
respectively. There were no significant differences in endothelin receptor mRNA 
expression between sex and control/PAH hPASMCs (Figure 4-6A-B). Interestingly, 
prepro-ET-1 mRNA expression was significantly lower in female control hPASMCs 
compared to male control and male patient hPASMCs (Figure 4-6C). However, ETA mRNA 
expression was found to be significantly higher than ETB expression in female/male control 
hPASMCs (Figure 4-7A) and in female PAH patient hPASMCs (Figure 4-7B) but not in 
male PAH patient hPASMCs (Figure 4-7B). Endothelin receptor protein expression did not 
change between females and males or control/PAH patient hPASMC group (Figure 4-8A-
B). The lack of significant change may be partially due to the high variability in the 
expression of the endothelin receptors, specifically the ETB receptor in individual 
hPASMCs examined (Figure 4-9C-D). The addition of a specific ETA antagonist sitaxentan 
sodium did not significant change the anti-proliferative effect of treprostinil combined with 
ET-1 (Figure 4-10A). The dual endothelin receptor antagonist SB-217242 significantly 
reduced the anti-proliferative effect of treprostinil, at 100pM, combined with ET-1 (Figure 
4-10B). Sitaxentan sodium and did not significantly change the AUC (Figure 4-11A), 
however the addition of SB-2172424 did significantly change the AUC (Figure 4-11B). The 
data also suggests that the additive effects of endothelin-1 on treprostinil may be mediated 
by ETA and ETB receptors. 
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Figure 4-6 Endothelin receptors mRNA and in female and male hPASMC  
MRNA expression of (A) ETA, (B) ETB and (C) Prepro-ET-1 were assessed in female/male control 
and PAH patient hPASMCs by Taqman® quantitative Real Time-PCR. Results were normalised to 
β2-microglobulin. N=3-4 per group in triplicate for Taqman®. *P<0.05, **P<0.01 cf. Female Control, 
Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as RQ ± RQmax/RQmin and mean 
± SEM. RQ= relative quantification.  
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Figure 4-7 Comparison of endothelin receptor mRNA expression in female and male 
hPASMC 
MRNA expression of ETA and ETB receptors in (A) female/male control hPASMCs and (B) 
female/male PAH patient hPASMCs by Taqman® quantitative Real Time-PCR. Results were 
normalised to β2-microglobulin. N=3-4 per group in triplicate for Taqman®. *P<0.05, ***P<0.001 cf. 
Female ETA, ɸɸ P<0.01 cf. Male ETA, Two-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as RQ ± RQmax/RQmin and mean ± SEM. RQ= relative quantification. 
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Figure 4-8 Endothelin receptors protein expression in female and male hPASMC 
Protein expression of (A) ETA (A) and (B) ETB were assessed in female/male control and PAH 
patient hPASMCs by western blot. Representative immunoblot (E), Results were normalised to α-
tubulin was used as the internal loading control. N=3 per group, Two-way ANOVA with Bonferroni’s 
post-hoc test. ETA = Endothelin receptor A, ETB = Endothelin receptor B. 
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Figure 4-9 Endothelin receptor non-pulled protein expression in female and male hPASMC 
Protein expression of ETA and ETB were assessed in female/male control and PAH patient 
hPASMCs by western blot. Results were normalised to α-tubulin was used as the internal loading 
control. N=3-4 per group. Data expressed as individual values. ETA = Endothelin receptor A, ETB = 
Endothelin
 
receptor B. 
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Figure 4-10 Treprostinil in combination with endothelin-1: effect of an ETA and ETA+B receptor 
antagonist 
HPASMCs from female controls were quiesced for 24 hours in 0.5% FBS phenol free DMEM media. 
PASMCs were pre-incubated with (A) endothelin-A receptor (ETA) antagonist sitaxentan sodium 
(1µM) or a (B) dual endothelin receptor (ETB) antagonist SB-217242 (1µM) for 30 minutes prior to 
the addition treprostinil (1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM) in the presence 
or absence of endothelin-1 (30nM). Experiments were carried out in the presence of 7% FBS phenol 
free DMEM media. Cell counts were assessed 72 hours later by haemocytometer. N=3-4 human 
samples per group, in duplicate/triplicate, ɸɸ P<0.01 cf. Trep + ET-1, Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as % of 7% control. Sita Ant= sitaxentan sodium, SB 
Ant= SB-217242, Trep= treprostinil, ET-1= endothelin-1, ETA = Endothelin receptor A, ETB = 
Endothelin
 
receptor B. 
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Figure 4-11 The area under the curve is changed by the addition of an ETA+B antagonist in 
female control hPASMCs 
HPASMCs from female controls were quiesced for 24 hours in 0.5% FBS phenol free DMEM media. 
PASMCs were pre-incubated with either an ETA receptor antagonist sitaxentan sodium (1µM) (A) 
or an ETA+B receptor antagonist SB-217242 (1µM) (B) for 30 minutes prior to the addition treprostinil 
(1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM) in the presence or absence of endothelin-
1 (30nM). Experiments were carried out in the presence of 7% FBS phenol free DMEM media. N=3-
4 per group, *P<0.05 cf. Trep + ET-1, un-paired t-test. Data expressed as mean ± SEM. Sita Ant= 
sitaxentan sodium, SB Ant= SB-217242, Trep= treprostinil, ET-1= endothelin-1, ETA = Endothelin 
receptor A, ETB = Endothelin receptor B. 
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4.2.3. Prostaglandin receptors mRNA and protein in control and PAH patient 
hPASMCs 
Treprostinil is prostacyclin analogue that is known to act through multiple prostaglandin 
receptors, primarily treprostinil binds with the highest affinity to the DP1, IP and EP2 
receptors respectively (Whittle et al., 2012). It is currently unknown if expression of these 
receptors differs between sexes therefore the expression of the prostaglandin receptors 
was measured by Taqman® analysis and Western blot. In hPASMCs from women and 
men, mRNA expression of the IP, EP1, EP2 and DP1 receptors did not significantly change 
between sexes or control and PAH groups (Figure 4-12A-D). Interestingly, the mRNA 
expression of the EP2 receptor was found to be significantly higher in both control and PAH 
patient hPASMCs groups than IP, EP1 and DP1 expression (Figure 4-13A-B). Also, the 
mRNA expression of the DP1 receptor was found to be significantly lower than the other 
prostaglandin receptors in all hPASMCs groups (Figure 4-13A-B). Comparing IP, EP2 and 
DP1 mRNA expression to whole lung homogenates from the Chapter 3 second hypoxic 
study led to different patterns between hPASMCs and rats (Figure 4-14-Figure 4-15). The 
main difference from comparing control hPASMC to normoxic rats was that EP2 mRNA 
expression is much higher than IP mRNA in hPASMCs, whereas the opposite occurs in 
rats (Figure 4-14A&B). The same pattern is clear in the comparison of patient hPASMCs 
with hypoxic rats (Figure 4-15A&B). Interestingly, the DP1 was identified as the lowest 
expressing receptor in both hPASMCs and whole rat lung (Figure 4-14-Figure 4-15). The 
level of IP receptor protein was not reduced in the PAH patient hPASMCs examined as 
has been previously reported by Falcetti and colleagues (Falcetti et al., 2010) (Figure 4-
16A). Protein expression of the EP2 and DP1 receptors were also found not to change 
across sex and hPASMCs groups (Figure 4-16B-C). To account for any variability within 
each hPASMC group, individual densitometric values for each prostaglandin receptor was 
plotted (Figure 4-17-Figure 4-18).  
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Figure 4-12 Expression of prostaglandin receptors mRNA under basal conditions in control 
and PAH hPASMCs 
Expression of (A) IP, (B) EP1, (C) EP2 and (D) DP1 mRNA were assessed from female and male 
control and PAH patient hPASMCs by Taqman® quantitative Real Time-PCR. Results were 
normalised to β2-microglobulin. N=3-4 per group in triplicate, Two-way ANOVA with Bonferroni’s 
post-hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. 
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Figure 4-13 Differential expression of prostaglandin receptors mRNA under basal conditions 
in control and PAH hPASMCs 
Expression of IP, EP1, EP2 and DP1 mRNA were assessed from (A) female and male control and 
(B) female and male PAH patient hPASMCs by Taqman® quantitative Real Time-PCR. Results 
were normalised to β2-microglobulin. N=3-4 per group in triplicate. ***P<0.001 cf. IP (Female), ɸɸɸ 
P<0.001 cf. EP1 (Female), ξξξ P<0.001 cf. EP2 (Female), ǂǂ P<0.01 cf. IP (Male), ŦŦŦ P<0.01 cf. 
EP1 (Male), ƚƚƚ P<0.01 cf. EP2 (Male), Two-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as RQ ± RQmax/RQmin. RQ= relative quantification. 
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Figure 4-14 Comparison of prostaglandin receptors mRNA under basal conditions in control 
hPASMCs with vehicle dosed normoxic rats 
Expression of IP, EP2 and DP1 mRNA were assessed from (A) female control hPASMCs and female 
normoxic (Veh) rats and (B) male control hPASMCs and female normoxic (Veh) rats by Taqman® 
quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=3-6 per group in 
triplicate. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Veh= Vehicle dosed. 
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Figure 4-15 Comparison of prostaglandin receptors mRNA under basal conditions in PAH 
patient hPASMCs with vehicle dosed hypoxic rats 
Expression of IP, EP2 and DP1 mRNA were assessed from (A) female PAH patient hPASMCs and 
female hypoxic (Veh) rats and (B) male PAH patient hPASMCs and female normoxic (Veh) rats by 
Taqman® quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=3-6 per 
group in triplicate. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Veh= Vehicle 
dosed. 
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Figure 4-16 Expression of prostaglandin receptors protein under basal conditions in control 
and PAH hPASMCs 
Expression of (A) IP, (B) EP2 and (C) DP1 were assessed from were assessed from female/male 
control and PAH patient hPASMCs homogenates by western blot. (D) Representative immunoblot 
(D), α-tubulin was used as the internal loading control. N=3-4 in duplicate. Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as mean ± SEM.  
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Figure 4-17 Expression of prostaglandin receptors protein (non-pulled) under basal 
conditions in control hPASMCs 
Expression of (A) IP, (B) EP2 and (C) DP1 were assessed from were assessed from female/male 
control hPASMCs homogenates by western blot. α-tubulin was used as the internal loading control. 
N=3-4 (per group) in duplicate. Data expressed as individual values. 
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Figure 4-18 Expression of prostaglandin receptors protein (non-pulled) under basal 
conditions in PAH hPASMCs 
Expression of (A) IP, (B) EP2 and (C) DP1 were assessed from were assessed from female/male 
PAH patient hPASMCs homogenates by western blot. α-tubulin was used as the internal loading 
control. N=3 (per group) in duplicate. Data expressed as individual values. 
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4.2.4. Prostaglandin receptor antagonists can influence the anti-proliferative effect 
of treprostinil 
Treprostinil is prescribed therapy for the treatment of PAH. As a prostacyclin analogue 
treprostinil carries out its effects primarily through the prostaglandin receptors. The impact 
of blocking the IP, EP2 and DP1 receptors with selective antagonists; RO1138452, PF-
04418948 and BW 245C respectively, was examined by haemocytometer cell counts. 
Briefly, the effectiveness and specificity of the antagonists were examined in female control 
hPASMCs. The IP receptor antagonist RO1138452 (1µM) significantly reversed the anti-
proliferative effect of the IP receptor agonist MRE-269 (Figure 4-19A). The anti-
proliferative effects of the EP2 receptor agonist butaprost were successfully blocked by the 
addition of the EP2 receptor antagonist (PF-04418948) (Figure 4-19B). The DP1 receptor 
antagonist BW A868C inhibited the anti-proliferative actions of the DP1 receptor agonist 
BW 245C (Figure 4-19C). The effect of the antagonists on the anti-proliferative effects of 
treprostinil were examined in the presence or absence of endothelin-1. These were 
compared to previously run experiments in the absence of the antagonists. Without 
endothelin-1 the IP and EP2 antagonists had no significant effects on the anti-proliferative 
effects of treprostinil in female control hPASMCs (Figure 4-20A-B). However, the addition 
of the DP1 antagonist did significantly shift the anti-proliferative effect of treprostinil at 1nM 
(Figure 4-20C). Previously, the combination of treprostinil and endothelin-1 led to an 
increase in the anti-proliferative effect of treprostinil in female control hPASMCs (Figure 4-
3A). In the presence of endothelin-1, the effects of treprostinil at 10nM were significantly 
reduced by the addition of the IP receptor antagonist (Figure 4-21A). Both the EP2 and 
DP1 antagonists had no effect on the anti-proliferative actions of treprostinil at any 
concentration (Figure 4-21B-C). In female PAH patient hPASMCs, none of the antagonists 
significantly altered the effects of treprostinil (Figure 4-22A-C). In the presence of 
endothelin-1, the effects of treprostinil at 10nM and 100nM were significantly reduced by 
the addition of the EP2 receptor antagonist (Figure 4-23B). The addition of endothelin-1 
did not lead to any significant changes for the IP or DP1 receptor antagonists (Figure 4-
23A, C). As demonstrated in the female PAH patient hPASMCs, the addition of the IP, EP2 
and DP1 antagonists had no significant effect on the anti-proliferative effects of treprostinil 
in male PAH patient hPASMCs (Figure 4-24A-C). The anti-proliferative effects of 
treprostinil at 100nM were inhibited by the EP2 receptor antagonist, in the presence of 
endothelin-1 (Figure 4-25B). In male PAH patient hPASMCs, the IP and DP1 receptor 
antagonists had no significant effect on the anti-proliferative actions of treprostinil in the 
presence of endothelin-1 (Figure 4-25A, C).  
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Figure 4-19 The IP, EP2 and DP1 prostaglandin receptor antagonists block their respective 
agonists anti-proliferative actions in female control hPASMCs 
HPASMCs from female controls were quiesced for 24 hours in 0.5% FBS phenol free DMEM media. 
PASMCs were pre-incubated with 1µM of either an (A) IP (RO1138452), (B) EP2 (PF-04418948) or 
(C) DP1 (BW A868C) receptor antagonists (1µM) for 30 minutes prior to the addition of 100nM and 
1µM of respective receptor agonists, (A) MRE-269, (B) Butaprost and (C) BW 245C. Experiments 
were carried out in the presence of 7% FBS phenol free DMEM media. Cell counts were assessed 
72 hours later by haemocytometer. N=3-4 human samples per group, in triplicate, ***P<0.001 cf. 
0.5% FBS, ɸɸ P<0.01, ɸɸɸ P<0.001 c.f 7% FBS, ξξ P<0.01, ξξξ P<0.001 cf. 7% + respective 
antagonist.  One-way ANOVA with Bonferroni’s post-hoc test. Data expressed as % of 7% control. 
IP Antagonist = RO1138452, EP2 antagonist = PF-04418948, DP1 antagonist = BW A868C. 
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Figure 4-20 The IP and EP2 prostaglandin receptor antagonists have no significant effect on 
the anti-proliferative effect of treprostinil in the absence of endothelin-1 
HPASMCs from female controls were quiesced for 24 hours in 0.5% FBS phenol free DMEM media. 
PASMCs were pre-incubated with 1µM of either an (A) IP (RO1138452), (B) EP2 (PF-04418948) or 
(C) DP1 (BW A868C) receptor antagonists (1µM) for 30 minutes prior to the addition treprostinil 
(1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM). Experiments were carried out in the 
presence of 7% FBS phenol free DMEM media. Cell counts were assessed 72 hours later by 
haemocytometer. N=3-4 human samples per group, in duplicate/triplicate. *P<0.05 cf. Trep, Two-
way ANOVA with Bonferroni’s post-hoc test. Data expressed as % of 7% control. IP Antagonist = 
RO1138452, EP2 antagonist = PF-04418948, DP1 antagonist = BW A868C, Trep= treprostinil. 
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Figure 4-21 The IP receptor antagonist significantly reduced the anti-proliferative effect of 
treprostinil in female control hPASMCs in the presence of endothelin-1 
HPASMCs from female controls were quiesced for 24 hours in 0.5% FBS phenol free DMEM media. 
PASMCs were pre-incubated with 1µM of either an (A) IP (RO1138452), (B) EP2 (PF-04418948) or 
(C) DP1 (BW A868C) receptor antagonists (1µM) for 30 minutes prior to the addition treprostinil 
(1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM) in the presence endothelin-1 (30nM). 
Experiments were carried out in the presence of 7% FBS phenol free DMEM media. Cell counts 
were assessed 72 hours later by haemocytometer. N=3-4 human samples per group, in 
duplicate/triplicate, **P<0.01 cf. Trep + ET-1. Two-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as % of 7% control. IP Antagonist = RO1138452, EP2 antagonist = PF-04418948, DP1 
antagonist = BW A868C, ET-1 = endothelin-1, Trep= treprostinil. 
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Figure 4-22 The IP, EP2 and DP1 prostaglandin receptor antagonists have no significant 
effect on the anti-proliferative effects of treprostinil in female PAH patient hPASMCs in the 
absence of endothelin-1 
HPASMCs from female PAH patients were quiesced for 24 hours in 0.5% FBS phenol free DMEM 
media. PASMCs were pre-incubated with 1µM of either an (A) IP (RO1138452), (B) EP2 (PF-
04418948) or (C) DP1 (BW A868C) receptor antagonists (1µM) for 30 minutes prior to the addition 
treprostinil (1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM). Experiments were carried 
out in the presence of 7% FBS phenol free DMEM media. Cell counts were assessed 72 hours later 
by haemocytometer. N=3-4 human samples per group, in duplicate/triplicate. Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as % of 7% control. IP Antagonist = RO1138452, EP2 
antagonist = PF-04418948, DP1 antagonist = BW A868C, Trep= treprostinil. 
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Figure 4-23 The EP2 receptor antagonist significantly reduced the anti-proliferative effect of 
treprostinil in female PAH patient hPASMCs in the presence of endothelin-1 
HPASMCs from female PAH patient were quiesced for 24 hours in 0.5% FBS phenol free DMEM 
media. PASMCs were pre-incubated with 1µM of either an (A) IP (RO1138452), (B) EP2 (PF-
04418948) or (C) DP1 (BW A868C) receptor antagonists (1µM) for 30 minutes prior to the addition 
treprostinil (1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM) in the presence endothelin-1 
(30nM). Experiments were carried out in the presence of 7% FBS phenol free DMEM media. Cell 
counts were assessed 72 hours later by haemocytometer. N=3-4 human samples per group, in 
duplicate/triplicate, *P<0.05, **P<0.01 cf. Trep + ET-1. Two-way ANOVA with Bonferroni’s post-hoc 
test. Data expressed as % of 7% control. IP Antagonist = RO1138452, EP2 antagonist = PF-
04418948, DP1 antagonist = BW A868C, ET-1 = endothelin-1, Trep= treprostinil 
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Figure 4-24 The IP, EP2 and DP1 prostaglandin receptor antagonists have no significant 
effect on the anti-proliferative effects of treprostinil in male PAH patient hPASMCs in the 
absence of endothelin-1 
HPASMCs from male PAH patients were quiesced for 24 hours in 0.5% FBS phenol free DMEM 
media. PASMCs were pre-incubated with 1µM of either an (A) IP (RO1138452), (B) EP2 (PF-
04418948) or (C) DP1 (BW A868C) receptor antagonists (1µM) for 30 minutes prior to the addition 
treprostinil (1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM). Experiments were carried 
out in the presence of 7% FBS phenol free DMEM media. Cell counts were assessed 72 hours later 
by haemocytometer. N=2-3 human samples per group, in duplicate/triplicate, Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as % of 7% control. IP Antagonist = RO1138452, EP2 
antagonist = PF-04418948, DP1 antagonist = BW A868C, Trep= treprostinil. 
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Figure 4-25 The EP2 receptor antagonist significantly reduced the anti-proliferative effect of 
treprostinil in male PAH patient hPASMCs in the presence of endothelin-1 
HPASMCs from male PAH patients were quiesced for 24 hours in 0.5% FBS phenol free DMEM 
media. PASMCs were pre-incubated with 1µM of either an IP (RO1138452) (A), EP2 (PF-04418948) 
(B) or DP1 (BW A868C) (C) receptor antagonists (1µM) for 30 minutes prior to the addition 
treprostinil (1pM, 10pM, 100pM, 1nM, 10nM, 100nM, 1µM and 10µM) in the presence endothelin-1 
(30nM). Experiments were carried out in the presence of 7% FBS phenol free DMEM media. Cell 
counts were assessed 72 hours later by haemocytometer. N=2-3 human samples per group, in 
duplicate/triplicate, *P<0.05 cf. Trep + ET-1, Two-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as % of 7% control. IP Antagonist = RO1138452, EP2 antagonist = PF-04418948, DP1 
antagonist = BW A868C, ET-1 = endothelin-1, Trep= treprostinil. 
 Chapter Four In-vitro 
167 
 
4.2.5. The effects of treprostinil on BMPR-II protein signalling in control and PAH 
patient hPASMCs 
As the BMPR-II signalling pathway is important in cases of HPAH and IPAH. The effect of 
treprostinil, in the presence or absence of endothelin-1, on BMPR-II signalling was 
examined. This was carried out under the same conditions as the proliferation cell count 
experiments. BMPR-II, pSmad1/5/9, Id1 and Id3 were examined by western blot protein 
analysis. In female control hPASMCs, it was found that BMPR-II, pSmad1/5/9 and Id1 
protein expression were not altered by the addition of treprostinil with or without endothelin-
1 (Figure 4-26A-C). However, 1µM treprostinil stimulation significantly increased Id3 
protein expression. The addition of endothelin-1 did not significantly increase this effect 
(Figure 4-26D). No significant changes in BMPR-II, pSmad1/5/9, Id1 or Id3 were observed 
following treprostinil stimulation in male control hPASMCs (Figure 4-27A-D). Both female 
(Figure 4-28A-C) and male (Figure 4-29A-C) PAH hPASMCs had no significant increase 
in BMPR-II, pSmad 1/5/9 and Id1 protein with treprostinil stimulation. However, Id3 protein 
expression was increased by treprostinil stimulation (1µM) in female PAH patient 
hPASMCs (Figure 4-28D). There was no significant increase in Id3 expression in male 
PAH patient hPASMCs (Figure 4-29D). The data suggests that although treprostinil can 
activate components of the BMPR-II signalling pathway endothelin-1 does not increase 
this effect. 
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Figure 4-26 Expression of Id3 protein is increased by the addition of treprostinil (1µM) at 72 
hours in female control hPASMCs; the addition of endothelin-1 (30nM) has no additional 
effect on BMPR-II signalling 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from female control 
hPASMCs stimulated with treprostinil (100nM and 1µM) in presence or absence of endothelin-1 
(30nM) over 72 hours by western blot. (E) Representative immunoblot, α-tubulin was used as the 
internal loading control. N=4 (n=3 in duplicate). *P<0.05, **P<0.01 cf. Basal, ɸɸ P<0.01, ɸɸɸ 
P<0.001 cf. 7% FBS, ξ P<0.05, ξξ P<0.01 cf. 7% FBS + Endothelin-1. One-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as mean ± SEM. Basal = non-quiesced hPASMCs in 
10% FBS phenol red DMEM media. ET-1 = endothelin-1, Trep= treprostinil. 
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Figure 4-27 Treprostinil does not affect BMPR-II signalling at 72 hours in male control 
hPASMCs; the addition of endothelin-1 (30nM) has no additional effect on BMPR-II signalling 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from male control 
hPASMCs stimulated with treprostinil (100nM and 1µM) in presence or absence of endothelin-1 
(30nM) over 72 hours by western blot. (E) Representative immunoblot, α-tubulin was used as the 
internal loading control. N=3-4 (n=3 in duplicate). One-way ANOVA with Bonferroni’s post-hoc test. 
Data expressed as mean ± SEM. Basal = non-quiesced hPASMCs in 10% FBS phenol red DMEM 
media. ET-1 = endothelin-1, Trep= treprostinil. 
 Chapter Four In-vitro 
170 
 
 
Figure 4-28 Expression of Id3 protein is increased by the addition of treprostinil (1µM) at 72 
hours in female patient hPASMCs; the addition of endothelin-1 (30nM) has no additional 
effect on BMPR-II signalling 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from female patient 
hPASMCs stimulated with treprostinil (100nM and 1µM) in presence or absence of endothelin-1 
(30nM) over 72 hours by western blot. (E) Representative immunoblot, α-tubulin was used as the 
internal loading control. N=3 in duplicate. *P<0.05 cf. Basal, ɸ P<0.05 cf. 7% FBS, ξ P<0.05 cf. 7% 
FBS + Endothelin-1. One-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± 
SEM. Basal = non-quiesced hPASMCs in 10% FBS phenol red DMEM media. ET-1 = endothelin-
1, Trep= treprostinil. 
 Chapter Four In-vitro 
171 
 
 
Figure 4-29 Treprostinil does not affect BMPR-II signalling at 72 hours in male patient 
hPASMCs 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from male patient 
hPASMCs stimulated with treprostinil (100nM and 1µM) in presence or absence of endothelin-1 
(30nM) over 72 hours by western blot. (E) Representative immunoblot, α-tubulin was used as the 
internal loading control. N=3 in duplicate (n=2 for BMPR-II blot). One-way ANOVA with Bonferroni’s 
post-hoc test. Data expressed as mean ± SEM. Basal = non-quiesced hPASMCs in 10% FBS 
phenol red DMEM media. ET-1 = endothelin-1, Trep= treprostinil. 
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4.2.6. The effects of treprostinil on BMPR-II signalling in control and PAH patient 
hPASMCs: mRNA 
As endothelin-1 had no effect on treprostinil activation of BMPR-II signalling, the effects of 
treprostinil alone were examined by Taqman® analysis. BMPR-II, Id1 and Id3 mRNA was 
assessed in female and male control/PAH hPASMCs groups. BMPR-II mRNA expression 
was not significantly affected by any experimental condition in control or PAH patient 
hPASMC group (Figure 4-30A, Figure 4-31A). 100nM and 1µM treprostinil stimulations 
caused a significant increase in Id1 mRNA in female control hPASMCs (Figure 4-30B). No 
reciprocal increase in Id1 mRNA expression was observed in male control hPASMCs 
(Figure 4-28B) or in PAH patient hPASMCs (Figure 4-31B). Treprostinil stimulation (100nM 
and 1µM) significantly increased Id3 mRNA expression in female control hPASMCs, this 
effect was not observed in male control hPASMCs (Figure 4-30C). However, treprostinil 
(1µM) significantly up-regulated Id3 mRNA expression in both female and male PAH 
hPASMCs (Figure 4-31C). The significant increase in Id3 was much greater in female PAH 
patients (Figure 4-31C). In female control hPASMCs 100nM treprostinil stimulation led to 
a significant increase in Id1 mRNA expression over the equivalent BMPR-II mRNA level 
(Figure 4-32A). Also, basal and 7% FBS mRNA expression of Id3 was significantly lower 
than BMPR-II expression under the same conditions (Figure 4-32A). No differences were 
detected between BMPR-II, Id1 or Id3 in male control hPASMCs (Figure 4-32B). In female 
PAH patient hPASMCs 1µM treprostinil stimulation led to higher Id3 mRNA levels than 
observed in BMPR-II mRNA under the same conditions (Figure 4-33A). As with male 
control hPASMCs, male PAH patient hPASMCs expressed no significant difference in 
BMPR-II, Id1 or Id3 mRNA expression (Figure 4-33B). 
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Figure 4-30 Id1 and Id3 mRNA expression is increased by treprostinil in female control 
hPASMCs but not in male control hPASMCs 
Expression of (A) BMPR-II, (B) Id1 and (C) Id3 mRNA were assessed from female and male control 
hPASMCs stimulated with treprostinil (100nM and 1µM) over 72 hours by Taqman® quantitative 
Real Time-PCR. Results were normalised to β2-microglobulin. N=4 per group in triplicate, **P<0.01, 
****P<0.0001 cf. Basal, ɸ P<0.05, ɸɸ P<0.01, ɸɸɸ P<0.001 cf. 7% FBS. Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Basal 
= non-quiesced hPASMCs in 10% FBS phenol red DMEM media, Trep= treprostinil. 
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Figure 4-31 Id3 mRNA expression is increased by treprostinil in female and male patient 
hPASMCs 
Expression of (A) BMPR-II, (B) Id1 and (C) Id3 mRNA were assessed from female and male PAH 
patient hPASMCs stimulated with treprostinil (100nM and 1µM) over 72 hours by Taqman® 
quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=3 per group in 
triplicate, ***P<0.001 cf. Basal, ɸɸ P<0.01 cf. 7% FBS. Two-way ANOVA with Bonferroni’s post-hoc 
test. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Basal = non-quiesced 
hPASMCs in 10% FBS phenol red DMEM media, Trep=treprostinil. 
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Figure 4-32 Comparison of overall BMPR-II, Id1 and Id3 mRNA expression within female and 
male control hPASMCs 
Expression of BMPR-II, Id1 and Id3 mRNA were assessed from (A) female and (B) male control 
hPASMCs stimulated with treprostinil (100nM and 1µM) over 72 hours by Taqman® quantitative 
Real Time-PCR. Results were normalised to β2-microglobulin. N=4 per group in triplicate. *P<0.05 
cf. BMPR-II (respective group), Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed 
as RQ ± RQmax/RQmin. RQ= relative quantification. Basal = non-quiesced hPASMCs in 10% FBS 
phenol red DMEM media, Trep= treprostinil. 
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Figure 4-33 Comparison of overall BMPR-II, Id1 and Id3 mRNA expression within female and 
male PAH patient hPASMCs 
Expression of BMPR-II, Id1 and Id3 mRNA were assessed from (A) female and (B) male PAH 
patient hPASMCs stimulated with treprostinil (100nM and 1µM) over 72 hours by Taqman® 
quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=3 per group in 
triplicate. *P<0.05 cf. BMPR-II (respective group), Two-way ANOVA with Bonferroni’s post-hoc test. 
Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Basal = non-quiesced hPASMCs 
in 10% FBS phenol red DMEM media, Trep= treprostinil. 
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4.2.7. The increase in Id3 protein, by treprostinil (1µM) for 72 hours, is greater in 
female control hPASMCs 
A comparison of BMPR-II signalling after 72-hour treprostinil stimulation between female 
and male control hPASMCs was carried out by western blot protein analysis. Sex or 
treprostinil had no effect on in BMPR-II, pSmad 1/5/9 or Id1 protein levels (Figure 4-34A-
C). However, 1µM treprostinil stimulation caused a significant induction of Id3 protein 
expression specifically in female control hPASMCs (Figure 4-34D). This effect was not 
observed in male control hPASMCs (Figure 4-32D).  
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Figure 4-34 The increase in Id3 protein is greater in female control hPASMCs over male 
control hPASMCs when stimulated with treprostinil (1µM) for 72 hours 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from female and 
male control hPASMCs stimulated with treprostinil (100nM and 1µM) over 72 hours by western blot. 
Representative immunoblot (E), α-tubulin was used as the internal loading control. N=3-4 (n=3 for 
BMPR-II blot) in duplicate. ****P<0.0001 cf. Basal, ɸɸɸɸ P<0.0001 cf. 7% FBS, ξξ P<0.01 cf. Trep 
(0.1µM), Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. Basal 
= non-quiesced hPASMCs in 10% FBS phenol red DMEM media, Trep= treprostinil.  
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4.2.8. BMPR-II signalling protein is increased in both control and patient hPASMCs 
groups after 24 hour treprostinil stimulation 
Due to the low levels of induction of the BMPR-II signalling pathway after 72-hour of 
stimulation with treprostinil, effects of treprostinil on BMPR-II signalling after 24 hours. The 
BMPR-II pathway and the impact of endothelin-1 on the effect of treprostinil were 
investigated by western blot protein analysis. In female control hPASMCs, BMPR-II and 
pSmad 1/5/9 were not significantly changed by the addition of treprostinil in the presence 
or absence of endothelin (Figure 4-35A, B). Both concentrations of treprostinil significantly 
increased Id1 protein (Figure 4-35C), this differed to the results observed at 72-hours 
(Figure 4-26C). Previously, treprostinil only significantly induced Id3 protein at 1µM (Figure 
4-26D). Presently, a much greater significant increase was observed after treprostinil 
stimulation at both 100nM and 1µM (Figure 4-35D). The addition of endothelin-1 did not 
have significant influence on the effects of treprostinil. Previously, in male control 
hPASMCs, no changes to the BMPR-II pathway were observed (Figure 4-27). Presently, 
1µM of treprostinil was found to increase the induction of Id3 protein when combined with 
endothelin-1 above the FBS level (Figure 4-36D). No significant changes were observed 
in BMPR-II, pSmad 1/5/9 or Id1 protein after treprostinil stimulation (Figure 4-36A-C). The 
shorter experimental time also improved the female PAH patient response to treprostinil. 
Despite no significant increases in BMPR-II, pSmad 1/5/9 and Id1 protein (Figure 4-37A-
C), 100nM and 1µM of treprostinil significantly increased Id3 protein induction (Figure 4-
37D). Treprostinil did not significantly increase protein expression of BMPR-II, pSmad 
1/5/9, Id1 or Id3 in male PAH patient hPASMCs (Figure 4-38A-D).  
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Figure 4-35 Expression of Id1 and Id3 protein is increased by the addition of treprostinil 
(100nM and 1µM) for 24 hours in female control hPASMCs 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed in female control 
hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by western blot. (E) 
Representative immunoblot, α-tubulin was used as the internal loading control. N=4 in duplicate. 
**P<0.01 cf. Basal, ɸ P<0.05, ɸɸ P<0.01, ɸɸɸ P<0.001 cf. 7% FBS, ξξ P<0.01, ξξξ P<0.001 cf. 7% 
FBS + ET-1. One-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. 
Basal = non-quiesced hPASMCs in 10% FBS phenol red DMEM media, ET-1 = endothelin-1, Trep= 
treprostinil. 
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Figure 4-36 Expression of Id3 protein is increased by the addition of treprostinil (1µM) when 
combined with endothelin-1 (30nM) for 24 hours in male control hPASMCs 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed in male control 
hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by western blot. (E) 
Representative immunoblot, α-tubulin was used as the internal loading control. N=4 in duplicate. 
*P<0.05 cf. 7 % FBS. One-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± 
SEM. Basal = non-quiesced hPASMCs in 10% FBS phenol red DMEM media, ET-1 = endothelin-
1, Trep= treprostinil. 
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Figure 4-37 Expression of Id3 protein is increased by the addition of treprostinil (100nM and 
1µM) for 24 hours in female patient hPASMCs 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed in female patient 
hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by western blot. (E) 
Representative immunoblot, α-tubulin was used as the internal loading control. N=4 in duplicate 
(n=3 for pSmad 1/5/9).  *P<0.05, **P<0.01 cf. Basal, ɸ P<0.05, ɸɸ P<0.01 cf. 7% FBS, ξ P<0.05, ξξ 
P<0.01 cf. 7% FBS + ET-1. One-way ANOVA with Bonferroni’s post-hoc test. Data expressed as 
mean ± SEM. Basal = non-quiesced hPASMCs in 10% FBS phenol red DMEM media, ET-1 = 
endothelin-1, Trep= treprostinil. 
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Figure 4-38 BMPR-II signalling is not significantly changed by 24 hour treprostinil 
stimulation in male PAH patient hPASMCs 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from male patient 
hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by western blot. (E) 
Representative immunoblot, α-tubulin was used as the internal loading control. N=3 in duplicate. 
One-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. Basal = non-
quiesced hPASMCs in 10% FBS phenol red DMEM media, ET-1 = endothelin-1, Trep= treprostinil. 
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4.2.9. The effect of treprostinil on BMPR-II signalling pathway mRNA in control and 
PAH patient hPASMCs at 24 hours 
The changes in the BMPR-II (mRNA) signalling was investigated by Taqman® analysis. 
Consistent with previous results, treprostinil stimulation led to no change in BMPR-II 
mRNA expression in control and PAH patient hPASMCs (Figure 4-39A, Figure 4-40A). 
Interestingly, treprostinil did not change Id1 mRNA expression in female control hPASMCs 
(Figure 4-39B). This differs from the increase that was observed at 72-hours (Figure 4-
30B). Id1 mRNA was not up-regulated in male control hPASMCs (Figure 4-39B), this was 
consistent with previous results (Figure 4-30B). Treprostinil increased Id3 mRNA 
expression at 100nM and 1µM in both female and male control hPASMCs (Figure 4-39C). 
Previously after 72-hours, treprostinil increased Id3 expression in female control 
hPASMCs (Figure 4-30C). Id1 mRNA was upregulated in female and male PAH patient 
hPASMCs. However, the increase was observed at both 100nM and 1µM of treprostinil in 
females (Figure 4-40B) but only at 1µM in male patients (Figure 4-40B). Similarly, Id3 was 
increased in female and male PAH patients, although in females the increase was 
observed after treprostinil stimulation at 100nM and 1µM (Figure 4-40C). In female control 
hPASMCs, 1µM treprostinil stimulation significantly increased both Id1 and Id3 mRNA 
expression over equivalently treated BMPR-II mRNA (Figure 4-41A). Only Id3 mRNA was 
significantly higher than BMPR-II mRNA after 1µM treprostinil in male control hPASMCs 
(Figure 4-41B). Both 100nM and 1µM treprostinil stimulation led to significantly higher 
mRNA expression Id3 compared to Id1 and BMPR-II under the same stimulations (Figure 
4-42A). In male PAH patients 100nM and 1µM treprostinil stimulation significantly 
increased Id3 mRNA expression compared to BMPR-II mRNA (Figure 4-42B). Also, Id1 
mRNA was significantly higher than BMPR-II mRNA after 1µM treprostinil stimulation 
(Figure 4-42B). 
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Figure 4-39 Id3 mRNA expression is increased in both female and male control hPASMCs 
after 24 hours of treprostinil stimulation 
Expression of BMPR-II (A), Id1 (B) and Id3 (C) mRNA were assessed from female and male control 
hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by Taqman® quantitative 
Real Time-PCR. Results were normalised to β2-microglobulin. N=4 per group in triplicate, ɸɸ 
P<0.01 cf. (Female) 7% FBS, ξ P<0.05, ξξ P<0.01 cf. (Male) 7% FBS, Two-way ANOVA with 
Bonferroni’s post-hoc test. Data expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Basal 
= non-quiesced hPASMCs in 10% FBS phenol red DMEM media, Trep= treprostinil. 
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Figure 4-40 Id1 and Id3 mRNA expression is increased in both female and male patient 
hPASMCs after 24 hours of treprostinil stimulation 
Expression of BMPR-II (A), Id1 (B) and Id3 (C) mRNA were assessed from female and male PAH 
patient hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by Taqman® 
quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=3-4 per group in 
triplicate, *P<0.05 cf. (Female) Basal, ɸ P<0.05, ɸɸ P<0.01 cf. (Female) 7% FBS, ξ P<0.05 cf. 
(Male) 7% FBS, Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as RQ ± 
RQmax/RQmin. RQ= relative quantification. Basal = non-quiesced hPASMCs in 10% FBS phenol red 
DMEM media, Trep = treprostinil. 
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Figure 4-41 Comparison of overall BMPR-II, Id1 and Id3 mRNA expression within female and 
male control hPASMCs 
Expression of BMPR-II, Id1 and Id3 mRNA were assessed from (A) female and (B) male control 
hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by Taqman® quantitative 
Real Time-PCR. Results were normalised to β2-microglobulin. N=3-4 per group in triplicate, 
*P<0.05 cf. BMPR-II (respective group), Two-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as RQ ± RQmax/RQmin. RQ= relative quantification. Basal = non-quiesced hPASMCs 
in 10% FBS phenol red DMEM media, Trep= treprostinil. 
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Figure 4-42 Comparison of overall BMPR-II, Id1 and Id3 mRNA expression within female and 
male PAH patient hPASMCs 
Expression of BMPR-II, Id1 and Id3 mRNA were assessed from (A) female and (B) male PAH 
patient hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by Taqman® 
quantitative Real Time-PCR. Results were normalised to β2-microglobulin. N=3-4 per group in 
triplicate, *P<0.05, ****P<0.0001 cf. BMPR-II (respective group), ɸɸ P<0.01, ɸɸɸɸ P<0.0001 cf. Id1 
(respective group), Two-way ANOVA with Bonferroni’s post-hoc test Data expressed as RQ ± 
RQmax/RQmin. RQ= relative quantification. Basal = non-quiesced hPASMCs in 10% FBS phenol 
red DMEM media, Trep= treprostinil. 
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4.2.10. The effect of treprostinil on BMPR-II signalling after 24-hour treprostinil 
stimulation demonstrates greater induction of Id proteins in female control 
hPASMCs 
BMPR-II signalling was investigated in the absence of endothelin-1 by western blot 
analysis after 24-hour stimulation with treprostinil. BMPR-II and pSmad 1/5/9 were 
unchanged with treprostinil stimulation, in both female and male control hPASMCs (Figure 
4-43A-B). As observed previously, treprostinil elevated Id3 protein significantly in female 
control hPASMCs (Figure 4-43D). Consistent with previous results, there was no 
significant increase in Id3 protein expression in male control hPASMCs (Figure 4-43D). In 
PAH patients, there was no significant increase in BMPR-II, pSmad 1/5/9 and Id1 protein 
expression after 24-hour treprostinil stimulation (Figure 4-44A-C). In female PAH patients, 
both 100nM and 1µM of treprostinil significantly increase Id3 protein, however this only 
1µM of treprostinil increased Id3 in male PAH hPASMCs (Figure 4-44D). The data 
demonstrates that females have moderately better induction of the Id proteins after 24-
hour of treprostinil stimulation. However, as observed previously the greatest difference 
was between female and male control hPASMCs. 
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Figure 4-43 The increase Id3 protein is greater in female control hPASMCs than in male 
control hPASMCs when stimulated with treprostinil at 100nM and 1µM for 24 hours 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from female and 
male control hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by western blot.  
(E) Representative immunoblot, α-tubulin was used as the internal loading control. N=4 in duplicate. 
**P<0.01 cf. Basal, ɸɸɸ P<0.001 cf. 7% FBS (Female). Two-way ANOVA with Bonferroni’s post-
hoc test. Data expressed as mean ± SEM. Basal = non-quiesced hPASMCs in 10% FBS phenol 
red DMEM media, Trep=treprostinil.  
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Figure 4-44 The increase in Id3 protein is greater in female PAH patient hPASMCs over male 
PAH patient hPASMCs when stimulated with treprostinil (1µM) for 24 hours 
Expression of (A) BMPR-II, (B) pSmad 1/5/9, (C) Id1 and (D) Id3 were assessed from female and 
male PAH patient hPASMCs stimulated with treprostinil (100nM and 1µM) over 24 hours by western 
blot. (E) Representative immunoblot, α-tubulin was used as the internal loading control. N=3 in 
duplicate. *P<0.05, **P<0.01 cf. Basal, ɸɸ P<0.01 cf. 7% FBS (Female), ξ P<0.05 cf. 7% FBS 
(Male), Two-way ANOVA with Bonferroni’s post-hoc test. Data expressed as mean ± SEM. Basal 
= non-quiesced hPASMCs in 10% FBS phenol red DMEM media, Trep= treprostinil.  
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4.2.11. Dual prostaglandin receptor antagonism block treprostinil’s induction of Id 
proteins 
The influence of the prostaglandin receptors on Id protein induction was investigated by 
western blot. Female control and PAH patient hPASMCs were stimulated with treprostinil 
in the absence or combined with prostaglandin receptor antagonists, for 24 hours. In 
female control hPASMCs, treprostinil increased both Id1 and Id3 (Figure 4-45A-B). Id1 and 
Id3 increases at 100nM were significantly blocked by the addition of 1µM of IP and EP2 
receptor antagonists; RO1138452 and PF-04418948 (Figure 4-45A-B). Interestingly, the 
combination of the IP and EP2 antagonists with 1µM of a DP1 receptor antagonist (BW 
A868C) did not lead to a significant reduction in Id1 and Id3 (Figure 4-45C-D). In female 
PAH patient hPASMCs, treprostinil at 100nM and 1µM increased Id3 protein expression 
(Figure 4-46B). Similarly, to female control hPASMCs the increase in Id3 at 100nM of 
treprostinil was abolished by the addition of the IP and EP2 receptor antagonists (Figure 
4-46B). As before, the combination of the IP and EP2 antagonists with the DP1 receptor 
antagonist did not preserve the significant reversal of the Id3 protein (Figure 4-46D).  
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Figure 4-45 Id1 and 3 protein expression in female control hPASMCs after treatment with 
treprostinil +/- IP and EP2 antagonists 
Expression of (A, C) Id1 and (B, D) Id3 were assessed from female control hPASMCs pre-incubated 
for 30 minutes with a combination of 1µM of IP (RO1138452) and EP2 (PF-04418948) antagonists 
or IP, EP2 and DP1 (BW A868C) antagonists, then stimulated with treprostinil (100nM and 1µM) 
over 24 hours by western blot. (E) Representative immunoblot, α-tubulin was used as the internal 
loading control. N=3 in duplicate. *P<0.05, **P<0.01 cf. Basal, ɸ P<0.05, ɸɸ P<0.01 cf. 7% FBS, ξ 
P<0.05, ξξξ P<0.001 cf. Trep (0.1µM). One-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as mean ± SEM. Basal = non-quiesced hPASMCs in 10% FBS phenol red DMEM media, 
Trep= treprostinil.  
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Figure 4-46 Increase in Id3 protein, by treprostinil, is partially reversed by the dual 
antagonism of the IP and EP2 prostaglandin receptors in female patient hPASMCs  
Expression of (A, C) Id1 and (B, D) Id3 were assessed from female PAH patient hPASMCs pre-
incubated for 30 minutes with a combination of 1µM of IP (RO1138452) and EP2 (PF-04418948) 
antagonists or IP, EP2 and DP1 (BW A868C) antagonists, then stimulated with treprostinil (100nM 
and 1µM) over 24 hours by western blot. (E) Representative immunoblot, α-tubulin was used as the 
internal loading control. N=3 in duplicate. **P<0.01, ***P<0.001 cf. Basal, ɸɸ P<0.01, ɸɸɸ P<0.01 
cf. 7% FBS, ξξξ P<0.001 cf. Trep (0.1µM). One-way ANOVA with Bonferroni’s post-hoc test. Data 
expressed as mean ± SEM. Basal = non-quiesced hPASMCs in 10% FBS phenol red DMEM media, 
Trep=treprostinil. 
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4.3. Discussion 
There are many therapies that are prescribed to treat PAH, these include endothelin 
receptor antagonists, phosphodiesterase 5 inhibitors and prostacyclin analogues 
(Jasinska-Stroschein and Orszulak-Michalak, 2014). Treprostinil and other prostacyclin 
analogues are known to act through the prostaglandin receptors to mediate vasodilatory 
and anti-proliferative effects (Clapp and Gurung, 2015). Male PAH patients have a poorer 
survival outcome compared to female PAH patients (Benza et al., 2010). Previously, a 
phosphodiesterase 5 inhibitor and a endothelin receptor antagonist have exhibited greater 
beneficial effects in male and female respectively (Mathai et al., 2015, Gabler et al., 2012).  
This was the first study to investigate the potential role of sex in the anti-proliferative effects 
of treprostinil. Through in-vitro investigations, sex was found to a have an influencing role 
in the anti-proliferative effects of treprostinil however, the main differences were observed 
between control hPASMCs not PAH patient hPASMCs. The female control hPASMCs had 
a more diverse and significant anti-proliferative response to treprostinil than male control 
hPASMCs. The addition of endothelin-1 (30nM) to the FBS moderately improved the anti-
proliferative activity of treprostinil in all groups, although, significant improvement was 
observed only in female control hPASMCs. The BMPR-II signalling pathway was 
implicated in the anti-proliferative effects of treprostinil. After 72-hour stimulation with 
treprostinil female control hPASMCs had significant increases in Id mRNA and protein 
whereas male control hPASMCs did not. 72-hour stimulation with treprostinil led to 
increases in Id3 mRNA expression in both female and patient PAH hPASMCs, however 
protein expression did not increase. A shorter 24-hour stimulation with treprostinil led to 
greater induction in both Id1 and Id3 protein in female control hPASMCs. A smaller female 
bias was observed in PAH patient hPASMCs. The role prostaglandin receptors play in 
treprostinil’s effects, was observed not only in anti-proliferation, but also in the drugs’ ability 
to increase Id protein expression. 
Until recently, the underlying pharmacological reasons for treprostinil’s actions were not 
well understood. Treprostinil was discovered to increase levels of cAMP in hPASMCs 
(Clapp et al., 2002) and latterly found to reduce proliferation in both HEK cells and 
hPASMCs (Falcetti et al., 2007). Presently, this study demonstrates that female control 
hPASMCs have a greater significant response to treprostinil than equivalently treated male 
control hPASMCs. Much of the research into sex influencing drug effects is limited to the 
study of adverse drug reactions, primarily occurring in women (Fattinger et al., 2000). 
However, it has been shown that serotonin receptor 1B receptor expression was much 
higher in females, whereas serotonin transporter binding potential was significantly lower 
compared to males (Jovanovic et al., 2008). Sex differences in the serotonin system in 
PAH have also been demonstrated recently in animal models and in hPASMCs (Wallace 
et al., 2015). In this study, endothelin-1 combined with FBS was shown to partially improve 
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the anti-proliferative effects of treprostinil in female control hPASMCs. This appears 
counter-intuitive as endothelin-1 is a pro-proliferative vasoconstrictor that is elevated in 
PAH patients (Stewart et al., 1991, Giaid et al., 1993, Hall et al., 2011). Interestingly, there 
was no significant difference in endothelin receptor protein or mRNA in the hPASMCs 
tested that could adequately explain the increased treprostinil effect in female control 
hPASMCs. However, significantly lower levels of preproET-1 mRNA were identified in 
female control hPASMCs suggesting lower local ET-1 production. The actions of anti-
proliferative therapies for PAH were examined under similar conditions (Patel et al., 2014). 
However, these were not compared to equivalent experiments without endothelin-1. The 
additive effects of treprostinil and endothelin were also demonstrated in isolated human 
pulmonary arteries. Pre-constriction with endothelin-1 led to a greater treprostinil mediated 
vasodilation than in those vessels pre-constricted with norepinephrine (Benyahia et al., 
2015). In the present study, the treprostinil response in combination with ET-1 was blunted 
by the addition of the dual endothelin receptor antagonist SB-217242, suggesting that 
involvement of both endothelin receptors. Treprostinil has also previously been found to 
inhibit serum induced increases in ET-1 in PAH patient hPASMCs, this effect was 
hampered by the addition of the dual endothelin receptor antagonist bosentan and ETB 
specific antagonist BQ-788 (Jigisha et al., 2012). Consensus about ET-1 in PAH suggests 
that it is a causative factor in disease development. However, there may be potential 
benefits to its presence in pulmonary circulation. In proximal hPASMCs, endothelin-1 was 
found to increase the release of cAMP via a cyclooxygenase-2/IP (COX-2/IP) receptor 
autocrine loop (Deacon and Knox, 2010). This autocrine loop involved the local 
prostacyclin synthesis which then could act on the IP receptor, triggering cAMP increase 
and activation of cAMP response binding elements (CREBs). Deacon and Knox also 
identified the ET-1 increased cyclooxygenase 1 and 2 (COX1/2) protein levels, however 
any ET-1 mediated cAMP increase was removed by COX-1/2 inhibition and IP receptor 
inhibition (Deacon and Knox, 2010). ET-1 was also shown to increase PGI2 and PGE2 
secretion from hPASMCs (Deacon and Knox, 2010).  Since treprostinil can bind and 
activate the IP receptor as well as other prostaglandin receptors it may be a possible 
explanation for the increased treprostinil effect in combination with ET-1. However, as the 
previously published work was carried out in proximal hPASMCs, it would need to be 
repeated in distal hPASMCs.  
A primary consequence of activating Gs coupled receptors like the IP, EP2 and DP1 is an 
increase in cAMP levels (Hata and Breyer, 2004). Although not measured in this study 
cAMP induction may differ between the hPASMC groups, specifically it may explain the 
weaker response to treprostinil in male hPASMCs. For future studies, it would be prudent 
to investigate cAMP induction from each prostaglandin receptor in the absence and 
presence of the specific antagonists. The specificity of treprostinil to each receptor would 
 Chapter Four In-vitro 
197 
 
then be able to be ascertained. Although the ability of treprostinil to increase cAMP levels 
has been determined previously, it has not been investigated regarding the EP2 and DP1 
receptors in hPASMCs (Falcetti et al., 2010, Nikam et al., 2011). Yang and colleagues 
successfully identified a link between prostacyclin analogues increasing cAMP and the 
activation of BMPR-II signalling (Yang et al., 2010). Therefore, measuring cAMP levels 
may also offer insight into the different levels of BMPR-II signalling induction observed 
between sexes and control/PAH patient hPASMCs. 
The differing effects of treprostinil across the hPASMCs groups led to investigation of the 
role of prostaglandin receptors.  Presently, the IP receptor mRNA and protein expression 
was not downregulated in PAH patient hPASMCs. The results achieved from this study 
differ from established research, specifically the IP receptor was shown to be 
downregulated in adult IPAH and child IPAH patient hPASMCs both at mRNA and protein 
levels (Falcetti et al., 2010). However, the PAH patient hPASMCs used in the current 
experiment were a mix of IPAH, HPAH and APAH suggesting that the IP receptor may not 
universally down-regulated in all forms of PAH. Although not investigated in the current 
study, IP receptor desensitisation has been shown to occur after stimulation with the 
prostacyclin analogue iloprost (Smyth et al., 1998). Rat pulmonary arteries demonstrate a 
desensitisation of the IP receptor after cicaprost stimulation, which was sustained for up 
to 12 hours after the removal of the agonist (Sobolewski et al., 2004). Presently, the PAH 
patient hPASMCs used in the experiments may have been treated extensively with 
prostacyclin analogues which may have desensitised the IP receptor but not lowered the 
expression. There was no observable sex difference in the mRNA or protein of the 
prostaglandin receptors. Due to the lack of suitable anti-proliferative response to 
treprostinil in male control hPASMC, the other hPASMCs groups were studied in the 
presence of prostaglandin receptor antagonists. The combination of endothelin-1 and 
treprostinil was again found to influence all the hPASMCs when responding to specific 
antagonists. The reduction in treprostinil’s effects by the IP receptor antagonist has been 
demonstrated previously (Falcetti et al., 2010). A possible reason for observing a 
significant reduction in the presence of endothelin-1 may be due to the increased anti-
proliferative effect in the presence of treprostinil, therefore the antagonist has a greater 
effect to block. This is also demonstrated within the PAH patient hPASMCs, where the EP2 
antagonist blocks the effects of treprostinil but only in the presence of endothelin-1. The 
influence of the EP2 receptor on the anti-proliferative actions of treprostinil have been 
recently explored (Jigisha et al., 2015). This suggests that the EP2 receptor plays a role 
with the IP receptor in accounting for anti-proliferative effects of treprostinil. It is important 
to note that the IP receptor has been shown to be desensitised and internalised after 
agonist stimulation (Smyth et al., 1998). Recently, Askai and colleagues discovered that 
the IP specific agonist selexipag did not promote the recruitment of β-arrestin, which is 
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essential for the internalisation process (Asaki et al., 2015). This may be due to the non-
prostanoid structure of selexipag. Interestingly, other IP agonists like treprostinil and 
iloprost did promote the recruitment of β-arrestin (Asaki et al., 2015).  Interestingly, EP2 
receptors do not demonstrate receptor desensitisation in human airway smooth muscle 
cells under conditions where other prostaglandin receptors like EP4 do desensitise (Penn 
et al., 2001). A further comparison of EP2 and EP4 desensitisation found that EP4 receptor 
underwent short term agonist induced desensitisation that did not occur in EP2 receptors 
(Nishigaki et al., 1996). Also discovered was that long-term exposure to PGE2 led to equal 
desensitisation of both receptors (Nishigaki et al., 1996). As stated previously, the non-
prostanoid nature of selexipag prevented the recruitment of β-arrestin, this reaction to 
different types of agonists may be occurring in the EP receptors. This emphasises the 
importance of the EP2 receptor in the effects mediated by treprostinil. This study was the 
first to examine the potential anti-proliferative role of DP1 receptors in hPASMCs. Like the 
IP and EP2 receptors, the DP1 receptor has been previously identified as a Gs coupled 
receptor that leads to cAMP production in eosinophils (Chiba et al., 2011) and airway 
smooth muscle cells (Maher et al., 2015). The interaction of treprostinil and the DP1 
receptor has been explored within the pulmonary vein, where treprostinil was found to be 
a potent relaxant due to its high affinity to the DP1 receptors (Benyahia et al., 2013). 
Presently, we detect the DP1 receptor mRNA and protein expression in all hPASMCs 
groups, however the lack of an inhibitory effect by the antagonist suggests it may not play 
a key role in anti-proliferation of hPASMCs under these conditions. As previously stated, 
treprostinil has high binding affinities for the IP, EP2 and DP1 receptors however, this study 
has not investigated the influence of other prostaglandin receptors like Gi/Gq subunit 
associated receptors EP1, TP or EP4 receptors. When activated the EP4 receptor increases 
cAMP levels whereas the EP1 and TP receptors are associated with vasoconstriction and 
are known to increase intracellular calcium or reduce cAMP levels (Woodward et al., 
2011). In monocrotaline rats, iloprost has been found to activate the EP4 receptor to 
compensate for the reduced expression of the IP receptor (Lai et al., 2008). Treprostinil 
and other prostacyclin analogues can bind and activate the EP1 receptor, which has the 
potential to limit their anti-proliferative or vasodilatory properties (Whittle et al., 2012). 
Presently, protein expression of the EP1 receptor was not confirmed in hPASMCs 
however, mRNA expression was identified although it was unchanged across both sexes 
and in control/PAH patient hPASMC groups. The thromboxane receptor has been previous 
shown to dimerise with the IP receptor and increase cAMP levels (Wilson et al., 2004). 
This could be significant in PAH due to the high levels of thromboxane that exist in the 
disease (Christman et al., 1992). These results provide insight into the differing actions of 
treprostinil between sex, control and PAH patients. 
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Disrupted BMPR-II signalling is known to play a role in smooth muscle and endothelial cell 
proliferation in PAH (Machado et al., 2001, Yang et al., 2005, Machado et al., 2009a). 
Proliferation is mediated through reduction of Smad signalling and Id proteins, which inhibit 
cell cycle progression (Yang et al., 2005). Much of the original research into the Id proteins 
focused on cancer development, however more recently the Id proteins have been 
implicated in angiogenesis and atherosclerosis (Nishiyama et al., 2005, Doran et al., 
2010). Iloprost and treprostinil have been shown previously to directly induce both pSmad 
1/5/9 and Id1 protein levels in hPASMCs (Yang et al., 2010). The PDE5 inhibitor sildenafil 
has also been shown to activate Smad signalling via activation of a cGMP dependant 
kinase 1 (cGKI) (Schwappacher et al., 2009). Also, sildenafil could recover reduced 
BMPR-II signalling in BMPR-II mutant hPASMCs (Yang et al., 2013a). Therefore, 
investigation of this signalling pathway under the present experimental conditions was 
undertaken. The data demonstrated that across all hPASMCs groups there was no change 
in the BMPR-II receptor mRNA or protein upon treprostinil stimulation. However, the 
present study investigated the changes in BMPR-II signalling under different conditions to 
those previously published. Presently, BMP-4 was not added to pre-activate the BMPR-II 
pathway. This may account for the lack of significant change observed in pSmad 1/5/9 
across the hPASMCs groups. After 72-hour stimulation with treprostinil, female control and 
female PAH patient hPASMCs expressed a significant increase in Id3 protein expression. 
The influence of sex on the BMPR-II pathway has been investigated previously however, 
it was demonstrated that female hPASMCs have lower expression of BMPR-II, Smad 1, 
Id1 and Id3 (Mair et al., 2015). These supressed levels identified in female control 
hPASMCs may be a possible reason for the ability of treprostinil to significantly increase 
the expression of the Id proteins. The enhanced effect of treprostinil combined with ET-1 
was not explained by any changes in BMPR-II signalling, suggesting that these effects are 
mediated down alternative signalling pathways or through an un-investigated branch of 
BMPR-II/TGF-β signalling. To account for variability in separate western blot analysis, the 
female and male control hPASMCs were re-examined on the same western blot gel. This 
re-affirmed the sex difference observed, with much greater Id3 protein induction in female 
control hPASMCs, the Id3 mRNA levels also support this increased female control 
hPASMC response. The Id3 induction observed in female control hPASMCs may explain 
the slightly greater anti-proliferative response compared to male control hPASMCs. 
However, the lack of response in male PAH patient hPASMC would suggest that the 
BMPR-II signalling pathway, specifically, the Id proteins are not the only mechanism for 
the anti-proliferative effects of treprostinil. The data presented a contradiction with mRNA 
levels of Id1 increasing in female control hPASMCs with no reciprocal increase in protein 
levels. This also occurred with increasing Id3 mRNA in male PAH patient hPASMCs. 
Interestingly, there was no difference in BMPR-II, Id1 and Id3 mRNA expression levels in 
unstimulated hPASMCs. Correlation of mRNA and protein data has been a difficult process 
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due to the potential of post-translational changes (Maier et al., 2009) and the potential 
short half-life of specific proteins (Doherty et al., 2009). Previously, Id proteins have been 
associated with a short half-life although this can vary between different cell types (Deed 
et al., 1996). Therefore, in line with previous Id studies carried out in hPASMCs, a shorter 
experimental time of 24 hours was chosen to examine the effect of treprostinil stimulation 
on BMPR-II signalling (Yang et al., 2010, Yang et al., 2013b, Yang et al., 2013a). The 
shorter experimental time point appeared to be vindicated with a combination either Id1, 
Id3 or both protein levels increasing with treprostinil stimulation. Earlier it was hypothesised 
that the mixture of PAH patient disease types may influence the expression of 
prostaglandin receptors, this may have also occurred in BMPR-II signalling. It was not 
possible to test one PAH disease across the different sexes, therefore there was a mix of 
IPAH, HPAH and APAH tested.  
The current study has demonstrated increased expression of the Id genes across all both 
control and PAH patient hPASMC groups. However, we did not have a definitive link 
between Id gene increase and the anti-proliferative effects of treprostinil. A possible 
method for scrutinising this would be to knock-out aspects of the BMPR-II signalling 
pathway using small interfering RNA (siRNA) (Dunmore et al., 2013). Using a siRNA for 
the BMPR-II receptor was found to blunt BMP4 induced Smad1/4 phosphorylation in 
hPASMCs (Zhang et al., 2014).  Additional published research has shown the knocking 
out the BMPR-II receptor reversed the anti-proliferative effects of TGF-β1 in control 
hPASMCs (Davies et al., 2012). Currently, we have found that treprostinil has no direct 
effect on BMPR-II receptor expression suggesting that neither antagonising or knocking 
out the receptor would significantly change the increase in Id genes. Previously it was 
shown by Yang and colleagues that using a siRNA specific to Id1 increased the level of 
proliferation in hPASMCs under FBS conditions, but also removed the anti-proliferative 
effect of iloprost on hPASMCs (Yang et al., 2010). Additionally Yang and colleagues 
demonstrated that transfecting a lentivirus to overexpress Id3 led to a reduction in 
proliferation in control hPASMCs and in hPASMCs with a BMPR-II mutation (Yang et al., 
2013b). Both these studies demonstrate that increasing Id genes can lead to anti-
proliferative effects in hPASMCs. To confirm if one or both Id genes are responsible for 
the effects of treprostinil, siRNAs specific to Id1 and Id3 genes would be used in 
combination with treprostinil stimulation. This would link activation of BMPR-II signalling 
directly with anti-proliferative effects of treprostinil. 
This study investigated the effect of treprostinil on BMPR-II signalling, however many of 
the underlying interactions that occur in BMPR-II signalling are not completely understood 
in PAH. The degradation of both Smad and Id proteins, while not examined in this study, 
may play an important role in observations reported. Ubiquitin ligases like Smad specific 
E3 ubiquitin protein ligase 1 and 2 (SMURF1/2) have been implicated in reducing BMPR-
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II levels in the pulmonary arteries of the hypoxic mouse model of PH (Murakami et al., 
2010). SMURF1 has been found to be elevated in newly diagnosed PAH patients and 
highly expressed in the endothelial and smooth muscle cells in pulmonary vascular lesions 
of HPAH patients with BMPR-II mutations and APAH patients (Rothman et al., 2016). In 
the present study, this may explain the weaker induction of Id proteins in male PAH 
hPASMCs.  Genetic deletion of SMURF1 was also found to offer protection against the 
development of sugen hypoxic PH (Rothman et al., 2016). In breast cancer studies, 
SMURF2 was found to induce the degradation of SMURF1 to prevent cell migration 
(Fukunaga et al., 2008). 
An analogue of cAMP, dibutyryl cAMP (dbcAMP) was previously found to stimulate an 
increase in Id1 through direct action on a cyclic AMP response element (CRE) found in 
the Id1 promoter (Ohta et al., 2008). The study also found that the increase in Id1 could 
be blocked by the addition of H89, a protein kinase A inhibitor. This was replicated in 
hPASMCs (Yang et al., 2010). Presently, the data demonstrates that a blockade of the IP 
and EP2 receptors can significantly reduce the treprostinil mediated induction observed in 
Id1 and Id3 protein in female control hPASMCs. Under these experimental conditions, the 
induction of Id proteins may be dependent on the cAMP generated from more than one 
prostaglandin receptor. The ability of treprostinil to induce a cAMP increase by activating 
the IP receptor is well defined (Clapp et al., 2002); however, treprostinil was also found to 
induce cAMP activation through activation of the EP2 receptor in macrophages (Aronoff et 
al., 2007). As this study, did not investigate cAMP levels in hPASMCs it is not possible to 
definitively conclude that the induction of Id proteins was dependent on cAMP. A possible 
influence of the results obtained in this study would be the actions of PKA on adenylyl 
cyclase (AC) activity. In cardiac tissue, PKA has been identified as directly phosphorylating 
the major isoform of AC by inhibiting its catalytic activity (Iwami et al., 1995). This reduces 
the catalytic rate of AC not the affinity for ATP (Iwami et al., 1995). Greater response in 
female hPASMCs could be explained by different localisation of PKA relative to AC. Kim 
and colleagues discovered that when A-kinase anchoring proteins (AKAPs) anchor PKA 
close to AC, this generates significantly higher PKA activity compared to PKA anchored 
away from AC (Kim et al., 2011).  It is also possible that treprostinil is not exclusively 
activating Id proteins through cAMP activation of protein kinase A but also through 
activation of the exchange protein directly activated by cAMP (Epac) (Cheng et al., 2008). 
Epac has been implicated, together with PKA, in inhibiting vascular smooth muscle 
proliferation (Hewer et al., 2011) and also it was found to be down-regulated, along with 
Rap-1, in both PAH patient hPASMCs and a monocrotaline rat model of PH (Murray et al., 
2009). Epac has also been shown to influence Id1 expression in angiogenesis studies in 
endothelial cells (Doebele et al., 2009). In neural stem cells Id1 has been identified as 
repressing the activity of Rap1GAP, which downregulates the activity of Rap-1 (Niola et 
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al., 2012).  It may also be possible that Epac/Rap-1 may play a role in the sex difference 
in Id protein observed in control hPASMCs, however further study is required to confirm 
this. Another influencer of cAMP signalling is the presence of phosphodiesterases (PDEs), 
which catalyses the breakdown of cAMP. Murray and colleagues identified that the PDE 
isoforms PDE1 and PDE3 had increased expression in PAH patients (Murray et al., 2007). 
These increases in PDEs influenced the cAMP generating ability of beraprost (Murray et 
al., 2007). More recently, both PDE3A and PDE5A were found to have the highest 
expression of any PDE isoforms in PASMCs. In PAH patients increased expression of 
PDE1 and PDE3 was linked to an increased PDE1 and PDE3 contribution to total cAMP-
PDE activity (Murray et al., 2011). Sex differences have also been identified in the mRNA 
expression of PDE isoforms in endothelial cells isolated from female and male rats (Wang 
et al., 2010b). Expression of PDE3B was found to be higher in females compared to males 
and the reverse was true of PDE1B (Wang et al., 2010b). It may be possible that different 
PDE expressions or activity could be effect the anti-proliferative response to treprostinil, 
therefore changes in PDEs should be investigated in the future. Interestingly, the 
combination of a PDE2 inhibitor with prostacyclin analogues was found to augment cAMP 
increases in IPAH hPASMCs thereby increasing the anti-proliferation effects (Bubb et al., 
2014). This suggests that other PDEs can play a role in the effectiveness of cAMP 
increasing PAH therapies. 
Over the course of the current study a haemocytometer was used to manual cell count to 
ascertain the anti-proliferative effects of treprostinil.  A primary concern of manual cell 
counting is the potential subjective nature of the results. However, replacing the 
haemocytometer with an automated counting machine may remove any doubts about the 
result. Recently, a comparison was made of haemocytometer counting versus a semi-
automated counter and a fully automated counter (Cadena-Herrera et al., 2015). 
Interestingly, all three methods of counting produced very similar results, the main 
advantage that the other counting methods had over the haemocytometer was the ability 
to process a higher throughput of samples (Cadena-Herrera et al., 2015). An alternative 
to cell counting would be the measurement of the incorporation of thymidine or a close 
analogue into cellular DNA, as a measurement of DNA replication. This can be achieved 
in by the addition of radioactive tritiated thymidine or the addition of 5-bromo-2’-
deoxyuridine (BrdU) incorporation, which is an analogue of thymidine, into cells. The main 
advantage of BrdU assays is the lack of radioactivity, which may damage the cells. Another 
alternative measure of proliferation is the measurement of cell metabolism. This is an 
indirect method of measuring cell proliferation, a common assay is the 2-(4,5-Dimethyl-2-
thiazolyl)-3,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Both BrdU and MTT assays 
can be scaled to high or low throughput options also both assay produce colour changes 
that can be analysed by spectrophotometer. Although, BrdU can also be combined with 
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flow cytometry analysis. However, in a carcinoma cell line BrdU was deemed to be more 
sensitive and accurately reflect the proliferative state of the cells (Bergler et al., 1993).  
In conclusion, this study has demonstrated that sex can have an influence on the anti-
proliferative activity of treprostinil in hPASMCs. The influence of sex was predominately 
observed in control hPASMCs and can be partially explained by differing inductions of the 
Id proteins of the BMPR-II signalling pathway. We also observed that induction of the Id 
proteins by treprostinil is dependent on the activation of more than one prostaglandin 
receptor. Ultimately, it is difficult to draw clinical significance from these results as 
individual PAH patients could respond differently to treatment. However, in PAH treatment 
the influence of sex must be considered in both research and clinical settings. 
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5.1. General Discussion 
PH is an incurable vascular disease that is subdivided into five major categories; PAH, 
pulmonary hypertension due to left heart disease, pulmonary hypertension due to chronic 
lung disease and/or hypoxia, chronic thromboembolic pulmonary hypertension and 
pulmonary hypertension with unclear multifactorial mechanisms (Simonneau et al., 2013). 
Dysfunctional signalling pathways play a major role in the pathogenesis of PAH. Three 
examples include; endothelin (ET), nitric oxide (NO) and prostacyclin (PGI2). Increased 
production of endothelin-1 (ET-1) and its major pre-cursor, preproendothelin-1 (preproET-
1) in PAH patients were linked to increases in pulmonary vascular resistance (PVR) and 
the severity of structural abnormalities in small resistance pulmonary arteries (Stewart et 
al., 1991, Giaid et al., 1993, Bressollette et al., 2001). Giaid and Saleh demonstrated that 
greater vasoconstriction in PAH patient pulmonary arteries was associated with reduced 
endothelial nitric oxide synthase expression (Giaid and Saleh, 1995). PAH patients 
demonstrated reduced expression of prostacyclin and prostacyclin synthase (Christman 
et al., 1992, Tuder et al., 1999). The ET, NO and PGI2 pathways are therefore considered 
to be the major targets of therapeutic intervention for PAH.  
The greater number of females diagnosed with PAH is well described. An increased female 
predisposition to PAH was highlighted by Dresdale as early as  the 1950s (Dresdale et al., 
1951). Recent UK/Ireland and French epidemiology studies identified that 70% and 65% 
respectively of diagnosed patients were female (Ling et al., 2012, Montani et al., 2010). 
The increased incidence in PAH in females led to the investigation of estrogen as a 
causative factor in the development of PAH. This hypothesis is supported by studies 
showing that inhibition of the estrogen synthesising enzyme aromatase can reverse a PH 
phenotypes in hypoxic mice and sugen hypoxic rats (Mair et al., 2014). An initial clinical 
trial has demonstrated that treatment with anastrazole, which targets aromatase, 
increased 6MWD in treated patients’ vs placebo controls (Kawut et al., 2016).  Removal of 
ovaries prevented development of PH in female-specific experimental models such as 
SERT+ and dexfenfluramine mice (White et al., 2011a, Dempsie et al., 2013). 
Alternatively, estrogen treatment has been found to reduce RVSP, RVH and remodelling 
in ovariectomised sugen hypoxic rats (Frump et al., 2015a). At higher doses, estrogen has 
also been found to inhibit proliferation in hPASMCs (Tofovic et al., 2008). These differing 
effects had led to the description of an estrogen paradox. 
In the clinic, despite increased female incidence of PAH, male sex is a predictor of poorer 
survival (Humbert et al., 2010a). Greater survival in females has been attributed to better 
right ventricle adaptation after treatment specifically the right ventricle ejection fraction 
(Jacobs et al., 2014). Sex has been shown to influence clinical outcomes in two different 
therapies of PAH. 6-minute walk distances (6MWD) improvements were found to be 
greater in females after treatment with endothelin receptor antagonists than those 
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observed in men (Gabler et al., 2012). Conversely, the phosphodiesterase 5 inhibitor 
tadalafil was found to have better outcomes effects in males (Mathai et al., 2015). This 
was thought to be caused by lower male retention of NO thereby they would respond better 
to a NO raising therapy (Forte et al., 1998). 
Here, we sought to examine the influence of sex on treprostinil in both a well described 
animal model of PH and in isolated human PASMCs from both control and PAH patients. 
The potential mechanisms by which the effects of treprostinil are mediated were also 
examined, as was the role of the prostaglandin receptors and BMPR-II signalling in 
mediating the effects of treprostinil. 
In Chapter 3 the effects of two separate doses of treprostinil were examined in a well-
defined animal model of PH. We observed difference in response to both treprostinil doses, 
where females had greater reduction in RVSP. Relating the results to clinical research is 
difficult due to the differences that exist in the chronic hypoxic model of PH versus PAH. 
The use of the monocrotaline (MCT) or sugen-5416 hypoxic (SU-Hx) models of PH would 
allow a closely matched comparison due to their similarities to human PAH (Colvin and 
Yeager, 2014). Also, as treprostinil is usually prescribed to late stage PAH disease, it may 
offer a better comparison with isolated PAH patient tissue. Due to the less severe PH that 
chronic hypoxia induces we were unable to measure survival however interestingly, female 
patients receiving the synthetic prostacyclin epoprostenol were found to have less 
hospitalisations and a greater survival rate than male patients suggesting a female bias 
(Frantz et al., 2015). It is unknown if this was due to a greater severity of disease in male 
patients or better treatment response in female patients, however this is one aspect of 
PAH that the chronic hypoxic model replicates. A common action of research in pre-clinical 
animal models of disease is to give a larger dose of a therapy than you would to human 
patients, this is due to differences in metabolic rates and physiological processes (Nair 
and Jacob, 2016). With our study, a comparison to clinical data can be made between the 
dose and levels of treprostinil in the blood. In Chapter 3, the blood plasma concentration 
of treprostinil ranges from 10pg/ml to 27pg/ml for the 100ng/kg/min study and 12pg/ml to 
55pg/ml for the 400ng/kg/min study. Clinically, prescribed doses of treprostinil range from 
an initial dose of 1.25ng/kg/min, this can be increased incrementally to 40ng/kg/min, in 
some cases this can increase to 125ng/kg/min (Lang et al., 2006, McSwain et al., 2008). 
Blood plasma concentrations of treprostinil can range from 14.5pg/ml to 18,248pg/ml post 
treatment (McSwain et al., 2008). In the clinic, treprostinil doses can be adjusted due to 
changes in patient’s weight or if the current dose is not tolerated. However, the slow-
release pellets do not allow for this adjustment. To treat rats with a dose that would closely 
resemble that of a human, Axelgaard and colleagues used 900ng/kg/min of treprostinil 
administered via osmotic mini-pumps (Axelgaard et al., 2016). This produced the closest 
blood plasma concentration to that observed in clinic (Axelgaard et al., 2016). It is also 
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important to observe that the rats treated with 900ng/kg/min also suffered from a significant 
decrease in mean arterial pressure (MAP) (Axelgaard et al., 2016).  
PGI2 plays a key role in maintaining cardiovascular homeostasis, initially it was found to 
mediate the anti-thrombotic properties of the endothelium (Moncada et al., 1977). The 
vasoactive effects of PGI2 also extend to the pulmonary vasculature although its levels are 
known to be diminished in PAH patients (Christman et al., 1992). The effects of PGI2 are 
primarily mediated by the IP receptor. In Chapter 4 of this study, it was demonstrated that 
the IP receptor plays a role in mediating the anti-proliferative effects of treprostinil, as well 
partially accounting for the increases in Id protein expression in female control and PAH 
patient hPASMCs. We also did not find any expression differences between sexes or 
control/PAH patient groups to account for the different responses to treprostinil that were 
observed. Although previous studies highlighted lower expression of the receptor in IPAH 
patients (Lai et al., 2008, Falcetti et al., 2010). Functionality of receptors has long been of 
interest in PAH research, this has included the study of many known receptor mutation 
that are positively correlated with PAH development. These include the BMPR-II, KCNK3, 
Angiotensin II type I receptor (AGTR1), ENG and ALK1 (Machado et al., 2009b). Indeed, 
in this study we examined treprostinil in female and male PAH patients with BMPR-II 
mutations. However, it may be possible that a reason for a sex difference in the response 
to treprostinil could be due mutations in the IP or other prostaglandin receptor. Mutations 
in the prostacyclin synthase gene have already been identified as protective in non-PAH 
carriers of BMPR-II mutations (Stearman et al., 2014). Stitham and colleagues highlighted 
that the polymorphism R212H located at the third intracellular loop of the receptor led to 
significantly lessened cAMP response after iloprost stimulation (Stitham et al., 2002). The 
EC50 of the cAMP response was 6-fold higher for the IP receptor with R212H polymorphism 
that a wild type IP receptor (Stitham et al., 2002). This polymorphism was latterly identified 
as effecting arginine codons (Stitham et al., 2007). Interestingly, in a clinical setting an 
arginine variant was associated with reduced response to a beta blocker and decrease G-
protein coupling (Liggett et al., 2006, Mason et al., 1999). The L104R and M113T 
polymorphisms have been identified within the IP receptor, that disrupt the structural 
integrity leading to protein misfolding (Stitham et al., 2011). Importantly, in Chapter 4 we 
observed a role for the EP2 receptor in mediating the effects of treprostinil both in 
hPASMCs counts experiments and in the induction of the Id proteins of the BMPR-II 
pathway, also that hPASMC EP2 mRNA expression was higher than the other 
prostaglandin receptors. Interestingly, it was thought that due to the 100% conservation 
across the prostaglandin receptors, the L104R and M113T polymorphisms may affect 
other receptors (Stitham et al., 2011). However, within the EP2 receptor only one single 
nucleotide polymorphism (SNP) has been implicated as a marker of essential hypertension 
(Sato et al., 2007). Also, research into polymorphism in prostaglandin receptors usually 
 Chapter Five General Discussion 
208 
 
finds varying susceptibly in difference races (Jinnai et al., 2004, Shimizu et al., 2013, Liang 
et al., 2016), while in this current study we cannot say if that played any part in the results 
we obtained. Within the current study it was not possible to identify any polymorphism in 
the receptors that were examined, so it not possible to confirm if they are responsible for 
the differences in response to treprostinil. However, it would be crucial to identify any 
prostaglandin receptor mutations in the future as they could impact the effectiveness of all 
prostacyclin analogues not just treprostinil. 
5.1.1. Targeting cAMP in PAH 
This current study has proposed a link the anti-proliferative actions of treprostinil to cAMP, 
although cAMP levels were not measured in this study. The initial therapies for PAH 
included the use of either synthetic prostacyclin or prostacyclin analogues, which are 
cAMP elevating agents (Duarte et al., 2013). Classically, receptor expression was thought 
to be a primary influence on the effectiveness of an agonist (Milligan et al., 1998). In this 
study, no differences were observed in prostaglandin receptor expression that could 
account for the sex difference observed. For the generation of cAMP, the activation of a 
receptor like IP, EP2 or DP1 is only the initial step. Expression of the receptor/s does not 
give the complete stoichiometry of cAMP. To take this into account the levels of receptor 
occupancy, G-protein subunit, adenylyl cyclase (AC), adenosine triphosphate (ATP) and 
protein kinase A (PKA) should be considered. Alousi and colleagues reviewed the 
stoichiometry of the adenylyl cyclase pathway focusing on the β-adrenergic receptor in 
murine lymphoma cells. They highlighted that the ratio of receptor to G-protein subunit to 
adenylyl cyclase was 1:100:3 (Alousi et al., 1991). They concluded that the main limiting 
factors on efficacy was the receptor or AC, these results were later repeated in rat 
cardiomyocytes  (Alousi et al., 1991, Post et al., 1995). More recently, heightened 
expression of the β-adrenergic receptor or the Gαs protein subunit only accounted for a 
small increase in cAMP maximum response in mouse cardiac tissue (Gaudin et al., 1995). 
Whereas other groups discovered that overexpression of AC6 increased the cAMP 
response and improved cardiac function through cAMP release via the β-adrenergic 
receptor (Gao et al., 1998, Roth et al., 1999). Although, induction of ACs and cAMP is 
intrinsically linked with the action of the Gαs subunit, the AC2 isoform has been shown to 
be activated by the Gβγ subunit (Federman et al., 1992, Pian and Dobbs, 1995). This could 
be a compensatory mechanism when other AC isoforms are inhibited by the Gαi subunit. 
Within the context of PAH, specific AC isoforms have been identified as being important 
in cAMP regulation. Interestingly, Jourdan and colleagues found that hypoxia did not 
change the expression of ACs and that AC2, 3, 5 and 6 were found in smooth muscle cells 
from the pulmonary artery and bronchus (Jourdan et al., 2001). In Chapter 3 of our current 
study, we observed an increase in EP2 receptor mRNA expression in female rats under 
hypoxic conditions with treprostinil treatment. This combined with Jourdan and colleagues’ 
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observation that AC isoforms do not decrease in hypoxia may partially explain the 
increased effect we observed in female rats treated with treprostinil. 
As previously stated, increasing cAMP signalling is a feature of synthetic and prostacyclin 
analogues therapies for PAH. Targeting cAMP directly may prove difficult as it is an 
important second messenger in many systems not just the pulmonary vasculature, 
potentially leading to an increased risk of side effects. In-directly targeting cAMP may offer 
more precise targets like specific isoforms of AC. Jourdan and colleagues discovered that 
the AC5 isoform plays a key role in mediating cAMP increases and anti-proliferative 
actions on rat PASMCs (Jourdan et al., 2001). NKH-477, a specific AC5 stimulator was 
also found to elevate cAMP levels greater than forskolin  (Toya et al., 1998, Jourdan et al., 
2001). To further avoid unwanted side-effects of universal drug dosing, adenovirus can be 
used to obtain tissue specificity (Robson and Hirst, 2003). Adenovirus containing AC5 was 
demonstrated to increase left ventricular function and increase cAMP levels in the hearts 
of pigs (Lai et al., 2000). Elevating AC6 expression has been previously proposed as way 
reducing endothelial cell permeability. Bundey and Insel linked overexpression of AC6 via 
an adenovirus to a reduction in endothelial barrier permeability through prostacyclin action 
(Bundey and Insel, 2006). An adenovirus expressing AC6 was also introduced to heart 
failure patients, where it increased LV function over standard heart failure therapies 
(Hammond et al., 2016). As endothelial dysfunction is hallmark of PAH development 
targeting AC6 may be a novel method of treating the disease and it may act a compliment 
to PGI2 analogue therapy (Budhiraja et al., 2004). Additionally, AC6 overexpression co-
localised with the IP receptor was linked to a reduction in cardiac fibroblast activity via a 
cAMP increase (Liu et al., 2008). Morecroft and colleagues demonstrated that 
adenoviruses can also knock-down mediators of PH, specifically tryptophan hydroxylase-
1 (TPH-1) in pulmonary endothelial cells (Morecroft et al., 2012). As well as increase 
aspects of cAMP signalling adenoviruses could be used to knock-down PDEs, which 
breakdown cAMP. Knock-down of PDE2A by an adenovirus reduced alveolar inflammation 
and doubled the production of cAMP (Rentsendorj et al., 2011). As PDE1, specifically 
PDE1A and PDE1C, are known to be elevated and animal models of PH and PAH patients 
(Schermuly et al., 2007, Murray et al., 2007), it may be a novel target of adenovirus 
mediated knockdown. The combination of therapies specifically increasing aspects of 
cAMP signalling like AC with established prostacyclin analogues may open new routes in 
the treatment of PAH. 
5.1.2. Links between BMPR-II signalling and cAMP: Where does treprostinil fit in? 
The BMPR-II signalling pathway is an important therapeutic target in PAH. Targeting of 
BMP signalling is also a developing field within cancer research, with small molecule 
inhibitors used to reduce expression of Id genes (Anido et al., 2010). In Chapter 4 of this 
study, we demonstrated that treprostinil up-regulates both mRNA and protein expression 
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of downstream components of BMPR-II signalling namely Id1 and Id3. We did not 
completely identify the reason/s for the increase in Id expression however we hypothesise 
that the cAMP triggers the upregulation. The actions of cAMP on BMPR-II signalling has 
been explored in osteoblasts, through investigation into both cAMP-response elements 
(CREs), cAMP-response binding protein (CREB) and s BMP response elements (BREs) 
(Ohta et al., 2008). The Id1 gene was previously identified as having a CRE site it promoter 
region (Korchynskyi and ten Dijke, 2002). The use of a siRNA targeting CREB led to a 
reduction in cAMP mediated enhancement of Smad-mediated transcription (Ohta et al., 
2008). In Chapter 4 we did not identify a significant increase in Smad signalling 
accompanying Id increase therefore if cAMP was involved it may be bypassing Smad. In 
PAH context, Yang and colleagues investigated the effects of iloprost and treprostinil on 
Id1 expression. Both prostacyclin analogues increased expression of Id1 but not Smad 
1/5/8 (Yang et al., 2010). Interestingly, Yang did not observe an increase in Id1 protein 
expression after 100nm treprostinil stimulation after 24 hours, however we did observe a 
change in female control at the same timepoint. This may due to protocol differences, 
although it emphasises the stronger response we observed in female hPASMCs. Id3 
induction was a feature of treprostinil stimulation in our current study that has not observed 
before, however the link between cAMP and Id3 has not been studied directly within the 
PAH field. Research with PC12 cells isolated rat adrenal medulla identified that after 
stimulation with a cAMP-analogue, Id3 expression significantly increased suggesting that 
Id3 is a cAMP-responsive gene like Id1 (Ghzili et al., 2006). Also, overexpression of the 
oncoprotein Lyl1 was identified to increase expression of Id1 and Id3 through the action of 
CREB (San-Marina et al., 2008). With the previously discussed research we can estimate 
the link between the upregulation of cAMP with the increase in Id expression (Figure 5-1). 
We have examined the effects of treprostinil in one cell type, however in PAH both 
hPASMCs and pulmonary endothelial cells (PAECs) contribute to disease development 
(Zhang et al., 2003, Teichert-Kuliszewska et al., 2006). Clinically, treprostinil therapy 
increased the level of endothelial colony forming cells in children with PAH (Smadja et al., 
2011, Smadja et al., 2015). Whereas, targeting BMPR-II signalling with BMP-9 in PAECs 
was associated with a reversal of PAH in three models of animal PAH (Long et al., 2015). 
An analysis that incorporates an investigation into the actions of treprostinil on BMPR-II 
signalling in PAECs may offer a chance to have a more complete understanding of the 
effects of treprostinil in the pulmonary vasculature.  
5.1.3. Concluding remarks 
In summary, through in-vivo and in-vitro investigations sex has been shown to have 
potential role in the therapeutic effects of treprostinil. The major novel observations from 
this study were that females have a greater response to treprostinil stimulation and that 
this is partially mediated through greater increases in BMPR-II signalling, specifically the 
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Id genes. Additionally, increase in BMPR-II signalling by treprostinil was mediated by 
activation of more than one prostaglandin receptor. Further research is required to confirm 
if the general hypothesis of the study is true. For future perspective, to account for greater 
survival amongst female PAH patients, the role of sex influencing therapeutic response 
must be considered. 
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Figure 5-1 Treprostinil mediates BMPR-II signalling through an increase in cAMP levels (Legend on next page)
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Figure 5-1: Treprostinil mediates BMPR-II signalling through an increase in cAMP levels 
Treprostinil activates Gαs coupled receptors (IP and EP2) triggering activation of adenylyl cyclase 
leading to an increase in cAMP. cAMP activates protein kinase A, which then translocates to the 
nucleus and activates cAMP response binding protein, which in turn binds to the cAMP response 
element in the promotor region of the Id genes. BMPR-II receptor activation can also lead to 
increase Id expression. Activation leads to phosphorylation of Smad 1/5/9. Smad 1/5/9 forms a 
complex with Smad4 that then translocates to the nucleus where it can regulate Id transcription 
through binding to transcription factors.  cAMP= cyclic AMP, PKA=protein kinase A, EPAC= 
exchange factor directly activated by cAMP 1, CREB= cAMP response binding protein, CRE= cAMP 
response element, SMAD= Sma and MAD (mothers against decapentaplegic), TF= Transcription 
factor, Id= inhibitor of DNA binding.
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5.2 Future Perspective 
The primary goal of biological scientific research is the ability to translate attributes 
determined in the laboratory to a clinical setting where they can benefit patients. During 
this study, the effects of treprostinil were examined in female and male chronic hypoxic 
rats and in isolated hPASMCs from both control and PAH patients.   
Treprostinil is a recommended therapy for PAH patients with WHO classification III and IV, 
(Galie et al., 2009b, Badesch et al., 2007). As the chronic hypoxic model of PH resembles 
early forms of group 1 human PH (PAH) but is also more reflective of group 3 human PH, 
it would be useful to confirm the effects of treprostinil in both female and males using the 
Su-Hx model of PH as it closely recapitulates late phase human PAH. Also, it would useful 
to confirm if the influence of sex exists in an animal model that has a greater relevance to 
PAH. In PAH, higher survival rates in women are attributed to the ability of the right 
ventricle to adapt to increasing pressure (Jacobs et al., 2014). The underlying molecular 
mechanisms in the RV should be investigated in the future. This could be achieved by IHC, 
qRT-PCR, western blot. Interestingly, Holbome and colleagues observed that treprostinil 
can improve RV function in healthy rats and that this improvement is lost in pulmonary 
artery banded rats (Holmboe et al., 2016). Recently, BMPR-II mutant patients were 
discovered to have lower RV function in comparison to non-mutant patients (Van Der 
Bruggen et al., 2016). However, there were no significant differences in BMPR-II signalling 
found in the cardiomyocytes of the heart (Van Der Bruggen et al., 2016). 
Presently, we have identified the potential role of sex in influencing the anti-proliferative 
effects of treprostinil. Here, we have shown increased BMPR-II associated signalling 
attributed to treprostinil stimulation. However, recent research has identified that high 
levels of glucose can increase specific ubiquitin ligases (SMURF-1), which can disrupt 
canonical BMPR-II signalling (Barnes et al., 2016). As discussed earlier in this chapter, a 
greater examination of GPCRs signalling is required to fully understand the effects of 
treprostinil. This would help elucidate the reasons for the differences in anti-proliferative 
and BMPR-II signalling induction we observed in this study. Personalised medicine, where 
treatments are individually tailored to a specific patient’s circumstances, is a growing trend 
in the medical profession. In PAH, there are many underlying molecular processes that 
are not fully understood, this also extends to therapeutic interventions. This study suggests 
that in the drive towards personalised medicine the influence of sex on therapeutic 
intervention needs to be quantified. 
 215 
 
References 
AARONSON, P. I., ROBERTSON, T. P. & WARD, J. P. 2002. Endothelium-derived 
mediators and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol, 132, 
107-20. 
ABE, K., KUO, L. & ZUKOWSKA, Z. 2010. Neuropeptide Y is a mediator of chronic 
vascular and metabolic maladaptations to stress and hypernutrition. Exp Biol Med 
(Maywood), 235, 1179-84. 
ABE, K., TILAN, J. U. & ZUKOWSKA, Z. 2007. NPY and NPY receptors in vascular 
remodeling. Curr Top Med Chem, 7, 1704-9. 
ABE, Y., TATSUMI, K., SUGITO, K., IKEDA, Y., KIMURA, H. & KURIYAMA, T. 2001. 
Effects of inhaled prostacyclin analogue on chronic hypoxic pulmonary 
hypertension. J Cardiovasc Pharmacol, 37, 239-51. 
ABRAMOVITZ, M., ADAM, M., BOIE, Y., CARRIERE, M., DENIS, D., GODBOUT, C., 
LAMONTAGNE, S., ROCHETTE, C., SAWYER, N., TREMBLAY, N. M., BELLEY, 
M., GALLANT, M., DUFRESNE, C., GAREAU, Y., RUEL, R., JUTEAU, H., 
LABELLE, M., OUIMET, N. & METTERS, K. M. 2000. The utilization of 
recombinant prostanoid receptors to determine the affinities and selectivities of 
prostaglandins and related analogs. Biochim Biophys Acta, 1483, 285-93. 
AHN, B. H., PARK, H. K., CHO, H. G., LEE, H. A., LEE, Y. M., YANG, E. K. & LEE, W. J. 
2003. Estrogen and enalapril attenuate the development of right ventricular 
hypertrophy induced by monocrotaline in ovariectomized rats. J Korean Med Sci, 
18, 641-8. 
ALASTALO, T. P., LI, M., PEREZ VDE, J., PHAM, D., SAWADA, H., WANG, J. K., 
KOSKENVUO, M., WANG, L., FREEMAN, B. A., CHANG, H. Y. & RABINOVITCH, 
M. 2011. Disruption of PPARgamma/beta-catenin-mediated regulation of apelin 
impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin 
Invest, 121, 3735-46. 
ALEXANDER, S. P., MATHIE, A. & PETERS, J. A. 2007. Guide to Receptors and 
Channels (GRAC), 2nd edition (2007 Revision). Br J Pharmacol, 150 Suppl 1, S1-
168. 
ALFRANCA, A., INIGUEZ, M. A., FRESNO, M. & REDONDO, J. M. 2006. Prostanoid 
signal transduction and gene expression in the endothelium: role in cardiovascular 
diseases. Cardiovasc Res, 70, 446-56. 
ALOUSI, A. A., JASPER, J. R., INSEL, P. A. & MOTULSKY, H. J. 1991. Stoichiometry of 
receptor-Gs-adenylate cyclase interactions. FASEB J, 5, 2300-3. 
AMESHIMA, S., GOLPON, H., COOL, C. D., CHAN, D., VANDIVIER, R. W., GARDAI, S. 
J., WICK, M., NEMENOFF, R. A., GERACI, M. W. & VOELKEL, N. F. 2003. 
Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is 
 216 
 
decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res, 
92, 1162-9. 
ANDERSEN, C. U., HILBERG, O., MELLEMKJAER, S., NIELSEN-KUDSK, J. E. & 
SIMONSEN, U. 2011. Apelin and pulmonary hypertension. Pulm Circ, 1, 334-46. 
ANIDO, J., SAEZ-BORDERIAS, A., GONZALEZ-JUNCA, A., RODON, L., FOLCH, G., 
CARMONA, M. A., PRIETO-SANCHEZ, R. M., BARBA, I., MARTINEZ-SAEZ, E., 
PRUDKIN, L., CUARTAS, I., RAVENTOS, C., MARTINEZ-RICARTE, F., POCA, 
M. A., GARCIA-DORADO, D., LAHN, M. M., YINGLING, J. M., RODON, J., 
SAHUQUILLO, J., BASELGA, J. & SEOANE, J. 2010. TGF-beta Receptor 
Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in 
Human Glioblastoma. Cancer Cell, 18, 655-68. 
ANTIGNY, F., HAUTEFORT, A., MELOCHE, J., BELACEL-OUARI, M., MANOURY, B., 
RUCKER-MARTIN, C., PECHOUX, C., POTUS, F., NADEAU, V., TREMBLAY, E., 
RUFFENACH, G., BOURGEOIS, A., DORFMULLER, P., BREUILS-BONNET, S., 
FADEL, E., RANCHOUX, B., JOURDON, P., GIRERD, B., MONTANI, D., 
PROVENCHER, S., BONNET, S., SIMONNEAU, G., HUMBERT, M. & PERROS, 
F. 2016. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the 
Development of Pulmonary Arterial Hypertension. Circulation, 133, 1371-85. 
APLIN, M., CHRISTENSEN, G. L., SCHNEIDER, M., HEYDORN, A., GAMMELTOFT, S., 
KJØLBYE, A. L., SHEIKH, S. P. & HANSEN, J. L. 2007. Differential Extracellular 
Signal-Regulated Kinases 1 and 2 Activation by the Angiotensin Type 1 Receptor 
Supports Distinct Phenotypes of Cardiac Myocytes. Basic & Clinical Pharmacology 
& Toxicology, 100, 296-301. 
ARCHER, S. L., LONDON, B., HAMPL, V., WU, X., NSAIR, A., PUTTAGUNTA, L., 
HASHIMOTO, K., WAITE, R. E. & MICHELAKIS, E. D. 2001. Impairment of hypoxic 
pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel 
Kv1.5. FASEB J, 15, 1801-3. 
ARCHER, S. L., SOUIL, E., DINH-XUAN, A. T., SCHREMMER, B., MERCIER, J. C., EL 
YAAGOUBI, A., NGUYEN-HUU, L., REEVE, H. L. & HAMPL, V. 1998. Molecular 
identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic 
pulmonary vasoconstriction and control of resting membrane potential in rat 
pulmonary artery myocytes. J Clin Invest, 101, 2319-30. 
ARIAZI, E. A., BRAILOIU, E., YERRUM, S., SHUPP, H. A., SLIFKER, M. J., CUNLIFFE, 
H. E., BLACK, M. A., DONATO, A. L., ARTERBURN, J. B., OPREA, T. I., 
PROSSNITZ, E. R., DUN, N. J. & JORDAN, V. C. 2010. The G protein-coupled 
receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer 
cells. Cancer Res, 70, 1184-94. 
 217 
 
ARONICA, S. M., KRAUS, W. L. & KATZENELLENBOGEN, B. S. 1994. Estrogen action 
via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-
regulated gene transcription. Proc Natl Acad Sci U S A, 91, 8517-21. 
ARONOFF, D. M., PERES, C. M., SEREZANI, C. H., BALLINGER, M. N., CARSTENS, J. 
K., COLEMAN, N., MOORE, B. B., PEEBLES, R. S., FACCIOLI, L. H. & PETERS-
GOLDEN, M. 2007. Synthetic prostacyclin analogs differentially regulate 
macrophage function via distinct analog-receptor binding specificities. J Immunol, 
178, 1628-34. 
ASAHARA, T., MUROHARA, T., SULLIVAN, A., SILVER, M., VAN DER ZEE, R., LI, T., 
WITZENBICHLER, B., SCHATTEMAN, G. & ISNER, J. M. 1997. Isolation of 
putative progenitor endothelial cells for angiogenesis. Science, 275, 964-7. 
ASAKI, T., KUWANO, K., MORRISON, K., GATFIELD, J., HAMAMOTO, T. & CLOZEL, 
M. 2015. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for 
the Treatment of Pulmonary Arterial Hypertension. Journal of Medicinal Chemistry, 
58, 7128-7137. 
ATKINSON, C., STEWART, S., UPTON, P. D., MACHADO, R., THOMSON, J. R., 
TREMBATH, R. C. & MORRELL, N. W. 2002. Primary pulmonary hypertension is 
associated with reduced pulmonary vascular expression of type II bone 
morphogenetic protein receptor. Circulation, 105, 1672-8. 
ATTWOOD, T. K. & FINDLAY, J. B. C. 1994. Fingerprinting G-protein-coupled receptors. 
Protein Engineering, Design and Selection, 7, 195-203. 
AUSTIN, E. D., HAMID, R., HEMNES, A. R., LOYD, J. E., BLACKWELL, T., YU, C., 
PHILLIPS III, J. A., GADDIPATI, R., GLADSON, S., GU, E., WEST, J. & LANE, K. 
B. 2012. BMPR2 expression is suppressed by signaling through the estrogen 
receptor. Biol Sex Differ, 3, 6. 
AUSTIN, E. D., PHILLIPS, J. A., COGAN, J. D., HAMID, R., YU, C., STANTON, K. C., 
PHILLIPS, C. A., WHEELER, L. A., ROBBINS, I. M., NEWMAN, J. H. & LOYD, J. 
E. 2009. Truncating and missense BMPR2 mutations differentially affect the 
severity of heritable pulmonary arterial hypertension. Respir Res, 10, 87. 
AXELGAARD, S., HOLMBOE, S., RINGGAARD, S., HILLGAARD, T. K., ANDERSEN, S., 
HANSEN, M. S., ANDERSEN, A. & NIELSEN-KUDSK, J. E. 2016. Effects of 
chronic treprostinil treatment on experimental right heart hypertrophy and failure. 
Cardiol Young, 1-11. 
BABIKER, F. A., LIPS, D., MEYER, R., DELVAUX, E., ZANDBERG, P., JANSSEN, B., 
VAN EYS, G., GROHE, C. & DOEVENDANS, P. A. 2006. Estrogen receptor beta 
protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb 
Vasc Biol, 26, 1524-30. 
 218 
 
BADESCH, D. B., ABMAN, S. H., SIMONNEAU, G., RUBIN, L. J. & MCLAUGHLIN, V. V. 
2007. Medical therapy for pulmonary arterial hypertension: updated ACCP 
evidence-based clinical practice guidelines. Chest, 131, 1917-28. 
BADESCH, D. B., CHAMPION, H. C., SANCHEZ, M. A., HOEPER, M. M., LOYD, J. E., 
MANES, A., MCGOON, M., NAEIJE, R., OLSCHEWSKI, H., OUDIZ, R. J. & 
TORBICKI, A. 2009. Diagnosis and assessment of pulmonary arterial 
hypertension. J Am Coll Cardiol, 54, S55-66. 
BADESCH, D. B., RASKOB, G. E., ELLIOTT, C. G., KRICHMAN, A. M., FARBER, H. W., 
FROST, A. E., BARST, R. J., BENZA, R. L., LIOU, T. G., TURNER, M., GILES, S., 
FELDKIRCHER, K., MILLER, D. P. & MCGOON, M. D. 2010. Pulmonary arterial 
hypertension: baseline characteristics from the REVEAL Registry. Chest, 137, 376-
87. 
BAKER, G. L., SHULTZ, M. A., FANUCCHI, M. V., MORIN, D. M., BUCKPITT, A. R. & 
PLOPPER, C. G. 2004. Assessing gene expression in lung subcompartments 
utilizing in situ RNA preservation. Toxicol Sci, 77, 135-41. 
BARMAN, S. A., ZHU, S., HAN, G. & WHITE, R. E. 2003. cAMP activates 
BK<sub>Ca</sub> channels in pulmonary arterial smooth muscle via cGMP-
dependent protein kinase. American Journal of Physiology - Lung Cellular and 
Molecular Physiology, 284, L1004-L1011. 
BARNES, J. W., KUCERA, E. T., TIAN, L., MELLOR, N. E., DVORINA, N., BALDWIN, W. 
W., 3RD, ALDRED, M. A., FARVER, C. F., COMHAIR, S. A., AYTEKIN, M. & 
DWEIK, R. A. 2016. Bone Morphogenic Protein Type 2 Receptor Mutation-
Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in 
Idiopathic Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol, 55, 564-
575. 
BARST, R. J., GALIE, N., NAEIJE, R., SIMONNEAU, G., JEFFS, R., ARNESON, C. & 
RUBIN, L. J. 2006. Long-term outcome in pulmonary arterial hypertension patients 
treated with subcutaneous treprostinil. Eur Respir J, 28, 1195-203. 
BARST, R. J., MCGOON, M., MCLAUGHLIN, V., TAPSON, V., OUDIZ, R., SHAPIRO, S., 
ROBBINS, I. M., CHANNICK, R., BADESCH, D., RAYBURN, B. K., 
FLINCHBAUGH, R., SIGMAN, J., ARNESON, C. & JEFFS, R. 2003. Beraprost 
therapy for pulmonary arterial hypertension. Journal of the American College of 
Cardiology, 41, 2119-2125. 
BARST, R. J., MCGOON, M., TORBICKI, A., SITBON, O., KROWKA, M. J., 
OLSCHEWSKI, H. & GAINE, S. 2004. Diagnosis and differential assessment of 
pulmonary arterial hypertension. J Am Coll Cardiol, 43, 40S-47S. 
BARST, R. J., RUBIN, L. J., LONG, W. A., MCGOON, M. D., RICH, S., BADESCH, D. B., 
GROVES, B. M., TAPSON, V. F., BOURGE, R. C., BRUNDAGE, B. H., 
KOERNER, S. K., LANGLEBEN, D., KELLER, C. A., MURALI, S., URETSKY, B. 
 219 
 
F., CLAYTON, L. M., JOBSIS, M. M., BLACKBURN, S. D., SHORTINO, D., CROW, 
J. W. & PRIMARY PULMONARY HYPERTENSION STUDY, G. 1996. A 
comparison of continuous intravenous epoprostenol (prostacyclin) with 
conventional therapy for primary pulmonary hypertension. N Engl J Med, 334, 296-
301. 
BAUER, M., WILKENS, H., LANGER, F., SCHNEIDER, S. O., LAUSBERG, H. & 
SCHAFERS, H. J. 2002. Selective upregulation of endothelin B receptor gene 
expression in severe pulmonary hypertension. Circulation, 105, 1034-6. 
BEHR, J. & RYU, J. H. 2008. Pulmonary hypertension in interstitial lung disease. Eur 
Respir J, 31, 1357-67. 
BENYAHIA, C., BOUKAIS, K., GOMEZ, I., SILVERSTEIN, A., CLAPP, L., FABRE, A., 
DANEL, C., LESÉCHE, G., LONGROIS, D. & NOREL, X. 2013. A comparative 
study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary 
arteries and veins, role of the DP-receptor. Prostaglandins & Other Lipid Mediators, 
107, 48-55. 
BENYAHIA, C., OZEN, G., ORIE, N., LEDWOZYW, A., LOUEDEC, L., LI, F., SENBEL, A. 
M., SILVERSTEIN, A., DANEL, C., LONGROIS, D., CLAPP, L. H., NOREL, X. & 
TOPAL, G. 2015. Ex vivo relaxations of pulmonary arteries induced by prostacyclin 
mimetics are highly dependent of the precontractile agents. Prostaglandins Other 
Lipid Mediat, 121, 46-52. 
BENZA, R. L., MILLER, D. P., BARST, R. J., BADESCH, D. B., FROST, A. E. & MCGOON, 
M. D. 2012. An evaluation of long-term survival from time of diagnosis in pulmonary 
arterial hypertension from the REVEAL Registry. Chest, 142, 448-56. 
BENZA, R. L., MILLER, D. P., GOMBERG-MAITLAND, M., FRANTZ, R. P., FOREMAN, 
A. J., COFFEY, C. S., FROST, A., BARST, R. J., BADESCH, D. B., ELLIOTT, C. 
G., LIOU, T. G. & MCGOON, M. D. 2010. Predicting survival in pulmonary arterial 
hypertension: insights from the Registry to Evaluate Early and Long-Term 
Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation, 
122, 164-72. 
BERETTA, L., CARONNI, M., ORIGGI, L., PONTI, A., SANTANIELLO, A. & SCORZA, R. 
2006. Hormone replacement therapy may prevent the development of isolated 
pulmonary hypertension in patients with systemic sclerosis and limited cutaneous 
involvement. Scand J Rheumatol, 35, 468-71. 
BERGLER, W., PETROIANU, G. & SCHADEL, A. 1993. Feasibility of proliferation studies 
using the BrdU and MTT assays with a head and neck carcinoma cell line. ORL J 
Otorhinolaryngol Relat Spec, 55, 230-5. 
BIRNBAUMER, L., ZHU, X., JIANG, M., BOULAY, G., PEYTON, M., VANNIER, B., 
BROWN, D., PLATANO, D., SADEGHI, H., STEFANI, E. & BIRNBAUMER, M. 
 220 
 
1996. On the molecular basis and regulation of cellular capacitative calcium entry: 
roles for Trp proteins. Proc Natl Acad Sci U S A, 93, 15195-202. 
BOPASSA, J. C., EGHBALI, M., TORO, L. & STEFANI, E. 2010. A novel estrogen receptor 
GPER inhibits mitochondria permeability transition pore opening and protects the 
heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol, 298, 
H16-23. 
BOS, C. L., RICHEL, D. J., RITSEMA, T., PEPPELENBOSCH, M. P. & VERSTEEG, H. H. 
2004. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem 
Cell Biol, 36, 1187-205. 
BOTNEY, M. D., PARKS, W. C., CROUCH, E. C., STENMARK, K. & MECHAM, R. P. 
1992. Transforming growth factor-beta 1 is decreased in remodeling hypertensive 
bovine pulmonary arteries. J Clin Invest, 89, 1629-35. 
BOURASSA, P. A., MILOS, P. M., GAYNOR, B. J., BRESLOW, J. L. & AIELLO, R. J. 
1996. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-
deficient mice. Proceedings of the National Academy of Sciences of the United 
States of America, 93, 10022-10027. 
BRESSOLLETTE, E., DUPUIS, J., BONAN, R., DOUCET, S., CERNACEK, P. & TARDIF, 
J. C. 2001. Intravascular ultrasound assessment of pulmonary vascular disease in 
patients with pulmonary hypertension. Chest, 120, 809-15. 
BREYER, R. M., BAGDASSARIAN, C. K., MYERS, S. A. & BREYER, M. D. 2001. 
Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol, 41, 
661-90. 
BRIDGES, T. M. & LINDSLEY, C. W. 2008. G-protein-coupled receptors: from classical 
modes of modulation to allosteric mechanisms. ACS Chem Biol, 3, 530-41. 
BROCK, M., SAMILLAN, V. J., TRENKMANN, M., SCHWARZWALD, C., ULRICH, S., 
GAY, R. E., GASSMANN, M., OSTERGAARD, L., GAY, S., SPEICH, R. & HUBER, 
L. C. 2014. AntagomiR directed against miR-20a restores functional BMPR2 
signalling and prevents vascular remodelling in hypoxia-induced pulmonary 
hypertension. Eur Heart J, 35, 3203-11. 
BROSELID, S., BERG, K. A., CHAVERA, T. A., KAHN, R., CLARKE, W. P., OLDE, B. & 
LEEB-LUNDBERG, L. M. F. 2014. G protein-coupled Receptor 30 (GPR30) Forms 
a Plasma Membrane Complex with Membrane-associated Guanylate Kinases 
(MAGUKs) and Protein Kinase A-anchoring Protein 5 (AKAP5) That Constitutively 
Inhibits cAMP Production. Journal of Biological Chemistry, 289, 22117-22127. 
BUBB, K. J., TRINDER, S. L., BALIGA, R. S., PATEL, J., CLAPP, L. H., MACALLISTER, 
R. J. & HOBBS, A. J. 2014. Inhibition of phosphodiesterase 2 augments cGMP and 
cAMP signaling to ameliorate pulmonary hypertension. Circulation, 130, 496-507. 
BUDHIRAJA, R., TUDER, R. M. & HASSOUN, P. M. 2004. Endothelial Dysfunction in 
Pulmonary Hypertension. Circulation, 109, 159-165. 
 221 
 
BUNDEY, R. A. & INSEL, P. A. 2006. Adenylyl cyclase 6 overexpression decreases the 
permeability of endothelial monolayers via preferential enhancement of 
prostacyclin receptor function. Mol Pharmacol, 70, 1700-7. 
BURNSTOCK, G. 2009. Purinergic cotransmission. Exp Physiol, 94, 20-4. 
BURTON, V. J., CIUCLAN, L. I., HOLMES, A. M., RODMAN, D. M., WALKER, C. & BUDD, 
D. C. 2011. Bone morphogenetic protein receptor II regulates pulmonary artery 
endothelial cell barrier function. Blood, 117, 333-41. 
CACOUB, P., DORENT, R., MAISTRE, G., NATAF, P., CARAYON, A., PIETTE, C., 
GODEAU, P., CABROL, C. & GANDJBAKHCH, I. 1993. Endothelin-1 in primary 
pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol, 71, 448-
50. 
CACOUB, P., DORENT, R., NATAF, P., CARAYON, A., RIQUET, M., NOE, E., PIETTE, 
J. C., GODEAU, P. & GANDJBAKHCH, I. 1997. Endothelin-1 in the lungs of 
patients with pulmonary hypertension. Cardiovasc Res, 33, 196-200. 
CADENA-HERRERA, D., ESPARZA-DE LARA, J. E., RAMÍREZ-IBAÑEZ, N. D., LÓPEZ-
MORALES, C. A., PÉREZ, N. O., FLORES-ORTIZ, L. F. & MEDINA-RIVERO, E. 
2015. Validation of three viable-cell counting methods: Manual, semi-automated, 
and automated. Biotechnology Reports, 7, 9-16. 
CAI, J., PARDALI, E., SANCHEZ-DUFFHUES, G. & TEN DIJKE, P. 2012. BMP signaling 
in vascular diseases. FEBS Lett, 586, 1993-2002. 
CAMPIAN, M. E., HARDZIYENKA, M., MICHEL, M. C. & TAN, H. L. 2006. How valid are 
animal models to evaluate treatments for pulmonary hypertension? Naunyn 
Schmiedebergs Arch Pharmacol, 373, 391-400. 
CASTELLANI, S., PALADINI, B., PANICCIA, R., DI SERIO, C., VALLOTTI, B., UNGAR, 
A., FUMAGALLI, S., CANTINI, C., POGGESI, L. & NERI SERNERI, G. G. 1997. 
Increased renal formation of thromboxane A2 and prostaglandin F2 alpha in heart 
failure. Am Heart J, 133, 94-100. 
ČECH, S. 1969. Adrenergic innervation of blood vessels in the lung of some mammals. 
Cells Tissues Organs, 74, 169-182. 
CHAN, Q. K., LAM, H. M., NG, C. F., LEE, A. Y., CHAN, E. S., NG, H. K., HO, S. M. & 
LAU, K. M. 2010. Activation of GPR30 inhibits the growth of prostate cancer cells 
through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, 
and induction of G(2) cell-cycle arrest. Cell Death Differ, 17, 1511-23. 
CHANNICK, R. N., OLSCHEWSKI, H., SEEGER, W., STAUB, T., VOSWINCKEL, R. & 
RUBIN, L. J. 2006. Safety and efficacy of inhaled treprostinil as add-on therapy to 
bosentan in pulmonary arterial hypertension. J Am Coll Cardiol, 48, 1433-7. 
CHELLADURAI, P., SEEGER, W. & PULLAMSETTI, S. S. 2012. Matrix 
metalloproteinases and their inhibitors in pulmonary hypertension. European 
Respiratory Journal, 40, 766-782. 
 222 
 
CHEN, X., TALATI, M., FESSEL, J. P., HEMNES, A. R., GLADSON, S., FRENCH, J., 
SHAY, S., TRAMMELL, A., PHILLIPS, J. A., HAMID, R., COGAN, J. D., DAWSON, 
E. P., WOMBLE, K. E., HEDGES, L. K., MARTINEZ, E. G., WHEELER, L. A., 
LOYD, J. E., MAJKA, S. J., WEST, J. & AUSTIN, E. D. 2016. Estrogen Metabolite 
16alpha-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type 
II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated 
Modulation of Cellular Metabolism. Circulation, 133, 82-97. 
CHEN, Y., HARRY, A., LI, J., SMIT, M. J., BAI, X., MAGNUSSON, R., PIERONI, J. P., 
WENG, G. & IYENGAR, R. 1997. Adenylyl cyclase 6 is selectively regulated by 
protein kinase A phosphorylation in a region involved in Gα(s) stimulation. 
Proceedings of the National Academy of Sciences of the United States of America, 
94, 14100-14104. 
CHENG, X., JI, Z., TSALKOVA, T. & MEI, F. 2008. Epac and PKA: a tale of two intracellular 
cAMP receptors. Acta Biochim Biophys Sin (Shanghai), 40, 651-62. 
CHEREZOV, V., ROSENBAUM, D. M., HANSON, M. A., RASMUSSEN, S. G. F., THIAN, 
F. S., KOBILKA, T. S., CHOI, H.-J., KUHN, P., WEIS, W. I., KOBILKA, B. K. & 
STEVENS, R. C. 2007. High Resolution Crystal Structure of an Engineered Human 
β(2)-Adrenergic G protein-Coupled Receptor. Science (New York, N.Y.), 318, 
1258-1265. 
CHIBA, T., UEKI, S., ITO, W., KATO, H., KAMADA, R., TAKEDA, M., KAYABA, H., 
FURUE, M. & CHIHARA, J. 2011. The opposing role of two prostaglandin D2 
receptors, DP and CRTH2, in human eosinophil migration. Ann Allergy Asthma 
Immunol, 106, 511-7. 
CHIN, K. M. & RUBIN, L. J. 2008. Pulmonary arterial hypertension. J Am Coll Cardiol, 51, 
1527-38. 
CHIN, K. M., RUGGIERO, R., BARTOLOME, S., VELEZ-MARTINEZ, M., DARSAKLIS, 
K., KINGMAN, M., HARDEN, S. & TORRES, F. 2015. Long-term therapy with oral 
treprostinil in pulmonary arterial hypertension failed to lead to improvement in 
important physiologic measures: results from a single center. Pulm Circ, 5, 513-20. 
CHO, H., HARRISON, K. & KEHRL, J. H. 2004. Regulators of G protein signaling: potential 
drug targets for controlling cardiovascular and immune function. Curr Drug Targets 
Immune Endocr Metabol Disord, 4, 107-18. 
CHRISTMAN, B. W., MCPHERSON, C. D., NEWMAN, J. H., KING, G. A., BERNARD, G. 
R., GROVES, B. M. & LOYD, J. E. 1992. An Imbalance between the Excretion of 
Thromboxane and Prostacyclin Metabolites in Pulmonary-Hypertension. New 
England Journal of Medicine, 327, 70-75. 
CHRIVIA, J. C., KWOK, R. P., LAMB, N., HAGIWARA, M., MONTMINY, M. R. & 
GOODMAN, R. H. 1993. Phosphorylated CREB binds specifically to the nuclear 
protein CBP. Nature, 365, 855-9. 
 223 
 
CLAPP, L. H., FINNEY, P., TURCATO, S., TRAN, S., RUBIN, L. J. & TINKER, A. 2002. 
Differential effects of stable prostacyclin analogs on smooth muscle proliferation 
and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol, 
26, 194-201. 
CLAPP, L. H. & GURUNG, R. 2015. The mechanistic basis of prostacyclin and its stable 
analogues in pulmonary arterial hypertension: Role of membrane versus nuclear 
receptors. Prostaglandins Other Lipid Mediat, 120, 56-71. 
CLOZEL, M., BREU, V., GRAY, G. A. & LOFFLER, B. M. 1993. In vivo pharmacology of 
Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: 
implications for endothelin physiology. J Cardiovasc Pharmacol, 22 Suppl 8, S377-
9. 
COLVIN, K. L. & YEAGER, M. E. 2014. Animal Models of Pulmonary Hypertension: 
Matching Disease Mechanisms to Etiology of the Human Disease. Journal of 
pulmonary & respiratory medicine, 4, 198. 
COMROE, J. H., JR. 1966. The main functions of the pulmonary circulation. Circulation, 
33, 146-58. 
CORBIN, J. D., BEASLEY, A., BLOUNT, M. A. & FRANCIS, S. H. 2005. High lung PDE5: 
a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem 
Biophys Res Commun, 334, 930-8. 
COURBOULIN, A., PAULIN, R., GIGUERE, N. J., SAKSOUK, N., PERREAULT, T., 
MELOCHE, J., PAQUET, E. R., BIARDEL, S., PROVENCHER, S., COTE, J., 
SIMARD, M. J. & BONNET, S. 2011. Role for miR-204 in human pulmonary arterial 
hypertension. J Exp Med, 208, 535-48. 
CRYSTAL, R. G. 1997. The Lung: Scientific Foundations, Lippincott-Raven. 
CUMMING, G., HARDING, L. K., HORSFIELD, K., PROWSE, K., SINGHAL, S. S. & 
WOLDENBERG, M. 1970. Morphological aspects of the pulmonary circulation and 
of the airways. in: Fluid Dynamics of Blood Circulation and Respiratory Flow. Agard 
Conf. Proc, 65, 23. 
DAVIE, N., HALEEN, S. J., UPTON, P. D., POLAK, J. M., YACOUB, M. H., MORRELL, N. 
W. & WHARTON, J. 2002. ET(A) and ET(B) receptors modulate the proliferation 
of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med, 165, 
398-405. 
DAVIES, R. J., HOLMES, A. M., DEIGHTON, J., LONG, L., YANG, X., BARKER, L., 
WALKER, C., BUDD, D. C., UPTON, P. D. & MORRELL, N. W. 2012. BMP type II 
receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary 
artery smooth muscle cells: role of proinflammatory cytokines. American Journal of 
Physiology - Lung Cellular and Molecular Physiology, 302, L604-L615. 
 224 
 
DE ROOIJ, J., ZWARTKRUIS, F. J., VERHEIJEN, M. H., COOL, R. H., NIJMAN, S. M., 
WITTINGHOFER, A. & BOS, J. L. 1998. Epac is a Rap1 guanine-nucleotide-
exchange factor directly activated by cyclic AMP. Nature, 396, 474-7. 
DEACON, K. & KNOX, A. J. 2010. Endothelin-1 (ET-1) increases the expression of 
remodeling genes in vascular smooth muscle through linked calcium and cAMP 
pathways: role of a phospholipase A(2)(cPLA(2))/cyclooxygenase-2 (COX-
2)/prostacyclin receptor-dependent autocrine loop. J Biol Chem, 285, 25913-27. 
DEED, R. W., ARMITAGE, S. & NORTON, J. D. 1996. Nuclear localization and regulation 
of Id protein through an E protein-mediated chaperone mechanism. J Biol Chem, 
271, 23603-6. 
DEED, R. W., HARA, E., ATHERTON, G. T., PETERS, G. & NORTON, J. D. 1997. 
Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation. Mol Cell 
Biol, 17, 6815-21. 
DEMELLO, D. E., SAWYER, D., GALVIN, N. & REID, L. M. 1997. Early fetal development 
of lung vasculature. Am J Respir Cell Mol Biol, 16, 568-81. 
DEMPSIE, Y., MACRITCHIE, N. A., WHITE, K., MORECROFT, I., WRIGHT, A. F., 
NILSEN, M., LOUGHLIN, L., MAIR, K. M. & MACLEAN, M. R. 2013. 
Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the 
development of pulmonary arterial hypertension. Cardiovasc Res, 99, 24-34. 
DEMPSIE, Y., NILSEN, M., WHITE, K., MAIR, K. M., LOUGHLIN, L., AMBARTSUMIAN, 
N., RABINOVITCH, M. & MACLEAN, M. R. 2011. Development of pulmonary 
arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. 
Respir Res, 12, 159. 
DENG, Z., HAGHIGHI, F., HELLEBY, L., VANTERPOOL, K., HORN, E. M., BARST, R. J., 
HODGE, S. E., MORSE, J. H. & KNOWLES, J. A. 2000. Fine mapping of PPH1, a 
gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 
2q33. Am J Respir Crit Care Med, 161, 1055-9. 
DERUITER, M. C., POELMANN, R. E., VANMUNSTEREN, J. C., MIRONOV, V., 
MARKWALD, R. R. & GITTENBERGER-DE GROOT, A. C. 1997. Embryonic 
endothelial cells transdifferentiate into mesenchymal cells expressing smooth 
muscle actins in vivo and in vitro. Circ Res, 80, 444-51. 
DESCHAMPS, A. M. & MURPHY, E. 2009. Activation of a novel estrogen receptor, GPER, 
is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol, 297, 
H1806-13. 
DEVILLIER, P. & BESSARD, G. 1997. Thromboxane A2 and related prostaglandins in 
airways. Fundam Clin Pharmacol, 11, 2-18. 
DIEBOLD, I., HENNIGS, J. K., MIYAGAWA, K., LI, C. G., NICKEL, N. P., KASCHWICH, 
M., CAO, A., WANG, L., REDDY, S., CHEN, P. I., NAKAHIRA, K., ALCAZAR, M. 
A., HOPPER, R. K., JI, L., FELDMAN, B. J. & RABINOVITCH, M. 2015. BMPR2 
 225 
 
preserves mitochondrial function and DNA during reoxygenation to promote 
endothelial cell survival and reverse pulmonary hypertension. Cell Metab, 21, 596-
608. 
DILLER, G. P., VAN EIJL, S., OKONKO, D. O., HOWARD, L. S., ALI, O., THUM, T., 
WORT, S. J., BEDARD, E., GIBBS, J. S., BAUERSACHS, J., HOBBS, A. J., 
WILKINS, M. R., GATZOULIS, M. A. & WHARTON, J. 2008. Circulating endothelial 
progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary 
arterial hypertension. Circulation, 117, 3020-30. 
DOEBELE, R. C., SCHULZE-HOEPFNER, F. T., HONG, J., CHLENSKI, A., ZEITLIN, B. 
D., GOEL, K., GOMES, S., LIU, Y., ABE, M. K., NOR, J. E., LINGEN, M. W. & 
ROSNER, M. R. 2009. A novel interplay between Epac/Rap1 and mitogen-
activated protein kinase kinase 5/extracellular signal-regulated kinase 5 
(MEK5/ERK5) regulates thrombospondin to control angiogenesis. Blood, 114, 
4592-600. 
DOHERTY, M. K., HAMMOND, D. E., CLAGUE, M. J., GASKELL, S. J. & BEYNON, R. J. 
2009. Turnover of the human proteome: determination of protein intracellular 
stability by dynamic SILAC. J Proteome Res, 8, 104-12. 
DORAN, A. C., LEHTINEN, A. B., MELLER, N., LIPINSKI, M. J., SLAYTON, R. P., 
OLDHAM, S. N., SKAFLEN, M. D., YEBOAH, J., RICH, S. S., BOWDEN, D. W. & 
MCNAMARA, C. A. 2010. Id3 is a novel atheroprotective factor containing a 
functionally significant single-nucleotide polymorphism associated with intima-
media thickness in humans. Circ Res, 106, 1303-11. 
DOWNING, S. E. & LEE, J. C. 1980. Nervous control of the pulmonary circulation. Annu 
Rev Physiol, 42, 199-210. 
DOYLE, B., METHAROM, P. & CAPLICE, N. M. 2006. Endothelial progenitor cells. 
Endothelium, 13, 403-10. 
DRESDALE, D. T., MICHTOM, R. J. & SCHULTZ, M. 1954. Recent studies in primary 
pulmonary hypertension, including pharmacodynamic observations on pulmonary 
vascular resistance. Bull N Y Acad Med, 30, 195-207. 
DRESDALE, D. T., SCHULTZ, M. & MICHTOM, R. J. 1951. Primary pulmonary 
hypertension. I. Clinical and hemodynamic study. Am J Med, 11, 686-705. 
DU, G. Q., ZHOU, L., CHEN, X. Y., WAN, X. P. & HE, Y. Y. 2012. The G protein-coupled 
receptor GPR30 mediates the proliferative and invasive effects induced by 
hydroxytamoxifen in endometrial cancer cells. Biochem Biophys Res Commun, 
420, 343-9. 
DUARTE, J. D., HANSON, R. L. & MACHADO, R. F. 2013. Pharmacologic treatments for 
pulmonary hypertension: exploring pharmacogenomics. Future cardiology, 9, 
10.2217/fca.13.6. 
 226 
 
DUMITRASCU, R., WEISSMANN, N., GHOFRANI, H. A., DONY, E., BEUERLEIN, K., 
SCHMIDT, H., STASCH, J. P., GNOTH, M. J., SEEGER, W., GRIMMINGER, F. & 
SCHERMULY, R. T. 2006. Activation of soluble guanylate cyclase reverses 
experimental pulmonary hypertension and vascular remodeling. Circulation, 113, 
286-95. 
DUNMORE, B. J., DRAKE, K. M., UPTON, P. D., TOSHNER, M. R., ALDRED, M. A. & 
MORRELL, N. W. 2013. The lysosomal inhibitor, chloroquine, increases cell 
surface BMPR-II levels and restores BMP9 signalling in endothelial cells 
harbouring BMPR-II mutations. Human Molecular Genetics, 22, 3667-3679. 
EARLEY, S. & RESTA, T. C. 2002. Estradiol attenuates hypoxia-induced pulmonary 
endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol, 283, L86-93. 
EDDAHIBI, S., HANOUN, N., LANFUMEY, L., LESCH, K. P., RAFFESTIN, B., HAMON, 
M. & ADNOT, S. 2000. Attenuated hypoxic pulmonary hypertension in mice lacking 
the 5-hydroxytryptamine transporter gene. J Clin Invest, 105, 1555-62. 
EDDAHIBI, S., HUMBERT, M., FADEL, E., RAFFESTIN, B., DARMON, M., CAPRON, F., 
SIMONNEAU, G., DARTEVELLE, P., HAMON, M. & ADNOT, S. 2001. Serotonin 
transporter overexpression is responsible for pulmonary artery smooth muscle 
hyperplasia in primary pulmonary hypertension. J Clin Invest, 108, 1141-50. 
EICHSTAEDT, C. A., SONG, J., BENJAMIN, N., HARUTYUNOVA, S., FISCHER, C., 
GRUNIG, E. & HINDERHOFER, K. 2016. EIF2AK4 mutation as "second hit" in 
hereditary pulmonary arterial hypertension. Respir Res, 17, 141. 
EL-BERMANI, A. W., BLOOMQUIST, E. I. & MONTVILO, J. A. 1982. Distribution of 
pulmonary cholinergic nerves in the rabbit. Thorax, 37, 703-710. 
EULER, U. S. V. & LILJESTRAND, G. 1946. Observations on the Pulmonary Arterial Blood 
Pressure in the Cat. Acta Physiologica Scandinavica, 12, 301-320. 
FADINI, G. P., DE KREUTZENBERG, S., ALBIERO, M., CORACINA, A., PAGNIN, E., 
BAESSO, I., CIGNARELLA, A., BOLEGO, C., PLEBANI, M., NARDELLI, G. B., 
SARTORE, S., AGOSTINI, C. & AVOGARO, A. 2008. Gender differences in 
endothelial progenitor cells and cardiovascular risk profile: the role of female 
estrogens. Arterioscler Thromb Vasc Biol, 28, 997-1004. 
FALCETTI, E., FLAVELL, D. M., STAELS, B., TINKER, A., HAWORTH, S. G. & CLAPP, 
L. H. 2007. IP receptor-dependent activation of PPARgamma by stable 
prostacyclin analogues. Biochem Biophys Res Commun, 360, 821-7. 
FALCETTI, E., HALL, S. M., PHILLIPS, P. G., PATEL, J., MORRELL, N. W., HAWORTH, 
S. G. & CLAPP, L. H. 2010. Smooth Muscle Proliferation and Role of the 
Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension. American 
Journal of Respiratory and Critical Care Medicine, 182, 1161-1170. 
FARHAT, M. Y., ABI-YOUNES, S., DINGAAN, B., VARGAS, R. & RAMWELL, P. W. 1996. 
Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular 
 227 
 
smooth muscle cells by a nongenomic mechanism. J Pharmacol Exp Ther, 276, 
652-7. 
FARHAT, M. Y., CHEN, M. F., BHATTI, T., IQBAL, A., CATHAPERMAL, S. & RAMWELL, 
P. W. 1993. Protection by oestradiol against the development of cardiovascular 
changes associated with monocrotaline pulmonary hypertension in rats. Br J 
Pharmacol, 110, 719-23. 
FATTINGER, K., ROOS, M., VERGERES, P., HOLENSTEIN, C., KIND, B., MASCHE, U., 
STOCKER, D. N., BRAUNSCHWEIG, S., KULLAK-UBLICK, G. A., GALEAZZI, R. 
L., FOLLATH, F., GASSER, T. & MEIER, P. J. 2000. Epidemiology of drug 
exposure and adverse drug reactions in two swiss departments of internal 
medicine. Br J Clin Pharmacol, 49, 158-67. 
FEDERMAN, A. D., CONKLIN, B. R., SCHRADER, K. A., REED, R. R. & BOURNE, H. R. 
1992. Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma 
subunits. Nature, 356, 159-61. 
FILARDO, E. J., QUINN, J. A., BLAND, K. I. & FRACKELTON, A. R., JR. 2000. Estrogen-
induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor 
homolog, GPR30, and occurs via trans-activation of the epidermal growth factor 
receptor through release of HB-EGF. Mol Endocrinol, 14, 1649-60. 
FILARDO, E. J., QUINN, J. A., FRACKELTON, A. R., JR. & BLAND, K. I. 2002. Estrogen 
action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase 
and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK 
signaling axis. Mol Endocrinol, 16, 70-84. 
FILARDO, E. J. & THOMAS, P. 2005. GPR30: a seven-transmembrane-spanning 
estrogen receptor that triggers EGF release. Trends Endocrinol Metab, 16, 362-7. 
FILIGHEDDU, N., SAMPIETRO, S., CHIANALE, F., PORPORATO, P. E., GAGGIANESI, 
M., GREGNANIN, I., RAINERO, E., FERRARA, M., PEREGO, B., RIBONI, F., 
BALDANZI, G., GRAZIANI, A. & SURICO, N. 2011. Diacylglycerol kinase alpha 
mediates 17-beta-estradiol-induced proliferation, motility, and anchorage-
independent growth of Hec-1A endometrial cancer cell line through the G protein-
coupled estrogen receptor GPR30. Cell Signal, 23, 1988-96. 
FIMIA, G. M. & SASSONE-CORSI, P. 2001. Cyclic AMP signalling. Journal of Cell 
Science, 114, 1971-1972. 
FISHER, A. W. 1965. The intrinsic innervation of the pulmonary vessels. Acta Anat (Basel), 
60, 481-96. 
FITSCHA, P., TISO, B., KRAIS, T. & SINZINGER, H. 1987. Effect of iloprost on in vivo and 
in vitro platelet function in patients with peripheral vascular disease (PVD). Adv 
Prostaglandin Thromboxane Leukot Res, 17a, 450-4. 
 228 
 
FORBES, J. F., CUZICK, J., BUZDAR, A., HOWELL, A., TOBIAS, J. S. & BAUM, M. 2008. 
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast 
cancer: 100-month analysis of the ATAC trial. Lancet Oncol, 9, 45-53. 
FORTE, P., KNEALE, B. J., MILNE, E., CHOWIENCZYK, P. J., JOHNSTON, A., 
BENJAMIN, N. & RITTER, J. M. 1998. Evidence for a difference in nitric oxide 
biosynthesis between healthy women and men. Hypertension, 32, 730-4. 
FRANCIS, S. H., NOBLETT, B. D., TODD, B. W., WELLS, J. N. & CORBIN, J. D. 1988. 
Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs 
that preferentially activate purified cGMP-dependent protein kinase. Mol 
Pharmacol, 34, 506-17. 
FRANTZ, R. P., SCHILZ, R. J., CHAKINALA, M. M., BADESCH, D. B., FROST, A. E., 
MCLAUGHLIN, V. V., BARST, R. J., ROSENBERG, D. M., MILLER, D. P., 
HARTLINE, B. K., BENTON, W. W. & FARBER, H. W. 2015. Hospitalization and 
survival in patients using epoprostenol for injection in the PROSPECT 
observational study. Chest, 147, 484-94. 
FRASER, I. D., CONG, M., KIM, J., ROLLINS, E. N., DAAKA, Y., LEFKOWITZ, R. J. & 
SCOTT, J. D. 2000. Assembly of an A kinase-anchoring protein-beta(2)-adrenergic 
receptor complex facilitates receptor phosphorylation and signaling. Curr Biol, 10, 
409-12. 
FRID, M. G., DEMPSEY, E. C., DURMOWICZ, A. G. & STENMARK, K. R. 1997. Smooth 
muscle cell heterogeneity in pulmonary and systemic vessels. Importance in 
vascular disease. Arterioscler Thromb Vasc Biol, 17, 1203-9. 
FROST, A. E., BARST, R. J., HOEPER, M. M., CHANG, H. J., FRANTZ, R. P., 
FUKUMOTO, Y., GALIE, N., HASSOUN, P. M., KLOSE, H., MATSUBARA, H., 
MORRELL, N. W., PEACOCK, A. J., PFEIFER, M., SIMONNEAU, G., TAPSON, 
V. F., TORRES, F., DARIO VIZZA, C., LAWRENCE, D., YANG, W., FELSER, J. 
M., QUINN, D. A. & GHOFRANI, H. A. 2015. Long-term safety and efficacy of 
imatinib in pulmonary arterial hypertension. J Heart Lung Transplant, 34, 1366-75. 
FRUMP, A. L., GOSS, K. N., VAYL, A., ALBRECHT, M., FISHER, A., TURSUNOVA, R., 
FIERST, J., WHITSON, J., CUCCI, A. R., BROWN, M. B. & LAHM, T. 2015a. 
Estradiol improves right ventricular function in rats with severe angioproliferative 
pulmonary hypertension: effects of endogenous and exogenous sex hormones. 
Am J Physiol Lung Cell Mol Physiol, 308, L873-90. 
FRUMP, A. L., GOSS, K. N., VAYL, A., ALBRECHT, M., FISHER, A., TURSUNOVA, R., 
FIERST, J., WHITSON, J., CUCCI, A. R., BROWN, M. B. & LAHM, T. 2015b. 
Estradiol improves right ventricular function in rats with severe angioproliferative 
pulmonary hypertension: effects of endogenous and exogenous sex hormones. 
American Journal of Physiology - Lung Cellular and Molecular Physiology, 308, 
L873-L890. 
 229 
 
FUKUNAGA, E., INOUE, Y., KOMIYA, S., HORIGUCHI, K., GOTO, K., SAITOH, M., 
MIYAZAWA, K., KOINUMA, D., HANYU, A. & IMAMURA, T. 2008. Smurf2 induces 
ubiquitin-dependent degradation of Smurf1 to prevent migration of breast cancer 
cells. J Biol Chem, 283, 35660-7. 
FULLERTON, D. A., AGRAFOJO, J. & MCINTYRE, R. C., JR. 1996. Pulmonary vascular 
smooth muscle relaxation by cAMP-mediated pathways. J Surg Res, 61, 444-8. 
FULLERTON, D. A., HAHN, A. R., BANERJEE, A. & HARKEN, A. H. 1994. Pulmonary 
vascular smooth muscle relaxation by cGMP- versus cAMP-mediated 
mechanisms. J Surg Res, 57, 259-63. 
FULTON, R. M., HUTCHINSON, E. C. & JONES, A. M. 1952. Ventricular weight in cardiac 
hypertrophy. Br Heart J, 14, 413-20. 
GABLER, N. B., FRENCH, B., STROM, B. L., LIU, Z., PALEVSKY, H. I., TAICHMAN, D. 
B., KAWUT, S. M. & HALPERN, S. D. 2012. Race and sex differences in response 
to endothelin receptor antagonists for pulmonary arterial hypertension. Chest, 141, 
20-6. 
GALIE, N., BRUNDAGE, B. H., GHOFRANI, H. A., OUDIZ, R. J., SIMONNEAU, G., 
SAFDAR, Z., SHAPIRO, S., WHITE, R. J., CHAN, M., BEARDSWORTH, A., 
FRUMKIN, L., BARST, R. J., PULMONARY ARTERIAL, H. & RESPONSE TO 
TADALAFIL STUDY, G. 2009a. Tadalafil therapy for pulmonary arterial 
hypertension. Circulation, 119, 2894-903. 
GALIÈ , N., GHOFRANI , H. A., TORBICKI , A., BARST , R. J., RUBIN , L. J., BADESCH 
, D., FLEMING , T., PARPIA , T., BURGESS , G., BRANZI , A., GRIMMINGER , 
F., KURZYNA , M. & SIMONNEAU , G. 2005. Sildenafil Citrate Therapy for 
Pulmonary Arterial Hypertension. New England Journal of Medicine, 353, 2148-
2157. 
GALIE, N., HOEPER, M. M., HUMBERT, M., TORBICKI, A., VACHIERY, J. L., BARBERA, 
J. A., BEGHETTI, M., CORRIS, P., GAINE, S., GIBBS, J. S., GOMEZ-SANCHEZ, 
M. A., JONDEAU, G., KLEPETKO, W., OPITZ, C., PEACOCK, A., RUBIN, L., 
ZELLWEGER, M., SIMONNEAU, G. & GUIDELINES, E. S. C. C. F. P. 2009b. 
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task 
Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European 
Society of Cardiology (ESC) and the European Respiratory Society (ERS), 
endorsed by the International Society of Heart and Lung Transplantation (ISHLT). 
Eur Heart J, 30, 2493-537. 
GALIE, N., HUMBERT, M., VACHIERY, J. L., VIZZA, C. D., KNEUSSL, M., MANES, A., 
SITBON, O., TORBICKI, A., DELCROIX, M., NAEIJE, R., HOEPER, M., 
CHAOUAT, A., MORAND, S., BESSE, B. & SIMONNEAU, G. 2002. Effects of 
beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial 
 230 
 
hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll 
Cardiol, 39, 1496-502. 
GAO, M., PING, P., POST, S., INSEL, P. A., TANG, R. & HAMMOND, H. K. 1998. 
Increased expression of adenylylcyclase type VI proportionately increases β-
adrenergic receptor-stimulated production of cAMP in neonatal 
rat cardiac myocytes. Proceedings of the National Academy of Sciences, 95, 1038-
1043. 
GATFIELD, J., MENYHART, K. & NAYLER, O. 2014. Anti-contractile and anti-proliferative 
responses in human pulmonary arterial smooth muscle cells induced by ACT-
333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin 
receptor agonist. European Respiratory Journal, 44. 
GAUDIN, C., ISHIKAWA, Y., WIGHT, D. C., MAHDAVI, V., NADAL-GINARD, B., 
WAGNER, T. E., VATNER, D. E. & HOMCY, C. J. 1995. Overexpression of Gs 
alpha protein in the hearts of transgenic mice. J Clin Invest, 95, 1676-83. 
GHODSI, F. & WILL, J. A. 1981. Changes in pulmonary structure and function induced by 
monocrotaline intoxication. Am J Physiol, 240, H149-55. 
GHOFRANI, H. A., GALIE, N., GRIMMINGER, F., GRUNIG, E., HUMBERT, M., JING, Z. 
C., KEOGH, A. M., LANGLEBEN, D., KILAMA, M. O., FRITSCH, A., NEUSER, D. 
& RUBIN, L. J. 2013. Riociguat for the treatment of pulmonary arterial 
hypertension. N Engl J Med, 369, 330-40. 
GHZILI, H., GRUMOLATO, L., THOUENNON, E., VAUDRY, H. & ANOUAR, Y. 2006. 
Possible implication of the transcriptional regulator Id3 in PACAP-induced pro-
survival signaling during PC12 cell differentiation. Regul Pept, 137, 89-94. 
GIAID, A. & SALEH, D. 1995. Reduced expression of endothelial nitric oxide synthase in 
the lungs of patients with pulmonary hypertension. N Engl J Med, 333, 214-21. 
GIAID, A., YANAGISAWA, M., LANGLEBEN, D., MICHEL, R. P., LEVY, R., SHENNIB, H., 
KIMURA, S., MASAKI, T., DUGUID, W. P. & STEWART, D. J. 1993. Expression of 
endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 
328, 1732-9. 
GIRERD, B., MONTANI, D., COULET, F., SZTRYMF, B., YAICI, A., JAIS, X., TREGOUET, 
D., REIS, A., DROUIN-GARRAUD, V., FRAISSE, A., SITBON, O., 
O'CALLAGHAN, D. S., SIMONNEAU, G., SOUBRIER, F. & HUMBERT, M. 2010a. 
Clinical outcomes of pulmonary arterial hypertension in patients carrying an 
ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med, 181, 851-61. 
GIRERD, B., MONTANI, D., EYRIES, M., YAICI, A., SZTRYMF, B., COULET, F., SITBON, 
O., SIMONNEAU, G., SOUBRIER, F. & HUMBERT, M. 2010b. Absence of 
influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary 
arterial hypertension. Respir Res, 11, 73. 
 231 
 
GIRERD, B., PERROS, F., ANTIGNY, F., HUMBERT, M. & MONTANI, D. 2014. KCNK3: 
new gene target for pulmonary hypertension? Expert Rev Respir Med, 8, 385-7. 
GOETZE, J. P., REHFELD, J. F., CARLSEN, J., VIDEBAEK, R., ANDERSEN, C. B., 
BOESGAARD, S. & FRIIS-HANSEN, L. 2006. Apelin: a new plasma marker of 
cardiopulmonary disease. Regul Pept, 133, 134-8. 
GONZALES, R. J., WALKER, B. R. & KANAGY, N. L. 2001. 17beta-estradiol increases 
nitric oxide-dependent dilation in rat pulmonary arteries and thoracic aorta. Am J 
Physiol Lung Cell Mol Physiol, 280, L555-64. 
GONZALEZ, G. A. & MONTMINY, M. R. 1989. Cyclic AMP stimulates somatostatin gene 
transcription by phosphorylation of CREB at serine 133. Cell, 59, 675-80. 
GRANTON, J., LANGLEBEN, D., KUTRYK, M. B., CAMACK, N., GALIPEAU, J., 
COURTMAN, D. W. & STEWART, D. J. 2015. Endothelial NO-Synthase Gene-
Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The 
PHACeT Trial. Circ Res, 117, 645-54. 
GREEN, S., WALTER, P., KUMAR, V., KRUST, A., BORNERT, J. M., ARGOS, P. & 
CHAMBON, P. 1986. Human oestrogen receptor cDNA: sequence, expression and 
homology to v-erb-A. Nature, 320, 134-9. 
GRYGLEWSKI, R. J., BOTTING, R. M. & VANE, J. R. 1988. Mediators produced by the 
endothelial cell. Hypertension, 12, 530-48. 
GUIGNABERT, C., ALVIRA, C. M., ALASTALO, T. P., SAWADA, H., HANSMANN, G., 
ZHAO, M., WANG, L., EL-BIZRI, N. & RABINOVITCH, M. 2009a. Tie2-mediated 
loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF 
receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung 
Cell Mol Physiol, 297, L1082-90. 
GUIGNABERT, C., IZIKKI, M., TU, L. I., LI, Z., ZADIGUE, P., BARLIER-MUR, A. M., 
HANOUN, N., RODMAN, D., HAMON, M., ADNOT, S. & EDDAHIBI, S. 2006. 
Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in 
smooth muscle develop pulmonary hypertension. Circ Res, 98, 1323-30. 
GUIGNABERT, C., TU, L., IZIKKI, M., DEWACHTER, L., ZADIGUE, P., HUMBERT, M., 
ADNOT, S., FADEL, E. & EDDAHIBI, S. 2009b. Dichloroacetate treatment partially 
regresses established pulmonary hypertension in mice with SM22alpha-targeted 
overexpression of the serotonin transporter. Faseb j, 23, 4135-47. 
HAAS, E., BHATTACHARYA, I., BRAILOIU, E., DAMJANOVIC, M., BRAILOIU, G. C., 
GAO, X., MUELLER-GUERRE, L., MARJON, N. A., GUT, A., MINOTTI, R., 
MEYER, M. R., AMANN, K., AMMANN, E., PEREZ-DOMINGUEZ, A., GENONI, 
M., CLEGG, D. J., DUN, N. J., RESTA, T. C., PROSSNITZ, E. R. & BARTON, M. 
2009. Regulatory role of G protein-coupled estrogen receptor for vascular function 
and obesity. Circ Res, 104, 288-91. 
 232 
 
HAGIWARA, M., ALBERTS, A., BRINDLE, P., MEINKOTH, J., FERAMISCO, J., DENG, 
T., KARIN, M., SHENOLIKAR, S. & MONTMINY, M. 1992. Transcriptional 
attenuation following cAMP induction requires PP-1-mediated dephosphorylation 
of CREB. Cell, 70, 105-13. 
HALE, S. L., BIRNBAUM, Y. & KLONER, R. A. 1996. beta-Estradiol, but not alpha-
estradiol, reduced myocardial necrosis in rabbits after ischemia and reperfusion. 
Am Heart J, 132, 258-62. 
HALL, S. M., DAVIE, N., KLEIN, N. & HAWORTH, S. G. 2011. Endothelin receptor 
expression in idiopathic pulmonary arterial hypertension: effect of bosentan and 
epoprostenol treatment. European Respiratory Journal, 38, 851-860. 
HALL, S. M., HISLOP, A. A., PIERCE, C. M. & HAWORTH, S. G. 2000. Prenatal origins 
of human intrapulmonary arteries: formation and smooth muscle maturation. Am J 
Respir Cell Mol Biol, 23, 194-203. 
HAMID, R., COGAN, J. D., HEDGES, L. K., AUSTIN, E., PHILLIPS, J. A., NEWMAN, J. 
H. & LOYD, J. E. 2009. Penetrance of Pulmonary Arterial Hypertension Is 
Modulated by the Expression of Normal BMPR2 Allele. Human Mutation, 30, 649-
654. 
HAMIDI, S. A., LIN, R. Z., SZEMA, A. M., LYUBSKY, S., JIANG, Y. P. & SAID, S. I. 2011. 
VIP and endothelin receptor antagonist: an effective combination against 
experimental pulmonary arterial hypertension. Respir Res, 12, 141. 
HAMIDI, S. A., PRABHAKAR, S. & SAID, S. I. 2008. Enhancement of pulmonary vascular 
remodelling and inflammatory genes with VIP gene deletion. Eur Respir J, 31, 135-
9. 
HAMMOND, H., PENNY, W. F., TRAVERSE, J. H. & ET AL. 2016. Intracoronary gene 
transfer of adenylyl cyclase 6 in patients with heart failure: A randomized clinical 
trial. JAMA Cardiology, 1, 163-171. 
HANNA, I. H., DAWLING, S., ROODI, N., GUENGERICH, F. P. & PARL, F. F. 2000. 
Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of 
polymorphisms with functional differences in estrogen hydroxylation activity. 
Cancer Res, 60, 3440-4. 
HANS, B.-O., PETRINE, W. & ANDERS, A. J. 2007. Structure, Pharmacology and 
Therapeutic Prospects of Family C G-Protein Coupled Receptors. Current Drug 
Targets, 8, 169-184. 
HANSMANN, G., DE JESUS PEREZ, V. A., ALASTALO, T. P., ALVIRA, C. M., 
GUIGNABERT, C., BEKKER, J. M., SCHELLONG, S., URASHIMA, T., WANG, L., 
MORRELL, N. W. & RABINOVITCH, M. 2008. An antiproliferative BMP-
2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary 
hypertension. J Clin Invest, 118, 1846-57. 
 233 
 
HANSTEIN, B., ECKNER, R., DIRENZO, J., HALACHMI, S., LIU, H., SEARCY, B., 
KUROKAWA, R. & BROWN, M. 1996. p300 is a component of an estrogen 
receptor coactivator complex. Proceedings of the National Academy of Sciences 
of the United States of America, 93, 11540-11545. 
HANYALOGLU, A. C. & VON ZASTROW, M. 2008. Regulation of GPCRs by endocytic 
membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol, 
48, 537-68. 
HARADA, N. 1997. Aberrant expression of aromatase in breast cancer tissues. J Steroid 
Biochem Mol Biol, 61, 175-84. 
HARADA, N. & HONDA, S. 1998. Molecular analysis of aberrant expression of aromatase 
in breast cancer tissues. Breast Cancer Res Treat, 49 Suppl 1, S15-21; discussion 
S33-7. 
HARADA, N., SASANO, H., MURAKAMI, H., OHKUMA, T., NAGURA, H. & TAKAGI, Y. 
1999. Localized expression of aromatase in human vascular tissues. Circ Res, 84, 
1285-91. 
HARMAR, A. J. 2001. Family-B G-protein-coupled receptors. Genome Biology, 2, 
reviews3013.1. 
HARRISON, R. E., FLANAGAN, J. A., SANKELO, M., ABDALLA, S. A., ROWELL, J., 
MACHADO, R. D., ELLIOTT, C. G., ROBBINS, I. M., OLSCHEWSKI, H., 
MCLAUGHLIN, V., GRUENIG, E., KERMEEN, F., HALME, M., RAISANEN-
SOKOLOWSKI, A., LAITINEN, T., MORRELL, N. W. & TREMBATH, R. C. 2003. 
Molecular and functional analysis identifies ALK-1 as the predominant cause of 
pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med 
Genet, 40, 865-71. 
HASUNUMA, K., RODMAN, D. M. & MCMURTRY, I. F. 1991. Effects of K+ channel 
blockers on vascular tone in the perfused rat lung. Am Rev Respir Dis, 144, 884-
7. 
HATA, A. N. & BREYER, R. M. 2004. Pharmacology and signaling of prostaglandin 
receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther, 
103, 147-66. 
HAYNES, W. G., FERRO, C. J., O'KANE, K. P., SOMERVILLE, D., LOMAX, C. C. & 
WEBB, D. J. 1996. Systemic endothelin receptor blockade decreases peripheral 
vascular resistance and blood pressure in humans. Circulation, 93, 1860-70. 
HEATH, D. & EDWARDS, J. E. 1958. The pathology of hypertensive pulmonary vascular 
disease; a description of six grades of structural changes in the pulmonary arteries 
with special reference to congenital cardiac septal defects. Circulation, 18, 533-47. 
HELDIN, C. H., MIYAZONO, K. & TEN DIJKE, P. 1997. TGF-beta signalling from cell 
membrane to nucleus through SMAD proteins. Nature, 390, 465-71. 
 234 
 
HEWER, R. C., SALA-NEWBY, G. B., WU, Y. J., NEWBY, A. C. & BOND, M. 2011. PKA 
and Epac synergistically inhibit smooth muscle cell proliferation. J Mol Cell Cardiol, 
50, 87-98. 
HIRATA, Y., EMORI, T., EGUCHI, S., KANNO, K., IMAI, T., OHTA, K. & MARUMO, F. 
1993. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured 
bovine endothelial cells. J Clin Invest, 91, 1367-73. 
HIROSE, S., HOSODA, Y., FURUYA, S., OTSUKI, T. & IKEDA, E. 2000. Expression of 
vascular endothelial growth factor and its receptors correlates closely with 
formation of the plexiform lesion in human pulmonary hypertension. Pathol Int, 50, 
472-9. 
HOEPER, M. M., BARST, R. J., BOURGE, R. C., FELDMAN, J., FROST, A. E., GALIE, 
N., GOMEZ-SANCHEZ, M. A., GRIMMINGER, F., GRUNIG, E., HASSOUN, P. M., 
MORRELL, N. W., PEACOCK, A. J., SATOH, T., SIMONNEAU, G., TAPSON, V. 
F., TORRES, F., LAWRENCE, D., QUINN, D. A. & GHOFRANI, H. A. 2013. 
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of 
the randomized IMPRES study. Circulation, 127, 1128-38. 
HOEPER, M. M., LEE, S. H., VOSWINCKEL, R., PALAZZINI, M., JAIS, X., MARINELLI, 
A., BARST, R. J., GHOFRANI, H. A., JING, Z. C., OPITZ, C., SEYFARTH, H. J., 
HALANK, M., MCLAUGHLIN, V., OUDIZ, R. J., EWERT, R., WILKENS, H., 
KLUGE, S., BREMER, H. C., BAROKE, E. & RUBIN, L. J. 2006. Complications of 
right heart catheterization procedures in patients with pulmonary hypertension in 
experienced centers. J Am Coll Cardiol, 48, 2546-52. 
HOLM, A., BALDETORP, B., OLDE, B., LEEB-LUNDBERG, L. M. & NILSSON, B. O. 2011. 
The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA 
synthesis and accumulating cells in the S and G2 phases of the cell cycle. J Vasc 
Res, 48, 327-35. 
HOLMBOE, S., ANDERSEN, A., JOHNSEN, J., NIELSEN, J. M., NORREGAARD, R., 
BOTKER, H. E., CLAPP, L. H. & NIELSEN-KUDSK, J. E. 2016. Inotropic effects of 
prostacyclins on the right ventricle are abolished in isolated rat hearts with right 
ventricular hypertrophy and failure. J Cardiovasc Pharmacol. 
HOOD, K. Y., MONTEZANO, A. C., HARVEY, A. P., NILSEN, M., MACLEAN, M. R. & 
TOUYZ, R. M. 2016. Nicotinamide Adenine Dinucleotide Phosphate Oxidase-
Mediated Redox Signaling and Vascular Remodeling by 16alpha-Hydroxyestrone 
in Human Pulmonary Artery Cells: Implications in Pulmonary Arterial Hypertension. 
Hypertension, 68, 796-808. 
HOSHIKAWA, Y., NANA-SINKAM, P., MOORE, M. D., SOTTO-SANTIAGO, S., PHANG, 
T., KEITH, R. L., MORRIS, K. G., KONDO, T., TUDER, R. M., VOELKEL, N. F. & 
GERACI, M. W. 2003. Hypoxia induces different genes in the lungs of rats 
compared with mice. Physiol Genomics, 12, 209-19. 
 235 
 
HOSHIKAWA, Y., VOELKEL, N. F., GESELL, T. L., MOORE, M. D., MORRIS, K. G., 
ALGER, L. A., NARUMIYA, S. & GERACI, M. W. 2001. Prostacyclin receptor-
dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care 
Med, 164, 314-8. 
HOSSMANN, V., AUEL, H., RUCKER, W. & SCHROR, K. 1984. Prolonged infusion of 
prostacyclin in patients with advanced stages of peripheral vascular disease: a 
placebo-controlled cross-over study. Klin Wochenschr, 62, 1108-14. 
HUANG, W., YEN, R. T., MCLAURINE, M. & BLEDSOE, G. 1996. Morphometry of the 
human pulmonary vasculature. J Appl Physiol (1985), 81, 2123-33. 
HUMBERT, M., MONTI, G., FARTOUKH, M., MAGNAN, A., BRENOT, F., RAIN, B., 
CAPRON, F., GALANAUD, P., DUROUX, P., SIMONNEAU, G. & EMILIE, D. 1998. 
Platelet-derived growth factor expression in primary pulmonary hypertension: 
comparison of HIV seropositive and HIV seronegative patients. Eur Respir J, 11, 
554-9. 
HUMBERT, M., SANCHEZ, O., FARTOUKH, M., JAGOT, J. L., LE GALL, C., SITBON, O., 
PARENT, F. & SIMONNEAU, G. 1999. Short-term and long-term epoprostenol 
(prostacyclin) therapy in pulmonary hypertension secondary to connective tissue 
diseases: results of a pilot study. Eur Respir J, 13, 1351-6. 
HUMBERT, M., SITBON, O., CHAOUAT, A., BERTOCCHI, M., HABIB, G., GRESSIN, V., 
YAICI, A., WEITZENBLUM, E., CORDIER, J. F., CHABOT, F., DROMER, C., 
PISON, C., REYNAUD-GAUBERT, M., HALOUN, A., LAURENT, M., HACHULLA, 
E., COTTIN, V., DEGANO, B., JAIS, X., MONTANI, D., SOUZA, R. & 
SIMONNEAU, G. 2010a. Survival in patients with idiopathic, familial, and 
anorexigen-associated pulmonary arterial hypertension in the modern 
management era. Circulation, 122, 156-63. 
HUMBERT, M., SITBON, O., CHAOUAT, A., BERTOCCHI, M., HABIB, G., GRESSIN, V., 
YAICI, A., WEITZENBLUM, E., CORDIER, J. F., CHABOT, F., DROMER, C., 
PISON, C., REYNAUD-GAUBERT, M., HALOUN, A., LAURENT, M., HACHULLA, 
E. & SIMONNEAU, G. 2006. Pulmonary arterial hypertension in France: results 
from a national registry. Am J Respir Crit Care Med, 173, 1023-30. 
HUMBERT, M., SITBON, O., YAICI, A., MONTANI, D., O'CALLAGHAN, D. S., JAIS, X., 
PARENT, F., SAVALE, L., NATALI, D., GUNTHER, S., CHAOUAT, A., CHABOT, 
F., CORDIER, J. F., HABIB, G., GRESSIN, V., JING, Z. C., SOUZA, R., 
SIMONNEAU, G. & FRENCH PULMONARY ARTERIAL HYPERTENSION, N. 
2010b. Survival in incident and prevalent cohorts of patients with pulmonary arterial 
hypertension. Eur Respir J, 36, 549-55. 
HYMAN, A. L., LIPPTON, H. L. & KADOWITZ, P. J. 1986. Nature of alpha 1 and 
postjunctional alpha 2 adrenoceptors in the pulmonary vascular bed. Fed Proc, 45, 
2336-40. 
 236 
 
HYMAN, A. L., LIPPTON, H. L. & KADOWITZ, P. J. 1990. Analysis of pulmonary vascular 
responses in cats to sympathetic nerve stimulation under elevated tone conditions. 
Evidence that neuronally released norepinephrine acts on alpha 1-, alpha 2-, and 
beta 2-adrenoceptors. Circ Res, 67, 862-70. 
HYMAN, A. L., NANDIWADA, P., KNIGHT, D. S. & KADOWITZ, P. J. 1981. Pulmonary 
vasodilator responses to catecholamines and sympathetic nerve stimulation in the 
cat. Evidence that vascular beta-2 adrenoreceptors are innervated. Circ Res, 48, 
407-15. 
ILKIW, R., TODOROVICH-HUNTER, L., MARUYAMA, K., SHIN, J. & RABINOVITCH, M. 
1989. SC-39026, a serine elastase inhibitor, prevents muscularization of peripheral 
arteries, suggesting a mechanism of monocrotaline-induced pulmonary 
hypertension in rats. Circ Res, 64, 814-25. 
INTERNATIONAL, P. P. H. C., LANE, K. B., MACHADO, R. D., PAUCIULO, M. W., 
THOMSON, J. R., PHILLIPS, J. A., 3RD, LOYD, J. E., NICHOLS, W. C. & 
TREMBATH, R. C. 2000. Heterozygous germline mutations in BMPR2, encoding 
a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet, 
26, 81-4. 
IVY, D. D., MCMURTRY, I. F., COLVIN, K., IMAMURA, M., OKA, M., LEE, D. S., GEBB, 
S. & JONES, P. L. 2005. Development of occlusive neointimal lesions in distal 
pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe 
pulmonary arterial hypertension. Circulation, 111, 2988-96. 
IWABUCHI, S., ONO, S., TANITA, T., KOIKE, K. & FUJIMURA, S. 1997. Vasoactive 
intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated 
rat lung. Respiration, 64, 54-8. 
IWAMI, G., KAWABE, J.-I., EBINA, T., CANNON, P. J., HOMCY, C. J. & ISHIKAWA, Y. 
1995. Regulation of Adenylyl Cyclase by Protein Kinase A. Journal of Biological 
Chemistry, 270, 12481-12484. 
JACKSON, V. M., TROUT, S. J. & CUNNANE, T. C. 2002. Regional variation in 
electrically-evoked contractions of rabbit isolated pulmonary artery. Br J 
Pharmacol, 137, 488-96. 
JACOBS, W., VAN DE VEERDONK, M. C., TRIP, P., DE MAN, F., HEYMANS, M. W., 
MARCUS, J. T., KAWUT, S. M., BOGAARD, H. J., BOONSTRA, A. & VONK 
NOORDEGRAAF, A. 2014. The right ventricle explains sex differences in survival 
in idiopathic pulmonary arterial hypertension. Chest, 145, 1230-6. 
JAIN, R., SHAUL, P. W., BOROK, Z. & WILLIS, B. C. 2007. Endothelin-1 induces alveolar 
epithelial-mesenchymal transition through endothelin type A receptor-mediated 
production of TGF-beta1. Am J Respir Cell Mol Biol, 37, 38-47. 
 237 
 
JASINSKA-STROSCHEIN, M. & ORSZULAK-MICHALAK, D. 2014. The current approach 
into signaling pathways in pulmonary arterial hypertension and their implication in 
novel therapeutic strategies. Pharmacol Rep, 66, 552-64. 
JEN, Y., MANOVA, K. & BENEZRA, R. 1996. Expression patterns of Id1, Id2, and Id3 are 
highly related but distinct from that of Id4 during mouse embryogenesis. Dev Dyn, 
207, 235-52. 
JIANG, Z. L., KASSAB, G. S. & FUNG, Y. C. 1994. Diameter-defined Strahler system and 
connectivity matrix of the pulmonary arterial tree. J Appl Physiol (1985), 76, 882-
92. 
JIGISHA, P., LEI, S., SUSAN, H., XAVIER, N., ROBIN, M., ADAM, S., BRENDAN, W. & 
LUCIE, H. C. 2015. EP2 Receptors Play a Key Role in Mediating the Anti-
Proliferative Activity of Treprostinil in Smooth Muscle Cells Derived from the Lungs 
of Pulmonary Hypertensive Patients. D43. CELL FATE. American Thoracic 
Society. 
JIGISHA, P., SUSAN, M. H. & LUCIE, H. C. 2012. Inhibition Of Endothelin-1 Levels By 
Treprostinil Is Counteracted By Bostentan And Ambrisentan In Smooth Muscle 
Cells Derived From Patients With Pulmonary Arterial Hypertension. C62. 
EXPERIMENTAL MODELS IN PULMONARY HYPERTENSION II. American 
Thoracic Society. 
JING, Z. C., PARIKH, K., PULIDO, T., JERJES-SANCHEZ, C., WHITE, R. J., ALLEN, R., 
TORBICKI, A., XU, K. F., YEHLE, D., LALIBERTE, K., ARNESON, C. & RUBIN, L. 
J. 2013. Efficacy and safety of oral treprostinil monotherapy for the treatment of 
pulmonary arterial hypertension: a randomized, controlled trial. Circulation, 127, 
624-33. 
JING, Z. C., YU, Z. X., SHEN, J. Y., WU, B. X., XU, K. F., ZHU, X. Y., PAN, L., ZHANG, 
Z. L., LIU, X. Q., ZHANG, Y. S., JIANG, X. & GALIE, N. 2011. Vardenafil in 
pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled 
study. Am J Respir Crit Care Med, 183, 1723-9. 
JINNAI, N., SAKAGAMI, T., SEKIGAWA, T., KAKIHARA, M., NAKAJIMA, T., YOSHIDA, 
K., GOTO, S., HASEGAWA, T., KOSHINO, T., HASEGAWA, Y., INOUE, H., 
SUZUKI, N., SANO, Y. & INOUE, I. 2004. Polymorphisms in the prostaglandin E2 
receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a 
candidate gene approach. Hum Mol Genet, 13, 3203-17. 
JOHANSSON, L., THOMSEN, J. S., DAMDIMOPOULOS, A. E., SPYROU, G., 
GUSTAFSSON, J. A. & TREUTER, E. 1999. The orphan nuclear receptor SHP 
inhibits agonist-dependent transcriptional activity of estrogen receptors ERalpha 
and ERbeta. J Biol Chem, 274, 345-53. 
 238 
 
JONES, R., JACOBSON, M. & STEUDEL, W. 1999. alpha-smooth-muscle actin and 
microvascular precursor smooth-muscle cells in pulmonary hypertension. Am J 
Respir Cell Mol Biol, 20, 582-94. 
JOURDAN, K. B., MASON, N. A., LONG, L., PHILIPS, P. G., WILKINS, M. R. & 
MORRELL, N. W. 2001. Characterization of adenylyl cyclase isoforms in rat 
peripheral pulmonary arteries. American Journal of Physiology - Lung Cellular and 
Molecular Physiology, 280, L1359-L1369. 
JOVANOVIC, H., LUNDBERG, J., KARLSSON, P., CERIN, A., SAIJO, T., VARRONE, A., 
HALLDIN, C. & NORDSTROM, A. L. 2008. Sex differences in the serotonin 1A 
receptor and serotonin transporter binding in the human brain measured by PET. 
Neuroimage, 39, 1408-19. 
JUNHUI, Z., XINGXIANG, W., GUOSHENG, F., YUNPENG, S., FURONG, Z. & JUNZHU, 
C. 2008. Reduced number and activity of circulating endothelial progenitor cells in 
patients with idiopathic pulmonary arterial hypertension. Respir Med, 102, 1073-9. 
KADOWAKI, M., MIZUNO, S., DEMURA, Y., AMESHIMA, S., MIYAMORI, I. & ISHIZAKI, 
T. 2007. Effect of hypoxia and Beraprost sodium on human pulmonary arterial 
smooth muscle cell proliferation: the role of p27(kip1). Respiratory Research, 8, 
77-77. 
KADOWITZ, P. J., JOINER, P. D. & HYMAN, A. L. 1974. Effect of sympathetic nerve 
stimulation on pulmonary vascular resistance in the intact spontaneously breathing 
dog. Proc Soc Exp Biol Med, 147, 68-71. 
KANKI-HORIMOTO, S., HORIMOTO, H., MIENO, S., KISHIDA, K., WATANABE, F., 
FURUYA, E. & KATSUMATA, T. 2006. Implantation of mesenchymal stem cells 
overexpressing endothelial nitric oxide synthase improves right ventricular 
impairments caused by pulmonary hypertension. Circulation, 114, I181-5. 
KARAS, R. H., SCHULTEN, H., PARE, G., ARONOVITZ, M. J., OHLSSON, C., 
GUSTAFSSON, J. A. & MENDELSOHN, M. E. 2001. Effects of estrogen on the 
vascular injury response in estrogen receptor alpha, beta (double) knockout mice. 
Circ Res, 89, 534-9. 
KASAHARA, Y., KIYATAKE, K., TATSUMI, K., SUGITO, K., KAKUSAKA, I., YAMAGATA, 
S., OHMORI, S., KITADA, M. & KURIYAMA, T. 1997. Bioactivation of 
monocrotaline by P-450 3A in rat liver. J Cardiovasc Pharmacol, 30, 124-9. 
KAWABATA, M., IMAMURA, T. & MIYAZONO, K. 1998. Signal transduction by bone 
morphogenetic proteins. Cytokine Growth Factor Rev, 9, 49-61. 
KAWUT, S. M., ARCHER-CHICKO, C. L., DIMICHELE, A., FRITZ, J. S., KLINGER, J. R., 
KY, B., PALEVSKY, H. I., PALMISCIANO, A. J., PATEL, M., PINDER, D., 
PROPERT, K. J., SMITH, K. A., STANCZYK, F., TRACY, R., VAIDYA, A., 
WHITTENHALL, M. E. & VENTETUOLO, C. E. 2016. Anastrozole in Pulmonary 
 239 
 
Arterial Hypertension (AIPH): A Randomized, Double-Blind Placebo-Controlled 
Trial. Am J Respir Crit Care Med. 
KAY, J. M., HARRIS, P. & HEATH, D. 1967. Pulmonary hypertension produced in rats by 
ingestion of Crotalaria spectabilis seeds. Thorax, 22, 176-179. 
KAZMI, N., MÁRQUEZ-GARBÁN, D. C., AIVAZYAN, L., HAMILTON, N., GARON, E. B., 
GOODGLICK, L. & PIETRAS, R. J. 2012. The role of estrogen, progesterone and 
aromatase in human non-small-cell lung cancer. Lung cancer management, 1, 
259-272. 
KHOSLA, S., ATKINSON, E. J., MELTON, L. J., 3RD & RIGGS, B. L. 1997. Effects of age 
and estrogen status on serum parathyroid hormone levels and biochemical 
markers of bone turnover in women: a population-based study. J Clin Endocrinol 
Metab, 82, 1522-7. 
KIELSTEIN, J. T., BODE-BOGER, S. M., HESSE, G., MARTENS-LOBENHOFFER, J., 
TAKACS, A. & FLISER, D. 2005. Asymmetrical dimethylarginine in idiopathic 
pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol, 25. 
KIERMAYER, S., BIONDI, R. M., IMIG, J., PLOTZ, G., HAUPENTHAL, J., ZEUZEM, S. & 
PIIPER, A. 2005. Epac activation converts cAMP from a proliferative into a 
differentiation signal in PC12 cells. Mol Biol Cell, 16, 5639-48. 
KILLILEA, D. W., HESTER, R., BALCZON, R., BABAL, P. & GILLESPIE, M. N. 2000. Free 
radical production in hypoxic pulmonary artery smooth muscle cells. American 
Journal of Physiology - Lung Cellular and Molecular Physiology, 279, L408-L412. 
KILNER, P. J. 2004. Pulmonary resistance in cardiovascular context. Int J Cardiol, 97 
Suppl 1, 3-6. 
KIM, E. K., LEE, J. H., OH, Y. M., LEE, Y. S. & LEE, S. D. 2010. Rosiglitazone attenuates 
hypoxia-induced pulmonary arterial hypertension in rats. Respirology, 15, 659-68. 
KIM, M., PARK, A. J., HAVEKES, R., CHAY, A., GUERCIO, L. A., OLIVEIRA, R. F., ABEL, 
T. & BLACKWELL, K. T. 2011. Colocalization of Protein Kinase A with Adenylyl 
Cyclase Enhances Protein Kinase A Activity during Induction of Long-Lasting 
Long-Term-Potentiation. PLOS Computational Biology, 7, e1002084. 
KLEIN, P., SUN, T., SAXE, C., KIMMEL, A., JOHNSON, R. & DEVREOTES, P. 1988. A 
chemoattractant receptor controls development in Dictyostelium discoideum. 
Science, 241, 1467-1472. 
KLINGER, J. R., ABMAN, S. H. & GLADWIN, M. T. 2013. Nitric oxide deficiency and 
endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care 
Med, 188, 639-46. 
KORCHYNSKYI, O. & TEN DIJKE, P. 2002. Identification and Functional Characterization 
of Distinct Critically Important Bone Morphogenetic Protein-specific Response 
Elements in the Id1 Promoter. Journal of Biological Chemistry, 277, 4883-4891. 
 240 
 
KOZŁOWSKA, H., BARANOWSKA-KUCZKO, M., SCHLICKER, E., KOZŁOWSKI, M., 
KLOZA, M. & MALINOWSKA, B. 2013. Relaxation of human pulmonary arteries by 
PPARγ agonists. Naunyn-Schmiedeberg's Archives of Pharmacology, 386, 445-
453. 
KRENZ, G. S., LIN, J., DAWSON, C. A. & LINEHAN, J. H. 1994. Impact of parallel 
heterogeneity on a continuum model of the pulmonary arterial tree. J Appl Physiol 
(1985), 77, 660-70. 
KUMAR, P., THUDIUM, E., LALIBERTE, K., ZACCARDELLI, D. & NELSEN, A. 2016. A 
Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of 
Administration. Clinical Pharmacokinetics, 55, 1495-1505. 
KUWANO, K., HASHINO, A., ASAKI, T., HAMAMOTO, T., YAMADA, T., OKUBO, K. & 
KUWABARA, K. 2007. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-
(methylsulfonyl)acetam ide (NS-304), an orally available and long-acting 
prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther, 322, 1181-8. 
KUWANO, K., HASHINO, A., NODA, K., KOSUGI, K. & KUWABARA, K. 2008. A long-
acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-
diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetam ide (NS-
304), ameliorates rat pulmonary hypertension with unique relaxant responses of its 
active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid 
(MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther, 326, 691-9. 
LABRIE, F., BELANGER, A., LUU-THE, V., LABRIE, C., SIMARD, J., CUSAN, L., 
GOMEZ, J. L. & CANDAS, B. 1998. DHEA and the intracrine formation of 
androgens and estrogens in peripheral target tissues: its role during aging. 
Steroids, 63, 322-8. 
LAGERSTROM, M. C. & SCHIOTH, H. B. 2008. Structural diversity of G protein-coupled 
receptors and significance for drug discovery. Nat Rev Drug Discov, 7, 339-57. 
LAGRANHA, C. J., DESCHAMPS, A., APONTE, A., STEENBERGEN, C. & MURPHY, E. 
2010. Sex differences in the phosphorylation of mitochondrial proteins result in 
reduced production of reactive oxygen species and cardioprotection in females. 
Circ Res, 106, 1681-91. 
LAHM, T., ALBRECHT, M., FISHER, A. J., SELEJ, M., PATEL, N. G., BROWN, J. A., 
JUSTICE, M. J., BROWN, M. B., VAN DEMARK, M., TRULOCK, K. M., 
DIEUDONNE, D., REDDY, J. G., PRESSON, R. G. & PETRACHE, I. 2012. 17beta-
Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-
mediated effects. Am J Respir Crit Care Med, 185, 965-80. 
LAHM, T., CRISOSTOMO, P. R., MARKEL, T. A., WANG, M., WANG, Y., TAN, J. & 
MELDRUM, D. R. 2008. Selective estrogen receptor-alpha and estrogen receptor-
beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide-
dependent mechanism. Am J Physiol Regul Integr Comp Physiol, 295, R1486-93. 
 241 
 
LAI, J., JIN, H., YANG, R., WINER, J., LI, W., YEN, R., KING, K. L., ZEIGLER, F., KO, A., 
CHENG, J., BUNTING, S. & PAONI, N. F. 1996. Prostaglandin F2 alpha induces 
cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol, 271, 
H2197-208. 
LAI, N. C., ROTH, D. M., GAO, M. H., FINE, S., HEAD, B. P., ZHU, J., MCKIRNAN, M. D., 
KWONG, C., DALTON, N., URASAWA, K., ROTH, D. A. & HAMMOND, H. K. 2000. 
Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left 
ventricular function and cAMP-generating capacity. Circulation, 102, 2396-401. 
LAI, Y. J., PULLAMSETTI, S. S., DONY, E., WEISSMANN, N., BUTROUS, G., BANAT, 
G. A., GHOFRANI, H. A., SEEGER, W., GRIMMINGER, F. & SCHERMULY, R. T. 
2008. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in 
pulmonary hypertension. Am J Respir Crit Care Med, 178, 188-96. 
LANG, I., GOMEZ-SANCHEZ, M., KNEUSSL, M., NAEIJE, R., ESCRIBANO, P., SKORO-
SAJER, N. & VACHIERY, J. L. 2006. Efficacy of long-term subcutaneous 
treprostinil sodium therapy in pulmonary hypertension. Chest, 129, 1636-43. 
LAWRIE, A., HAMEED, A. G., CHAMBERLAIN, J., ARNOLD, N., KENNERLEY, A., 
HOPKINSON, K., PICKWORTH, J., KIELY, D. G., CROSSMAN, D. C. & FRANCIS, 
S. E. 2011. Paigen diet-fed apolipoprotein E knockout mice develop severe 
pulmonary hypertension in an interleukin-1-dependent manner. Am J Pathol, 179, 
1693-705. 
LAWRIE, A., SPIEKERKOETTER, E., MARTINEZ, E. C., AMBARTSUMIAN, N., 
SHEWARD, W. J., MACLEAN, M. R., HARMAR, A. J., SCHMIDT, A. M., 
LUKANIDIN, E. & RABINOVITCH, M. 2005. Interdependent serotonin transporter 
and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary 
vascular disease. Circ Res, 97, 227-35. 
LEDUC, M., BRETON, B., GALES, C., LE GOUILL, C., BOUVIER, M., CHEMTOB, S. & 
HEVEKER, N. 2009. Functional selectivity of natural and synthetic prostaglandin 
EP4 receptor ligands. J Pharmacol Exp Ther, 331, 297-307. 
LEE, C., MITSIALIS, S. A., ASLAM, M., VITALI, S. H., VERGADI, E., KONSTANTINOU, 
G., SDRIMAS, K., FERNANDEZ-GONZALEZ, A. & KOUREMBANAS, S. 2012. 
Exosomes mediate the cytoprotective action of mesenchymal stromal cells on 
hypoxia-induced pulmonary hypertension. Circulation, 126, 2601-11. 
LESCH, K. P., WOLOZIN, B. L., MURPHY, D. L. & REIDERER, P. 1993. Primary structure 
of the human platelet serotonin uptake site: identity with the brain serotonin 
transporter. J Neurochem, 60, 2319-22. 
LEWIS, R. A., SOTER, N. A., DIAMOND, P. T., AUSTEN, K. F., OATES, J. A. & 
ROBERTS, L. J., 2ND 1982. Prostaglandin D2 generation after activation of rat 
and human mast cells with anti-IgE. J Immunol, 129, 1627-31. 
 242 
 
LI, Y., CONNOLLY, M., NAGARAJ, C., TANG, B., BALINT, Z., POPPER, H., SMOLLE-
JUETTNER, F. M., LINDENMANN, J., KWAPISZEWSKA, G., AARONSON, P. I., 
WOHLKOENIG, C., LEITHNER, K., OLSCHEWSKI, H. & OLSCHEWSKI, A. 2012. 
Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in 
prostacyclin-induced pulmonary vasodilation. Am J Respir Cell Mol Biol, 46, 372-
9. 
LIANG, L., ZHANG, Q., LUO, L. L., YUE, J., ZHAO, Y. L., HAN, M., LIU, L. R. & XIAO, H. 
P. 2016. Polymorphisms in the prostaglandin receptor EP2 gene confers 
susceptibility to tuberculosis. Infect Genet Evol, 46, 23-27. 
LIAO, B., ZHENG, Y. M., YADAV, V. R., KORDE, A. S. & WANG, Y. X. 2011. Hypoxia 
induces intracellular Ca2+ release by causing reactive oxygen species-mediated 
dissociation of FK506-binding protein 12.6 from ryanodine receptor 2 in pulmonary 
artery myocytes. Antioxid Redox Signal, 14, 37-47. 
LIGGETT, S. B., MIALET-PEREZ, J., THANEEMIT-CHEN, S., WEBER, S. A., GREENE, 
S. M., HODNE, D., NELSON, B., MORRISON, J., DOMANSKI, M. J., WAGONER, 
L. E., ABRAHAM, W. T., ANDERSON, J. L., CARLQUIST, J. F., KRAUSE-
STEINRAUF, H. J., LAZZERONI, L. C., PORT, J. D., LAVORI, P. W. & BRISTOW, 
M. R. 2006. A polymorphism within a conserved beta(1)-adrenergic receptor motif 
alters cardiac function and beta-blocker response in human heart failure. Proc Natl 
Acad Sci U S A, 103, 11288-93. 
LING, Y., JOHNSON, M. K., KIELY, D. G., CONDLIFFE, R., ELLIOT, C. A., GIBBS, J. S., 
HOWARD, L. S., PEPKE-ZABA, J., SHEARES, K. K., CORRIS, P. A., FISHER, A. 
J., LORDAN, J. L., GAINE, S., COGHLAN, J. G., WORT, S. J., GATZOULIS, M. A. 
& PEACOCK, A. J. 2012. Changing demographics, epidemiology, and survival of 
incident pulmonary arterial hypertension: results from the pulmonary hypertension 
registry of the United Kingdom and Ireland. Am J Respir Crit Care Med, 186, 790-
6. 
LIU, H., YANG, E., LU, X., ZUO, C., HE, Y., JIA, D., ZHU, Q., YU, Y. & LV, A. 2015. Serum 
levels of tumor necrosis factor-related apoptosis-inducing ligand correlate with the 
severity of pulmonary hypertension. Pulmonary Pharmacology & Therapeutics, 33, 
39-46. 
LIU, Q., SHAM, J. S. K., SHIMODA, L. A. & SYLVESTER, J. T. 2001. Hypoxic constriction 
of porcine distal pulmonary arteries: endothelium and endothelin dependence. 
American Journal of Physiology - Lung Cellular and Molecular Physiology, 280, 
L856-L865. 
LIU, X., THANGAVEL, M., SUN, S. Q., KAMINSKY, J., MAHAUTMR, P., STITHAM, J., 
HWA, J. & OSTROM, R. S. 2008. Adenylyl cyclase type 6 overexpression 
selectively enhances β-adrenergic and prostacyclin receptor-mediated inhibition of 
 243 
 
cardiac fibroblast function because of colocalization in lipid rafts. Naunyn-
Schmiedeberg's archives of pharmacology, 377, 359-369. 
LONG, L., CROSBY, A., YANG, X., SOUTHWOOD, M., UPTON, P. D., KIM, D. K. & 
MORRELL, N. W. 2009. Altered bone morphogenetic protein and transforming 
growth factor-beta signaling in rat models of pulmonary hypertension: potential for 
activin receptor-like kinase-5 inhibition in prevention and progression of disease. 
Circulation, 119, 566-76. 
LONG, L., MACLEAN, M. R., JEFFERY, T. K., MORECROFT, I., YANG, X., 
RUDARAKANCHANA, N., SOUTHWOOD, M., JAMES, V., TREMBATH, R. C. & 
MORRELL, N. W. 2006. Serotonin increases susceptibility to pulmonary 
hypertension in BMPR2-deficient mice. Circ Res, 98, 818-27. 
LONG, L., ORMISTON, M. L., YANG, X., SOUTHWOOD, M., GRAF, S., MACHADO, R. 
D., MUELLER, M., KINZEL, B., YUNG, L. M., WILKINSON, J. M., MOORE, S. D., 
DRAKE, K. M., ALDRED, M. A., YU, P. B., UPTON, P. D. & MORRELL, N. W. 
2015. Selective enhancement of endothelial BMPR-II with BMP9 reverses 
pulmonary arterial hypertension. Nat Med, 21, 777-85. 
LOWERY, J. W., FRUMP, A. L., ANDERSON, L., DICARLO, G. E., JONES, M. T. & DE 
CAESTECKER, M. P. 2010. ID family protein expression and regulation in hypoxic 
pulmonary hypertension. American Journal of Physiology - Regulatory, Integrative 
and Comparative Physiology, 299, R1463-R1477. 
LOYD, J. E., BUTLER, M. G., FOROUD, T. M., CONNEALLY, P. M., PHILLIPS, J. A., 3RD 
& NEWMAN, J. H. 1995. Genetic anticipation and abnormal gender ratio at birth in 
familial primary pulmonary hypertension. Am J Respir Crit Care Med, 152, 93-7. 
LU, A., ZUO, C., HE, Y., CHEN, G., PIAO, L., ZHANG, J., XIAO, B., SHEN, Y., TANG, J., 
KONG, D., ALBERTI, S., CHEN, D., ZUO, S., ZHANG, Q., YAN, S., FEI, X., YUAN, 
F., ZHOU, B., DUAN, S., YU, Y., LAZARUS, M., SU, Y., BREYER, R. M., FUNK, 
C. D. & YU, Y. 2015. EP3 receptor deficiency attenuates pulmonary hypertension 
through suppression of Rho/TGF-beta1 signaling. J Clin Invest, 125, 1228-42. 
LUO, L. J., LIU, F., LIN, Z. K., XIE, Y. F., XU, J. L., TONG, Q. C. & SHU, R. 2012. Genistein 
regulates the IL-1 beta induced activation of MAPKs in human periodontal ligament 
cells through G protein-coupled receptor 30. Arch Biochem Biophys, 522, 9-16. 
MA, L., ROMAN-CAMPOS, D., AUSTIN, E. D., EYRIES, M., SAMPSON, K. S., 
SOUBRIER, F., GERMAIN, M., TREGOUET, D. A., BORCZUK, A., 
ROSENZWEIG, E. B., GIRERD, B., MONTANI, D., HUMBERT, M., LOYD, J. E., 
KASS, R. S. & CHUNG, W. K. 2013. A novel channelopathy in pulmonary arterial 
hypertension. N Engl J Med, 369, 351-61. 
MACHADO, R. D., ALDRED, M. A., JAMES, V., HARRISON, R. E., PATEL, B., 
SCHWALBE, E. C., GRUENIG, E., JANSSEN, B., KOEHLER, R., SEEGER, W., 
EICKELBERG, O., OLSCHEWSKI, H., ELLIOTT, C. G., GLISSMEYER, E., 
 244 
 
CARLQUIST, J., KIM, M., TORBICKI, A., FIJALKOWSKA, A., SZEWCZYK, G., 
PARMA, J., ABRAMOWICZ, M. J., GALIE, N., MORISAKI, H., KYOTANI, S., 
NAKANISHI, N., MORISAKI, T., HUMBERT, M., SIMONNEAU, G., SITBON, O., 
SOUBRIER, F., COULET, F., MORRELL, N. W. & TREMBATH, R. C. 2006. 
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial 
hypertension. Hum Mutat, 27, 121-32. 
MACHADO, R. D., EICKELBERG, O., ELLIOTT, C. G., GERACI, M. W., HANAOKA, M., 
LOYD, J. E., NEWMAN, J. H., PHILLIPS, J. A., 3RD, SOUBRIER, F., TREMBATH, 
R. C. & CHUNG, W. K. 2009a. Genetics and genomics of pulmonary arterial 
hypertension. J Am Coll Cardiol, 54, S32-42. 
MACHADO, R. D., EICKELBERG, O., ELLIOTT, G., GERACI, M. W., HANAOKA, M., 
LOYD, J. E., NEWMAN, J. H., PHILLIPS, J. A., SOUBRIER, F., TREMBATH, R. 
C. & CHUNG, W. K. 2009b. Genetics and Genomics of Pulmonary Arterial 
Hypertension. Journal of the American College of Cardiology, 54, S32-S42. 
MACHADO, R. D., PAUCIULO, M. W., THOMSON, J. R., LANE, K. B., MORGAN, N. V., 
WHEELER, L., PHILLIPS, J. A., 3RD, NEWMAN, J., WILLIAMS, D., GALIE, N., 
MANES, A., MCNEIL, K., YACOUB, M., MIKHAIL, G., ROGERS, P., CORRIS, P., 
HUMBERT, M., DONNAI, D., MARTENSSON, G., TRANEBJAERG, L., LOYD, J. 
E., TREMBATH, R. C. & NICHOLS, W. C. 2001. BMPR2 haploinsufficiency as the 
inherited molecular mechanism for primary pulmonary hypertension. Am J Hum 
Genet, 68, 92-102. 
MACLEAN, M. R., DEUCHAR, G. A., HICKS, M. N., MORECROFT, I., SHEN, S., 
SHEWARD, J., COLSTON, J., LOUGHLIN, L., NILSEN, M., DEMPSIE, Y. & 
HARMAR, A. 2004. Overexpression of the 5-hydroxytryptamine transporter gene: 
effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. 
Circulation, 109, 2150-5. 
MACLEAN, M. R., HERVE, P., EDDAHIBI, S. & ADNOT, S. 2000. 5-hydroxytryptamine 
and the pulmonary circulation: receptors, transporters and relevance to pulmonary 
arterial hypertension. Br J Pharmacol, 131, 161-8. 
MACLEAN, M. R., MCCULLOCH, K. M. & BAIRD, M. 1994. Endothelin ETA- and ETB-
receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J 
Cardiovasc Pharmacol, 23, 838-45. 
MACLEAN, M. R., SWEENEY, G., BAIRD, M., MCCULLOCH, K. M., HOUSLAY, M. & 
MORECROFT, I. 1996. 5-Hydroxytryptamine receptors mediating vasoconstriction 
in pulmonary arteries from control and pulmonary hypertensive rats. Br J 
Pharmacol, 119, 917-30. 
MACRITCHIE, A. N., JUN, S. S., CHEN, Z., GERMAN, Z., YUHANNA, I. S., SHERMAN, 
T. S. & SHAUL, P. W. 1997. Estrogen upregulates endothelial nitric oxide synthase 
gene expression in fetal pulmonary artery endothelium. Circ Res, 81, 355-62. 
 245 
 
MAH, V., SELIGSON, D. B., LI, A., MÁRQUEZ, D. C., WISTUBA, I. I., ELSHIMALI, Y., 
FISHBEIN, M. C., CHIA, D., PIETRAS, R. J. & GOODGLICK, L. 2007. Aromatase 
Expression Predicts Survival in Women with Early-Stage Non–Small Cell Lung 
Cancer. Cancer research, 67, 10484-10490. 
MAHER, S. A., BIRRELL, M. A., ADCOCK, J. J., WORTLEY, M. A., DUBUIS, E. D., 
BONVINI, S. J., GRACE, M. S. & BELVISI, M. G. 2015. Prostaglandin D2 and the 
role of the DP1, DP2 and TP receptors in the control of airway reflex events. Eur 
Respir J, 45, 1108-18. 
MAIER, T., GUELL, M. & SERRANO, L. 2009. Correlation of mRNA and protein in complex 
biological samples. FEBS Lett, 583, 3966-73. 
MAIR, K. M., WRIGHT, A. F., DUGGAN, N., ROWLANDS, D. J., HUSSEY, M. J., 
ROBERTS, S., FULLERTON, J., NILSEN, M., LOUGHLIN, L., THOMAS, M. & 
MACLEAN, M. R. 2014. Sex-dependent influence of endogenous estrogen in 
pulmonary hypertension. Am J Respir Crit Care Med, 190, 456-67. 
MAIR, K. M., YANG, X. D., LONG, L., WHITE, K., WALLACE, E., EWART, M. A., 
DOCHERTY, C. K., MORRELL, N. W. & MACLEAN, M. R. 2015. Sex affects bone 
morphogenetic protein type II receptor signaling in pulmonary artery smooth 
muscle cells. Am J Respir Crit Care Med, 191, 693-703. 
MALBON, C. C. 2004. Frizzleds: new members of the superfamily of G-protein-coupled 
receptors. Front Biosci, 9, 1048-58. 
MALININ, V., LI, Z., CHAPMAN, R., LEIFER, F., OMIATEK, D., ONG, J., SALVAIL, D., 
LAURENT, C. & PERKINS, W. 2014. Treprostinil pharmacokinetics in rats are 
extended using inhaled prodrug formulations. European Respiratory Journal, 44. 
MÁRQUEZ-GARBÁN, D. C., CHEN, H.-W., GOODGLICK, L., FISHBEIN, M. C. & 
PIETRAS, R. J. 2009. Targeting Aromatase and Estrogen Signaling in Human Non-
Small Cell Lung Cancer. Annals of the New York Academy of Sciences, 1155, 194-
205. 
MARRONE, G., MAMONE, G., LUCA, A., VITULO, P., BERTANI, A., PILATO, M. & 
GRIDELLI, B. 2010. The role of 1.5T cardiac MRI in the diagnosis, prognosis and 
management of pulmonary arterial hypertension. Int J Cardiovasc Imaging, 26, 
665-81. 
MARSH, L. & HERSKOWITZ, I. 1988. STE2 protein of Saccharomyces kluyveri is a 
member of the rhodopsin/beta-adrenergic receptor family and is responsible for 
recognition of the peptide ligand alpha factor. Proceedings of the National 
Academy of Sciences, 85, 3855-3859. 
MARSHALL, B. E., MARSHALL, C., BENUMOF, J. & SAIDMAN, L. J. 1981. Hypoxic 
pulmonary vasoconstriction in dogs: effects of lung segment size and oxygen 
tension. Journal of Applied Physiology, 51, 1543-1551. 
 246 
 
MARSHALL, C., MAMARY, A. J., VERHOEVEN, A. J. & MARSHALL, B. E. 1996. 
Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary 
vasoconstriction. Am J Respir Cell Mol Biol, 15, 633-44. 
MARSHALL, C. & MARSHALL, B. E. 1992. Hypoxic pulmonary vasoconstriction is not 
endothelium dependent. Proc Soc Exp Biol Med, 201, 267-70. 
MARTLING, C. R., MATRAN, R., ALVING, K., HOKFELT, T. & LUNDBERG, J. M. 1990. 
Innervation of lower airways and neuropeptide effects on bronchial and vascular 
tone in the pig. Cell Tissue Res, 260, 223-33. 
MARUYAMA, K., YE, C. L., WOO, M., VENKATACHARYA, H., LINES, L. D., SILVER, M. 
M. & RABINOVITCH, M. 1991. Chronic hypoxic pulmonary hypertension in rats 
and increased elastolytic activity. Am J Physiol, 261, H1716-26. 
MASON, D. A., MOORE, J. D., GREEN, S. A. & LIGGETT, S. B. 1999. A gain-of-function 
polymorphism in a G-protein coupling domain of the human beta1-adrenergic 
receptor. J Biol Chem, 274, 12670-4. 
MASSAGUE, J. & CHEN, Y. G. 2000. Controlling TGF-beta signaling. Genes Dev, 14, 
627-44. 
MASSAGUE, J., SEOANE, J. & WOTTON, D. 2005. Smad transcription factors. Genes 
Dev, 19, 2783-810. 
MASUDA, N., SAGARA, Y., KINOSHITA, T., IWATA, H., NAKAMURA, S., YANAGITA, Y., 
NISHIMURA, R., IWASE, H., KAMIGAKI, S., TAKEI, H. & NOGUCHI, S. 2012. 
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for 
premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. 
Lancet Oncol, 13, 345-52. 
MATHAI, S. C., HASSOUN, P. M., PUHAN, M. A., ZHOU, Y. & WISE, R. A. 2015. Sex 
differences in response to tadalafil in pulmonary arterial hypertension. Chest, 147, 
188-97. 
MATHAI, S. C., HUMMERS, L. K., CHAMPION, H. C., WIGLEY, F. M., ZAIMAN, A., 
HASSOUN, P. M. & GIRGIS, R. E. 2009. Survival in pulmonary hypertension 
associated with the scleroderma spectrum of diseases: impact of interstitial lung 
disease. Arthritis Rheum, 60, 569-77. 
MATORI, H., UMAR, S., NADADUR, R. D., SHARMA, S., PARTOW-NAVID, R., 
AFKHAMI, M., AMJEDI, M. & EGHBALI, M. 2012. Genistein, a soy phytoestrogen, 
reverses severe pulmonary hypertension and prevents right heart failure in rats. 
Hypertension, 60, 425-30. 
MCGOON, M. D., BENZA, R. L., ESCRIBANO-SUBIAS, P., JIANG, X., MILLER, D. P., 
PEACOCK, A. J., PEPKE-ZABA, J., PULIDO, T., RICH, S., ROSENKRANZ, S., 
SUISSA, S. & HUMBERT, M. 2013. Pulmonary arterial hypertension: epidemiology 
and registries. J Am Coll Cardiol, 62, D51-9. 
 247 
 
MCGOON, M. D., FROST, A. E., OUDIZ, R. J., BADESCH, D. B., GALIE, N., 
OLSCHEWSKI, H., MCLAUGHLIN, V. V., GERBER, M. J., DUFTON, C., 
DESPAIN, D. J. & RUBIN, L. J. 2009. Ambrisentan therapy in patients with 
pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to 
liver function test abnormalities. Chest, 135, 122-9. 
MCINTOSH, V. J., CHANDRASEKERA, P. C. & LASLEY, R. D. 2011. Sex differences and 
the effects of ovariectomy on the β-adrenergic contractile response. American 
Journal of Physiology - Heart and Circulatory Physiology, 301, H1127-H1134. 
MCLAUGHLIN, V. V., ARCHER, S. L., BADESCH, D. B., BARST, R. J., FARBER, H. W., 
LINDNER, J. R., MATHIER, M. A., MCGOON, M. D., PARK, M. H., ROSENSON, 
R. S., RUBIN, L. J., TAPSON, V. F., VARGA, J., AMERICAN COLLEGE OF 
CARDIOLOGY FOUNDATION TASK FORCE ON EXPERT CONSENSUS, D., 
AMERICAN HEART, A., AMERICAN COLLEGE OF CHEST, P., AMERICAN 
THORACIC SOCIETY, I. & PULMONARY HYPERTENSION, A. 2009. ACCF/AHA 
2009 expert consensus document on pulmonary hypertension a report of the 
American College of Cardiology Foundation Task Force on Expert Consensus 
Documents and the American Heart Association developed in collaboration with 
the American College of Chest Physicians; American Thoracic Society, Inc.; and 
the Pulmonary Hypertension Association. J Am Coll Cardiol, 53, 1573-619. 
MCLAUGHLIN, V. V., BENZA, R. L., RUBIN, L. J., CHANNICK, R. N., VOSWINCKEL, R., 
TAPSON, V. F., ROBBINS, I. M., OLSCHEWSKI, H., RUBENFIRE, M. & SEEGER, 
W. 2010. Addition of inhaled treprostinil to oral therapy for pulmonary arterial 
hypertension: a randomized controlled clinical trial. J Am Coll Cardiol, 55, 1915-22. 
MCLAUGHLIN, V. V., GENTHNER, D. E., PANELLA, M. M. & RICH, S. 1998. Reduction 
in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) 
therapy in primary pulmonary hypertension. N Engl J Med, 338, 273-7. 
MCMAHON, T. J., HOOD, J. S. & KADOWITZ, P. J. 1992. Pulmonary vasodilator response 
to vagal stimulation is blocked by N omega-nitro-L-arginine methyl ester in the cat. 
Circ Res, 70, 364-9. 
MCMURTRY, M. S., BONNET, S., WU, X., DYCK, J. R., HAROMY, A., HASHIMOTO, K. 
& MICHELAKIS, E. D. 2004. Dichloroacetate prevents and reverses pulmonary 
hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ 
Res, 95, 830-40. 
MCSWAIN, C. S., BENZA, R., SHAPIRO, S., HILL, N., SCHILZ, R., ELLIOTT, C. G., 
ZWICKE, D. L., OUDIZ, R. J., STASZEWSKI, J. P., ARNESON, C. P., WADE, M., 
ZACCARDELLI, D. & MCLAUGHLIN, V. 2008. Dose proportionality of treprostinil 
sodium administered by continuous subcutaneous and intravenous infusion. J Clin 
Pharmacol, 48, 19-25. 
 248 
 
MCTERNAN, P. G., ANDERSON, L. A., ANWAR, A. J., EGGO, M. C., CROCKER, J., 
BARNETT, A. H., STEWART, P. M. & KUMAR, S. 2002. Glucocorticoid regulation 
of p450 aromatase activity in human adipose tissue: gender and site differences. J 
Clin Endocrinol Metab, 87, 1327-36. 
MEI, F. C., QIAO, J., TSYGANKOVA, O. M., MEINKOTH, J. L., QUILLIAM, L. A. & 
CHENG, X. 2002. Differential Signaling of Cyclic AMP: OPPOSING EFFECTS OF 
EXCHANGE PROTEIN DIRECTLY ACTIVATED BY CYCLIC AMP AND cAMP-
DEPENDENT PROTEIN KINASE ON PROTEIN KINASE B ACTIVATION. Journal 
of Biological Chemistry, 277, 11497-11504. 
MENDELSOHN, M. E. 2002. Genomic and nongenomic effects of estrogen in the 
vasculature. Am J Cardiol, 90, 3F-6F. 
MEYER, M. R., HAAS, E. & BARTON, M. 2006. Gender differences of cardiovascular 
disease: new perspectives for estrogen receptor signaling. Hypertension, 47, 1019-
26. 
MEYRICK, B. & REID, L. 1978. The effect of continued hypoxia on rat pulmonary arterial 
circulation. An ultrastructural study. Lab Invest, 38, 188-200. 
MEYRICK, B. & REID, L. 1980. Hypoxia-induced structural changes in the media and 
adventitia of the rat hilar pulmonary artery and their regression. Am J Pathol, 100, 
151-78. 
MEYRICK, B. & REID, L. 1983. Pulmonary hypertension. Anatomic and physiologic 
correlates. Clin Chest Med, 4, 199-217. 
MEYRICK, B. O. & PERKETT, E. A. 1989. The sequence of cellular and hemodynamic 
changes of chronic pulmonary hypertension induced by hypoxia and other stimuli. 
Am Rev Respir Dis, 140, 1486-9. 
MICHELAKIS, E. D. 2003. The role of the NO axis and its therapeutic implications in 
pulmonary arterial hypertension. Heart Fail Rev, 8, 5-21. 
MICHELAKIS, E. D., MCMURTRY, M. S., WU, X. C., DYCK, J. R., MOUDGIL, R., 
HOPKINS, T. A., LOPASCHUK, G. D., PUTTAGUNTA, L., WAITE, R. & ARCHER, 
S. L. 2002. Dichloroacetate, a metabolic modulator, prevents and reverses chronic 
hypoxic pulmonary hypertension in rats: role of increased expression and activity 
of voltage-gated potassium channels. Circulation, 105, 244-50. 
MILLER, P. J. 1971. An elastin stain. Med Lab Technol, 28, 148-9. 
MILLIGAN, G., MULLANEY, I., KIM, G. D. & MACEWAN, D. 1998. Regulation of the 
stoichiometry of protein components of the stimulatory adenylyl cyclase cascade. 
Adv Pharmacol, 42, 462-5. 
MIN, T. Q., ZHU, C. J., XIANG, W. X., HUI, Z. J. & PENG, S. Y. 2004. Improvement in 
endothelial progenitor cells from peripheral blood by ramipril therapy in patients 
with stable coronary artery disease. Cardiovasc Drugs Ther, 18, 203-9. 
 249 
 
MITTENDORF, J., WEIGAND, S., ALONSO-ALIJA, C., BISCHOFF, E., FEURER, A., 
GERISCH, M., KERN, A., KNORR, A., LANG, D., MUENTER, K., RADTKE, M., 
SCHIROK, H., SCHLEMMER, K. H., STAHL, E., STRAUB, A., WUNDER, F. & 
STASCH, J. P. 2009. Discovery of riociguat (BAY 63-2521): a potent, oral 
stimulator of soluble guanylate cyclase for the treatment of pulmonary 
hypertension. ChemMedChem, 4, 853-65. 
MIYATA, M., UENO, Y., SEKINE, H., ITO, O., SAKUMA, F., KOIKE, H., NISHIO, S., 
NISHIMAKI, T. & KASUKAWA, R. 1996. Protective effect of beraprost sodium, a 
stable prostacyclin analogue, in development of monocrotaline-induced pulmonary 
hypertension. J Cardiovasc Pharmacol, 27, 20-6. 
MIYAZONO, K., KAMIYA, Y. & MORIKAWA, M. 2010. Bone morphogenetic protein 
receptors and signal transduction. J Biochem, 147, 35-51. 
MOLINA FERNÁNDEZ-POSSE, M., DAMAS FUENTES, R., VARELA GONZÁLEZ, M., 
MOLERO GÓMEZ, R., OLIVA HERNÁNDEZ, L. & SANGIL MONROY, N. 2014. 
PS-064 Hepatotoxicity associated with bosentan. European Journal of Hospital 
Pharmacy: Science and Practice, 21, A169-A170. 
MONCADA, S., GRYGLEWSKI, R., BUNTING, S. & VANE, J. R. 1976. An enzyme 
isolated from arteries transforms prostaglandin endoperoxides to an unstable 
substance that inhibits platelet aggregation. Nature, 263, 663-5. 
MONCADA, S., HERMAN, A. G., HIGGS, E. A. & VANE, J. R. 1977. Differential formation 
of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the 
anti-thrombotic properties of vascular endothelium. Thrombosis Research, 11, 
323-344. 
MONCADA, S. & VANE, J. R. 1978. Pharmacology and endogenous roles of prostaglandin 
endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev, 30, 293-331. 
MONTALESCOT, G., LOWENSTEIN, E., OGLETREE, M. L., GREENE, E. M., 
ROBINSON, D. R., HARTL, K. & ZAPOL, W. M. 1990. Thromboxane receptor 
blockade prevents pulmonary hypertension induced by heparin-protamine 
reactions in awake sheep. Circulation, 82, 1765-77. 
MONTANI, D., SAVALE, L., NATALI, D., JAIS, X., HERVE, P., GARCIA, G., HUMBERT, 
M., SIMONNEAU, G. & SITBON, O. 2010. Long-term response to calcium-channel 
blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J, 31, 1898-
907. 
MONTMINY, M. R., SEVARINO, K. A., WAGNER, J. A., MANDEL, G. & GOODMAN, R. 
H. 1986. Identification of a cyclic-AMP-responsive element within the rat 
somatostatin gene. Proc Natl Acad Sci U S A, 83, 6682-6. 
MORANI, A., BARROS, R. P., IMAMOV, O., HULTENBY, K., ARNER, A., WARNER, M. 
& GUSTAFSSON, J. A. 2006. Lung dysfunction causes systemic hypoxia in 
 250 
 
estrogen receptor beta knockout (ERbeta-/-) mice. Proc Natl Acad Sci U S A, 103, 
7165-9. 
MORECROFT, I., HEELEY, R. P., PRENTICE, H. M., KIRK, A. & MACLEAN, M. R. 1999. 
5-hydroxytryptamine receptors mediating contraction in human small muscular 
pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol, 128, 730-
4. 
MORECROFT, I., WHITE, K., CARUSO, P., NILSEN, M., LOUGHLIN, L., ALBA, R., 
REYNOLDS, P. N., DANILOV, S. M., BAKER, A. H. & MACLEAN, M. R. 2012. 
Gene therapy by targeted adenovirus-mediated knockdown of pulmonary 
endothelial Tph1 attenuates hypoxia-induced pulmonary hypertension. Mol Ther, 
20, 1516-28. 
MORENO-VINASCO, L., GOMBERG-MAITLAND, M., MAITLAND, M. L., DESAI, A. A., 
SINGLETON, P. A., SAMMANI, S., SAM, L., LIU, Y., HUSAIN, A. N., LANG, R. M., 
RATAIN, M. J., LUSSIER, Y. A. & GARCIA, J. G. N. 2008. Genomic assessment 
of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. 
Physiological Genomics, 33, 278-291. 
MORRELL, N. W. 2010. Role of bone morphogenetic protein receptors in the development 
of pulmonary arterial hypertension. Adv Exp Med Biol, 661, 251-64. 
MORRISON, K., STUDER, R., ERNST, R., HAAG, F., KAUSER, K. & CLOZEL, M. 2012. 
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat 
pulmonary artery. J Pharmacol Exp Ther, 343, 547-55. 
MORSE, J. H., HORN, E. M. & BARST, R. J. 1999. Hormone replacement therapy: a 
possible risk factor in carriers of familial primary pulmonary hypertension. Chest, 
116, 847. 
MOSSELMAN, S., POLMAN, J. & DIJKEMA, R. 1996. ER beta: identification and 
characterization of a novel human estrogen receptor. FEBS Lett, 392, 49-53. 
MOTLEY, H. L., COURNAND, A. & ET AL. 1947. The influence of short periods of induced 
acute anoxia upon pulmonary artery pressures in man. Am J Physiol, 150, 315-20. 
MOUCHAERS, K. T., SCHALIJ, I., DE BOER, M. A., POSTMUS, P. E., VAN HINSBERGH, 
V. W., VAN NIEUW AMERONGEN, G. P., VONK NOORDEGRAAF, A. & VAN 
DER LAARSE, W. J. 2010. Fasudil reduces monocrotaline-induced pulmonary 
arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J, 36, 
800-7. 
MOVAFAGH, S., HOBSON, J. P., SPIEGEL, S., KLEINMAN, H. K. & ZUKOWSKA, Z. 
2006. Neuropeptide Y induces migration, proliferation, and tube formation of 
endothelial cells bimodally via Y1, Y2, and Y5 receptors. Faseb j, 20, 1924-6. 
MUBARAK, K. K. 2010. A review of prostaglandin analogs in the management of patients 
with pulmonary arterial hypertension. Respir Med, 104, 9-21. 
 251 
 
MURAKAMI, K., MATHEW, R., HUANG, J., FARAHANI, R., PENG, H., OLSON, S. C. & 
ETLINGER, J. D. 2010. Smurf1 ubiquitin ligase causes downregulation of BMP 
receptors and is induced in monocrotaline and hypoxia models of pulmonary 
arterial hypertension. Exp Biol Med (Maywood), 235, 805-13. 
MURATA, T., DIETRICH, H. H., XIANG, C. & DACEY, R. G., JR. 2013. G protein-coupled 
estrogen receptor agonist improves cerebral microvascular function after 
hypoxia/reoxygenation injury in male and female rats. Stroke, 44, 779-85. 
MURRAY, F., MACLEAN, M. R. & INSEL, P. A. 2011. Role of phosphodiesterases in adult-
onset pulmonary arterial hypertension. Handb Exp Pharmacol, 279-305. 
MURRAY, F., MACLEAN, M. R. & PYNE, N. J. 2002. Increased expression of the cGMP-
inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) 
phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol, 137, 
1187-94. 
MURRAY, F., PATEL, H. H., SUDA, R. Y., ZHANG, S., THISTLETHWAITE, P. A., YUAN, 
J. X. & INSEL, P. A. 2007. Expression and activity of cAMP phosphodiesterase 
isoforms in pulmonary artery smooth muscle cells from patients with pulmonary 
hypertension: role for PDE1. Am J Physiol Lung Cell Mol Physiol, 292, L294-303. 
MURRAY, F., SUDA, R. Y., KWON, O., LI, X., REMILLARD, C. V., THISTLETHWAITE, P. 
A., YUAN, J. X. & INSEL, P. A. 2009. Decreased Expression and Activity of Epac 
(Exchange Protein Directly Activated by cAMP) in Pulmonary Arterial 
Hypertension. A51. EXPERIMENTAL MODELS OF PULMONARY 
HYPERTENSION. American Thoracic Society. 
MURRAY, P. A., LODATO, R. F. & MICHAEL, J. R. 1986. Neural antagonists modulate 
pulmonary vascular pressure-flow plots in conscious dogs. J Appl Physiol (1985), 
60, 1900-7. 
MURRAY, T. R., CHEN, L., MARSHALL, B. E. & MACARAK, E. J. 1990. Hypoxic 
contraction of cultured pulmonary vascular smooth muscle cells. Am J Respir Cell 
Mol Biol, 3, 457-65. 
NADADUR, R. D., UMAR, S., WONG, G., EGHBALI, M., IORGA, A., MATORI, H., 
PARTOW-NAVID, R. & EGHBALI, M. 2012. Reverse right ventricular structural and 
extracellular matrix remodeling by estrogen in severe pulmonary hypertension. J 
Appl Physiol (1985), 113, 149-58. 
NAGENDRAN, J., ARCHER, S. L., SOLIMAN, D., GURTU, V., MOUDGIL, R., HAROMY, 
A., ST AUBIN, C., WEBSTER, L., REBEYKA, I. M., ROSS, D. B., LIGHT, P. E., 
DYCK, J. R. & MICHELAKIS, E. D. 2007. Phosphodiesterase type 5 is highly 
expressed in the hypertrophied human right ventricle, and acute inhibition of 
phosphodiesterase type 5 improves contractility. Circulation, 116, 238-48. 
NAIR, A. B. & JACOB, S. 2016. A simple practice guide for dose conversion between 
animals and human. Journal of Basic and Clinical Pharmacy, 7, 27-31. 
 252 
 
NAKAMURA, K., AKAGI, S., OGAWA, A., KUSANO, K. F., MATSUBARA, H., MIURA, D., 
FUKE, S., NISHII, N., NAGASE, S., KOHNO, K., MORITA, H., OTO, T., 
YAMANAKA, R., OTSUKA, F., MIURA, A., YUTANI, C., OHE, T. & ITO, H. 2012. 
Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth 
muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J 
Cardiol, 159, 100-6. 
NEITZEL, K. L. & HEPLER, J. R. 2006. Cellular mechanisms that determine selective RGS 
protein regulation of G protein-coupled receptor signaling. Seminars in Cell & 
Developmental Biology, 17, 383-389. 
NEVES, S. R., RAM, P. T. & IYENGAR, R. 2002. G Protein Pathways. Science, 296, 1636-
1639. 
NEWMAN, J. H., TREMBATH, R. C., MORSE, J. A., GRUNIG, E., LOYD, J. E., ADNOT, 
S., COCCOLO, F., VENTURA, C., PHILLIPS, J. A., 3RD, KNOWLES, J. A., 
JANSSEN, B., EICKELBERG, O., EDDAHIBI, S., HERVE, P., NICHOLS, W. C. & 
ELLIOTT, G. 2004. Genetic basis of pulmonary arterial hypertension: current 
understanding and future directions. J Am Coll Cardiol, 43, 33S-39S. 
NICHOLS, W. C., KOLLER, D. L., SLOVIS, B., FOROUD, T., TERRY, V. H., ARNOLD, N. 
D., SIEMIENIAK, D. R., WHEELER, L., PHILLIPS, J. A., 3RD, NEWMAN, J. H., 
CONNEALLY, P. M., GINSBURG, D. & LOYD, J. E. 1997. Localization of the gene 
for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet, 
15, 277-80. 
NIKAM, V. S., SCHERMULY, R. T., DUMITRASCU, R., WEISSMANN, N., 
KWAPISZEWSKA, G., MORRELL, N., KLEPETKO, W., FINK, L., SEEGER, W. & 
VOSWINCKEL, R. 2010. Treprostinil inhibits the recruitment of bone marrow-
derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur 
Respir J, 36, 1302-14. 
NIKAM, V. S., WECKER, G., SCHERMULY, R., RAPP, U., SZELEPUSA, K., SEEGER, 
W. & VOSWINCKEL, R. 2011. Treprostinil inhibits the adhesion and differentiation 
of fibrocytes via the cyclic adenosine monophosphate-dependent and Ras-
proximate protein-dependent inactivation of extracellular regulated kinase. Am J 
Respir Cell Mol Biol, 45, 692-703. 
NILSSON, S., MAKELA, S., TREUTER, E., TUJAGUE, M., THOMSEN, J., ANDERSSON, 
G., ENMARK, E., PETTERSSON, K., WARNER, M. & GUSTAFSSON, J. A. 2001. 
Mechanisms of estrogen action. Physiol Rev, 81, 1535-65. 
NIOLA, F., ZHAO, X., SINGH, D., CASTANO, A., SULLIVAN, R., LAURIA, M., NAM, H. 
S., ZHUANG, Y., BENEZRA, R., DI BERNARDO, D., IAVARONE, A. & 
LASORELLA, A. 2012. Id proteins synchronize stemness and anchorage to the 
niche of neural stem cells. Nat Cell Biol, 14, 477-87. 
 253 
 
NISHIGAKI, N., NEGISHI, M. & ICHIKAWA, A. 1996. Two Gs-coupled prostaglandin E 
receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the 
metabolic inactivation of the agonist. Mol Pharmacol, 50, 1031-7. 
NISHIO, S. & KURUMATANI, H. 2001. [Pharmacological and clinical properties of 
beraprost sodium, orally active prostacyclin analogue]. Nihon Yakurigaku Zasshi, 
117, 123-30. 
NISHIYAMA, K., TAKAJI, K., KATAOKA, K., KURIHARA, Y., YOSHIMURA, M., KATO, A., 
OGAWA, H. & KURIHARA, H. 2005. Id1 gene transfer confers angiogenic property 
on fully differentiated endothelial cells and contributes to therapeutic angiogenesis. 
Circulation, 112, 2840-50. 
NONG, Z., HOYLAERTS, M., VAN PELT, N., COLLEN, D. & JANSSENS, S. 1997. Nitric 
oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary 
thrombosis in rats. Circ Res, 81, 865-9. 
NOOTENS, M., KAUFMANN, E., RECTOR, T., TOHER, C., JUDD, D., FRANCIS, G. S. & 
RICH, S. 1995. Neurohormonal activation in patients with right ventricular failure 
from pulmonary hypertension: relation to hemodynamic variables and endothelin 
levels. J Am Coll Cardiol, 26, 1581-5. 
NOREL, X. 2007. Prostanoid receptors in the human vascular wall. ScientificWorldJournal, 
7, 1359-74. 
NUEDLING, S., KAHLERT, S., LOEBBERT, K., DOEVENDANS, P. A., MEYER, R., 
VETTER, H. & GROHE, C. 1999. 17 Beta-estradiol stimulates expression of 
endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. 
Cardiovasc Res, 43, 666-74. 
OATES, J. A., FITZGERALD, G. A., BRANCH, R. A., JACKSON, E. K., KNAPP, H. R. & 
ROBERTS, L. J., 2ND 1988. Clinical implications of prostaglandin and 
thromboxane A2 formation (2). N Engl J Med, 319, 761-7. 
OHE, M., OGATA, M., SHIRATO, K. & TAKISHIMA, T. 1989. Effects of verapamil and BAY 
K 8644 on the hypoxic contraction of the isolated human pulmonary artery. Tohoku 
J Exp Med, 157, 81-2. 
OHLSTEIN, E. H., ARLETH, A., BRYAN, H., ELLIOTT, J. D. & SUNG, C. P. 1992. The 
selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-
mediated mitogenesis. Eur J Pharmacol, 225, 347-50. 
OHTA, Y., NAKAGAWA, K., IMAI, Y., KATAGIRI, T., KOIKE, T. & TAKAOKA, K. 2008. 
Cyclic AMP enhances smad-mediated BMP signaling through PKA-CREB 
pathway. Journal of Bone and Mineral Metabolism, 26, 478-484. 
OKADA, K., TANAKA, Y., BERNSTEIN, M., ZHANG, W., PATTERSON, G. A. & BOTNEY, 
M. D. 1997. Pulmonary hemodynamics modify the rat pulmonary artery response 
to injury. A neointimal model of pulmonary hypertension. Am J Pathol, 151, 1019-
25. 
 254 
 
OLSCHEWSKI, A., LI, Y., TANG, B., HANZE, J., EUL, B., BOHLE, R. M., WILHELM, J., 
MORTY, R. E., BRAU, M. E., WEIR, E. K., KWAPISZEWSKA, G., KLEPETKO, W., 
SEEGER, W. & OLSCHEWSKI, H. 2006a. Impact of TASK-1 in human pulmonary 
artery smooth muscle cells. Circ Res, 98, 1072-80. 
OLSCHEWSKI, A., LI, Y. J., HANZE, J., EUL, B., BOHLE, R. M., WILHELM, J., MORTY, 
R. E., BRAU, M. E., WEIR, E. K., KWAPISZEWSKA, G., KLEPETKO, W., 
SEEGER, W. & OLSCHEWSKI, H. 2006b. Impact of TASK-1 in human pulmonary 
artery smooth muscle cells. Circulation Research, 98, 1072-1080. 
OLSCHEWSKI, H., ROHDE, B., BEHR, J., EWERT, R., GESSLER, T., GHOFRANI, H. A. 
& SCHMEHL, T. 2003. Pharmacodynamics and pharmacokinetics of inhaled 
iloprost, aerosolized by three different devices, in severe pulmonary hypertension. 
Chest, 124, 1294-304. 
OLSCHEWSKI , H., SIMONNEAU , G., GALIÈ , N., HIGENBOTTAM , T., NAEIJE , R., 
RUBIN , L. J., NIKKHO , S., SPEICH , R., HOEPER , M. M., BEHR , J., WINKLER 
, J., SITBON , O., POPOV , W., GHOFRANI , H. A., MANES , A., KIELY , D. G., 
EWERT , R., MEYER , A., CORRIS , P. A., DELCROIX , M., GOMEZ-SANCHEZ , 
M., SIEDENTOP , H. & SEEGER , W. 2002. Inhaled Iloprost for Severe Pulmonary 
Hypertension. New England Journal of Medicine, 347, 322-329. 
OLSSON, K. M., DELCROIX, M., GHOFRANI, H. A., TIEDE, H., HUSCHER, D., SPEICH, 
R., GRÜNIG, E., STAEHLER, G., ROSENKRANZ, S., HALANK, M., HELD, M., 
LANGE, T. J., BEHR, J., KLOSE, H., CLAUSSEN, M., EWERT, R., OPITZ, C. F., 
VIZZA, C. D., SCELSI, L., VONK-NOORDEGRAAF, A., KAEMMERER, H., GIBBS, 
J. S. R., COGHLAN, G., PEPKE-ZABA, J., SCHULZ, U., GORENFLO, M., 
PITTROW, D. & HOEPER, M. M. 2013. Anticoagulation and Survival in Pulmonary 
Arterial Hypertension: Results from the COMPERA Registry. Circulation. 
OPARIL, S., CHEN, S. J., MENG, Q. C., ELTON, T. S., YANO, M. & CHEN, Y. F. 1995. 
Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary 
hypertension in the rat. Am J Physiol, 268, L95-100. 
PALCZEWSKI, K., KUMASAKA, T., HORI, T., BEHNKE, C. A., MOTOSHIMA, H., FOX, B. 
A., LE TRONG, I., TELLER, D. C., OKADA, T., STENKAMP, R. E., YAMAMOTO, 
M. & MIYANO, M. 2000. Crystal structure of rhodopsin: A G protein-coupled 
receptor. Science, 289, 739-45. 
PALMER, R. M., ASHTON, D. S. & MONCADA, S. 1988. Vascular endothelial cells 
synthesize nitric oxide from L-arginine. Nature, 333, 664-6. 
PANDEY, D. P., LAPPANO, R., ALBANITO, L., MADEO, A., MAGGIOLINI, M. & PICARD, 
D. 2009. Estrogenic GPR30 signalling induces proliferation and migration of breast 
cancer cells through CTGF. Embo j, 28, 523-32. 
 255 
 
PATEL, A. J., HONORE, E., LESAGE, F., FINK, M., ROMEY, G. & LAZDUNSKI, M. 1999. 
Inhalational anesthetics activate two-pore-domain background K+ channels. Nat 
Neurosci, 2, 422-6. 
PATEL, A. J., LAZDUNSKI, M. & HONORE, E. 1997. Kv2.1/Kv9.3, a novel ATP-dependent 
delayed-rectifier K+ channel in oxygen-sensitive pulmonary artery myocytes. Embo 
j, 16, 6615-25. 
PATEL, J., ABRAHAM, D., NELSON, A., SILVERSTEIN, A. & CLAPP, L. 2014. 
Comparison of current therapies against endothelin-induced growth in pulmonary 
smooth arterial muscle cells (PASMCs) derived from patients with pulmonary 
arterial hypertension. European Respiratory Journal, 44. 
PAUVERT, O., SALVAIL, D., ROUSSEAU, E., LUGNIER, C., MARTHAN, R. & 
SAVINEAU, J. P. 2002. Characterisation of cyclic nucleotide phosphodiesterase 
isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol, 63, 
1763-72. 
PENG, J., XU, X., MACE, B. E., VANDERVEER, L. A., WORKMAN, L. R., SLIFKER, M. 
J., SULLIVAN, P. M., VEENSTRA, T. D. & CLAPPER, M. L. 2013. Estrogen 
metabolism within the lung and its modulation by tobacco smoke. Carcinogenesis, 
34, 909-15. 
PENN, R. B., PASCUAL, R. M., KIM, Y. M., MUNDELL, S. J., KRYMSKAYA, V. P., 
PANETTIERI, R. A., JR. & BENOVIC, J. L. 2001. Arrestin specificity for G protein-
coupled receptors in human airway smooth muscle. J Biol Chem, 276, 32648-56. 
PETKOV, V., MOSGOELLER, W., ZIESCHE, R., RADERER, M., STIEBELLEHNER, L., 
VONBANK, K., FUNK, G.-C., HAMILTON, G., NOVOTNY, C., BURIAN, B. & 
BLOCK, L.-H. 2003. Vasoactive intestinal peptide as a new drug for treatment of 
primary pulmonary hypertension. Journal of Clinical Investigation, 111, 1339-1346. 
PIAN, M. S. & DOBBS, L. G. 1995. Evidence for Gβγ-mediated Cross-talk in Primary 
Cultures of Lung Alveolar Cells: PERTUSSIS TOXIN-SENSITIVE PRODUCTION 
OF cAMP. Journal of Biological Chemistry, 270, 7427-7430. 
PIAO, L., MARSBOOM, G. & ARCHER, S. L. 2010. Mitochondrial metabolic adaptation in 
right ventricular hypertrophy and failure. J Mol Med (Berl), 88, 1011-20. 
PITCHER, J. A., FREEDMAN, N. J. & LEFKOWITZ, R. J. 1998. G protein-coupled receptor 
kinases. Annu Rev Biochem, 67, 653-92. 
POLLOCK, D. M., KEITH, T. L. & HIGHSMITH, R. F. 1995. Endothelin receptors and 
calcium signaling. FASEB J, 9, 1196-204. 
POST, J. M., HUME, J. R., ARCHER, S. L. & WEIR, E. K. 1992. Direct role for potassium 
channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol, 262, C882-
90. 
POST, S. R., HILAL-DANDAN, R., URASAWA, K., BRUNTON, L. L. & INSEL, P. A. 1995. 
Quantification of signalling components and amplification in the beta-adrenergic-
 256 
 
receptor-adenylate cyclase pathway in isolated adult rat ventricular myocytes. 
Biochem J, 311 ( Pt 1), 75-80. 
PROSSNITZ, E. R., ARTERBURN, J. B., SMITH, H. O., OPREA, T. I., SKLAR, L. A. & 
HATHAWAY, H. J. 2008. Estrogen signaling through the transmembrane G 
protein-coupled receptor GPR30. Annu Rev Physiol, 70, 165-90. 
PULIDO, T., ADZERIKHO, I., CHANNICK, R. N., DELCROIX, M., GALIE, N., GHOFRANI, 
H. A., JANSA, P., JING, Z. C., LE BRUN, F. O., MEHTA, S., MITTELHOLZER, C. 
M., PERCHENET, L., SASTRY, B. K., SITBON, O., SOUZA, R., TORBICKI, A., 
ZENG, X., RUBIN, L. J., SIMONNEAU, G. & INVESTIGATORS, S. 2013. 
Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl 
J Med, 369, 809-18. 
PULLAMSETTI, S. S., DOEBELE, C., FISCHER, A., SAVAI, R., KOJONAZAROV, B., 
DAHAL, B. K., GHOFRANI, H. A., WEISSMANN, N., GRIMMINGER, F., 
BONAUER, A., SEEGER, W., ZEIHER, A. M., DIMMELER, S. & SCHERMULY, R. 
T. 2012. Inhibition of microRNA-17 improves lung and heart function in 
experimental pulmonary hypertension. Am J Respir Crit Care Med, 185, 409-19. 
PUTTI, T. C., EL-REHIM, D. M., RAKHA, E. A., PAISH, C. E., LEE, A. H., PINDER, S. E. 
& ELLIS, I. O. 2005. Estrogen receptor-negative breast carcinomas: a review of 
morphology and immunophenotypical analysis. Mod Pathol, 18, 26-35. 
RABE, K. F., TENOR, H., DENT, G., SCHUDT, C., NAKASHIMA, M. & MAGNUSSEN, H. 
1994. Identification of PDE isozymes in human pulmonary artery and effect of 
selective PDE inhibitors. Am J Physiol, 266, L536-43. 
RABINOVITCH, M., GAMBLE, W. J., MIETTINEN, O. S. & REID, L. 1981. Age and sex 
influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J 
Physiol, 240, H62-72. 
RAJKUMAR, R., KONISHI, K., RICHARDS, T. J., ISHIZAWAR, D. C., WIECHERT, A. C., 
KAMINSKI, N. & AHMAD, F. 2010. Genomewide RNA expression profiling in lung 
identifies distinct signatures in idiopathic pulmonary arterial hypertension and 
secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol, 298, H1235-
48. 
RAMAMOORTHY, S., BAUMAN, A. L., MOORE, K. R., HAN, H., YANG-FENG, T., 
CHANG, A. S., GANAPATHY, V. & BLAKELY, R. D. 1993. Antidepressant- and 
cocaine-sensitive human serotonin transporter: molecular cloning, expression, and 
chromosomal localization. Proc Natl Acad Sci U S A, 90, 2542-6. 
RANGARAJAN, S., ENSERINK, J. M., KUIPERIJ, H. B., DE ROOIJ, J., PRICE, L. S., 
SCHWEDE, F. & BOS, J. L. 2003. Cyclic AMP induces integrin-mediated cell 
adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic 
receptor. J Cell Biol, 160, 487-93. 
 257 
 
RANKOVIC, Z., BRUST, T. F. & BOHN, L. M. 2016. Biased agonism: An emerging 
paradigm in GPCR drug discovery. Bioorganic & Medicinal Chemistry Letters, 26, 
241-250. 
RAPPORT, M. M., GREEN, A. A. & PAGE, I. H. 1948. Serum vasoconstrictor, serotonin; 
isolation and characterization. J Biol Chem, 176, 1243-51. 
REID, L. M. 1986. Structure and function in pulmonary hypertension. New perceptions. 
Chest, 89, 279-88. 
REID, M. J., LAME, M. W., MORIN, D., WILSON, D. W. & SEGALL, H. J. 1998. 
Involvement of cytochrome P450 3A in the metabolism and covalent binding of 
14C-monocrotaline in rat liver microsomes. J Biochem Mol Toxicol, 12, 157-66. 
REITER, E. & LEFKOWITZ, R. J. 2006. GRKs and beta-arrestins: roles in receptor 
silencing, trafficking and signaling. Trends Endocrinol Metab, 17, 159-65. 
RENTSENDORJ, O., DAMARLA, M., AGGARWAL, N. R., CHOI, J. Y., JOHNSTON, L., 
D'ALESSIO, F. R., CROW, M. T. & PEARSE, D. B. 2011. Knockdown of lung 
phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-
hit mouse model of acute lung injury. Am J Physiol Lung Cell Mol Physiol, 301, 
L161-70. 
RESTA, T. C., KANAGY, N. L. & WALKER, B. R. 2001. Estradiol-induced attenuation of 
pulmonary hypertension is not associated with altered eNOS expression. Am J 
Physiol Lung Cell Mol Physiol, 280, L88-97. 
REYES, R., DUPRAT, F., LESAGE, F., FINK, M., SALINAS, M., FARMAN, N. & 
LAZDUNSKI, M. 1998. Cloning and expression of a novel pH-sensitive two pore 
domain K+ channel from human kidney. J Biol Chem, 273, 30863-9. 
RICH, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., 
DETRE, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, 
S. K. & ET AL. 1987. Primary pulmonary hypertension. A national prospective 
study. Ann Intern Med, 107, 216-23. 
RICH, S., KIERAS, K., HART, K., GROVES, B. M., STOBO, J. D. & BRUNDAGE, B. H. 
1986. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol, 
8, 1307-11. 
RICHMAN, J. G., BRADY, A. E., WANG, Q., HENSEL, J. L., COLBRAN, R. J. & LIMBIRD, 
L. E. 2001. Agonist-regulated Interaction between alpha2-adrenergic receptors and 
spinophilin. J Biol Chem, 276, 15003-8. 
RITTER, S. L. & HALL, R. A. 2009. Fine-tuning of GPCR activity by receptor-interacting 
proteins. Nat Rev Mol Cell Biol, 10, 819-830. 
ROBERTS, K. E., FALLON, M. B., KROWKA, M. J., BROWN, R. S., TROTTER, J. F., 
PETER, I., TIGHIOUART, H., KNOWLES, J. A., RABINOWITZ, D., BENZA, R. L., 
BADESCH, D. B., TAICHMAN, D. B., HORN, E. M., ZACKS, S., KAPLOWITZ, N., 
KAWUT, S. M. & PULMONARY VASCULAR COMPLICATIONS OF LIVER 
 258 
 
DISEASE STUDY, G. 2009. Genetic risk factors for portopulmonary hypertension 
in patients with advanced liver disease. Am J Respir Crit Care Med, 179, 835-42. 
ROBERTSON, T. P., WARD, J. P. & AARONSON, P. I. 2001. Hypoxia induces the release 
of a pulmonary-selective, Ca(2+)-sensitising, vasoconstrictor from the perfused rat 
lung. Cardiovasc Res, 50, 145-50. 
ROBSON, T. & HIRST, D. G. 2003. Transcriptional Targeting in Cancer Gene Therapy. 
Journal of Biomedicine and Biotechnology, 2003, 110-137. 
ROLLINS, K., LALIBERTE, K., GOTZKOWSKY, K., WADE, M. & MOTTOLA, D. 2009. 
Overview of the Drug-Drug Interaction Potential with Treprostinil. B55. 
PULMONARY HYPERTENSION -- CLINICAL. 
RONDELET, B., VAN BENEDEN, R., KERBAUL, F., MOTTE, S., FESLER, P., MCENTEE, 
K., BRIMIOULLE, S., KETELSLEGERS, J. M. & NAEIJE, R. 2003. Expression of 
the serotonin 1b receptor in experimental pulmonary hypertension. Eur Respir J, 
22, 408-12. 
ROTH, D. M., GAO, M. H., LAI, N. C., DRUMM, J., DALTON, N., ZHOU, J. Y., ZHU, J., 
ENTRIKIN, D. & HAMMOND, H. K. 1999. Cardiac-directed adenylyl cyclase 
expression improves heart function in murine cardiomyopathy. Circulation, 99, 
3099-102. 
ROTHMAN, A. M., ARNOLD, N. D., PICKWORTH, J. A., IREMONGER, J., CIUCLAN, L., 
ALLEN, R. M., GUTH-GUNDEL, S., SOUTHWOOD, M., MORRELL, N. W., 
THOMAS, M., FRANCIS, S. E., ROWLANDS, D. J. & LAWRIE, A. 2016. 
MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension. J Clin 
Invest, 126, 2495-508. 
RUBIN, L. J., BADESCH, D. B., BARST, R. J., GALIE, N., BLACK, C. M., KEOGH, A., 
PULIDO, T., FROST, A., ROUX, S., LECONTE, I., LANDZBERG, M. & 
SIMONNEAU, G. 2002. Bosentan therapy for pulmonary arterial hypertension. N 
Engl J Med, 346, 896-903. 
RUBIN, L. J., GALIE, N., GRIMMINGER, F., GRUNIG, E., HUMBERT, M., JING, Z. C., 
KEOGH, A., LANGLEBEN, D., FRITSCH, A., MENEZES, F., DAVIE, N. & 
GHOFRANI, H. A. 2015. Riociguat for the treatment of pulmonary arterial 
hypertension: a long-term extension study (PATENT-2). Eur Respir J, 45, 1303-13. 
RUBIN, L. J., GROVES, B. M., REEVES, J. T., FROSOLONO, M., HANDEL, F. & CATO, 
A. E. 1982. Prostacyclin-induced acute pulmonary vasodilation in primary 
pulmonary hypertension. Circulation, 66, 334-338. 
RUSSELL, L. J., AKASAKA, T., MAJID, A., SUGIMOTO, K.-J., KARRAN, E. L., NAGEL, 
I., HARDER, L., CLAVIEZ, A., GESK, S., MOORMAN, A. V., ROSS, F., 
MAZZULLO, H., STREFFORD, J. C., SIEBERT, R., DYER, M. J. & HARRISON, 
C. J. 2008. t(6;14)(p22;q32): a new recurrent IGH-translocation involving ID4 in B-
cell precursor acute lymphoblastic leukaemia. Blood, 111. 
 259 
 
RYBALKIN, S. D., YAN, C., BORNFELDT, K. E. & BEAVO, J. A. 2003. Cyclic GMP 
phosphodiesterases and regulation of smooth muscle function. Circ Res, 93, 280-
91. 
SAKAI, A. & VOELKEL, N. F. 1988. Dibutyryl cyclic adenosine monophosphate inhibits 
pulmonary vasoconstriction. Lung, 166, 221-31. 
SAN-MARINA, S., HAN, Y., SUAREZ SAIZ, F., TRUS, M. R. & MINDEN, M. D. 2008. Lyl1 
interacts with CREB1 and alters expression of CREB1 target genes. Biochim 
Biophys Acta, 1783, 503-17. 
SASANO, H., MURAKAMI, H., SHIZAWA, S., SATOMI, S., NAGURA, H. & HARADA, N. 
1999. Aromatase and sex steroid receptors in human vena cava. Endocr J, 46, 
233-42. 
SASANO, H., UZUKI, M., SAWAI, T., NAGURA, H., MATSUNAGA, G., KASHIMOTO, O. 
& HARADA, N. 1997. Aromatase in human bone tissue. J Bone Miner Res, 12, 
1416-23. 
SATO, M., NAKAYAMA, T., SOMA, M., AOI, N., KOSUGE, K., HAKETA, A., IZUMI, Y., 
MATSUMOTO, K., SATO, N. & KOKUBUN, S. 2007. Association between 
prostaglandin E2 receptor gene and essential hypertension. Prostaglandins Leukot 
Essent Fatty Acids, 77, 15-20. 
SAVINEAU, J. P., GONZALEZ DE LA FUENTE, P. & MARTHAN, R. 1995. Cellular 
mechanisms of hypoxia-induced contraction in human and rat pulmonary arteries. 
Respir Physiol, 99, 191-8. 
SBAROUNI, E., ILIODROMITIS, E. K., BOFILIS, E., KYRIAKIDES, Z. S. & 
KREMASTINOS, D. T. 2003. Estrogen alone or combined with 
medroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J 
Pharmacol, 467, 163-8. 
SCHERMULY, R. T., DONY, E., GHOFRANI, H. A., PULLAMSETTI, S., SAVAI, R., ROTH, 
M., SYDYKOV, A., LAI, Y. J., WEISSMANN, N., SEEGER, W. & GRIMMINGER, 
F. 2005. Reversal of experimental pulmonary hypertension by PDGF inhibition. J 
Clin Invest, 115, 2811-21. 
SCHERMULY, R. T., KREISSELMEIER, K. P., GHOFRANI, H. A., YILMAZ, H., 
BUTROUS, G., ERMERT, L., ERMERT, M., WEISSMANN, N., ROSE, F., 
GUENTHER, A., WALMRATH, D., SEEGER, W. & GRIMMINGER, F. 2004. 
Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary 
hypertension in rats. Am J Respir Crit Care Med, 169, 39-45. 
SCHERMULY, R. T., PULLAMSETTI, S. S., KWAPISZEWSKA, G., DUMITRASCU, R., 
TIAN, X., WEISSMANN, N., GHOFRANI, H. A., KAULEN, C., DUNKERN, T., 
SCHUDT, C., VOSWINCKEL, R., ZHOU, J., SAMIDURAI, A., KLEPETKO, W., 
PADDENBERG, R., KUMMER, W., SEEGER, W. & GRIMMINGER, F. 2007. 
 260 
 
Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for 
reverse-remodeling therapy. Circulation, 115, 2331-9. 
SCHERMULY, R. T., STASCH, J. P., PULLAMSETTI, S. S., MIDDENDORFF, R., 
MULLER, D., SCHLUTER, K. D., DINGENDORF, A., HACKEMACK, S., 
KOLOSIONEK, E., KAULEN, C., DUMITRASCU, R., WEISSMANN, N., 
MITTENDORF, J., KLEPETKO, W., SEEGER, W., GHOFRANI, H. A. & 
GRIMMINGER, F. 2008. Expression and function of soluble guanylate cyclase in 
pulmonary arterial hypertension. Eur Respir J, 32, 881-91. 
SCHUMACHER, G. & NEUHAUS, P. 2001. The physiological estrogen metabolite 2-
methoxyestradiol reduces tumor growth and induces apoptosis in human solid 
tumors. J Cancer Res Clin Oncol, 127, 405-10. 
SCHWAPPACHER, R., WEISKE, J., HEINING, E., EZERSKI, V., MAROM, B., HENIS, Y. 
I., HUBER, O. & KNAUS, P. 2009. Novel crosstalk to BMP signalling: cGMP-
dependent kinase I modulates BMP receptor and Smad activity. EMBO J, 28, 1537-
50. 
SCHWENKE, D. O., PEARSON, J. T., SONOBE, T., ISHIBASHI-UEDA, H., SHIMOUCHI, 
A., KANGAWA, K., UMETANI, K. & SHIRAI, M. 2011. Role of Rho-kinase signaling 
and endothelial dysfunction in modulating blood flow distribution in pulmonary 
hypertension. J Appl Physiol (1985), 110, 901-8. 
SEALY, W. C., CONNALLY, S. R. & DALTON, M. L. 1993. Naming the bronchopulmonary 
segments and the development of pulmonary surgery. Ann Thorac Surg, 55, 184-
8. 
SEO, B., OEMAR, B. S., SIEBENMANN, R., VON SEGESSER, L. & LUSCHER, T. F. 
1994. Both ETA and ETB receptors mediate contraction to endothelin-1 in human 
blood vessels. Circulation, 89, 1203-8. 
SEYLER, C., DUTHIL-STRAUB, E., ZITRON, E., GIERTEN, J., SCHOLZ, E. P., FINK, R. 
H., KARLE, C. A., BECKER, R., KATUS, H. A. & THOMAS, D. 2012. TASK1 
(K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-
dependent phosphorylation. Br J Pharmacol, 165, 1467-75. 
SHAM, J. S., CRENSHAW, B. R., JR., DENG, L. H., SHIMODA, L. A. & SYLVESTER, J. 
T. 2000. Effects of hypoxia in porcine pulmonary arterial myocytes: roles of K(V) 
channel and endothelin-1. Am J Physiol Lung Cell Mol Physiol, 279, L262-72. 
SHAPIRO, S., TRAIGER, G. L., TURNER, M., MCGOON, M. D., WASON, P. & BARST, 
R. J. 2012. Sex differences in the diagnosis, treatment, and outcome of patients 
with pulmonary arterial hypertension enrolled in the registry to evaluate early and 
long-term pulmonary arterial hypertension disease management. Chest, 141, 363-
73. 
 261 
 
SHENOY, S. K. & LEFKOWITZ, R. J. 2003. Multifaceted roles of beta-arrestins in the 
regulation of seven-membrane-spanning receptor trafficking and signalling. 
Biochem J, 375, 503-15. 
SHERMAN, T. S., CHAMBLISS, K. L., GIBSON, L. L., PACE, M. C., MENDELSOHN, M. 
E., PFISTER, S. L. & SHAUL, P. W. 2002. Estrogen acutely activates prostacyclin 
synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol, 
26, 610-6. 
SHICHIRI, M., KATO, H., MARUMO, F. & HIRATA, Y. 1997. Endothelin-1 as an 
autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension, 
30, 1198-203. 
SHIMIZU, M., YOSHIMURA, S., TAKIZAWA, S., KOHARA, S., INOKO, H. & TAKAGI, S. 
2013. Effect of single nucleotide polymorphisms of the prostacyclin receptor gene 
on platelet activation in Japanese healthy subjects and patients with cerebral 
infarction. J Clin Neurosci, 20, 851-6. 
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., 
KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., CROW, J. W., RUBIN, 
L. J. & TREPROSTINIL STUDY, G. 2002. Continuous subcutaneous infusion of 
treprostinil, a prostacyclin analogue, in patients with pulmonary arterial 
hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir 
Crit Care Med, 165, 800-4. 
SIMONNEAU, G., GATZOULIS, M. A., ADATIA, I., CELERMAJER, D., DENTON, C., 
GHOFRANI, A., GOMEZ SANCHEZ, M. A., KRISHNA KUMAR, R., LANDZBERG, 
M., MACHADO, R. F., OLSCHEWSKI, H., ROBBINS, I. M. & SOUZA, R. 2013. 
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol, 62, 
D34-41. 
SINGHAL, S., HENDERSON, R., HORSFIELD, K., HARDING, K. & CUMMING, G. 1973. 
Morphometry of the human pulmonary arterial tree. Circ Res, 33, 190-7. 
SITBON, O., BADESCH, D. B., CHANNICK, R. N., FROST, A., ROBBINS, I. M., 
SIMONNEAU, G., TAPSON, V. F. & RUBIN, L. J. 2003. Effects of the dual 
endothelin receptor antagonist bosentan in patients with pulmonary arterial 
hypertension: a 1-year follow-up study. Chest, 124, 247-54. 
SITBON, O., HUMBERT, M., JAGOT, J. L., TARAVELLA, O., FARTOUKH, M., PARENT, 
F., HERVE, P. & SIMONNEAU, G. 1998. Inhaled nitric oxide as a screening agent 
for safely identifying responders to oral calcium-channel blockers in primary 
pulmonary hypertension. Eur Respir J, 12, 265-70. 
SITBON, O., HUMBERT, M., JAIS, X., IOOS, V., HAMID, A. M., PROVENCHER, S., 
GARCIA, G., PARENT, F., HERVE, P. & SIMONNEAU, G. 2005. Long-term 
response to calcium channel blockers in idiopathic pulmonary arterial 
hypertension. Circulation, 111, 3105-11. 
 262 
 
SKORO-SAJER, N., BONDERMAN, D., WIESBAUER, F., HARJA, E., JAKOWITSCH, J., 
KLEPETKO, W., KNEUSSL, M. P. & LANG, I. M. 2007. Treprostinil for severe 
inoperable chronic thromboembolic pulmonary hypertension. Journal of 
Thrombosis and Haemostasis, 5, 483-489. 
SKORO-SAJER, N., LANG, I. & NAEIJE, R. 2008. Treprostinil for pulmonary hypertension. 
Vasc Health Risk Manag, 4, 507-13. 
SMADJA, D., LEVY, M., HUANG, L., ROSSI, E., ISRAEL-BIET, D., GAUSSEM, P. & 
BISCHOFF, J. 2015. 0304 : Treprostinil indirectly regulates endothelial colony 
forming cell angiogenic properties by increasing VEGF-A produced by 
mesenchymal stem cells. Archives of Cardiovascular Diseases Supplements, 7, 
148. 
SMADJA, D. M., MAUGE, L., GAUSSEM, P., D'AUDIGIER, C., ISRAEL-BIET, D., 
CELERMAJER, D. S., BONNET, D. & LEVY, M. 2011. Treprostinil increases the 
number and angiogenic potential of endothelial progenitor cells in children with 
pulmonary hypertension. Angiogenesis, 14, 17-27. 
SMITH, F. D., OXFORD, G. S. & MILGRAM, S. L. 1999. Association of the D2 dopamine 
receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-
interacting protein. J Biol Chem, 274, 19894-900. 
SMITH, P. K., KROHN, R. I., HERMANSON, G. T., MALLIA, A. K., GARTNER, F. H., 
PROVENZANO, M. D., FUJIMOTO, E. K., GOEKE, N. M., OLSON, B. J. & KLENK, 
D. C. 1985. Measurement of protein using bicinchoninic acid. Anal Biochem, 150, 
76-85. 
SMYTH, E. M., LI, W. H. & FITZGERALD, G. A. 1998. Phosphorylation of the prostacyclin 
receptor during homologous desensitization. A critical role for protein kinase c. J 
Biol Chem, 273, 23258-66. 
SOBOLEWSKI, A., JOURDAN, K. B., UPTON, P. D., LONG, L. & MORRELL, N. W. 2004. 
Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth 
muscle cells involves a PKA-mediated inhibition of adenylyl cyclase. Am J Physiol 
Lung Cell Mol Physiol, 287, L352-9. 
SOLDIN, O. P. & MATTISON, D. R. 2009. Sex Differences in Pharmacokinetics and 
Pharmacodynamics. Clinical pharmacokinetics, 48, 143-157. 
SOMA, S., TAKAHASHI, H., MURAMATSU, M., OKA, M. & FUKUCHI, Y. 1999. 
Localization and distribution of endothelin receptor subtypes in pulmonary 
vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol, 20, 
620-30. 
SOMLYO, A. P. & SOMLYO, A. V. 1994. Signal transduction and regulation in smooth 
muscle. Nature, 372, 231-6. 
SOUNTOULIDIS, A., STAVROPOULOS, A., GIAGLIS, S., APOSTOLOU, E., MONTEIRO, 
R., CHUVA DE SOUSA LOPES, S. M., CHEN, H., STRIPP, B. R., MUMMERY, C., 
 263 
 
ANDREAKOS, E. & SIDERAS, P. 2012. Activation of the canonical bone 
morphogenetic protein (BMP) pathway during lung morphogenesis and adult lung 
tissue repair. PLoS One, 7, e41460. 
STAMLER, J. S., LOH, E., RODDY, M. A., CURRIE, K. E. & CREAGER, M. A. 1994. Nitric 
oxide regulates basal systemic and pulmonary vascular resistance in healthy 
humans. Circulation, 89, 2035-40. 
STEARMAN, R. S., CORNELIUS, A. R., LU, X., CONKLIN, D. S., DEL ROSARIO, M. J., 
LOWE, A. M., ELOS, M. T., FETTIG, L. M., WONG, R. E., HARA, N., COGAN, J. 
D., PHILLIPS, J. A., 3RD, TAYLOR, M. R., GRAHAM, B. B., TUDER, R. M., LOYD, 
J. E. & GERACI, M. W. 2014. Functional prostacyclin synthase promoter 
polymorphisms. Impact in pulmonary arterial hypertension. Am J Respir Crit Care 
Med, 189, 1110-20. 
STENMARK, K. R., DAVIE, N., FRID, M., GERASIMOVSKAYA, E. & DAS, M. 2006a. Role 
of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda), 21, 
134-45. 
STENMARK, K. R., FAGAN, K. A. & FRID, M. G. 2006b. Hypoxia-Induced Pulmonary 
Vascular Remodeling. Cellular and Molecular Mechanisms, 99, 675-691. 
STENMARK, K. R. & FRID, M. G. 1998. Smooth muscle cell heterogeneity: role of specific 
smooth muscle cell subpopulations in pulmonary vascular disease. Chest, 114, 
82S-90S. 
STENMARK, K. R., MEYRICK, B., GALIE, N., MOOI, W. J. & MCMURTRY, I. F. 2009. 
Animal models of pulmonary arterial hypertension: the hope for etiological 
discovery and pharmacological cure. American Journal of Physiology - Lung 
Cellular and Molecular Physiology, 297, L1013. 
STEWART, D. J., LEVY, R. D., CERNACEK, P. & LANGLEBEN, D. 1991. Increased 
plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? 
Ann Intern Med, 114, 464-9. 
STITHAM, J., AREHART, E., ELDERON, L., GLEIM, S. R., DOUVILLE, K., KASZA, Z., 
FETALVERO, K., MACKENZIE, T., ROBB, J., MARTIN, K. A. & HWA, J. 2011. 
Comprehensive Biochemical Analysis of Rare Prostacyclin Receptor Variants: 
STUDY OF ASSOCIATION OF SIGNALING WITH CORONARY ARTERY 
OBSTRUCTION. The Journal of Biological Chemistry, 286, 7060-7069. 
STITHAM, J., AREHART, E. J., GLEIM, S., DOUVILLE, K., MACKENZIE, T. & HWA, J. 
2007. Arginine (CGC) codon targeting in the human prostacyclin receptor gene 
(PTGIR) and G-protein coupled receptors (GPCR). Gene, 396, 180-7. 
STITHAM, J., STOJANOVIC, A. & HWA, J. 2002. Impaired Receptor Binding and 
Activation Associated with a Human Prostacyclin Receptor Polymorphism. Journal 
of Biological Chemistry, 277, 15439-15444. 
 264 
 
STUPFEL, M., PESCE, V. H., GOURLET, V., BOULEY, G., ELABED, A. & 
LEMERCERRE, C. 1984. Sex-related factors in acute hypoxia survival in one strain 
of mice. Aviat Space Environ Med, 55, 136-40. 
TAKAHASHI, H., GOTO, N., KOJIMA, Y., TSUDA, Y., MORIO, Y., MURAMATSU, M. & 
FUKUCHI, Y. 2006. Downregulation of type II bone morphogenetic protein receptor 
in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol, 290, L450-
8. 
TAKAHASHI, K., KOGAKI, S., MATSUSHITA, T., NASUNO, S., KUROTOBI, S. & 
OZONO, K. 2007. Hypoxia induces alteration of bone morphogenetic protein 
receptor signaling in pulmonary artery endothelial cell. Pediatr Res, 61, 392-7. 
TAKAHASHI, T., KANDA, T., INOUE, M., SUMINO, H., KOBAYASHI, I., IWAMOTO, A. & 
NAGAI, R. 1998. Endothelin converting enzyme inhibitor protects development of 
right ventricular overload and medial thickening of pulmonary arteries in rats with 
monocrotaline-induced pulmonary hypertension. Life Sciences, 63, 137-143. 
TANG, B., LI, Y., NAGARAJ, C., MORTY, R. E., GABOR, S., STACHER, E., 
VOSWINCKEL, R., WEISSMANN, N., LEITHNER, K., OLSCHEWSKI, H. & 
OLSCHEWSKI, A. 2009. Endothelin-1 inhibits background two-pore domain 
channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J 
Respir Cell Mol Biol, 41, 476-83. 
TAPSON, V. F., JING, Z. C., XU, K. F., PAN, L., FELDMAN, J., KIELY, D. G., KOTLYAR, 
E., MCSWAIN, C. S., LALIBERTE, K., ARNESON, C., RUBIN, L. J. & TEAM, F.-
C. S. 2013. Oral treprostinil for the treatment of pulmonary arterial hypertension in 
patients receiving background endothelin receptor antagonist and 
phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a 
randomized controlled trial. Chest, 144, 952-8. 
TAPSON, V. F., TORRES, F., KERMEEN, F., KEOGH, A. M., ALLEN, R. P., FRANTZ, R. 
P., BADESCH, D. B., FROST, A. E., SHAPIRO, S. M., LALIBERTE, K., SIGMAN, 
J., ARNESON, C. & GALIE, N. 2012. Oral treprostinil for the treatment of 
pulmonary arterial hypertension in patients on background endothelin receptor 
antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C 
study): a randomized controlled trial. Chest, 142, 1383-90. 
TARASEVICIENE-STEWART, L., KASAHARA, Y., ALGER, L., HIRTH, P., MC MAHON, 
G., WALTENBERGER, J., VOELKEL, N. F. & TUDER, R. M. 2001. Inhibition of the 
VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent 
pulmonary endothelial cell proliferation and severe pulmonary hypertension. 
FASEB J, 15, 427-38. 
TASKEN, K. & AANDAHL, E. M. 2004. Localized effects of cAMP mediated by distinct 
routes of protein kinase A. Physiol Rev, 84, 137-67. 
 265 
 
TEEDE, H. J., MCGRATH, B. P., SMOLICH, J. J., MALAN, E., KOTSOPOULOS, D., 
LIANG, Y. L. & PEVERILL, R. E. 2000. Postmenopausal hormone replacement 
therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc 
Biol, 20, 1404-9. 
TEICHERT-KULISZEWSKA, K., KUTRYK, M. J., KULISZEWSKI, M. A., KAROUBI, G., 
COURTMAN, D. W., ZUCCO, L., GRANTON, J. & STEWART, D. J. 2006. Bone 
morphogenetic protein receptor-2 signaling promotes pulmonary arterial 
endothelial cell survival: implications for loss-of-function mutations in the 
pathogenesis of pulmonary hypertension. Circ Res, 98, 209-17. 
THOMPSON, P. & MCRAE, C. 1970. Familial pulmonary hypertension. Evidence of 
autosomal dominant inheritance. Br Heart J, 32, 758-60. 
TOFOVIC, S. P. 2010. Estrogens and development of pulmonary hypertension: interaction 
of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol, 
56, 696-708. 
TOFOVIC, S. P., SALAH, E. M., MADY, H. H., JACKSON, E. K. & MELHEM, M. F. 2005. 
Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in 
rats. J Cardiovasc Pharmacol, 46, 430-7. 
TOFOVIC, S. P., ZHANG, X., ZHU, H., JACKSON, E. K., RAFIKOVA, O. & 
PETRUSEVSKA, G. 2008. 2-Ethoxyestradiol is antimitogenic and attenuates 
monocrotaline-induced pulmonary hypertension and vascular remodeling. Vascul 
Pharmacol, 48, 174-83. 
TOYA, Y., SCHWENCKE, C. & ISHIKAWA, Y. 1998. Forskolin derivatives with increased 
selectivity for cardiac adenylyl cyclase. J Mol Cell Cardiol, 30, 97-108. 
TSUCHIYA, Y., NAKAJIMA, M. & YOKOI, T. 2005. Cytochrome P450-mediated 
metabolism of estrogens and its regulation in human. Cancer Lett, 227, 115-24. 
TUCKER, A., MCMURTRY, I. F., REEVES, J. T., ALEXANDER, A. F., WILL, D. H. & 
GROVER, R. F. 1975. Lung vascular smooth muscle as a determinant of 
pulmonary hypertension at high altitude. Am J Physiol, 228, 762-7. 
TUDER, R. M., CHACON, M., ALGER, L., WANG, J., TARASEVICIENE-STEWART, L., 
KASAHARA, Y., COOL, C. D., BISHOP, A. E., GERACI, M., SEMENZA, G. L., 
YACOUB, M., POLAK, J. M. & VOELKEL, N. F. 2001. Expression of angiogenesis-
related molecules in plexiform lesions in severe pulmonary hypertension: evidence 
for a process of disordered angiogenesis. J Pathol, 195, 367-74. 
TUDER, R. M., COOL, C. D., GERACI, M. W., WANG, J., ABMAN, S. H., WRIGHT, L., 
BADESCH, D. & VOELKEL, N. F. 1999. Prostacyclin synthase expression is 
decreased in lungs from patients with severe pulmonary hypertension. Am J Respir 
Crit Care Med, 159, 1925-32. 
 266 
 
TUDER, R. M., GROVES, B., BADESCH, D. B. & VOELKEL, N. F. 1994. Exuberant 
endothelial cell growth and elements of inflammation are present in plexiform 
lesions of pulmonary hypertension. Am J Pathol, 144, 275-85. 
TURNER, J. H., GELASCO, A. K. & RAYMOND, J. R. 2004. Calmodulin interacts with the 
third intracellular loop of the serotonin 5-hydroxytryptamine1A receptor at two 
distinct sites: putative role in receptor phosphorylation by protein kinase C. J Biol 
Chem, 279, 17027-37. 
TURNER, J. H. & RAYMOND, J. R. 2005. Interaction of Calmodulin with the Serotonin 5-
Hydroxytryptamine2A Receptor: A PUTATIVE REGULATOR OF G PROTEIN 
COUPLING AND RECEPTOR PHOSPHORYLATION BY PROTEIN KINASE C. 
Journal of Biological Chemistry, 280, 30741-30750. 
UMAR, S., IORGA, A., MATORI, H., NADADUR, R. D., LI, J., MALTESE, F., VAN DER 
LAARSE, A. & EGHBALI, M. 2011. Estrogen rescues preexisting severe 
pulmonary hypertension in rats. Am J Respir Crit Care Med, 184, 715-23. 
VACHIERY, J. L. & NAEIJE, R. 2004. Treprostinil for pulmonary hypertension. Expert Rev 
Cardiovasc Ther, 2, 183-91. 
VAN ALBADA, M. E., VAN VEGHEL, R., CROMME-DIJKHUIS, A. H., SCHOEMAKER, R. 
G. & BERGER, R. M. 2006. Treprostinil in advanced experimental pulmonary 
hypertension: beneficial outcome without reversed pulmonary vascular 
remodeling. J Cardiovasc Pharmacol, 48, 249-54. 
VAN DEN BROEK, R. W., BHALLA, P., VANDENBRINK, A. M., DE VRIES, R., SHARMA, 
H. S. & SAXENA, P. R. 2002. Characterization of sumatriptan-induced contractions 
in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor 
antagonists and in situ hybridization. Cephalalgia, 22, 83-93. 
VAN DER BRUGGEN, C. E. E., HAPPÉ, C. M., DORFMÜLLER, P., TRIP, P., SPRUIJT, 
O. A., ROL, N., HOEVENAARS, F., HOUWELING, A. C., GIRERD, B., MARCUS, 
J. T., MERCIER, O., HUMBERT, M., HANDOKO, M. L., VAN DER VELDEN, J., 
VONK NOORDEGRAAF, A., BOGAARD, H. J., GOUMANS, M.-J. & DE MAN, F. 
S. 2016. Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary 
Arterial Hypertension: A View on the Right Ventricle. Circulation. 
VAN EICKELS, M., GROHE, C., CLEUTJENS, J. P., JANSSEN, B. J., WELLENS, H. J. & 
DOEVENDANS, P. A. 2001. 17beta-estradiol attenuates the development of 
pressure-overload hypertrophy. Circulation, 104, 1419-23. 
VANE, J. & CORIN, R. E. 2003. Prostacyclin: a vascular mediator. Eur J Vasc Endovasc 
Surg, 26, 571-8. 
VASSILATIS, D. K., HOHMANN, J. G., ZENG, H., LI, F., RANCHALIS, J. E., MORTRUD, 
M. T., BROWN, A., RODRIGUEZ, S. S., WELLER, J. R., WRIGHT, A. C., 
BERGMANN, J. E. & GAITANARIS, G. A. 2003. The G protein-coupled receptor 
 267 
 
repertoires of human and mouse. Proceedings of the National Academy of 
Sciences, 100, 4903-4908. 
VOELKEL, N. F. & TUDER, R. M. 2000. Hypoxia-induced pulmonary vascular remodeling: 
a model for what human disease? The Journal of Clinical Investigation, 106, 733-
738. 
VOSWINCKEL, R., ENKE, B., REICHENBERGER, F., KOHSTALL, M., KRECKEL, A., 
KRICK, S., GALL, H., GESSLER, T., SCHMEHL, T., GHOFRANI, H. A., 
SCHERMULY, R. T., GRIMMINGER, F., RUBIN, L. J., SEEGER, W. & 
OLSCHEWSKI, H. 2006. Favorable effects of inhaled treprostinil in severe 
pulmonary hypertension: results from randomized controlled pilot studies. J Am 
Coll Cardiol, 48, 1672-81. 
WADE, M., HUNT, T. L. & LAI, A. A. 2003. Effect of Continuous Subcutaneous Treprostinil 
Therapy on the Pharmacodynamics and Pharmacokinetics of Warfarin. Journal of 
Cardiovascular Pharmacology, 41, 908-915. 
WALCH, L., LABAT, C., GASCARD, J. P., DE MONTPREVILLE, V., BRINK, C. & NOREL, 
X. 1999. Prostanoid receptors involved in the relaxation of human pulmonary 
vessels. Br J Pharmacol, 126, 859-66. 
WALKER, A. M., LANGLEBEN, D., KORELITZ, J. J., RICH, S., RUBIN, L. J., STROM, B. 
L., GONIN, R., KEAST, S., BADESCH, D., BARST, R. J., BOURGE, R. C., 
CHANNICK, R., FROST, A., GAINE, S., MCGOON, M., MCLAUGHLIN, V., 
MURALI, S., OUDIZ, R. J., ROBBINS, I. M., TAPSON, V., ABENHAIM, L. & 
CONSTANTINE, G. 2006. Temporal trends and drug exposures in pulmonary 
hypertension: an American experience. Am Heart J, 152, 521-6. 
WALLACE, E., MORRELL, N. W., YANG, X. D., LONG, L., STEVENS, H., NILSEN, M., 
LOUGHLIN, L., MAIR, K. M., BAKER, A. H. & MACLEAN, M. R. 2015. A Sex-
Specific MicroRNA-96/5-Hydroxytryptamine 1B Axis Influences Development of 
Pulmonary Hypertension. Am J Respir Crit Care Med, 191, 1432-42. 
WANG, C., LV, X., HE, C., HUA, G., TSAI, M. Y. & DAVIS, J. S. 2013. The G-protein-
coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer 
cells by blocking tubulin polymerization. Cell Death Dis, 4, e869. 
WANG, J., BINGAMAN, S. & HUXLEY, V. H. 2010a. Intrinsic sex-specific differences in 
microvascular endothelial cell phosphodiesterases. American Journal of 
Physiology - Heart and Circulatory Physiology, 298, H1146-H1154. 
WANG, J., BINGAMAN, S. & HUXLEY, V. H. 2010b. Intrinsic sex-specific differences in 
microvascular endothelial cell phosphodiesterases. Am J Physiol Heart Circ 
Physiol, 298, H1146-54. 
WANG, J., SHIMODA, L. A., WEIGAND, L., WANG, W., SUN, D. & SYLVESTER, J. T. 
2005a. Acute hypoxia increases intracellular [Ca2+] in pulmonary arterial smooth 
 268 
 
muscle by enhancing capacitative Ca2+ entry. Am J Physiol Lung Cell Mol Physiol, 
288, L1059-69. 
WANG, M., TSAI, B. M., REIGER, K. M., BROWN, J. W. & MELDRUM, D. R. 2006. 17-
beta-Estradiol decreases p38 MAPK-mediated myocardial inflammation and 
dysfunction following acute ischemia. J Mol Cell Cardiol, 40, 205-12. 
WANG, X., ZENG, W., KIM, M. S., ALLEN, P. B., GREENGARD, P. & MUALLEM, S. 
2007a. Spinophilin/neurabin reciprocally regulate signaling intensity by G protein-
coupled receptors. The EMBO Journal, 26, 2768-2776. 
WANG, X., ZENG, W., SOYOMBO, A. A., TANG, W., ROSS, E. M., BARNES, A. P., 
MILGRAM, S. L., PENNINGER, J. M., ALLEN, P. B., GREENGARD, P. & 
MUALLEM, S. 2005b. Spinophilin regulates Ca2+ signalling by binding the N-
terminal domain of RGS2 and the third intracellular loop of G-protein-coupled 
receptors. Nat Cell Biol, 7, 405-11. 
WANG, X. X., ZHANG, F. R., SHANG, Y. P., ZHU, J. H., XIE, X. D., TAO, Q. M., ZHU, J. 
H. & CHEN, J. Z. 2007b. Transplantation of autologous endothelial progenitor cells 
may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot 
randomized controlled trial. J Am Coll Cardiol, 49, 1566-71. 
WARD, J. P., ROBERTSON, T. P. & AARONSON, P. I. 2005. Capacitative calcium entry: 
a central role in hypoxic pulmonary vasoconstriction? Am J Physiol Lung Cell Mol 
Physiol, 289, L2-4. 
WARNE, T., SERRANO-VEGA, M. J., BAKER, J. G., MOUKHAMETZIANOV, R., 
EDWARDS, P. C., HENDERSON, R., LESLIE, A. G. W., TATE, C. G. & 
SCHERTLER, G. F. X. 2008. Structure of a β(1)-adrenergic G protein-coupled 
receptor. Nature, 454, 486-491. 
WAYPA, G. B., CHANDEL, N. S. & SCHUMACKER, P. T. 2001. Model for hypoxic 
pulmonary vasoconstriction involving mitochondrial oxygen sensing. Circ Res, 88, 
1259-66. 
WAYPA, G. B., GUZY, R., MUNGAI, P. T., MACK, M. M., MARKS, J. D., ROE, M. W. & 
SCHUMACKER, P. T. 2006. Increases in mitochondrial reactive oxygen species 
trigger hypoxia-induced calcium responses in pulmonary artery smooth muscle 
cells. Circ Res, 99, 970-8. 
WEIGAND, L., FOXSON, J., WANG, J., SHIMODA, L. A. & SYLVESTER, J. T. 2005. 
Inhibition of hypoxic pulmonary vasoconstriction by antagonists of store-operated 
Ca<sup>2+</sup> and nonselective cation channels. American Journal of 
Physiology - Lung Cellular and Molecular Physiology, 289, L5-L13. 
WEISSMANN, N., DIETRICH, A., FUCHS, B., KALWA, H., AY, M., DUMITRASCU, R., 
OLSCHEWSKI, A., STORCH, U., MEDEROS Y SCHNITZLER, M., GHOFRANI, 
H. A., SCHERMULY, R. T., PINKENBURG, O., SEEGER, W., GRIMMINGER, F. 
& GUDERMANN, T. 2006. Classical transient receptor potential channel 6 
 269 
 
(TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas 
exchange. Proc Natl Acad Sci U S A, 103, 19093-8. 
WEN, W., REN, Z., SHU, X. O., CAI, Q., YE, C., GAO, Y. T. & ZHENG, W. 2007. 
Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in breast 
tissue and their associations with breast cancer risk. Cancer Epidemiol Biomarkers 
Prev, 16, 917-20. 
WHARTON, J., DAVIE, N., UPTON, P. D., YACOUB, M. H., POLAK, J. M. & MORRELL, 
N. W. 2000. Prostacyclin analogues differentially inhibit growth of distal and 
proximal human pulmonary artery smooth muscle cells. Circulation, 102, 3130-6. 
WHITE, K., DEMPSIE, Y., NILSEN, M., WRIGHT, A. F., LOUGHLIN, L. & MACLEAN, M. 
R. 2011a. The serotonin transporter, gender, and 17beta oestradiol in the 
development of pulmonary arterial hypertension. Cardiovasc Res, 90, 373-82. 
WHITE, K., JOHANSEN, A. K., NILSEN, M., CIUCLAN, L., WALLACE, E., PATON, L., 
CAMPBELL, A., MORECROFT, I., LOUGHLIN, L., MCCLURE, J. D., THOMAS, 
M., MAIR, K. M. & MACLEAN, M. R. 2012. Activity of the estrogen-metabolizing 
enzyme cytochrome P450 1B1 influences the development of pulmonary arterial 
hypertension. Circulation, 126, 1087-98. 
WHITE, K., LOUGHLIN, L., MAQBOOL, Z., NILSEN, M., MCCLURE, J., DEMPSIE, Y., 
BAKER, A. H. & MACLEAN, M. R. 2011b. Serotonin transporter, sex, and hypoxia: 
microarray analysis in the pulmonary arteries of mice identifies genes with 
relevance to human PAH. Physiol Genomics, 43, 417-37. 
WHITE, R. E. 2002. Estrogen and vascular function. Vascular Pharmacology, 38, 73-80. 
WHITTLE, B. J., SILVERSTEIN, A. M., MOTTOLA, D. M. & CLAPP, L. H. 2012. Binding 
and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at 
human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist. 
Biochemical Pharmacology, 84, 68-75. 
WILLERS, E. D., NEWMAN, J. H., LOYD, J. E., ROBBINS, I. M., WHEELER, L. A., 
PRINCE, M. A., STANTON, K. C., COGAN, J. A., RUNO, J. R., BYRNE, D., 
HUMBERT, M., SIMONNEAU, G., SZTRYMF, B., MORSE, J. A., KNOWLES, J. 
A., ROBERTS, K. E., MCELROY, J. J., BARST, R. J. & PHILLIPS, J. A., 3RD 2006. 
Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial 
hypertension. Am J Respir Crit Care Med, 173, 798-802. 
WILSON, D. W., SEGALL, H. J., PAN, L. C. & DUNSTON, S. K. 1989. Progressive 
inflammatory and structural changes in the pulmonary vasculature of 
monocrotaline-treated rats. Microvasc Res, 38, 57-80. 
WILSON, S. J., ROCHE, A. M., KOSTETSKAIA, E. & SMYTH, E. M. 2004. Dimerization 
of the human receptors for prostacyclin and thromboxane facilitates thromboxane 
receptor-mediated cAMP generation. J Biol Chem, 279, 53036-47. 
 270 
 
WOLIN, M. S. 2000. Interactions of oxidants with vascular signaling systems. Arterioscler 
Thromb Vasc Biol, 20, 1430-42. 
WONG, W. & SCOTT, J. D. 2004. AKAP signalling complexes: focal points in space and 
time. Nat Rev Mol Cell Biol, 5, 959-70. 
WOODWARD, D. F., JONES, R. L. & NARUMIYA, S. 2011. International Union of Basic 
and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, 
Updating 15 Years of Progress. Pharmacological Reviews, 63, 471-538. 
WRIGHT, A. F., EWART, M. A., MAIR, K., NILSEN, M., DEMPSIE, Y., LOUGHLIN, L. & 
MACLEAN, M. R. 2015. Oestrogen receptor alpha in pulmonary hypertension. 
Cardiovasc Res, 106, 206-16. 
WU, O. 2005. Postmenopausal hormone replacement therapy and venous 
thromboembolism. Gend Med, 2 Suppl A, S18-27. 
XIAO-HUI, L., YING, L. & XIAO-HUI, L. 2012. ID PROTEINS IS INVOLVED IN VASCULAR 
REMODELLING IN HYPOXIA-INDUCED PULMONARY HYPERTENSION RATS. 
Heart, 98, E282. 
XU, D. Q., LUO, Y., LIU, Y., WANG, J., ZHANG, B., XU, M., WANG, Y. X., DONG, H. Y., 
DONG, M. Q., ZHAO, P. T., NIU, W., LIU, M. L., GAO, Y. Q. & LI, Z. C. 2010. Beta-
estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression 
of p27kip1 in rats. Respir Res, 11, 182. 
YAGHI, A., PATERSON, N. A. & MCCORMACK, D. G. 1997. Differential effect of nitric 
oxide synthase inhibitors on acetylcholine-induced relaxation of rat pulmonary and 
celiac artery rings. Can J Physiol Pharmacol, 75, 279-86. 
YANG, J., DAVIES, R. J., SOUTHWOOD, M., LONG, L., YANG, X., SOBOLEWSKI, A., 
UPTON, P. D., TREMBATH, R. C. & MORRELL, N. W. 2008. Mutations in bone 
morphogenetic protein type II receptor cause dysregulation of Id gene expression 
in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial 
hypertension. Circ Res, 102, 1212-21. 
YANG, J., LI, X., AL-LAMKI, R. S., WU, C., WEISS, A., BERK, J., SCHERMULY, R. T. & 
MORRELL, N. W. 2013a. Sildenafil potentiates bone morphogenetic protein 
signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary 
hypertension. Arterioscler Thromb Vasc Biol, 33, 34-42. 
YANG, J., LI, X., LI, Y., SOUTHWOOD, M., YE, L., LONG, L., AL-LAMKI, R. S. & 
MORRELL, N. W. 2013b. Id proteins are critical downstream effectors of BMP 
signaling in human pulmonary arterial smooth muscle cells. American Journal of 
Physiology - Lung Cellular and Molecular Physiology, 305, L312. 
YANG, J., LI, X. & MORRELL, N. W. 2014. Id proteins in the vasculature: from molecular 
biology to cardiopulmonary medicine. Cardiovascular Research, 104, 388-398. 
YANG, J., LI, X. H., AL-LAMKI, R. S., SOUTHWOOD, M., ZHAO, J., LEVER, A. M., 
GRIMMINGER, F., SCHERMULY, R. T. & MORRELL, N. W. 2010. Smad-
 271 
 
Dependent and Smad-Independent Induction of Id1 by Prostacyclin Analogues 
Inhibits Proliferation of Pulmonary Artery Smooth Muscle Cells In Vitro and In Vivo. 
Circulation Research, 107, 252-U170. 
YANG, X., LONG, L., REYNOLDS, P. N. & MORRELL, N. W. 2011. Expression of mutant 
BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors 
that stimulate proliferation of pulmonary arterial smooth muscle cells. Pulm Circ, 1, 
103-10. 
YANG, X., LONG, L., SOUTHWOOD, M., RUDARAKANCHANA, N., UPTON, P. D., 
JEFFERY, T. K., ATKINSON, C., CHEN, H., TREMBATH, R. C. & MORRELL, N. 
W. 2005. Dysfunctional Smad signaling contributes to abnormal smooth muscle 
cell proliferation in familial pulmonary arterial hypertension. Circ Res, 96, 1053-63. 
YI, E. S., KIM, H., AHN, H., STROTHER, J., MORRIS, T., MASLIAH, E., HANSEN, L. A., 
PARK, K. & FRIEDMAN, P. J. 2000. Distribution of obstructive intimal lesions and 
their cellular phenotypes in chronic pulmonary hypertension. A morphometric and 
immunohistochemical study. Am J Respir Crit Care Med, 162, 1577-86. 
YUAN, J. X., ALDINGER, A. M., JUHASZOVA, M., WANG, J., CONTE, J. V., JR., GAINE, 
S. P., ORENS, J. B. & RUBIN, L. J. 1998. Dysfunctional voltage-gated K+ channels 
in pulmonary artery smooth muscle cells of patients with primary pulmonary 
hypertension. Circulation, 98, 1400-6. 
YUAN, P., WU, W. H., GAO, L., ZHENG, Z. Q., LIU, D., MEI, H. Y., ZHANG, Z. L. & JING, 
Z. C. 2013. Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, 
prostacyclin and endothelin-1 pathways. Eur Respir J, 41, 1116-25. 
YUAN, X. J. 1995. Voltage-gated K+ currents regulate resting membrane potential and 
[Ca2+]i in pulmonary arterial myocytes. Circ Res, 77, 370-8. 
YUAN, X. J., GOLDMAN, W. F., TOD, M. L., RUBIN, L. J. & BLAUSTEIN, M. P. 1993. 
Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric 
arterial myocytes. Am J Physiol, 264, L116-23. 
ZAKRZEWICZ, D. & EICKELBERG, O. 2009. From arginine methylation to ADMA: a novel 
mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med, 9, 
5. 
ZHANG, S., FANTOZZI, I., TIGNO, D. D., YI, E. S., PLATOSHYN, O., THISTLETHWAITE, 
P. A., KRIETT, J. M., YUNG, G., RUBIN, L. J. & YUAN, J. X. 2003. Bone 
morphogenetic proteins induce apoptosis in human pulmonary vascular smooth 
muscle cells. Am J Physiol Lung Cell Mol Physiol, 285, L740-54. 
ZHANG, Y., CHANG, C., GEHLING, D. J., HEMMATI-BRIVANLOU, A. & DERYNCK, R. 
2001a. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin 
ligase. Proceedings of the National Academy of Sciences of the United States of 
America, 98, 974-979. 
 272 
 
ZHANG, Y., WANG, Y., YANG, K., TIAN, L., FU, X., WANG, Y., SUN, Y., JIANG, Q., LU, 
W. & WANG, J. 2014. BMP4 Increases the Expression of TRPC and Basal [Ca2+]i 
via the p38MAPK and ERK1/2 Pathways Independent of BMPRII in PASMCs. 
PLOS ONE, 9, e112695. 
ZHANG, Z., AUSTIN, S. C. & SMYTH, E. M. 2001b. Glycosylation of the human 
prostacyclin receptor: role in ligand binding and signal transduction. Mol 
Pharmacol, 60, 480-7. 
ZHAO, Y., NICHOLS, J. E., BULUN, S. E., MENDELSON, C. R. & SIMPSON, E. R. 1995. 
Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT 
pathway in regulation of the adipose-specific promoter. J Biol Chem, 270, 16449-
57. 
ZHAO, Y. D., COURTMAN, D. W., DENG, Y., KUGATHASAN, L., ZHANG, Q. & 
STEWART, D. J. 2005. Rescue of monocrotaline-induced pulmonary arterial 
hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy 
of combined cell and eNOS gene therapy in established disease. Circ Res, 96, 
442-50. 
ZIVADINOVIC, D., GAMETCHU, B. & WATSON, C. S. 2005. Membrane estrogen 
receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation 
responses. Breast Cancer Res, 7, R101-12. 
 
 
